<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002243.pub3" GROUP_ID="ANAESTH" ID="895399081908493005" MERGED_FROM="" MODIFIED="2018-05-05 00:48:12 +0100" MODIFIED_BY="Jane Cracknell" REVIEW_NO="121" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0"><COVER_SHEET MODIFIED="2018-05-05 00:48:11 +0100" MODIFIED_BY="Jane Cracknell"><TITLE MODIFIED="2015-01-05 14:04:17 +0000" MODIFIED_BY="Jane Cracknell">Corticosteroids for treating sepsis</TITLE><CONTACT MODIFIED="2018-05-05 00:48:11 +0100" MODIFIED_BY="Jane Cracknell"><PERSON ID="5686" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Djillali</FIRST_NAME><LAST_NAME>Annane</LAST_NAME><EMAIL_1>djillali.annane@aphp.fr</EMAIL_1><ADDRESS><DEPARTMENT>Department of Critical Care, Hyperbaric Medicine and Home Respiratory Unit</DEPARTMENT><ORGANISATION>Center for Neuromuscular Diseases; Raymond Poincaré Hospital (AP-HP)</ORGANISATION><ADDRESS_1>Faculty of Health Sciences Simone Veil, University of Versailles SQY- University of Paris Saclay</ADDRESS_1><ADDRESS_2>104 Boulevard Raymond Poincaré</ADDRESS_2><CITY>Garches</CITY><ZIP>92380</ZIP><COUNTRY CODE="FR">France</COUNTRY></ADDRESS></PERSON></CONTACT><CREATORS MODIFIED="2018-05-05 00:48:11 +0100" MODIFIED_BY="Jane Cracknell"><PERSON ID="5686" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Djillali</FIRST_NAME><LAST_NAME>Annane</LAST_NAME><EMAIL_1>djillali.annane@aphp.fr</EMAIL_1><ADDRESS><DEPARTMENT>Department of Critical Care, Hyperbaric Medicine and Home Respiratory Unit</DEPARTMENT><ORGANISATION>Center for Neuromuscular Diseases; Raymond Poincaré Hospital (AP-HP)</ORGANISATION><ADDRESS_1>Faculty of Health Sciences Simone Veil, University of Versailles SQY- University of Paris Saclay</ADDRESS_1><ADDRESS_2>104 Boulevard Raymond Poincaré</ADDRESS_2><CITY>Garches</CITY><ZIP>92380</ZIP><COUNTRY CODE="FR">France</COUNTRY></ADDRESS></PERSON><PERSON ID="14280" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Eric</FIRST_NAME><LAST_NAME>Bellissant</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>eric.bellissant@univ-rennes1.fr</EMAIL_1><EMAIL_2>eric.bellissant@chu-rennes.fr</EMAIL_2><ADDRESS><DEPARTMENT>Centre d'Investigation Clinique INSERM 0203</DEPARTMENT><ORGANISATION>Hôpital Pontchaillou</ORGANISATION><CITY>Rennes</CITY><ZIP>35033</ZIP><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>02 23 23 45 96</PHONE_1><FAX_1>02 23 23 46 05</FAX_1></ADDRESS></PERSON><PERSON ID="14282" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Pierre Edouard</FIRST_NAME><LAST_NAME>Bollaert</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Head of Department</POSITION><EMAIL_1>pe.bollaert@chu-nancy.fr</EMAIL_1><ADDRESS><DEPARTMENT>Intensive Care Unit</DEPARTMENT><ORGANISATION>Hôpital Central</ORGANISATION><CITY>Nancy</CITY><ZIP>54000</ZIP><COUNTRY CODE="FR">France</COUNTRY></ADDRESS></PERSON><PERSON ID="14284" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Josef</FIRST_NAME><LAST_NAME>Briegel</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>josef.briegel@med.uni-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik fur Anästhesiologie</DEPARTMENT><ORGANISATION>Klinikum der Universität</ORGANISATION><CITY>München</CITY><ZIP>81377</ZIP><COUNTRY CODE="DE">Germany</COUNTRY></ADDRESS></PERSON><PERSON ID="14303" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Didier</FIRST_NAME><LAST_NAME>Keh</LAST_NAME><EMAIL_1>didier.keh@charite.de</EMAIL_1><ADDRESS><DEPARTMENT>University Clinic of Anesthesiology and Intensive Care Medicine CCM/CVK</DEPARTMENT><ORGANISATION>Charité-Campus Virchow Clinic, Charité Universitätsmedizin Berlin</ORGANISATION><ADDRESS_2>Augustenburger Platz 1</ADDRESS_2><CITY>Berlin</CITY><ZIP>13353</ZIP><COUNTRY CODE="DE">Germany</COUNTRY></ADDRESS></PERSON><PERSON ID="14305" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Yizhak</FIRST_NAME><LAST_NAME>Kupfer</LAST_NAME><EMAIL_1>ykupfer@maimonidesmed.org</EMAIL_1><ADDRESS><DEPARTMENT>Division of Pulmonary and Critical Care Medicine</DEPARTMENT><ORGANISATION>Maimonides Medical Center</ORGANISATION><ADDRESS_1>4802  Tenth Avenue</ADDRESS_1><CITY>Brooklyn</CITY><ZIP>11219</ZIP><REGION>New York</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+ 1 718 283 8380</PHONE_1><FAX_1>+1 718 283 7884</FAX_1></ADDRESS></PERSON></CREATORS><DATES MODIFIED="2018-05-05 00:42:44 +0100" MODIFIED_BY="[Empty name]"><UP_TO_DATE><DATE DAY="31" MONTH="10" YEAR="2014"/></UP_TO_DATE><LAST_SEARCH><DATE DAY="31" MONTH="10" YEAR="2014"/></LAST_SEARCH><NEXT_STAGE><DATE DAY="31" MONTH="8" YEAR="2019"/></NEXT_STAGE><PROTOCOL_PUBLISHED ISSUE="3" YEAR="2000"/><REVIEW_PUBLISHED ISSUE="1" YEAR="2004"/><LAST_CITATION_ISSUE ISSUE="12" YEAR="2015"/></DATES><WHATS_NEW MODIFIED="2018-05-05 00:36:54 +0100" MODIFIED_BY="[Empty name]"><WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2018-05-05 00:36:54 +0100" MODIFIED_BY="[Empty name]"><DATE DAY="4" MONTH="5" YEAR="2018"/><DESCRIPTION><P>New <LINK TAG="FEEDBACK" TYPE="SECTION">Feedback</LINK> and reply posted in review</P></DESCRIPTION></WHATS_NEW_ENTRY></WHATS_NEW><HISTORY MODIFIED="2018-03-13 12:10:51 +0000" MODIFIED_BY="[Empty name]"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2018-03-13 12:10:51 +0000" MODIFIED_BY="[Empty name]"><DATE DAY="18" MONTH="1" YEAR="2016"/><DESCRIPTION><P>Typo corrected in plain language summary. (It was made clear that Corticosteroids decreased the number of organs that were not functioning properly (organ failure).)</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-01-18 15:45:05 +0000" MODIFIED_BY="Jane Cracknell"><DATE DAY="30" MONTH="11" YEAR="2015"/><DESCRIPTION><P>The new search of the literature identified nine additional trials. Cumulated evidence from 33 trials confirmed the direction and the magnitude of the point estimate for 28-day mortality with narrow confidence interval limits. Thus, this update suggested moderate evidence for reduced 28-day mortality with corticosteroids in the primary analysis. Evidence also confirmed significant interactions between the relative risk of dying at 28 days and treatment modalities (lower doses and longer durations yielded better chance of survival) and patient case mix (patients with septic shock, sepsis-related acute respiratory distress syndrome (ARDS) or community-acquired pneumonia may be more likely to benefit from corticosteroids).</P><P>We decided to change the title to "Corticosteroids for treating sepsis" owing to recent changes in the definition of sepsis suggesting that the term "severe sepsis" should be avoided.</P><P>We made several changes to the Methods section.</P><UL><LI>We now exclude quasi-randomized trials (three trials).</LI><LI>We changed the definition of "long course" from at least five days to at least three days. Indeed, and in keeping with the Surviving Sepsis Campaign recommendation, corticosteroids are often given at full dose until cessation of vasopressor therapy, which may occur faster than five days.</LI><LI>We changed the definition of "low dose" from 300 mg or less per day to 400 mg or less per day. Indeed, no consensus has been reached on the optimal dose, and several randomized controlled trials testing so called "low dose" of corticosteroids used variable doses up to 400 mg.</LI><LI>According to findings from meta-regression analysis, changes in the definitions of "low dose" and "long course" might have had a negative impact on the observed survival benefit of corticosteroids. Indeed, we found that both longer duration and lower dose were associated with better survival rates.</LI></UL><P>Sensitivity analyses based on methodological quality are now restricted to the primary outcome.</P><P>We used random-effects models only in cases of heterogeneity with an I<SUP>2 </SUP>statistic &gt; 30%. Otherwise, we used fixed-effect models.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-01-18 15:45:09 +0000" MODIFIED_BY="Jane Cracknell"><DATE DAY="30" MONTH="11" YEAR="2015"/><DESCRIPTION><P>We reran the search from October 2009 to October 2014.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><DATE DAY="14" MONTH="8" YEAR="2013"/><DESCRIPTION><P>Feedback was submitted and responded to. An error in numbers used for Analysis 1.12 (number of participants with superinfection) has been corrected in the amended version of this review. 'Risk of bias' tables and 'Summary of findings' tables have also been amended</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-11-30 11:24:00 +0000" MODIFIED_BY="Jane Cracknell"><DATE DAY="1" MONTH="11" YEAR="2010"/><DESCRIPTION><UL><LI>We reran the searches from August 2003 to October 2009.</LI><LI>We found 21 new trials. Of those 21 trials, we included 9 randomized controlled trials in this update (<LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Cicarelli-2007" TYPE="STUDY">Cicarelli 2007</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>; <LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK>); we excluded 3 (<LINK REF="STD-Cicarelli-2006" TYPE="STUDY">Cicarelli 2006</LINK>; <LINK REF="STD-Kaufman-2008" TYPE="STUDY">Kaufman 2008</LINK>; <LINK REF="STD-Mikami-2007" TYPE="STUDY">Mikami 2007</LINK>), and 9 are ongoing (IRSCTN99675218 2006; <LINK REF="STD-NCT00127985-2005" TYPE="STUDY">NCT00127985 2005</LINK>; NCT00149123 2005; <LINK REF="STD-NCT00368381-2008" TYPE="STUDY">NCT00368381 2008</LINK>; NCT00471640 2008; <LINK REF="STD-NCT00562835-2008" TYPE="STUDY">NCT00562835 2008</LINK>; <LINK REF="STD-NCT00625209-2008" TYPE="STUDY">NCT00625209 2008;</LINK> <LINK REF="STD-NCT00670254-2008" TYPE="STUDY">NCT00670254 2008</LINK>; <LINK REF="STD-NCT00732277--2008" TYPE="STUDY">NCT00732277 2008</LINK>).</LI><LI>Two (Oppert 2002; Sprung 2002) of the three previous ongoing studies (Oppert 2002; Sprung 2002; Tayer 2002) have now been published and are included in this update as <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK> and <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>. The third trial has never been completed, and no data are available.</LI><LI>In total, this updated review now describes 25 included studies, 10 excluded studies and 9 ongoing studies.</LI><LI>The additional included studies did not change the conclusions of this review.</LI><LI>We included 'Risk of bias' and 'Summary of findings' tables in this updated version.</LI><LI>Search strategies changed from Silver Platter to Ovid.</LI><LI>We changed the statistical analysis by using the random-effects model rather than the fixed-effect model, and we included meta-regression analysis to explore the influence of dose and duration of corticosteroids on risk of death.</LI></UL></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-07 13:49:28 +0100" MODIFIED_BY="Jane Cracknell"><DATE DAY="25" MONTH="3" YEAR="2008"/><DESCRIPTION><P>Converted to new review format.</P></DESCRIPTION></WHATS_NEW_ENTRY></HISTORY><SOURCES_OF_SUPPORT><INTERNAL_SOURCES><SOURCE><NAME>Hopital Raymond Poincaré, Garches</NAME><COUNTRY CODE="FR">France</COUNTRY><DESCRIPTION/></SOURCE></INTERNAL_SOURCES><EXTERNAL_SOURCES><SOURCE><NAME>Department for International Development</NAME><COUNTRY CODE="GB">UK</COUNTRY><DESCRIPTION/></SOURCE></EXTERNAL_SOURCES></SOURCES_OF_SUPPORT><MESH_TERMS VERIFIED="NO"/><KEYWORDS/></COVER_SHEET><MAIN_TEXT MODIFIED="2018-05-05 00:40:48 +0100" MODIFIED_BY="[Empty name]"><SUMMARY MODIFIED="2016-01-15 15:44:41 +0000" MODIFIED_BY="Jane Cracknell"><TITLE MODIFIED="2015-02-01 14:03:53 +0000" MODIFIED_BY="djillali annane">Corticosteroids for treating sepsis</TITLE><SUMMARY_BODY MODIFIED="2016-01-15 15:44:41 +0000" MODIFIED_BY="Jane Cracknell"><P><B>Review question</B></P><P>We reviewed the evidence on effects on survival at one month and on tolerance of systemic corticosteroids in people with sepsis.</P><P><B>Background</B></P><P>Sepsis, the most severe form of infection, is present when a site of infection is apparent and evidence suggests body-wide, systemic inflammation and organ failures. The person develops poor temperature control, an increase or decrease in white blood cells, an increase in heart rate and rapid breathing. Sepsis can interfere with effectiveness of the body&#8217;s own corticosteroids, which serve as key defence hormones against infection. Corticosteroids have been given for more than 60 years to people with severe infection resulting from various causes.</P><P><B>Search date</B></P><P>The evidence provided in this review was current to October 2014.</P><P><B>Study characteristics</B></P><P>This review included a total of 33 randomized controlled trials, accounting for 4268 hospitalized patients with sepsis. Three trials included children, and the remaining 30 trials included only adults. Corticosteroids were compared with placebo in all except five trials, in which they were compared with standard therapy alone.</P><P><B>Study funding sources</B></P><P>Ten out of 33 trials were funded by a drug company, 13 were funded by public organizations or received charitable funding and 10 stated no source of funding.</P><P><B>Key results</B></P><P>Corticosteroids reduced risk of death at 28 days by 13% (among 27 trials, 3176 participants). Both intensive care unit (ICU) and in-hospital deaths were reduced (13 and 17 trials, respectively). The review found that survival benefits were dependent on the dose of corticosteroids - the lower the dose (less than 400 mg of hydrocortisone or equivalent per day) for a longer duration of treatment (three or more days at the full dose) the better - and on the severity of illness. Corticosteroids increased the chance of recovery from septic shock by day seven (when drugs are required to support blood pressure) by 31% (from 12 trials) and and decreased the number of organs that were not functioning properly (organ failure) (from eight trials). Length of stay in the ICU was reduced by more than two days (10 trials). Corticosteroids did not cause harm, except for a mild increase in blood glucose and salt (sodium) levels (13 and three trials, respectively). Gastrointestinal bleeding and infection (19 trials) and neuromuscular weakness (three trials) were not increased.</P><P>We found sparse data on effects of corticosteroids in children with sepsis.</P><P><B>Quality of evidence</B></P><P>We judged the quality of evidence for 28-day mortality as low because of imprecision (the confidence interval of the statistical result approached no change) and inconsistency across trials. These findings were related in part to differences among study populations, type of corticosteroid given, dose and duration of treatment and use of additional interventions. The quality of evidence for 28-day mortality in the subgroup given a long course of low-dose corticosteroids was downgraded from high to moderate because one of the two largest trials on a long course of low-dose corticosteroids reported no survival benefit.</P></SUMMARY_BODY></SUMMARY><ABSTRACT MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><ABS_BACKGROUND MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Sepsis occurs when an infection is complicated by organ failures as defined by a sequential organ failure assessment (SOFA) score of two or higher. Sepsis may be complicated by impaired corticosteroid metabolism. Giving corticosteroids may benefit patients. The original review was published in 2004 and was updated in 2010 and again in 2015.</P></ABS_BACKGROUND><ABS_OBJECTIVES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>To examine the effects of corticosteroids on death at one month in patients with sepsis, and to examine whether dose and duration of corticosteroids influence patient response to this treatment.</P></ABS_OBJECTIVES><ABS_SEARCH_STRATEGY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>We searched the Central Register of Controlled Trials (CENTRAL; 2014, Issue 10), MEDLINE (October 2014), EMBASE (October 2014), Latin American Caribbean Health Sciences Literature (LILACS; October 2014) and reference lists of articles, and we contacted trial authors. The original searches were performed in August 2003 and in October 2009.</P></ABS_SEARCH_STRATEGY><ABS_SELECTION_CRITERIA MODIFIED="2015-02-01 13:50:06 +0000" MODIFIED_BY="djillali annane"><P>We included randomized controlled trials of corticosteroids versus placebo or supportive treatment in patients with sepsis.<BR/></P></ABS_SELECTION_CRITERIA><ABS_DATA_COLLECTION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>All review authors agreed on the eligibility of trials. One review author extracted data, which were checked by the other review authors, and by the primary author of the paper when possible. We obtained some missing data from trial authors. We assessed the methodological quality of trials.</P></ABS_DATA_COLLECTION><ABS_RESULTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>We identified nine additional studies since the last update, for a total of 33 eligible trials (n = 4268 participants). Twenty-three of these 33 trials were at low risk of selection bias, 22 were at low risk of performance and detection bias, 27 were at low risk of attrition bias and 14 were at low risk of selective reporting.</P><P>Corticosteroids reduced 28-day mortality (27 trials; n = 3176; risk ratio (RR) 0.87, 95% confidence interval (CI) 0.76 to 1.00; P value = 0.05, random-effects model). The quality of evidence for this outcome was downgraded from high to low for imprecision (upper limit of 95% CI = 1) and for inconsistency (significant heterogeneity across trial results). Heterogeneity was related in part to the dosing strategy. Treatment with a long course of low-dose corticosteroids significantly reduced 28-day mortality (22 trials; RR 0.87, 95% CI 0.78 to 0.97; P value = 0.01, fixed-effect model). The quality of evidence was downgraded from high to moderate for inconsistency (owing to non-significant effects shown by one large trial). Corticosteroids also reduced mortality rate in the intensive care unit (13 trials; RR 0.82, 95% CI 0.68 to 1.00; P value = 0.04, random-effects model) and at the hospital (17 trials; RR 0.85, 95% CI 0.73 to 0.98; P value = 0.03, random-effects model). Quality of the evidence for in-hospital mortality was downgraded from high to moderate for inconsistency and imprecision (upper limit of 95% CI for RR approaching 1). Corticosteroids increased the proportion of shock reversal by day seven (12 trials; RR 1.31, 95% CI 1.14 to 1.51; P value = 0.0001) and by day 28 (seven trials; n = 1013; RR 1.11, 95% CI 1.02 to 1.21; P value = 0.01) and reduced the SOFA score by day seven (eight trials; mean difference (MD) -1.53, 95% CI -2.04 to -1.03; P value &lt; 0.00001, random-effects model) and survivors' length of stay in the intensive care unit (10 trials; MD -2.19, 95% CI -3.93 to -0.46; P value = 0.01, fixed-effect model) without inducing gastroduodenal bleeding (19 trials; RR 1.24, 95% CI 0. 92 to 1.67; P value = 0.15, fixed-effect model), superinfection (19 trials; RR 1.02, 95% CI 0.87 to 1.20; P value = 0.81, fixed-effect model) or neuromuscular weakness (three trials; RR 0.62, 95% CI 0.21 to 1.88; P value = 0.40, fixed-effect model). Corticosteroid increased the risk of hyperglycaemia (13 trials; RR 1.26, 95% CI 1.16 to 1.37; P value &lt; 0.00001, fixed-effect model) and hypernatraemia (three trials; RR 1.64, 95% CI 1.28 to 2.09; P value &lt; 0.0001, fixed-effect model).</P></ABS_RESULTS><ABS_CONCLUSIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Overall, low-quality evidence indicates that corticosteroids reduce mortality among patients with sepsis. Moderate-quality evidence suggests that a long course of low-dose corticosteroids reduced 28-day mortality without inducing major complications and led to an increase in metabolic disorders.</P></ABS_CONCLUSIONS></ABSTRACT><BODY MODIFIED="2018-05-05 00:40:31 +0100" MODIFIED_BY="[Empty name]"><BACKGROUND MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><CONDITION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Sepsis occurs when a site of infection is apparent and evidence shows body-wide, systemic inflammation. Systemic inflammation is usually defined by two or more criteria: fever or low body temperature, an increase or decrease in white blood cells, an increase in heart rate and rapid breathing (<LINK REF="REF-ACCP_x002f_SCCM-1992" TYPE="REFERENCE">ACCP/SCCM 1992</LINK>; <LINK REF="REF-Bone-1991" TYPE="REFERENCE">Bone 1991</LINK>). Severe sepsis is diagnosed when sepsis is associated with organ failure or hypoperfusion. Septic shock is reported when severe sepsis is combined with a fall in systemic blood pressure that does not improve even when healthcare staff give intravenous fluids. Discussion among the scientific community reveals the need for a more pragmatic definition, such as sepsis corresponding to infection combined with organ failure or hypoperfusion, or septic shock corresponding to vasopressor-dependent sepsis (<LINK REF="REF-Vincent-2013" TYPE="REFERENCE">Vincent 2013</LINK>). A task force set up by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine recently introduced a new definition of sepsis and septic shock (<LINK REF="REF-Singer-2015" TYPE="REFERENCE">Singer 2015</LINK>). Sepsis is seen when an infection is complicated by organ failures, as defined by a sequential organ failure assessment (SOFA) score (<LINK REF="REF-Vincent-1996" TYPE="REFERENCE">Vincent 1996</LINK>) of two or higher. Septic shock is noted when infection is complicated by hypotension that requires use of vasopressor therapy while lactate levels are increased to above 2 mmol/L. Current incidence of sepsis in industrialized countries ranges from 50 to 100 cases per 100,000 population, with short-term mortality of 20% to 50% (<LINK REF="REF-Annane-2003" TYPE="REFERENCE">Annane 2003</LINK>; <LINK REF="REF-Finfer-2004" TYPE="REFERENCE">Finfer 2004</LINK>; <LINK REF="REF-Martin-2003" TYPE="REFERENCE">Martin 2003</LINK>; <LINK REF="REF-Padkin-2003" TYPE="REFERENCE">Padkin 2003</LINK>; <LINK REF="REF-The-EPISPESIS-Group-2004" TYPE="REFERENCE">The EPISPESIS Group 2004</LINK>). People usually die from hypotension or from progressive multiple organ failure (<LINK REF="REF-Angus-2013" TYPE="REFERENCE">Angus 2013</LINK>; <LINK REF="REF-Annane-2005" TYPE="REFERENCE">Annane 2005</LINK>; <LINK REF="REF-Parrillo-1993" TYPE="REFERENCE">Parrillo 1993</LINK>).</P></CONDITION><INTERVENTION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Corticosteroids include the natural steroid hormones produced by adrenocortical cells and a broad variety of synthetic analogues. These substances have various effects that may be grossly classified into glucocorticoid and mineralocorticoid effects. Glucocorticoid effects include mainly regulation of carbohydrates, lipids and proteins metabolism, as well as regulation of inflammation. Mineralocorticoid effects include mainly regulation of electrolytes and water metabolism. At molecular levels, glucocorticoids have non-genomic and genomic effects. Rapid (within minutes) non-genomic effects of glucocorticoids include a decrease in platelet aggregation, in cell adhesion and in intracellular phosphotyrosine kinases, and they include an increase in annexin 1 externalization (<LINK REF="REF-Lowenberg-2005" TYPE="REFERENCE">Lowenberg 2005</LINK>). These effects may result from interaction of glucocorticoids with specific membrane sites (<LINK REF="REF-Norman-2004" TYPE="REFERENCE">Norman 2004</LINK>). Glucocorticoids have indirect genomic effects, called transrepression (<LINK REF="REF-Rhen-2005" TYPE="REFERENCE">Rhen 2005</LINK>). These occur within a few hours following exposure of cells to glucocorticoids. They result from physical interaction between the monomeric glucocorticoid-glucocorticoid receptor (G-GR) &#945; complex and various nuclear transcription factors, such as nuclear factor (NF)-&#954;B and activator protein (AP)-1. Subsequently, these nuclear transcription factors are sequestrated in the cytosol and cannot enter the nucleus, preventing expression of genes encoding for most if not all pro-inflammatory mediators. Glucocorticoids also have direct genomic effects, called transactivation. They require only a few days of cell exposure to glucocorticoids. Indeed, conformational changes (i.e. dimerization of the G-GR&#945; complex) are needed before this complex can migrate to the nucleus to interact with glucocorticoid-responsive elements, that is, parts of genes encoding for regulators of termination of inflammation. Then, key anti-inflammatory factors are up-regulated, leading to phagocytosis, chemokinesis and anti-oxidative processes. The net effect of glucocorticoids involves reprogramming rather than inhibiting immune cell function (<LINK REF="REF-Erschen-2007" TYPE="REFERENCE">Erschen 2007</LINK>). Glucocorticoids induce specific activated anti-inflammatory monocyte subtypes that migrate quickly to inflamed tissues (<LINK REF="REF-Varga-2008" TYPE="REFERENCE">Varga 2008</LINK>). They prolonged survival of this subtype of monocytes via A3 adenosine receptor-triggered anti-apoptotic effects (<LINK REF="REF-Barczyk-2010" TYPE="REFERENCE">Barczyk 2010</LINK>). Obviously, these molecular mechanisms of action of glucocorticoids are appropriate for counteracting the uncontrolled inflammation that may characterize sepsis.</P></INTERVENTION><THEORY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Researchers have explored the biological mechanisms of sepsis to explore potential interventions. Corticosteroids have been a topic of particular focus because of their influence on the immune response. In sepsis, the hypothalamic-pituitary gland hormonal pathway to the adrenal glands stimulates corticosteroid production (<LINK REF="REF-Chrousos-1995" TYPE="REFERENCE">Chrousos 1995</LINK>; <LINK REF="REF-Cooper-2003" TYPE="REFERENCE">Cooper 2003</LINK>). These hormones affect inflammation through production of white blood cells, cytokines (proteins that influence the immune response) and nitric oxide. In sepsis, cytokines may suppress adrenocorticotropin hormone synthesis (<LINK REF="REF-Polito-2011" TYPE="REFERENCE">Polito 2011</LINK>; <LINK REF="REF-Sharshar-2003" TYPE="REFERENCE">Sharshar 2003</LINK>) and the cortisol response to exogenous adrenocorticotropin hormone (<LINK REF="REF-Hotta-1986" TYPE="REFERENCE">Hotta 1986</LINK>; <LINK REF="REF-Jaattela-1991" TYPE="REFERENCE">Jaattela 1991</LINK>). Likewise, sepsis may be associated with alterations in scavenger receptor B1-mediated cholesterol delivery (<LINK REF="REF-Cai-2008" TYPE="REFERENCE">Cai 2008</LINK>). This causes poor adrenal activity in almost half of patients (<LINK REF="REF-Annane-2000" TYPE="REFERENCE">Annane 2000</LINK>; <LINK REF="REF-Lipiner-2007" TYPE="REFERENCE">Lipiner 2007</LINK>; <LINK REF="REF-Marik-2008" TYPE="REFERENCE">Marik 2008</LINK>; <LINK REF="REF-Rothwell-1991" TYPE="REFERENCE">Rothwell 1991</LINK>) and possible resistance of body tissues to corticosteroids (<LINK REF="REF-Meduri-1998a" TYPE="REFERENCE">Meduri 1998a</LINK>) due to fewer corticosteroid receptors or receptors with lower affinity (<LINK REF="REF-Barnes-1995" TYPE="REFERENCE">Barnes 1995</LINK>; <LINK REF="REF-Huang-1987" TYPE="REFERENCE">Huang 1987</LINK>; <LINK REF="REF-Molijn-1995" TYPE="REFERENCE">Molijn 1995</LINK>). Alteration in corticosteroid receptor numbers and in binding capacity may be related at least in part to nitric oxide (<LINK REF="REF-Duma-2004" TYPE="REFERENCE">Duma 2004</LINK>; <LINK REF="REF-Galigniana-1999" TYPE="REFERENCE">Galigniana 1999</LINK>). Recent works suggest that immune cells - not steroid-secreting cells - are key regulators of the interaction between the immune sytem and the adrenals (<LINK REF="REF-Kanczkowski-2013" TYPE="REFERENCE">Kanczkowski 2013</LINK>). In addition, acute illness such as sepsis may be associated with decreased cortisol clearance from plasma (<LINK REF="REF-Boonen-2013" TYPE="REFERENCE">Boonen 2013</LINK>; <LINK REF="REF-Melby-1958" TYPE="REFERENCE">Melby 1958</LINK>), likely resulting from altered hepatic and renal inactivation of cortisol (<LINK REF="REF-Boonen-2013" TYPE="REFERENCE">Boonen 2013</LINK>), Early studies showed that a pharmacological dose of corticosteroids prolonged survival among animals with sepsis (<LINK REF="REF-Fabian-1982" TYPE="REFERENCE">Fabian 1982</LINK>). More recent studies in rodents have demonstrated that lower doses of corticosteroids, for example, 0.1 mg/kg of dexamethasone, improved haemodynamic and organ function, favourably modulated the inflammatory response and prolonged survival (<LINK REF="REF-di-Villa-Bianca-2003" TYPE="REFERENCE">di Villa Bianca 2003</LINK>; <LINK REF="REF-Heller-2003" TYPE="REFERENCE">Heller 2003</LINK>; <LINK REF="REF-Tsao-2004" TYPE="REFERENCE">Tsao 2004</LINK>; <LINK REF="REF-Vachharajani-2006" TYPE="REFERENCE">Vachharajani 2006</LINK>). Protective effects of these glucocorticoids against sepsis may be mediated in part by the endothelial glucocorticoid receptor (<LINK REF="REF-Goodwin-2013" TYPE="REFERENCE">Goodwin 2013</LINK>). In healthy volunteers challenged with endotoxin, a low dose of corticosteroids, for example, 10 mg of prednisolone, blocked the release of pro-inflammatory cytokines, prevented endothelial cell and neutrophil activation and inhibited the acute phase response without altering coagulation and fibrinolysis balance (<LINK REF="REF-de-Kruif-2007" TYPE="REFERENCE">de Kruif 2007</LINK>). Studies in patients with septic shock showed that a short course of corticosteroids may result in a rebound in the systemic inflammatory response (<LINK REF="REF-Briegel-1994" TYPE="REFERENCE">Briegel 1994</LINK>; <LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>). In addition, it is now recognized that increased pro-inflammatory cytokine release can be sustained for longer than a week in patients with sepsis (<LINK REF="REF-Kellum-2007" TYPE="REFERENCE">Kellum 2007</LINK>). Likewise, timing of initiation of corticosteroids may be an important factor in response to treatment. Indeed, in observational studies, short-term mortality increased with delayed initiation of hydrocortisone (<LINK REF="REF-Katsenos-2014" TYPE="REFERENCE">Katsenos 2014</LINK>; <LINK REF="REF-Park-2012" TYPE="REFERENCE">Park 2012</LINK>). For these reasons, we would anticipate that corticosteroid treatment is beneficial for patients with sepsis, and that differences in dose, timing or duration of steroid treatment may differentially affect patient response to treatment.</P></THEORY><IMPORTANCE MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Initially, researchers used high doses of corticosteroids, usually given as a single bolus, in an attempt to block potential bursts in pro-inflammatory cytokines. Two systematic reviews and meta-analyses of trials of corticosteroids in sepsis or in septic shock included 10 (<LINK REF="REF-Lefering-1995" TYPE="REFERENCE">Lefering 1995</LINK>) and nine (<LINK REF="REF-Cronin-1995" TYPE="REFERENCE">Cronin 1995</LINK>) randomized controlled trials, respectively. These systematic reviews showed no significant difference in relative risk of death, and no significant increase in risk of gastrointestinal bleeding or superinfection associated with corticosteroids.</P><P>Subsequently, most clinicians will not recommend use of high doses of corticosteroids in sepsis. However, this review covered a period from 1966 to 1993 and did not exclude potential benefits of a lower dose (&#8804; 300 mg of hydrocortisone or equivalent per day) and a longer duration at full dose (&#8805; three days) of treatment, as investigated in randomized controlled trials over the past two decades (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Cicarelli-2007" TYPE="STUDY">Cicarelli 2007</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>; <LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>; <LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>; <LINK REF="STD-Liu-2012" TYPE="STUDY">Liu 2012</LINK>; <LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK>; <LINK REF="STD-Meijvis-2011" TYPE="STUDY">Meijvis 2011</LINK>; <LINK REF="STD-Mikami-2007" TYPE="STUDY">Mikami 2007</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Rezk--2013" TYPE="STUDY">Rezk 2013</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Sabry-2011" TYPE="STUDY">Sabry 2011</LINK>; <LINK REF="STD-Snijders-2010" TYPE="STUDY">Snijders 2010</LINK>; <LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK>; <LINK REF="STD-Torres-2015" TYPE="STUDY">Torres 2015</LINK>; <LINK REF="STD-Valoor-2009" TYPE="STUDY">Valoor 2009</LINK>; <LINK REF="STD-Yildiz-2002" TYPE="STUDY">Yildiz 2002</LINK>; <LINK REF="STD-Yildiz-2011" TYPE="STUDY">Yildiz 2011</LINK>). Among these trials, the two largest yielded different findings (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>). In one study, the combination of hydrocortisone and fludrocortisone given at low doses for one week was associated with reduced duration of shock and of organ failure and reduced mortality among patients with septic shock, and a blunted response to corticotrophin was reported (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>). In the second trial, hydrocortisone was given alone for five days and was tapered off over six additional days (<LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>). This trial found significant reduction in duration and intensity of shock and organ failure showed no survival benefit. In addition to differences in treatment modalities, major discrepancies between these trials (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002 </LINK>vs <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>) included differences in routine practices at the time these studies were conducted (no vs broad use of corticosteroids in sepsis), differences in severity of illness (high vs low baseline risk of death) and differences in populations (mostly medical intensive care unit (ICU) patients with lung infection vs mostly surgical ICU patients with abdominal infection). Thereafter, international guidelines have suggested that corticosteroids should be used only in patients with septic shock who are poorly responsive to fluid replacement and vasopressor therapy (<LINK REF="REF-Dellinger-2008" TYPE="REFERENCE">Dellinger 2008</LINK>; <LINK REF="REF-Dellinger-2013" TYPE="REFERENCE">Dellinger 2013</LINK>).</P><P>We therefore aim to systematically review the effects of corticosteroids in patients with sepsis.</P></IMPORTANCE></BACKGROUND><OBJECTIVES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>To examine the effects of corticosteroids on death at one month in patients with sepsis, and to examine whether dose and duration of corticosteroids influence patient response to this treatment.</P></OBJECTIVES><METHODS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><SELECTION_CRITERIA MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><CRIT_STUDIES MODIFIED="2015-11-17 15:01:18 +0000" MODIFIED_BY="Jane Cracknell"><P>We included randomized controlled trials (RCTs) with or without blinding.</P></CRIT_STUDIES><CRIT_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>We included children and adults with sepsis defined by the following criteria (<LINK REF="REF-ACCP_x002f_SCCM-1992" TYPE="REFERENCE">ACCP/SCCM 1992</LINK>; <LINK REF="REF-Vincent-2013" TYPE="REFERENCE">Vincent 2013</LINK>).</P><UL><LI>Documented infection defined as culture or Gram stain of blood, sputum, urine or normally sterile body fluid that is positive for a pathogenic micro-organism; or a focus of infection identified by visual inspection (e.g. ruptured bowel with the presence of free air or bowel contents in the abdomen found at the time of surgery; wound with purulent drainage); and</LI><LI>At least two symptoms of a systemic inflammatory response syndrome, such as fever (body temperature &gt; 38°C) or hypothermia (&lt; 36°C), tachycardia (&gt; 90 beats per minute), tachypnoea (&gt; 20 breaths per minute) or hyperventilation (arterial carbon dioxide tension (PaCO<SUB>2</SUB>) &lt; 32 mm Hg) and abnormal white blood cell count (&gt; 12,000 cells/mL or &lt; 4000 cells/mL) or more than 10% immature band of neutrophils; and</LI><LI>At least one sign of organ dysfunction, that is, metabolic acidosis, arterial hypoxaemia (arterial oxygen tension [PaO<SUB>2</SUB>]:fractional inspired oxygen [FiO<SUB>2</SUB>] &lt; 250 mm Hg), oliguria (&lt; 30 mL/h for &#8805; three hours), coagulopathy or encephalopathy; and</LI><LI>Septic shock defined by a combination of these criteria and the presence of hypotension (persisting systolic arterial pressure &lt; 90 mm Hg) that is refractory to fluid resuscitation and requires vasopressor support, that is, more than 5 µg/kg of body weight per minute of dopamine or any dose of epinephrine or norepinephrine.</LI></UL><P>We included data from trials of acute respiratory distress syndrome (ARDS) when separate data were available for participants with sepsis, or when contact with study authors resulted in provision of the data.</P></CRIT_PARTICIPANTS><CRIT_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><SUBSECTION><HEADING LEVEL="4">Intervention</HEADING><P>Systemic treatment with any type of corticosteroid preparation (e.g. cortisone, hydrocortisone, methylprednisolone, betamethasone, dexamethasone).</P><P>Low-dose corticosteroid was defined by a total dose per day of 400 mg or less of hydrocortisone (or equivalent); otherwise the dose of corticosteroid would be considered as high. A long course for the intervention was defined by a full-dose treatment duration of three or more days; otherwise treatment was considered as a short course.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Control</HEADING><P>Standard therapy (which may have included antibiotics, fluid replacement, inotropic or vasopressor therapy, mechanical ventilation or renal replacement therapy) or placebo.</P></SUBSECTION></CRIT_INTERVENTIONS><CRIT_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><CRIT_OUTCOMES_PRIMARY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>28-Day all-cause mortality.</LI></UL><P>Indeed, this was the primary outcome measure in most of the RCTs on sepsis conducted since 1992 (<LINK REF="REF-Annane-2009b" TYPE="REFERENCE">Annane 2009b</LINK>). Most studies performed before 1992 looked at 14-day or hospital mortality rates. We used these data to compute the pooled analysis on 28-day mortality, unless we could obtain actual 28-day mortality rates from study authors.</P></CRIT_OUTCOMES_PRIMARY><CRIT_OUTCOMES_SECONDARY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>ICU mortality.</LI><LI>Hospital mortality.</LI><LI>Number of participants with shock reversal (as defined by stable haemodynamic status &#8805; 24 hours after withdrawal of vasopressor therapy) at day seven and at day 28.</LI><LI>Number of organs affected and severity of organ dysfunction at day seven, as measured by the sequential organ failure assessment (SOFA) score (<LINK REF="REF-Vincent-1996" TYPE="REFERENCE">Vincent 1996</LINK>).</LI><LI>Length of stay in the ICU (for all participants and for survivors only).</LI><LI>Length of hospital stay (for all participants and for survivors only).</LI><LI>Adverse events (i.e. gastrointestinal bleeding and superinfection or any other adverse effects or complications of corticosteroid treatment).</LI></UL></CRIT_OUTCOMES_SECONDARY></CRIT_OUTCOMES></SELECTION_CRITERIA><SEARCH_METHODS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>We attempted to identify all relevant studies regardless of language or publication status (published, unpublished, in press, in progress).</P><ELECTRONIC_SEARCHES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>We originally searched the Cochrane Infectious Diseases Group Trials Register for relevant trials (to August 2003) using the search terms 'sepsis' and 'septic shock'. Full details on the methods of the Cochrane Infectious Diseases Group and of the journals handsearched are published in <I>The</I> <I>Cochrane Library</I> in the section on Cochrane Review Groups.</P><P>In this updated version, we searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2014 Issue 10) using the search terms 'sepsis', 'septic shock', 'steroids' and 'corticosteroids' (for the detailed search strategy, see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</P><P>We also searched (up to October 2014) MEDLINE, EMBASE and Latin American Caribbean Health Sciences Literature (LILACS) using the topic search terms in combination with the search strategy for identifying trials developed by The Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). (For detailed search strategies, see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> (MEDLINE), <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> (EMBASE) and <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> (LILACS)).</P></ELECTRONIC_SEARCHES><OTHER_SEARCHES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>We checked the reference lists of all trials identified by these methods, and we contacted study authors to request additional published or unpublished data. We also searched the proceedings of annual meetings of major critical care medicine symposia, that is, Society of Critical Care Medicine, American Thoracic Society, International Symposium on Intensive Care and Emergency Medicine, American College of Chest Physicians and European Society of Intensive Care Medicine (1998 to 2014).</P><P>Finally, we searched for ongoing RCTs (October 2014) in the <I>meta</I>Register of Controlled Trials using the search terms 'septic shock', 'sepsis', steroids', 'corticosteroids', 'adrenal cortex hormones' and 'glucocorticoids' (<A HREF="http://www.controlled-trials.com/mrct/active">www.controlled-trials.com/mrct/active</A>).</P></OTHER_SEARCHES></SEARCH_METHODS><DATA_COLLECTION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><STUDY_SELECTION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>All review authors checked the titles and abstracts identified during the search. All review authors examined in full any trial that potentially met the inclusion criteria. Five review authors (Djillali Annane, Pierre Edouard Bollaert, Josef Briegel, Didier Keh and Yizhak Kupfer) evaluated all trials, except those in which they had participated. We decided which trials fitted the inclusion criteria and graded their methodological quality. We resolved disagreements between the five review authors by discussion with the sixth review author (Eric Bellissant) until consensus was reached. One review author (Djillali Annane) contacted study authors for clarification, when necessary.</P></STUDY_SELECTION><DATA_EXTRACTION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>One review author (DA) drew up a standard data extraction form, and four other review authors (PEB, JB, DK, YK) amended and validated the design of the form before data abstraction. Four review authors (DA, PEB, JB, DK) independently extracted data, except those from trials in which they had participated. One review author (DA) systematically contacted the authors of trials to request missing data when possible. One review author (DA) entered (DA secretary independently reentered all data to achieve a double entry) the data into the computer, and five review authors (EB, PEB, JB, DK, YK) checked the accuracy of data entered against the original articles.</P></DATA_EXTRACTION><QUALITY_ASSESSMENT MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>We assessed risk of bias within individual trials as recommended by the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We considered the following domains: selection bias, performance bias, detection bias, attrition bias, reporting bias and any other bias. We judged selection bias on the basis of how the random sequence was generated and how allocation was concealed. We judged performance bias and detection bias on the basis of who was blinded and how, among participants, care-givers, pharmacists, data collectors, outcome assessors and data analysts (<LINK REF="REF-Devereaux-2001" TYPE="REFERENCE">Devereaux 2001</LINK>). In judging attrition bias, we considered how many (and the reasons why) participants were lost to follow-up or were not included in analyses. When available, we compared outcomes reported in trial protocols versus actual results reported, to identify potential selective reporting bias. We resolved disagreements between the five review authors by discussion with the sixth review author (EB) until consensus was reached. One review author (DA) contacted study authors for clarification, when necessary.</P></QUALITY_ASSESSMENT><EFFECT_MEASURES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>We performed intention-to-treat (ITT) analyses. We performed all statistical calculations using <LINK REF="REF-RevMan-5" TYPE="REFERENCE">RevMan 5</LINK> or STATA/IC version 10.1 (Stata Corp, College Station, Texas) as appropriate.</LI><LI>We calculated a weighted treatment effect across trials. We expressed results as risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes, and as mean differences (MDs, 95% CIs) for continuous outcomes.</LI></UL></EFFECT_MEASURES><UNIT_OF_ANALYSIS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>In this review, we used data from trials in which the unit of randomization was an individual, and in which parallel groups were designed. For events that may occur repeatedly, such as receiving vasopressor therapy, we used only the first occurrence of the event.</P></UNIT_OF_ANALYSIS><MISSING_DATA MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>We systematically tried to contact primary authors of original trials to obtain missing information and unpublished data.</P></MISSING_DATA><HETEROGENEITY_ASSESSMENT MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>We considered that evidence for significant heterogeneity was present when I<SUP>2</SUP> &gt; 30%.</P></HETEROGENEITY_ASSESSMENT><BIAS_ASSESSMENT MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>We sought evidence of publication bias by using the funnel plot method. We used STATA/IC version 10.1 (Stata Corp, College Station, Texas) to prepare a contour-enhanced funnel plot (<LINK REF="REF-Peters-2008" TYPE="REFERENCE">Peters 2008</LINK>). This graphical analysis used the log of the RR and the standard error of the RR. We plotted contours illustrating the statistical significance of study effect estimates by using a two-tailed test.</P></BIAS_ASSESSMENT><DATA_SYNTHESIS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>We considered methods based on the random-effects model for all analyses, except when we found no evidence for significant heterogeneity in the results. Indeed, we suspected that we would observe heterogeneity across studies, as they were conducted over a wide period of time (almost half a century between first and last trials) and the rationale on which studies were designed varied greatly over time, with marked differences in treatment strategies and in populations between studies conducted before and after the early 90s.</P></DATA_SYNTHESIS><SUBGROUP_ANALYSIS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>To identify potential sources of heterogeneity, we sought a priori to conduct a subgroup analysis based on 'dose and duration', that is, a long course (three or more days) of low-dose (&lt; 400 mg/d) hydrocortisone or equivalent. This subgroup analysis allowed evaluation of a strategy based on developments in our understanding of the role of corticosteroids in host response to sepsis, as tested in trials performed after 1992. Older trials used a short course (one to four bolus doses within 24 hours) of high-dose corticosteroids (&gt; 400 mg of hydrocortisone or equivalent) as an anti-inflammatory approach, and trials conducted after 1992 used low-dose corticosteroids at full dose over a longer period (&#8805; three days). To further explore the putative interaction between corticosteroid dose and duration and the magnitude of effect, we considered performing a meta-regression analysis using 28-day all-cause mortality as the dependent variable, and dosage and duration of corticosteroids as predictors. We performed meta-regression analyses using STATA/IC version 10.1 (Stata Corp, College Station, Texas). We also tested a priori the interaction between baseline severity of illness and magnitude of effect in a meta-regression analysis using mortality rates in controls as predictors. Finally, we conducted a subgroup analysis based on targeted population, sepsis, only septic shock, sepsis with ARDS, community-acquired pneumonia and sepsis with critical illness-related corticosteroid insufficiency (<LINK REF="REF-Marik-2008" TYPE="REFERENCE">Marik 2008</LINK>).</LI><LI>We assessed the validity of subgroup analyses (based on treatment modalities, i.e. dose and duration, or on population) on the basis of the following criteria: (1) subgroup comparisons within studies rather than between studies; (2) hypothesis preceding the analysis; (3) one of very few hypotheses; (4) large and consistent differences across studies; and (5) external evidence supporting the results (<LINK REF="REF-Guyatt-2008b" TYPE="REFERENCE">Guyatt 2008b</LINK>). When subgroup analyses met these criteria and were found to be statistically significant, we applied GRADE (Grades of Recommendation, Assessment, Development and Evaluation) criteria to evaluate the quality of evidence (<LINK REF="REF-Guyatt-2008a" TYPE="REFERENCE">Guyatt 2008a</LINK>).</LI></UL></SUBGROUP_ANALYSIS><SENSITIVITY_ANALYSIS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>We conducted sensitivity analyses for generation of allocation sequence, concealment of allocation and blinding.</P><SUBSECTION><HEADING LEVEL="3">Assessment of quality of evidence using GRADE and selection of outcomes for 'Summary of findings' tables</HEADING><P>For assessments of the overall quality of evidence for each outcome that included pooled data from RCTs only, we downgraded the evidence from 'high quality' by one level for serious (or by two for very serious) study limitations (according to risk of bias evaluation), indirectness of evidence, serious inconsistency (i.e. when I<SUP>2</SUP> statistic &gt; 30%), imprecision of effect estimates (large 95% confidence intervals or small treatment effects) or potential publication bias. Data from observational studies were first determined to be of low quality.</P><P>We exported data from Review Manager to GRADE profiler (GRADEpro version 3.6) to create 'Summary of findings' tables. We included the following patient-centred outcomes in the 'Summary of findings' table.</P><UL><LI>28-Day all-cause mortality.</LI><LI>28-Day all-cause mortality for long courses of low-dose corticosteroids.</LI><LI>In-hospital all-cause mortality.</LI><LI>Number of participants with shock reversal at day seven.</LI><LI>Sepsis-related organ failure assessment score at day seven.</LI><LI>Length of stay in the ICU for survivors.</LI><LI>Number of participants with superinfection within 28 days.</LI></UL></SUBSECTION></SENSITIVITY_ANALYSIS></DATA_COLLECTION></METHODS><RESULTS MODIFIED="2018-05-05 00:40:31 +0100" MODIFIED_BY="[Empty name]"><STUDY_DESCRIPTION MODIFIED="2018-05-05 00:40:31 +0100" MODIFIED_BY="[Empty name]"><SEARCH_RESULTS MODIFIED="2015-11-22 11:17:30 +0000" MODIFIED_BY="[Empty name]"><P>Our search results are detailed in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P><P>The search strategy yielded 47 RCTs that evaluated corticosteroids in sepsis.</P></SEARCH_RESULTS><INCLUDED_STUDIES_DESCR MODIFIED="2018-05-05 00:40:31 +0100" MODIFIED_BY="[Empty name]"><P>Since the last update in 2010 (see <LINK TAG="PUBLIC_NOTES" TYPE="SECTION">Published notes</LINK>), we have included nine additional trials for a total of 33 trials (n = 4268 participants) and have described them below (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P><SUBSECTION><HEADING LEVEL="3">Source of information</HEADING><P>In addition to the data extracted from these publications, we obtained unpublished information from 19 trials by contacting the primary authors (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Cicarelli-2007" TYPE="STUDY">Cicarelli 2007</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>; <LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK>; <LINK REF="STD-Meijvis-2011" TYPE="STUDY">Meijvis 2011</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK>; <LINK REF="STD-Torres-2015" TYPE="STUDY">Torres 2015</LINK>; <LINK REF="STD-Yildiz-2002" TYPE="STUDY">Yildiz 2002</LINK>) (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>). In four cases, contact with study authors did not lead to provision of additional information (<LINK REF="STD-Luce-1988" TYPE="STUDY">Luce 1988</LINK>; <LINK REF="STD-Meijvis-2011" TYPE="STUDY">Meijvis 2011</LINK>; <LINK REF="STD-Rezk--2013" TYPE="STUDY">Rezk 2013</LINK>; <LINK REF="STD-Snijders-2010" TYPE="STUDY">Snijders 2010</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Trial centres</HEADING><P>Eleven trials were multi-centre trials (i.e. &gt; two centres) (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Bone-1987" TYPE="STUDY">Bone 1987</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-CSG-1963" TYPE="STUDY">CSG 1963</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK>; <LINK REF="STD-Sabry-2011" TYPE="STUDY">Sabry 2011</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-Torres-2015" TYPE="STUDY">Torres 2015</LINK>; <LINK REF="STD-VASSCSG-1987" TYPE="STUDY">VASSCSG 1987</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Age of participants</HEADING><P>One study enrolled both children and adults (<LINK REF="STD-CSG-1963" TYPE="STUDY">CSG 1963</LINK>). Two trials included only children (<LINK REF="STD-Slusher-1996" TYPE="STUDY">Slusher 1996</LINK>; <LINK REF="STD-Valoor-2009" TYPE="STUDY">Valoor 2009</LINK>). All remaining trials included only adults.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Description of participants</HEADING><P>Seven trials included both participants with sepsis and individuals with septic shock (<LINK REF="STD-Bone-1987" TYPE="STUDY">Bone 1987</LINK>; <LINK REF="STD-Liu-2012" TYPE="STUDY">Liu 2012</LINK>; <LINK REF="STD-Luce-1988" TYPE="STUDY">Luce 1988</LINK>; <LINK REF="STD-Slusher-1996" TYPE="STUDY">Slusher 1996</LINK>; <LINK REF="STD-VASSCSG-1987" TYPE="STUDY">VASSCSG 1987</LINK>; <LINK REF="STD-Yildiz-2002" TYPE="STUDY">Yildiz 2002</LINK>; <LINK REF="STD-Yildiz-2011" TYPE="STUDY">Yildiz 2011</LINK>). One trial included participants with sepsis (<LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>). Five trials targeted participants with community-acquired pneumonia-related sepsis (<LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-Meijvis-2011" TYPE="STUDY">Meijvis 2011</LINK>; <LINK REF="STD-Sabry-2011" TYPE="STUDY">Sabry 2011</LINK>; <LINK REF="STD-Snijders-2010" TYPE="STUDY">Snijders 2010</LINK>; <LINK REF="STD-Torres-2015" TYPE="STUDY">Torres 2015</LINK>). Three trials focused on participants with ARDS and sepsis (<LINK REF="STD-Liu-2012" TYPE="STUDY">Liu 2012</LINK>; <LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK>; <LINK REF="STD-Rezk--2013" TYPE="STUDY">Rezk 2013</LINK>). The remaining trials focused only on participants with septic shock treated by a vasopressor (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Cicarelli-2007" TYPE="STUDY">Cicarelli 2007</LINK>; <LINK REF="STD-CSG-1963" TYPE="STUDY">CSG 1963</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>; <LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>; <LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Schumer-1976" TYPE="STUDY">Schumer 1976</LINK>; <LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK>; <LINK REF="STD-Valoor-2009" TYPE="STUDY">Valoor 2009</LINK>). Two trials included only participants with septic shock with adrenal insufficiency as defined by a cortisol increment less than 9 µg/dL after a corticotropin bolus (<LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>; <LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK>). In 10 trials, investigators systematically performed a short corticotropin test at baseline (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>; <LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-Yildiz-2011" TYPE="STUDY">Yildiz 2011</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Control</HEADING><P>Two studies did not use a placebo and compared corticosteroid therapy versus standard therapy, that is, antibiotics, fluid resuscitation and vasopressor when needed (<LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>). In one study, only one centre used a placebo (<LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>). One trial that compared hydrocortisone versus hydrocortisone plus fludrocortisone did not use a placebo of fludrocortisone for technical reasons (<LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>). Another trial compared duration of hydrocortisone treatment (i.e. three vs seven days) and did not use a placebo (<LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>). In the remaining trials, corticosteroid therapy was compared with placebo.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Corticosteroid dose and treatment course</HEADING><P>Eighteen trials tested the effects of long-course (three or more days at full dose) of low-dose hydrocortisone (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>; <LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>; <LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>; <LINK REF="STD-Liu-2012" TYPE="STUDY">Liu 2012</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Sabry-2011" TYPE="STUDY">Sabry 2011</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK>; <LINK REF="STD-Valoor-2009" TYPE="STUDY">Valoor 2009</LINK>). In one trial (<LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>), investigators compared hydrocortisone 50 mg intravenously every six hours when given for three days versus seven days. Another trial compared seven-day treatment with hydrocortisone versus seven-day treatment with the combination of hydrocortisone plus fludrocortisone (<LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>). One trial compared a short course (two days at full dose) of low-dose (300 mg on day one and 250 mg on day two) intravenous hydrocortisone (<LINK REF="STD-CSG-1963" TYPE="STUDY">CSG 1963</LINK>). Another study used a cross-over design to compare a three-day course of low-dose hydrocortisone versus placebo (<LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>).</P><P>Three trials tested effects of a long course of low-dose prednisolone (<LINK REF="STD-Snijders-2010" TYPE="STUDY">Snijders 2010</LINK>; <LINK REF="STD-Yildiz-2002" TYPE="STUDY">Yildiz 2002</LINK>; <LINK REF="STD-Yildiz-2011" TYPE="STUDY">Yildiz 2011</LINK>).</P><P>Two trials tested effects of a long course of low-dose dexamethasone (<LINK REF="STD-Cicarelli-2007" TYPE="STUDY">Cicarelli 2007</LINK>; <LINK REF="STD-Meijvis-2011" TYPE="STUDY">Meijvis 2011</LINK>). Another trial tested effects of a short course of low-dose dexamethasone (<LINK REF="STD-Slusher-1996" TYPE="STUDY">Slusher 1996</LINK>).</P><P>Three studies tested effects of a long course of low-dose intravenous methylprednisolone (<LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK>; <LINK REF="STD-Rezk--2013" TYPE="STUDY">Rezk 2013</LINK>; <LINK REF="STD-Torres-2015" TYPE="STUDY">Torres 2015</LINK>).</P><P>Five trials tested effects of a short course of a large dose of methylprednisolone (<LINK REF="STD-Bone-1987" TYPE="STUDY">Bone 1987</LINK>; <LINK REF="STD-Luce-1988" TYPE="STUDY">Luce 1988</LINK>; <LINK REF="STD-Schumer-1976" TYPE="STUDY">Schumer 1976</LINK>; <LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>; <LINK REF="STD-VASSCSG-1987" TYPE="STUDY">VASSCSG 1987</LINK>), and two tested effects of dexamethasone (<LINK REF="STD-Schumer-1976" TYPE="STUDY">Schumer 1976</LINK>; <LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Outcomes</HEADING><P>Nineteen trials explicitly reported 28-day mortality rates (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Cicarelli-2007" TYPE="STUDY">Cicarelli 2007</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>; <LINK REF="STD-Liu-2012" TYPE="STUDY">Liu 2012</LINK>; <LINK REF="STD-Meijvis-2011" TYPE="STUDY">Meijvis 2011</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Snijders-2010" TYPE="STUDY">Snijders 2010</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK>; <LINK REF="STD-Valoor-2009" TYPE="STUDY">Valoor 2009</LINK>; <LINK REF="STD-Yildiz-2002" TYPE="STUDY">Yildiz 2002</LINK>; <LINK REF="STD-Yildiz-2011" TYPE="STUDY">Yildiz 2011</LINK>). For three trials, contact with the primary author of the paper led to recording of 28-day mortality rates (<LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>). Two trials reported only 14-day mortality rates (<LINK REF="STD-Bone-1987" TYPE="STUDY">Bone 1987</LINK>; <LINK REF="STD-VASSCSG-1987" TYPE="STUDY">VASSCSG 1987</LINK>). Five trials reported only hospital mortality rates (<LINK REF="STD-CSG-1963" TYPE="STUDY">CSG 1963</LINK>; <LINK REF="STD-Luce-1988" TYPE="STUDY">Luce 1988</LINK>; <LINK REF="STD-Schumer-1976" TYPE="STUDY">Schumer 1976</LINK>; <LINK REF="STD-Slusher-1996" TYPE="STUDY">Slusher 1996</LINK>; <LINK REF="STD-Torres-2015" TYPE="STUDY">Torres 2015</LINK>). One trial did not report mortality rates (<LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>). For one trial, the time point for mortality rate was unclear and remained unclear after contact with the trial primary author (<LINK REF="STD-Rezk--2013" TYPE="STUDY">Rezk 2013</LINK>).</P><P>Eleven trials explicitly reported ICU mortality rates (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>; <LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK>; <LINK REF="STD-Sabry-2011" TYPE="STUDY">Sabry 2011</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>), and the primary authors of three additional trials provided this outcome (<LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Torres-2015" TYPE="STUDY">Torres 2015</LINK>).</P><P>Hospital mortality rates were available for 20 trials (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-CSG-1963" TYPE="STUDY">CSG 1963</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Luce-1988" TYPE="STUDY">Luce 1988</LINK>; <LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK>; <LINK REF="STD-Meijvis-2011" TYPE="STUDY">Meijvis 2011</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Schumer-1976" TYPE="STUDY">Schumer 1976</LINK>; <LINK REF="STD-Slusher-1996" TYPE="STUDY">Slusher 1996</LINK>; <LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK>; <LINK REF="STD-Torres-2015" TYPE="STUDY">Torres 2015</LINK>; <LINK REF="STD-Yildiz-2002" TYPE="STUDY">Yildiz 2002</LINK>).</P><P>Twelve trials reported the rate of shock reversal at day seven (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK>; <LINK REF="STD-Bone-1987" TYPE="STUDY">Bone 1987</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Sabry-2011" TYPE="STUDY">Sabry 2011</LINK>; <LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>), and eight trials (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK>) the rate of shock reversal at day 28.</P><P>Nine trials reported the numbers of dysfunctional organs at seven days, that is, SOFA scores (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK>; <LINK REF="STD-Cicarelli-2007" TYPE="STUDY">Cicarelli 2007</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Sabry-2011" TYPE="STUDY">Sabry 2011</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>).</P><P>Fourteen trials reported length of ICU stay (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>; <LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>; <LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-Torres-2015" TYPE="STUDY">Torres 2015</LINK>), and 14 reported length of hospital stay (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK>; <LINK REF="STD-Meijvis-2011" TYPE="STUDY">Meijvis 2011</LINK>; <LINK REF="STD-Slusher-1996" TYPE="STUDY">Slusher 1996</LINK>; <LINK REF="STD-Snijders-2010" TYPE="STUDY">Snijders 2010</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-Torres-2015" TYPE="STUDY">Torres 2015</LINK>; <LINK REF="STD-Yildiz-2002" TYPE="STUDY">Yildiz 2002</LINK>).</P></SUBSECTION></INCLUDED_STUDIES_DESCR><EXCLUDED_STUDIES_DESCR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>We excluded 14 trials (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P><SUBSECTION><HEADING LEVEL="3">Ongoing studies</HEADING><P>We identified nine additional randomized trials of prolonged treatment with a low dose of corticosteroids from trials registries (but these nine studies were not included in the analysis; see <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>). Three of these trials never recruited participants because they lacked funding (<LINK REF="STD-NCT00127985-2005" TYPE="STUDY">NCT00127985 2005</LINK>; <LINK REF="STD-NCT00368381-2008" TYPE="STUDY">NCT00368381 2008</LINK>; <LINK REF="STD-NCT00562835-2008" TYPE="STUDY">NCT00562835 2008</LINK>). One trial was halted prematurely as the result of a too slow recruitment rate; no data are available at the time of this review update (<LINK REF="STD-NCT00732277--2008" TYPE="STUDY">NCT00732277 2008</LINK>). Two trials are now completed, but no data are available at the time of this review update (<LINK REF="STD-Blum--2015" TYPE="STUDY">Blum 2015</LINK>; <LINK REF="STD-NCT00670254-2008" TYPE="STUDY">NCT00670254 2008</LINK>). One trial was initiated with a 2 × 2 factorial design to also allow evaluation of the effects of drotrecogin alfa activated (DAA), a recombinant activated protein C (<LINK REF="STD-NCT00625209-2008" TYPE="STUDY">NCT00625209 2008</LINK>). Owing to the withdrawal of DAA from the market on October 25, 2011, the trial committees (Steering Committee and Data Safety and Monitoring Board) decided, with the approval of French health authorities and of the Comité de Protection des Personnes de Saint Germain en Laye, to release the data on DAA and to continue the trial using a two-parallel-group design corresponding to hydrocortisone and fludrocortisone (experimental arm) and their placebos (control arm) (<LINK REF="REF-Annane-2013" TYPE="REFERENCE">Annane 2013</LINK>). Trials included only adults, except one that evaluated treatment with hydrocortisone in children with sepsis (<LINK REF="STD-NCT00732277--2008" TYPE="STUDY">NCT00732277 2008</LINK>).</P></SUBSECTION></EXCLUDED_STUDIES_DESCR></STUDY_DESCRIPTION><STUDY_QUALITY MODIFIED="2018-05-05 00:40:26 +0100" MODIFIED_BY="[Empty name]"><P>The detailed methodological quality of individual trials is reported in the 'Risk of bias' tables, in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</P><SUBSECTION><HEADING LEVEL="3">Randomization</HEADING><P>In one trial, we considered that randomization (method of generation of allocation sequence) was inappropriate to minimize selection bias, that is, as based on a card system (<LINK REF="STD-Schumer-1976" TYPE="STUDY">Schumer 1976</LINK>); we judged the method for generation of allocation sequence as having high risk of bias. In six trials, the method was unclear (<LINK REF="STD-CSG-1963" TYPE="STUDY">CSG 1963</LINK>; <LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>; <LINK REF="STD-Rezk--2013" TYPE="STUDY">Rezk 2013</LINK>; <LINK REF="STD-Sabry-2011" TYPE="STUDY">Sabry 2011</LINK>; <LINK REF="STD-Slusher-1996" TYPE="STUDY">Slusher 1996</LINK>; <LINK REF="STD-Valoor-2009" TYPE="STUDY">Valoor 2009</LINK>), and it was deemed to have low risk of bias in the remaining trials. We judged the method used for allocation concealment to be at low risk of bias in all but 10 trials. In one trial, assignment of treatment was based on the use of unsealed envelopes (<LINK REF="STD-Schumer-1976" TYPE="STUDY">Schumer 1976</LINK>). In another trial, investigators enrolling participants at one of the two participating centres could have foreseen the upcoming assignment, as the local ethical committee refused to accept blind allocation (<LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>). In eight trials, study authors did not report the method used for allocation concealment (<LINK REF="STD-CSG-1963" TYPE="STUDY">CSG 1963</LINK>; <LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>; <LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>; <LINK REF="STD-Liu-2012" TYPE="STUDY">Liu 2012</LINK>; <LINK REF="STD-Rezk--2013" TYPE="STUDY">Rezk 2013</LINK>; <LINK REF="STD-Sabry-2011" TYPE="STUDY">Sabry 2011</LINK>; <LINK REF="STD-Slusher-1996" TYPE="STUDY">Slusher 1996</LINK>; <LINK REF="STD-Valoor-2009" TYPE="STUDY">Valoor 2009</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Blinding</HEADING><P>In four trials, we judged the method used for blinding as having high risk of bias (<LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>; <LINK REF="STD-Valoor-2009" TYPE="STUDY">Valoor 2009</LINK>). Four trials used open-label treatments (<LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Valoor-2009" TYPE="STUDY">Valoor 2009</LINK>). In the fifth trial (<LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>), the local ethical committee at one of the two centres did not permit double-blind allocation and administration of treatment. Therefore, blinding was not possible for 40 of the 59 participants included in the trial.</P><P>Six additional trials did not report the method used to ensure blinding (<LINK REF="STD-CSG-1963" TYPE="STUDY">CSG 1963</LINK>; <LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>; <LINK REF="STD-Liu-2012" TYPE="STUDY">Liu 2012</LINK>; <LINK REF="STD-Rezk--2013" TYPE="STUDY">Rezk 2013</LINK>; <LINK REF="STD-Sabry-2011" TYPE="STUDY">Sabry 2011</LINK>; <LINK REF="STD-Schumer-1976" TYPE="STUDY">Schumer 1976</LINK>).</P><P>The remaining trials were deemed appropriately double-blinded.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Withdrawal</HEADING><P>Fiftteen trials (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>; <LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK>; <LINK REF="STD-Meijvis-2011" TYPE="STUDY">Meijvis 2011</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Snijders-2010" TYPE="STUDY">Snijders 2010</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-Torres-2015" TYPE="STUDY">Torres 2015</LINK>; <LINK REF="STD-VASSCSG-1987" TYPE="STUDY">VASSCSG 1987</LINK>) explicitly provided the numbers of, and reasons for, withdrawals or losses to follow-up. In one trial, only 500 of the 800 expected participants were recruited, mainly as the result of loss of equipoise among investigators (<LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>). Another trial was halted prematurely for futility after enrolment of 75 of 150 foreseen participants (<LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Intention-to-treat analysis and adherence to the protocol</HEADING><P>Nineteen trials explicitly reported use of intention-to-treat analysis (as the primary analysis) and numbers of, and reasons for, non-adherence to the protocol (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Bone-1987" TYPE="STUDY">Bone 1987</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>; <LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK>; <LINK REF="STD-Meijvis-2011" TYPE="STUDY">Meijvis 2011</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Sabry-2011" TYPE="STUDY">Sabry 2011</LINK>; <LINK REF="STD-Snijders-2010" TYPE="STUDY">Snijders 2010</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-Torres-2015" TYPE="STUDY">Torres 2015</LINK>; <LINK REF="STD-VASSCSG-1987" TYPE="STUDY">VASSCSG 1987</LINK>). One trial reported only use of intention-to-treat analysis (<LINK REF="STD-Luce-1988" TYPE="STUDY">Luce 1988</LINK>). The remaining trials provided no information about these criteria. However, the number of analysed participants matched the number of randomly assigned participants, except for five trials. In one trial, 191 participants were randomly assigned to the placebo group and 190 were analysed for the mortality outcome (<LINK REF="STD-Bone-1987" TYPE="STUDY">Bone 1987</LINK>). In two trials (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>), one participant withdrew his or her consent and 499 of 500 and 299 of 300 randomly assigned participants were analysed, respectively. In two trials, contact with the primary author allowed us to obtain information on participants who were dropped out from the analysis (<LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>). In the first study, seven randomly assigned participants (five in the corticosteroid group and two in the placebo group) were not analysed (<LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>). Four of these participants (two in the corticosteroid group and two in the placebo group) were discharged alive from the ICU and then were lost to follow up. The three remaining participants (in the corticosteroid group) died - two before receiving hydrocortisone and the last at study day 17. In the second study, 12 of 52 participants were dropped out of the study - six in the control group and six in the corticosteroid group (<LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>). Nine participants (four in the control group) were excluded, as they developed renal failure. Two control participants died in the ICU at day five and day seven, respectively. Three of the corticosteroid-treated participants died, at days five, six and 28, respectively. Three other participants (two control group) were excluded, as they developed septic shock. All died at days three, five and six, respectively. In two trials, additional open-label corticosteroids were given to some participants (<LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Snijders-2010" TYPE="STUDY">Snijders 2010</LINK>). In the first trial, five participants in the placebo arm were given rescue corticosteroids for treatment of life-threatening hypotension and were considered as cross-overs (<LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>). In the second trial, 37 (17.4%) participants did not complete the full course of study treatment as a consequence of premature death in 10 participants, consent withdrawal in five participants, post-randomization exclusion in eight participants and additional open-label corticosteroid treatment in 14 participants (<LINK REF="STD-Snijders-2010" TYPE="STUDY">Snijders 2010</LINK>).<BR/><BR/></P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Explicit definition of septic shock</HEADING><P>Seventeen trials provided an explicit definition of sepsis (as defined in the Methods section of this review) (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Cicarelli-2007" TYPE="STUDY">Cicarelli 2007</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>; <LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>; <LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK>; <LINK REF="STD-Valoor-2009" TYPE="STUDY">Valoor 2009</LINK>; <LINK REF="STD-Yildiz-2011" TYPE="STUDY">Yildiz 2011</LINK>). Seven trials provided a definition of septic shock without referring to the need for vasopressor agents (<LINK REF="STD-Bone-1987" TYPE="STUDY">Bone 1987</LINK>; <LINK REF="STD-Luce-1988" TYPE="STUDY">Luce 1988</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Schumer-1976" TYPE="STUDY">Schumer 1976</LINK>; <LINK REF="STD-Slusher-1996" TYPE="STUDY">Slusher 1996</LINK>; <LINK REF="STD-VASSCSG-1987" TYPE="STUDY">VASSCSG 1987</LINK>; <LINK REF="STD-Yildiz-2002" TYPE="STUDY">Yildiz 2002</LINK>). One study did not explicitly provide the definition used for sepsis (<LINK REF="STD-CSG-1963" TYPE="STUDY">CSG 1963</LINK>). Six trials explicitly defined sepsis due to community-acquired pneumonia (<LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-Meijvis-2011" TYPE="STUDY">Meijvis 2011</LINK>; <LINK REF="STD-Mikami-2007" TYPE="STUDY">Mikami 2007</LINK>; <LINK REF="STD-Sabry-2011" TYPE="STUDY">Sabry 2011</LINK>; <LINK REF="STD-Snijders-2010" TYPE="STUDY">Snijders 2010</LINK>; <LINK REF="STD-Torres-2015" TYPE="STUDY">Torres 2015</LINK>). In two trials, participants were randomly assigned on the basis of the presence of ARDS, and data provided in papers confirmed the presence of sepsis (<LINK REF="STD-Liu-2012" TYPE="STUDY">Liu 2012</LINK>; <LINK REF="STD-Rezk--2013" TYPE="STUDY">Rezk 2013</LINK>). In another trial on early ARDS, contact with the primary author confirmed that explicit definitions of sepsis were used (<LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK>).</P></SUBSECTION></STUDY_QUALITY><INTERVENTION_EFFECTS MODIFIED="2015-11-30 11:24:17 +0000" MODIFIED_BY="Jane Cracknell"><P>We did not pool the data from three trials that included children (<LINK REF="STD-CSG-1963" TYPE="STUDY">CSG 1963</LINK>; <LINK REF="STD-Slusher-1996" TYPE="STUDY">Slusher 1996</LINK>; <LINK REF="STD-Valoor-2009" TYPE="STUDY">Valoor 2009</LINK>), one cross-over trial (<LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>), one trial that compared two durations of hydrocortisone treatment (<LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>) and one trial that compared hydrocortisone versus the combination of hydrocortisone plus fludrocortisone (<LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>).</P><SUBSECTION><HEADING LEVEL="3">28-Day all-cause mortality</HEADING><P>Data for 28-day mortality were available for 20 trials; among these, two trials had no corticosteroid-free arm. In addition, we used data on 14-day mortality (two trials), hospital mortality (four trials) or ICU mortality (two trials), or data on short-term mortality (one trial). Thus, we computed data from 27 trials that accounted for 3176 participants. In the treated group, 474 of 1618 participants died by day 28 compared with 495 of 1558 participants in the control group. Significant heterogeneity was evident in the results (Chi<SUP>2</SUP> test = 44.99, P value = 0.01, I<SUP>2 </SUP>statistic = 42%). The RR of dying at 28 days was 0.87 (95% CI 0.76 to 1.00, P value = 0.05, random-effects model) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). We downgraded the quality of evidence for this outcome from high to low for imprecision (upper limit of 95% CI = 1) and for inconsistency (significant heterogeneity across trial results).</P><P>We analysed separately the 18 studies for which 28-day mortality data were available and the two studies reporting only 14-day mortality (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). A total of 327 of 1009 deaths occurred at 28 days in the corticosteroid-treated group and 331 of 957 deaths in the control group (RR 0.90, 95% CI 0.80 to 1.00; P value = 0.06, fixed-effect model), and mild heterogeneity was evident in the results (Chi<SUP>2</SUP> test = 19.89, P value = 0.28, I<SUP>2 </SUP>statistic = 15%). Among studies reporting only 14-day mortality rates, 88 of 303 deaths were reported in the corticosteroid-treated group and 72 of 301 deaths in the control group (RR 1.21, 95% CI 0.93 to 1.59; P value = 0.15, random-effects model), and moderate heterogeneity was noted in the results (Chi<SUP>2</SUP> test = 1.32, P value = 0.25, I<SUP>2 </SUP>statistic = 24%). Subgroup differences were statistically significant (P value = 0.04).</P><P>Differences in methodological quality across trials may have accounted for observed heterogeneity in the results. Subgroup analyses based on trials reporting an adequate method for generation of the allocation sequence showed an RR for dying at 28 days of 0.97 (95% CI 0.86 to 1.10) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Similarly, subgroup analyses based on studies with adequate allocation concealment showed an RR for dying at 28 days of 0.96 (95% CI 0.84 to 1.09), and subgroup analyses on double-blind trials showed an RR for dying at 28 days of 0.95 (95% CI 0.84 to 1.08) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P><P>Heterogeneity across trials may have been the result of different therapeutic regimens and different populations. Subgroup analysis on the 22 trials that tested a long course of low-dose corticosteroids showed less heterogeneity across trials (Chi<SUP>2</SUP> test = 25.09, P value = 0.240, I<SUP>2 </SUP>statistic = 16%) and an RR for dying at 28 days of 0.87 (95% CI 0.78 to 0.9; P value = 0.01, fixed-effect model) in favour of the corticosteroid group (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). We downgraded the quality of evidence from high to moderate for inconsistency (owing to one large trial showing non-significant effects). Subgroup analyses on trials that tested a short course of high-dose corticosteroids showed significant heterogeneity across trials (Chi<SUP>2 </SUP>test = 18.73, P value = 0.0009, I<SUP>2 </SUP>statistic = 79%) and an RR for dying at 28 days of 0.96 (95% CI 0.80 to 1.16; random-effects model) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Subgroup differences were not statistically significant (P value = 0.35).</P><P>Meta-regression analysis confirmed the positive interaction between the dose given at day one (regression coefficient 0.051; P value = 0.04) (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>) and total dose (regression coefficient 0.072; P value = 0.05) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) and the RR for dying at 28 days, that is, the lower the dose of treatment with corticosteroids, the lower was the risk of dying. No significant interaction was observed between duration of treatment (regression co-efficient -0.057; P value = 0.15), mineralocorticoid activity of the experimental drug (regression co-efficient -0.21; P value = 0.48) or mortality in the control arm (regression co-efficient 0.0008; P value = 0.76) and the RR for dying.</P><P>Subgroup analysis based on targeted populations found significant subgroup differences (P value = 0.01) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). In studies of heterogenous populations of participants with sepsis, the RR for dying at 28 days was 1.11 (95% CI 0.91 to 1.34; six trials; n = 826; I<SUP>2</SUP> statistic = 0%). In studies of only participants with septic shock, the RR for dying at 28 days was 0.88 (95% CI 0.78 to 0.99; 12 trials; n = 1444; I<SUP>2</SUP> statistic = 57%). In studies of participants with sepsis and ARDS, the RR was 0.46 (95% CI 0.25 to 0.85; three trials; n = 114; I<SUP>2</SUP> = 0%), and in studies of participants with sepsis and community-acquired pneumonia, the RR was 0.62 (95% CI 0.38 to 1.02; five trials; n = 763; I<SUP>2</SUP> statistic = 2%).</P><P>Subgroup analysis of participants with adrenal insufficiency showed no heterogeneity in the results. Investigators reported 138 deaths among 294 participants in the treated group and 153 deaths among 289 in the placebo group. The RR for dying was 0.88 (95% CI 0.76 to 1.02; eight trials; n = 583; I<SUP>2</SUP> statistic = 0%) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P><P>One trial of a large dose of corticosteroids was a statistical outlier and was excluded from the meta-regression analysis (<LINK REF="STD-Schumer-1976" TYPE="STUDY">Schumer 1976</LINK>).</P><P>Funnel plot analysis, including all trials, suggested some asymmetry (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). Contour-enhanced funnel plot analysis including trials of a long course of low-dose corticosteroids also suggested significant asymmetry (P value = 0.01) (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P><P>In one trial comparing hydrocortisone alone versus hydrocortisone plus fludrocortisone, the hazard ratio of death was 0.94 (95% CI 0.73 to 1.21) (<LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Intensive care unit (ICU) mortality</HEADING><P>Data were available from 13 trials, accounting for 1463 participants. All of these trials investigated a long course of low-dose corticosteroids. A total of 264 of 748 participants in the treated group and 289 of 715 participants in the control group died in the ICU. Some heterogeneity was evident in the results (Chi<SUP>2</SUP> test = 17.21, P value = 0.14, I<SUP>2 </SUP>statistic = 30%). The RR for dying in the ICU was 0.82 (95% CI, 0.68 to 1.00, P value = 0.045; random-effects model) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Hospital mortality</HEADING><P>We could extract data on hospital mortality from 17 trials that accounted for 2014 participants. A total of 383 of 1041 participants in the treated group compared with 402 of 973 in the control group died in hospital. Heterogeneity in the results was significant (Chi<SUP>2</SUP> test = 30.11, P value = 0.02, I<SUP>2 </SUP>statistic = 47%). The RR for dying in hospital was 0.85 (95% CI, 0.73 to 0.98; P value = 0.03, random-effects model) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). The quality of evidence for this outcome was downgraded from high to moderate for inconsistency and imprecision (upper limit of 95% CI for RR approaching 1).</P><P>In one trial comparing hydrocortisone alone versus hydrocortisone plus fludrocortisone, the RR for death was 0.94 (95% CI 0.77 to 1.14) (<LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Shock reversal at day seven</HEADING><P>We could extract data from 12 trials that accounted for 1561 participants. A total of 532 of 806 participants in the treated group and 395 of 755 in the control group had shock reversed at day seven. Significant heterogeneity was evident in the results (Chi<SUP>2</SUP> test = 25.33, P value = 0.008, I<SUP>2 </SUP>statistic= 57%). The RR for having shock reversed at day seven was 1.31 (95% CI 1.14 to 1.51; P value = 0.0001, random-effects model) in favour of the corticosteroid group (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). We did not downgrade the quality of evidence for this outcome for inconsistency, as the direction of the effect was consistent across trials.</P><P>Heterogeneity in the results could be explained by differences in treatment strategies used in the various trials. Two trials evaluated one or two boluses of high-dose corticosteroids (<LINK REF="STD-Bone-1987" TYPE="STUDY">Bone 1987</LINK>; <LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>), and the 10 remaining trials studied treatment with a long course of low-dose corticosteroids. Analysis of these 10 trials (n = 1258) revealed no greater heterogeneity in the results (I<SUP>2</SUP> statistic = 0%). Then, 422 of 633 participants in the treated group and 306 of 625 participants in the control group had shock reversed at day seven. The RR for having shock reversed was 1.34 (95% CI 1.22 to 1.46; P value &lt; 0.00001) in favour of the corticosteroid group (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P><P>In one cross-over trial, hydrocortisone was given for three days at a dose of 240 mg per day (<LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>). Although this trial could not provide information on shock reversal at day seven, investigators showed that at day three, fewer hydrocortisone patients than placebo-treated patients required norepinephrine treatment (6/20 vs 14/20; P value = 0.025).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Shock reversal at day 28</HEADING><P>We could extract data from seven trials, accounting for 1013 participants. A total of 345 of 512 participants in the treated group had shock reversed at day 28, as did 297 of 501 in the placebo group. No heterogeneity was evident in the results (I<SUP>2</SUP> statistic = 0%). The RR for having shock reversed was 1.11 (95% CI 1.02 to 1.21; P value = 0.01) in favour of the corticosteroid group (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Number of organs affected and intensity of organ dysfunction according to SOFA score at day seven</HEADING><P>In one study (<LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>), corticosteroid treatment was associated with a non-significant (P value = 0.18) trend toward earlier resolution of organ dysfunction. Eight studies (n = 1132) reported the SOFA score at seven days post randomization. The MD in the SOFA score at day seven was -1.53 (95% CI -2.04 to -1.03; P value &lt; 0.00001, random-effects model) in favour of corticosteroids. Moderate heterogeneity across studies was noted (Chi² test = 10.80, P value = 0.15, I² statistic = 35%) (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>). We did not downgrade the quality of evidence for this outcome, as the direction of the effect was consistent across trials.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Length of stay in the intensive care unit (ICU)</HEADING><P>In 12 trials (n = 1384), the MD for ICU length of stay for all participants was -1.68 (95% CI -3.27 to -0.09; P value = 0.04, random-effects model) with some heterogeneity evident across studies (Chi² test = 16.03, P value = 0.14, I² statistic = 31%) (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>). We could extract data from 10 trials on 778 ICU survivors. The mean difference for ICU length of stay among these survivors was -2.19 (95% CI -3.93 to -0.46; P value = 0.01, fixed-effect model). No heterogeneity was evident across studies (Chi² test = 8.63, P value = 0.47, I² statistic = 0%) (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). We judged the quality of evidence for this outcome as high.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Length of hospital stay</HEADING><P>From 12 trials (n = 1802), we could extract data on all participants. Some heterogeneity in the results was evident (I<SUP>2</SUP> statistic = 22%). No evidence showed a difference between the two groups (MD -0.97, 95% CI -2.55 to 0.61, random-effects model) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>). We could extract data for hospital survivors from nine studies (n = 710). We noted some heterogeneity in the results (I<SUP>2</SUP> statistic = 43%). No evidence suggested a difference between the two groups (MD -4.11, 95% CI -8.50 to 0.28) (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Adverse events</HEADING><SUBSECTION><HEADING LEVEL="4">Gastroduodenal bleeding</HEADING><P>We could extract data from 19 trials (n = 2382). A total of 81 of 1219 participants in the treated group and 62 of 1163 in the control group had an episode of gastroduodenal bleeding. We noted no heterogeneity in the results (I<SUP>2</SUP> statistic = 0%). The RR for having gastroduodenal bleeding was 1.24 (95% CI 0. 92 to 1.67; P value = 0.15, fixed-effect model) (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Superinfection</HEADING><P>We could extract data from 19 trials (n = 2567). A total of 219 of 1307 participants in the treated group and 203 of 1260 participants in the control group had an episode of nosocomial infection. We noted moderate heterogeneity in the results (Chi² test = 18.98, P value = 0.21, I² statistic = 21%). The RR for superinfection was 1.02 (95% CI 0.87 to 1.20; P value = 0.81, fixed-effect model) (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Hyperglycaemia</HEADING><P>The number of participants who presented with hyperglycaemia was reported for 13 trials (n = 2081). Moderate heterogeneity was noted in the results (Chi² test = 13.60, P value = 0.19; I² statistic = 26%). The RR for hyperglycaemia was 1.26 (95% CI 1.16 to 1.37; P value &lt; 0.00001, fixed-effect model) (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P><P>One trial comparing tight glucose control versus standard care found no benefit in normalizing blood glucose levels among corticosteroid-treated septic shock participants (<LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Hypernatraemia</HEADING><P>The number of participants who presented with hypernatraemia was reported for three trials (n = 805). We noted no heterogeneity in the results (I<SUP>2</SUP> statistic = 0%). The RR for hypernatraemia was 1.64 (95% CI 1.28 to 2.09; P value &lt; 0.00001, fixed-effect model) (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Neuromuscular weakness</HEADING><P>The number of participants who presented with neuromuscular weakness was reported for three trials (n = 811). Moderate heterogeneity was evident in the results (I<SUP>2</SUP> statistic = 30%). The RR for neuromuscular weakness was 0.62 (95% CI 0.21 to 1.88; P value = 0.24) (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P><P>We have summarized the main results in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P></SUBSECTION></SUBSECTION></INTERVENTION_EFFECTS></RESULTS><DISCUSSION MODIFIED="2015-11-30 11:24:25 +0000" MODIFIED_BY="Jane Cracknell"><SUMMARY_OF_RESULTS MODIFIED="2015-11-30 11:24:25 +0000" MODIFIED_BY="Jane Cracknell"><SUBSECTION><HEADING LEVEL="3">Effects of corticosteroids on mortality</HEADING><P>Overall, this review suggested that, in sepsis, corticosteroids reduced all-cause 28-day mortality, although the P value was 0.05, and significantly reduced intensive care unit (ICU) and in-hospital mortality. For these outcomes, results showed strong heterogeneity.</P><P>Subgroup analysis based on treatment modalities showed that a long course of low-dose corticosteroids significantly reduced 28-day mortality with little heterogeneity in results. By contrast, a short course of high-dose corticosteroids did not affect mortality, in keeping with previous reports (<LINK REF="REF-Cronin-1995" TYPE="REFERENCE">Cronin 1995</LINK>; <LINK REF="REF-Lefering-1995" TYPE="REFERENCE">Lefering 1995</LINK>).</P><P>Patients with more severe forms of sepsis, such as those with vasopressor-dependent septic shock and those with acute respiratory distress syndrome (ARDS), may be more likely to derive a survival benefit from corticosteroids than patients with less severe sepsis. Patients whose sepsis is secondary to community-acquired pneumonia also are more likely to benefit from corticosteroids. Indeed, analysis based on the targeted population showed statistically significant subgroup differences. Analysis of eight trials including patients with critical illness-related corticosteroid insufficiency suggested a non-significant reduction in the risk of death. However, studies did not use the same definition for adrenal insufficiency. Additional studies are needed to determine the best diagnostic tool for critical illness-related corticosteroid insufficiency (<LINK REF="REF-Marik-2008" TYPE="REFERENCE">Marik 2008</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Effects of corticosteroids on morbidity outcomes</HEADING><P>The beneficial effects of corticosteroids on mortality may be related to the favourable effects of treatment on duration of shock. Indeed, this review showed that treatment with corticosteroids resulted in a substantial reduction in shock duration, with fewer patients remaining on vasopressor therapy by day seven and by day 28. Treatment with a long course of low-dose corticosteroids may attenuate the severity of inflammation (<LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>; <LINK REF="STD-Mikami-2007" TYPE="STUDY">Mikami 2007</LINK>a; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>) and the intensity and duration of organ system failure (<LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>), as shown in this review by a marked decrease in sequential organ failure assessment (SOFA) score at day seven. In addition, subsequent to favourable effects on cardiovascular and other organ functions, corticosteroid therapy resulted in substantial shortening of ICU length of stay.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Tolerance of corticosteroids</HEADING><P>Finally, this review also showed no evidence of effects of corticosteroids on rates of gastroduodenal bleeding or superinfection, or on the proportion of patients with acquired neuromuscular weakness. Corticosteroids were associated with increased risk for developing hyperglycaemia and hypernatraemia. One randomized controlled trial suggested that continuous infusion of hydrocortisone resulted in fewer episodes of hyperglycaemia than were seen with bolus administration (<LINK REF="REF-Loisa-2007" TYPE="REFERENCE">Loisa 2007</LINK>). One trial on 509 corticosteroid-treated patients with septic shock reported no benefit for normalizing blood glucose levels (<LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>).</P></SUBSECTION></SUMMARY_OF_RESULTS><APPLICABILITY_OF_FINDINGS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Although the subgroup analysis is a between-study and not a within-study hypothesis, we thought its validity was acceptable according to proposed criteria (<LINK REF="REF-Guyatt-2008b" TYPE="REFERENCE">Guyatt 2008b</LINK>). First, we defined the hypothesis for an interaction between dose and duration and effects of corticosteroids on mortality a priori. Second, we conducted only three subgroup analyses (based on methodological quality of studies, dose and duration and targeted population). Third, treatment effect was seen as a 4% absolute difference in mortality and rather consistent findings in terms of 28-day, ICU and hospital mortality (risk ratios (RRs) 0.87, 0.82 and 0.91, respectively). Meta-regression analysis further confirmed the interaction of dose and duration with effects of corticosteroids on mortality. Fourth, strong external evidence supports these results. Experimental and human studies have shown that a dose of 400 mg or less of hydrocortisone or equivalent can reverse the systemic inflammatory response, endothelial activation and coagulation disorders secondary to infection (<LINK REF="REF-Annane-2005" TYPE="REFERENCE">Annane 2005</LINK>), thus arguing against the use of higher doses. Moreover, at these low doses, corticosteroids have been shown to improve rather than suppress innate immunity in patients with septic shock (<LINK REF="STD-Kaufman-2008" TYPE="STUDY">Kaufman 2008</LINK>). It is now established that sepsis results in a sustained pro-inflammatory state, arguing against a short course of treatment (<LINK REF="REF-Kellum-2007" TYPE="REFERENCE">Kellum 2007</LINK>).</P></APPLICABILITY_OF_FINDINGS><QUALITY_OF_EVIDENCE MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>We judged the quality of evidence for 28-day mortality as low rather than high because some imprecision and inconsistency across trials were related in part to differences in study populations and to differences in treatment dose and duration. We downgraded the quality of evidence for 28-day mortality in the subgroup of long course of low-dose corticosteroids from high to moderate because one of the two largest trials on a long course of low-dose corticosteroids reported no survival benefit (<LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>). Other differences between trials included differences in targeted populations, in control of co-interventions or in type and dose of corticosteroids. In addition, ongoing trials (<LINK REF="STD-Gordon-2014a" TYPE="STUDY">Gordon 2014a</LINK>; <LINK REF="STD-NCT00625209-2008" TYPE="STUDY">NCT00625209 2008</LINK>; <LINK REF="STD-Venkatesh-2013" TYPE="STUDY">Venkatesh 2013</LINK>) may influence the direction and magnitude of treatment effects.</P></QUALITY_OF_EVIDENCE><POTENTIAL_BIASES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>In this review, we performed a comprehensive search of the literature with no restriction on language, so we can assume that the risk of missing important trials was very limited. The asymmetrical funnel plot for the primary outcome of this review suggests some publication bias. However, potential sources of an asymmetrical funnel plot also include selection biases, poor methodological quality of smaller studies, true heterogeneity, artefacts and chance (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). Visual inspection of the funnel plot suggests a small-study effect (i.e. among small studies, the positive ones are more likely to be published). Nevertheless, our thorough search strategy and the need to enrol studies in public clinical trial registries may have decreased the risk of missing any randomized controlled trial. As discussed in this review, all studies on low-dose corticosteroids described methods of acceptable quality. True heterogeneity seems to be a more plausible explanation for the observed asymmetrical funnel plot. Indeed, the effects of low-dose corticosteroids on mortality may be proportional to the basal risk of death, and the Corticosteroid Therapy of Septic Shock trial (CORTICUS) included patients at lower risk of death (<LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>). In addition, smaller intervention effects in the CORTICUS trial may have resulted from an improved standard of care introduced during the decade that separated most of the smaller trials from CORTICUS. Finally, the asymmetrical funnel plot may have been due to chance.</P><P>According to the primary objective of this systematic review, we included only trials that compared corticosteroids versus standard therapy alone or placebo. One trial used a cross-over design (<LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>), and we could obtain none of the foreseen outcomes for this review. This trial concluded that prolonged treatment with a low dose of hydrocortisone improved haemodynamic and immune outcomes. Another trial compared three days versus seven days of hydrocortisone therapy and suggested no evidence for differences in outcomes between patients treated for three days or seven days (<LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>). However, this trial has some limitations, including lack of blinding and small sample size. Three other trials have included children (<LINK REF="STD-CSG-1963" TYPE="STUDY">CSG 1963</LINK>; <LINK REF="STD-Slusher-1996" TYPE="STUDY">Slusher 1996</LINK>; <LINK REF="STD-Valoor-2009" TYPE="STUDY">Valoor 2009</LINK>). We considered that pooling the results of remaining trials in a meta-analysis was acceptable.</P><P>Two trials were published only as an abstract (<LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK>). Nevertheless, the primary investigators for these studies (<LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK>) provided sufficient unpublished data for review authors to compute the primary outcome and several secondary outcomes for this review, allowing us to include these trials in the meta-analysis. Both published and unpublished data were available for 17 trials (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK>; <LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Cicarelli-2007" TYPE="STUDY">Cicarelli 2007</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>; <LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-Torres-2015" TYPE="STUDY">Torres 2015</LINK>; <LINK REF="STD-Yildiz-2002" TYPE="STUDY">Yildiz 2002</LINK>), and the primary author for each trial validated the data extraction form. For four studies, contact with the primary investigator yielded no additional data (<LINK REF="STD-Luce-1988" TYPE="STUDY">Luce 1988</LINK>; <LINK REF="STD-Meijvis-2011" TYPE="STUDY">Meijvis 2011</LINK>; <LINK REF="STD-Rezk--2013" TYPE="STUDY">Rezk 2013</LINK>; <LINK REF="STD-Snijders-2010" TYPE="STUDY">Snijders 2010</LINK>).</P><P>We chose to convert outcome measures that correspond to censored data into dichotomous variables, that is, the proportion of participants with a particular event after one week and after four weeks, or at ICU or hospital discharge.</P></POTENTIAL_BIASES><AGREEMENT MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Findings in this review that a short course of high-dose corticosteroids provides no benefit for patients with sepsis are in line with reports from previous systematic reviews (<LINK REF="REF-Cronin-1995" TYPE="REFERENCE">Cronin 1995</LINK>; <LINK REF="REF-Lefering-1995" TYPE="REFERENCE">Lefering 1995</LINK>) and with current international guidelines (<LINK REF="REF-Dellinger-2013" TYPE="REFERENCE">Dellinger 2013</LINK>).</P><P>We found scarce data that could not allow conclusions on effects of corticosteroids in children with sepsis, in keeping with a recent systematic review (<LINK REF="REF-Menon-2013" TYPE="REFERENCE">Menon 2013</LINK>).</P><P>The beneficial effects of corticosteroids on shock reversal in patients with septic shock are consistent across recent systematic reviews (<LINK REF="REF-Kalil-2011" TYPE="REFERENCE">Kalil 2011</LINK>; <LINK REF="REF-Moran-2010" TYPE="REFERENCE">Moran 2010</LINK>; <LINK REF="REF-Sherwin-2012" TYPE="REFERENCE">Sherwin 2012</LINK>). The survival benefit derived from corticosteroids for patients with sepsis was suggested by some previous authors (<LINK REF="REF-Moran-2010" TYPE="REFERENCE">Moran 2010</LINK>) but not by others (<LINK REF="REF-Kalil-2011" TYPE="REFERENCE">Kalil 2011</LINK>; <LINK REF="REF-Sherwin-2012" TYPE="REFERENCE">Sherwin 2012</LINK>). Nevertheless, current systematic reviews have included trials that were not included in previous systematic reviews, as they were published only recently or were published in non-English language. Current reviews have included non-published information for a large number of trials after contact was made with original study authors, resulting in inclusion of qualitatively and quantitatively better data than were provided previously.</P></AGREEMENT></DISCUSSION><CONCLUSIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><IMPLICATIONS_PRACTICE MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Overall, corticosteroids may favourably impact all-cause mortality at 28 days, and at ICU and hospital discharge, in patients with sepsis. Subgroup analyses have suggested that corticosteroids should be given at a low dose (of &#8804; 400 mg per day, of hydrocortisone or equivalent) for three or more days at full dose, and preferably in patients with septic shock, sepsis and ARDS, community-acquired pneumonia or critical illness-related corticosteroid insufficiency. Evidence from this review is insufficient to support an abrupt or gradual interruption in treatment, or to support intravenous bolus or continuous infusion of treatment. Evidence accumulated from five trials uniformly does not support use of a short course of high-dose corticosteroids in patients with sepsis.</P></IMPLICATIONS_PRACTICE><IMPLICATIONS_RESEARCH MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>The criteria for critical illness-related corticosteroid insufficiency in septic shock remain to be defined.</P><P>Ongoing trials should clarify:</P><UL><LI>the role of a long course of low-dose corticosteroids for treatment of septic shock in children;</LI><LI>the role of a long course of low-dose corticosteroids for treatment of patients with sepsis without shock, or with a mild form of septic shock;</LI><LI>the role of mineralocorticoid replacement;</LI><LI>the optimal timing of initiation of treatment;</LI><LI>the optimal dose of hydrocortisone (or equivalent); and</LI><LI>the role of a long course of low-dose corticosteroids for treatment of sepsis caused by different types of infections.</LI></UL><P>The optimal timing for starting treatment, the optimal dose of hydrocortisone (or equivalent) and the duration and modality of withdrawal of treatment require additional trials.</P></IMPLICATIONS_RESEARCH></CONCLUSIONS></BODY><ACKNOWLEDGEMENTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>We would like to thank Harald Herkner (Content Editor), Jing Xie (Statistical Editor), Philipp Schuetz and Mirjam Christ-Crain (Peer Reviewers) and Janet Wale (Consumer Editor) for help and editorial advice provided during preparation of this 2015 updated systematic review.</P><P>We would like to thank Dr. R. DeGaudio, Dr. G.U. Meduri, Dr. M. Oppert, Dr. C. Sprung and Dr. S. Tandan for providing us with unpublished data. We also would like to thank Dr. Bin Du (Medical ICU, Peking Union Medical College Hospital, Beijing 100730, China) for helping with abstraction of information from papers in the Chinese language.</P><P>We would like to thank Prof. Harald Herkner (Content Editor); Marialena Trivella (Statistical Editor); Peter Minneci, Charles Natanson, Gordon Guyatt and Matthias Briel (Peer Reviewers) and Karen Hovhannisyan (Trials Search Co-ordinator) for help and editorial advice provided during preparation of the 2010 updated review.</P></ACKNOWLEDGEMENTS><CONFLICT_OF_INTEREST MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>The following review authors have been involved in randomized controlled trials of low-dose hydrocortisone that are included in this updated review: Djillali Annane in <LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK> and <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; Eric Bellissant in <LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; Pierre Edouard Bollaert in <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK> and <LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; Josef Briegel in <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK> and <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; Didier Keh in <LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK> and <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; and Yizhak Kupfer in <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>.</P><P>Djillali Annane is involved with one ongoing study: <LINK REF="STD-NCT00625209-2008" TYPE="STUDY">NCT00625209 2008</LINK>. This trial is funded by the French Ministry of Social Affairs, Health and Women Rights - Programme Hospitalier de Recherche Clinique PHRC-12-002-0030.</P><P>Didier Keh is involved with one ongoing study: <LINK REF="STD-NCT00670254-2008" TYPE="STUDY">NCT00670254 2008</LINK>. This trial is funded by the Federal Ministry of Education and Research (01KG0701).</P><P>Yizhak Kupfer: I am a member of the Pfizer/BMS speakers' bureau for epixaban. This product has no relationship to steroids in sepsis.</P></CONFLICT_OF_INTEREST><CONTRIBUTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Conceiving of the review: Djillali Annane (DA), Eric Bellissant (EB), Pierre Edouard Bollaert (PEB), Josef Briegel (JB), Didier Keh (DK), Yizhak Kupfer (YK).</P><P>Co-ordinating the review: DA.</P><P>Undertaking manual searches: DA, PEB, JB, DK.</P><P>Screening search results: DA, PEB, JB, DK, YK.</P><P>Organizing retrieval of papers: DA, PEB, JB, DK, YK.</P><P>Screening retrieved papers against inclusion criteria: DA, PEB, JB, DK, YK.</P><P>Appraising the quality of papers: DA, PEB, JB, DK, YK.</P><P>Abstracting data from papers: DA.</P><P>Writing to authors of papers to ask for additional information: DA.</P><P>Providing additional data about papers: DA, PEB, JB, DK, YK.</P><P>Obtaining and screening data on unpublished studies: DA, PEB, JB, DK, YK.</P><P>Managing data for the review: DA, EB.</P><P>Entering data into Review Manager (<LINK REF="REF-RevMan-5" TYPE="REFERENCE">RevMan 5</LINK>): DA.</P><P>Analysing RevMan statistical data: DA, EB.</P><P>Performing other statistical analyses not using RevMan: not applicable.</P><P>Performing double entry of data (data entered by person one: DA; data entered by person two: Laurenne Authelet).</P><P>Interpreting data: DA, EB, PEB, JB, DK, YK.</P><P>Making statistical inferences: EB.</P><P>Writing the review: DA, EB, PEB, JB, DK, YK.</P><P>Securing funding for the review: DA.</P><P>Performing previous work that served as the foundation of the present study: DA, EB, PEB, JB, DK, YK.</P><P>Serving as guarantor for the review (one review author): DA.</P><P>Taking responsibility for reading and checking the review before submission: DA.</P></CONTRIBUTIONS><PRO_REV_DIFF/><PUBLIC_NOTES MODIFIED="2018-05-05 00:40:48 +0100" MODIFIED_BY="[Empty name]"><P>This review was initially developed within the Infectious Diseases Group and was transferred to the Anaesthesia Group in May 2005.</P><SUBSECTION><HEADING LEVEL="2">Updated 2010</HEADING><P>The review was updated in 2010 (<LINK REF="REF-Annane-2004" TYPE="REFERENCE">Annane 2004</LINK>). At that time, Cochrane updates did not earn a new citation unless they had new review authors or included a change to conclusions. Review authors found 21 new trials in 2010. Of those 21 trials, they included nine randomized controlled trials in the 2010 update. Additional included studies did not change the conclusions of this review. Therefore the 2010 update did not earn a new citation.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="2">Updated 2015</HEADING><P>The new search of the literature identified nine additional trials. Cumulated evidence from 33 trials confirmed the direction and magnitude of the point estimate for 28-day mortality with narrow confidence interval limits. Thus, this update suggested moderate evidence for reduced 28-day mortality with corticosteroids in the primary analysis and confirmed significant interactions between the relative risk of dying at 28 days and treatment modalities used (lower doses and longer duration yielded better chance of survival) and patient case mix included (patients with septic shock, sepsis-related ARDS or community-acquired pneumonia may be more likely to benefit from corticosteroids).</P><P>We decided to change the title to "Corticosteroids for treating sepsis" owing to recent changes in the definition of sepsis, suggesting that the term "severe sepsis" should be avoided.</P><P>Several changes were made to the Methods section.</P><UL><LI>We now exclude quasi-randomized trials (three trials).</LI><LI>We changed the definition of "long course" from at least five days to at least three days. Indeed, and in keeping with the Surviving Sepsis Campaign recommendation, corticosteroids are often given at full dose until cessation of vasopressor therapy, which may occur sooner than five days. We changed the definition of "low dose" from 300 mg or less per day to 400 mg or less per day. Indeed, no consensus has been reached about what should be the optimal dose, and several RCTs testing so called "low-dose" corticosteroids used variable doses up to 400 mg. According to findings from the meta-regression analysis, changes in the definition of "low dose" and "long course" might have had a negative impact on observed survival benefits of corticosteroids. Indeed, we found that both longer duration and lower dose were associated with better survival rates.</LI><LI>We have incorporated information on how we used the GRADE system and how we selected outcomes for the 'Summary of findings' table.</LI></UL><P>Sensitivity analyses based on methodological quality are now restricted to the primary outcome.</P><P>Random-effects models are used only in cases of heterogeneity, with I<SUP>2 </SUP>statistic &gt; 30%. Otherwise, fixed-effect models are used.</P></SUBSECTION></PUBLIC_NOTES></MAIN_TEXT><STUDIES_AND_REFERENCES MODIFIED="2018-05-05 00:48:12 +0100" MODIFIED_BY="Jane Cracknell">
<STUDIES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell">
<INCLUDED_STUDIES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="MIX" ID="STD-Annane-2002" MODIFIED="2010-09-07 15:58:46 +0100" MODIFIED_BY="Jane Cracknell" NAME="Annane 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-09-07 15:58:46 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Annane D, Sebille V, Charpentier C, Bollaert PE, François B, Korach JM, et al</AU>
<TI>Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<NO>7</NO>
<PG>862-71</PG>
<IDENTIFIERS MODIFIED="2010-09-07 15:58:46 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691067"/><IDENTIFIER MODIFIED="2010-09-07 15:58:46 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 12186604"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691066"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Annane-2010" MODIFIED="2010-09-24 16:18:04 +0100" MODIFIED_BY="Jane Cracknell" NAME="Annane 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-09-24 16:18:04 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>COIITSS Study Investigators, Annane D, Cariou A, Maxime V, Azoulay E, D'honneur G, Timsit JF, et al</AU>
<TI>Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2010</YR>
<VL>303</VL>
<PG>341-8</PG>
<IDENTIFIERS MODIFIED="2010-09-07 15:58:13 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691069"/><IDENTIFIER MODIFIED="2010-09-07 15:58:13 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=""/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-02-20 07:18:10 +0000" MODIFIED_BY="Djillali Annane"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691068"/><IDENTIFIER MODIFIED="2010-02-20 07:18:10 +0000" MODIFIED_BY="Djillali Annane" TYPE="DOI" VALUE=""/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arabi-2011" MODIFIED="2015-02-01 13:22:03 +0000" MODIFIED_BY="djillali annane" NAME="Arabi 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-02-01 13:22:03 +0000" MODIFIED_BY="djillali annane" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arabi YM, Aljumah A, Dabbagh O, Tamim HM, Rishu AH, Al-Abdulkareem A, et al</AU>
<TI>Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2011</YR>
<VL>182</VL>
<PG>1971-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691071"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691070"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bollaert-1998" MODIFIED="2010-09-07 15:59:40 +0100" MODIFIED_BY="Jane Cracknell" NAME="Bollaert 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-09-07 15:59:40 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A</AU>
<TI>Reversal of late septic shock with supraphysiologic doses of hydrocortisone</TI>
<SO>Critical Care Medicine</SO>
<YR>1998</YR>
<VL>26</VL>
<NO>4</NO>
<PG>645-50</PG>
<IDENTIFIERS MODIFIED="2010-09-07 15:59:40 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691073"/><IDENTIFIER MODIFIED="2010-09-07 15:59:40 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9559600"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691072"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bone-1987" MODIFIED="2010-09-07 15:59:49 +0100" MODIFIED_BY="Jane Cracknell" NAME="Bone 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-09-07 15:59:49 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bone RG, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA</AU>
<TI>A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock</TI>
<SO>New England Journal of Medicine</SO>
<YR>1987</YR>
<VL>317</VL>
<NO>11</NO>
<PG>653-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691075"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691074"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Briegel-1999" MODIFIED="2010-09-07 16:01:05 +0100" MODIFIED_BY="Jane Cracknell" NAME="Briegel 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-09-07 16:01:05 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, et al</AU>
<TI>Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study</TI>
<SO>Critical Care Medicine</SO>
<YR>1999</YR>
<VL>27</VL>
<NO>4</NO>
<PG>723-32</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:01:05 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691077"/><IDENTIFIER MODIFIED="2010-09-07 16:01:05 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10321661"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691076"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Chawla-1999" MODIFIED="2009-10-24 15:28:41 +0100" MODIFIED_BY="Djillali Annane" NAME="Chawla 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chawla K, Kupfer Y, Tessler S</AU>
<TI>Hydrocortisone reverses refractory septic shock</TI>
<SO>Critical Care Medicine</SO>
<YR>1999</YR>
<VL>27</VL>
<NO>1</NO>
<PG>A33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691079"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691078"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cicarelli-2007" MODIFIED="2010-09-24 16:18:05 +0100" MODIFIED_BY="Jane Cracknell" NAME="Cicarelli 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-09-24 16:18:05 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cicarelli DD, Vieira JE, Benseñor FE</AU>
<TI>Early dexamethasone treatment for septic shock patients: a prospective randomized clinical trial</TI>
<SO>Sao Paulo Medical Journal</SO>
<YR>2007</YR>
<VL>125</VL>
<PG>237-41</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:03:43 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691081"/><IDENTIFIER MODIFIED="2010-09-07 16:03:43 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="17992396 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691080"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Confalonieri-2005" MODIFIED="2010-09-24 16:18:04 +0100" MODIFIED_BY="Jane Cracknell" NAME="Confalonieri 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-09-24 16:18:04 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Confalonieri M, Urbino R, Potena A, Piatella M, Parigi P, Giacomo P, et al</AU>
<TI>Hydrocortisone infusion for severe community acquired pneumonia: a preliminary randomized study</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2005</YR>
<VL>171</VL>
<PG>242-8</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:07:38 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691083"/><IDENTIFIER MODIFIED="2010-09-07 16:07:38 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=""/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691082"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CSG-1963" MODIFIED="2010-09-07 16:07:35 +0100" MODIFIED_BY="Jane Cracknell" NAME="CSG 1963" YEAR="1963">
<REFERENCE MODIFIED="2010-09-07 16:07:35 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cooperative Study Group</AU>
<TI>The effectiveness of hydrocortisone in the management of severe infections</TI>
<SO>JAMA</SO>
<YR>1963</YR>
<VL>183</VL>
<PG>462-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691085"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691084"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gordon-2014" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Gordon 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gordon AC, Mason AJ, Perkins GD, Stotz M, Terblanche M, Ashby D, et al</AU>
<TI>The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial</TI>
<SO>Critical Care Medicine</SO>
<YR>2014</YR>
<VL>42</VL>
<PG>1325-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691087"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691086"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2009" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Hu 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu B, Li JG, Liang H, Zhou Q, Yu Z, Li L, et al</AU>
<TI>The effect of low-dose hydrocortisone on requirement of norepinephrine and lactate clearance in patients with refractory septic shock</TI>
<SO>Zhongguo Wei Zhong Bing Ji Jiu Yi Xue</SO>
<YR>2009</YR>
<VL>21</VL>
<PG>529-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691089"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691088"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huh-2007" MODIFIED="2010-10-08 13:05:00 +0100" MODIFIED_BY="[Empty name]" NAME="Huh 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-10-08 13:05:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huh JW, Lim CM, Koh Y, Hong SB</AU>
<TI>Effect of low doses of hydrocortisone in patient with septic shock and relative adrenal insufficiency: 3 days versus 7 days treatment</TI>
<SO>Critical Care Medicine</SO>
<YR>2007</YR>
<VL>34 Suppl</VL>
<PG>A101</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691091"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691090"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Keh-2003" MODIFIED="2010-09-07 16:22:01 +0100" MODIFIED_BY="Jane Cracknell" NAME="Keh 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-07 16:22:01 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, et al</AU>
<TI>Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2003</YR>
<VL>167</VL>
<NO>4</NO>
<PG>512-20</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:22:01 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691093"/><IDENTIFIER MODIFIED="2010-09-07 16:22:01 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12426230 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691092"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2012" MODIFIED="2015-02-01 13:23:38 +0000" MODIFIED_BY="djillali annane" NAME="Liu 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-02-01 13:23:38 +0000" MODIFIED_BY="djillali annane" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu L, Li J, Huang YZ, Liu SQ, Yang CS, Guo FM, et al</AU>
<TI>The effect of stress dose glucocorticoid on patients with acute respiratory distress syndrome combined with critical illness-related corticosteroid insufficiency</TI>
<SO>Zhonghua Nei Ke Za Zhi</SO>
<YR>2012</YR>
<VL>51</VL>
<PG>599-603</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691095"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691094"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Luce-1988" MODIFIED="2010-09-07 16:23:51 +0100" MODIFIED_BY="Jane Cracknell" NAME="Luce 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-09-07 16:23:51 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF</AU>
<TI>Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock</TI>
<SO>American Review of Respiratory Diseases</SO>
<YR>1988</YR>
<VL>138</VL>
<NO>1</NO>
<PG>62-8</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:23:51 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691097"/><IDENTIFIER MODIFIED="2010-09-07 16:23:51 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3202402 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691096"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Meduri-2007" MODIFIED="2009-10-24 15:30:27 +0100" MODIFIED_BY="Djillali Annane" NAME="Meduri 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-10-21 06:37:49 +0100" MODIFIED_BY="Djillali Annane" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, et al</AU>
<TI>Methylprednislone infusion in early ARDS: result of a randomised controlled trial</TI>
<SO>Chest</SO>
<YR>2007</YR>
<VL>131</VL>
<NO>4</NO>
<PG>954-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691099"/><IDENTIFIER TYPE="PUBMED" VALUE="17426195"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691098"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meijvis-2011" MODIFIED="2015-02-01 13:24:11 +0000" MODIFIED_BY="djillali annane" NAME="Meijvis 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-02-01 13:24:11 +0000" MODIFIED_BY="djillali annane" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, van Velzen-Blad H, et al</AU>
<TI>Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial</TI>
<SO>The Lancet</SO>
<YR>2011</YR>
<VL>377</VL>
<PG>2023-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691101"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691100"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Oppert-2005" MODIFIED="2010-09-24 16:23:28 +0100" MODIFIED_BY="Jane Cracknell" NAME="Oppert 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-09-24 16:23:28 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oppert M, Schindler R, Husung C, Offerman K, Graef KJ, Boenisch O, et al</AU>
<TI>Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock</TI>
<SO>Critical Care Medicine</SO>
<YR>2005</YR>
<VL>33</VL>
<PG>2457-64</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:24:26 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691103"/><IDENTIFIER MODIFIED="2010-09-07 16:24:26 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="16276166 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691102"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rezk--2013" MODIFIED="2015-02-19 19:01:44 +0000" MODIFIED_BY="Jane Cracknell" NAME="Rezk  2013" YEAR="2013">
<REFERENCE MODIFIED="2015-02-19 19:01:44 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rezk NA, Ibrahim AM</AU>
<TI>Effects of methyl prednisolone in early ARDS</TI>
<SO>Egyptian Journal of Chest Diseases and Tuberculosis</SO>
<YR>2013</YR>
<VL>62</VL>
<NO>1</NO>
<PG>167&#8211;72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691105"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691104"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rinaldi-2006" MODIFIED="2010-09-07 16:24:54 +0100" MODIFIED_BY="Jane Cracknell" NAME="Rinaldi 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-07 16:24:54 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rinaldi S, Adembri C, Grechi S, DE Gaudio R</AU>
<TI>Low-dose hydrocortisone during severe sepsis: effects on microalbumineria</TI>
<SO>Critical Care Medicine</SO>
<YR>2006</YR>
<VL>34</VL>
<PG>2334-9</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:24:54 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691107"/><IDENTIFIER MODIFIED="2010-09-07 16:24:54 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="16850006"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691106"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sabry-2011" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Sabry 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sabry NA, El-Din Omar E</AU>
<TI>Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings</TI>
<SO>Pharmacology and Pharmacy</SO>
<YR>2011</YR>
<VL>2</VL>
<PG>73-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691109"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691108"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schumer-1976" MODIFIED="2010-09-07 16:25:41 +0100" MODIFIED_BY="Jane Cracknell" NAME="Schumer 1976" YEAR="1976">
<REFERENCE MODIFIED="2010-09-07 16:25:41 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schumer W</AU>
<TI>Steroids in the treatment of clinical septic shock</TI>
<SO>Annals of Surgery</SO>
<YR>1976</YR>
<VL>184</VL>
<NO>3</NO>
<PG>333-41</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:25:41 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691111"/><IDENTIFIER MODIFIED="2010-09-07 16:25:41 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 786190 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691110"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slusher-1996" MODIFIED="2010-09-07 16:26:09 +0100" MODIFIED_BY="Jane Cracknell" NAME="Slusher 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-09-07 16:26:09 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slusher T, Gbadero D, Howard C, Lewinson L, Giroir B, Toro L, et al</AU>
<TI>Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis</TI>
<SO>Pediatric Infectious Diseases Journal</SO>
<YR>1996</YR>
<VL>15</VL>
<NO>7</NO>
<PG>579-83</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:26:09 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691113"/><IDENTIFIER MODIFIED="2010-09-07 16:26:09 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8823850"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691112"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Snijders-2010" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Snijders 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Snijders D, Daniels JMA, de Graaff CS, van der Werf TS, Boersma WG</AU>
<TI>Efficacy of corticosteroids in community-acquired pneumonia &#8211; a randomized double blinded clinical trial</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2010</YR>
<VL>181</VL>
<PG>975-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691115"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691114"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sprung-1984" MODIFIED="2010-09-07 16:26:56 +0100" MODIFIED_BY="Jane Cracknell" NAME="Sprung 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-09-07 16:26:56 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, et al</AU>
<TI>The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study</TI>
<SO>New England Journal of Medicine</SO>
<YR>1984</YR>
<VL>311</VL>
<NO>18</NO>
<PG>1137-43</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:26:56 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691117"/><IDENTIFIER MODIFIED="2010-09-07 16:26:56 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="6384785 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691116"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sprung-2008" MODIFIED="2010-09-07 16:27:41 +0100" MODIFIED_BY="Jane Cracknell" NAME="Sprung 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-09-07 16:27:41 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sprung C, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al</AU>
<TI>The CORTICUS randomized, double-blind, placebo-controlled study of hydrocortisone therapy in patients with septic shock</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>358</VL>
<PG>111-24</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:27:41 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691119"/><IDENTIFIER MODIFIED="2010-09-07 16:27:41 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="18184957"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691118"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Tandan-2005" MODIFIED="2009-10-24 15:31:37 +0100" MODIFIED_BY="Djillali Annane" NAME="Tandan 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-04-11 11:52:38 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tandan SM, Guleria R, Gupta N</AU>
<TI>Low dose steroids and adrenocortical insufficiency in septic shock: a double-blind randomised controlled trial from India</TI>
<SO>Proceedings of the American Thoracic Society Meeting</SO>
<YR>2005</YR>
<PG>A24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691121"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691120"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Torres-2015" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Torres 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al</AU>
<TI>Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial</TI>
<SO>JAMA</SO>
<YR>2015</YR>
<VL>313</VL>
<PG>677-86</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691123"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691122"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valoor-2009" MODIFIED="2015-02-01 13:26:51 +0000" MODIFIED_BY="djillali annane" NAME="Valoor 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-02-01 13:26:51 +0000" MODIFIED_BY="djillali annane" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valoor HT, Singhi S, Jayashree M</AU>
<TI>Low-dose hydrocortisone in paediatric septic shock: an exploratory study in a third world setting</TI>
<SO>Pediatric Critical Care Medicine</SO>
<YR>2009</YR>
<VL>10</VL>
<PG>121-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691125"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691124"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VASSCSG-1987" MODIFIED="2010-09-24 16:18:04 +0100" MODIFIED_BY="Jane Cracknell" NAME="VASSCSG 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-09-24 16:18:04 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Veterans Administration Systemic Sepsis Cooperative Study Group</AU>
<TI>Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1987</YR>
<VL>317</VL>
<NO>11</NO>
<PG>659-65</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:28:55 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691127"/><IDENTIFIER MODIFIED="2010-09-07 16:28:55 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="2888017"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691126"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yildiz-2002" MODIFIED="2010-09-07 16:30:04 +0100" MODIFIED_BY="Jane Cracknell" NAME="Yildiz 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-09-07 16:30:04 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yildiz O, Doganay M, Aygen B, Guven M, Keleutimur F, Tutuu A</AU>
<TI>Physiologic-dose steroid therapy in sepsis</TI>
<SO>Critical Care</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>3</NO>
<PG>251-9</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:30:04 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691129"/><IDENTIFIER MODIFIED="2010-09-07 16:30:04 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12133187"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691128"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yildiz-2011" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Yildiz 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yildiz O, Tanriverdi F, Simsek S, Aygen B, Kelestimur F</AU>
<TI>The effects of moderate-dose steroid therapy in sepsis: a placebo-controlled, randomized study</TI>
<SO>Journal of Research in Medical Sciences</SO>
<YR>2011</YR>
<VL>16</VL>
<PG>1410-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691131"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691130"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Cicarelli-2006" MODIFIED="2010-09-07 16:32:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Cicarelli 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-07 16:32:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cicarelli DD, Bensenor FEM, Vieira JE</AU>
<TI>Effects of single dose of dexamethasone on patients with systemic inflammatory response</TI>
<SO>Sao Paulo Medical Journal</SO>
<YR>2006</YR>
<VL>124</VL>
<PG>90-5</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:32:12 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691133"/><IDENTIFIER MODIFIED="2010-09-07 16:32:12 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="16878192 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691132"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hahn-1951" MODIFIED="2009-10-24 15:32:28 +0100" MODIFIED_BY="Djillali Annane" NAME="Hahn 1951" YEAR="1951">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hahn EO, Houser HB, Rammelkamp CH, Denny FW, Wannamaker LW</AU>
<TI>Effect of cortisone on acute streptococcal infections and post-streptococcal complications</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1951</YR>
<VL>30</VL>
<PG>274-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691135"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691134"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-1984" MODIFIED="2010-09-07 16:32:59 +0100" MODIFIED_BY="Jane Cracknell" NAME="Hughes 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-09-07 16:32:59 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hughes GS Jr</AU>
<TI>Naloxone and methylprednisolone sodium succinate enhance sympathomedullary discharge in patients with septic shock</TI>
<SO>Life Sciences</SO>
<YR>1984</YR>
<VL>35</VL>
<NO>23</NO>
<PG>2319-26</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:32:59 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691137"/><IDENTIFIER MODIFIED="2010-09-07 16:32:59 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 6390057"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691136"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kaufman-2008" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Kaufman 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaufmann I, Briegel J, Schliephake F, Hoelzl A, Chouker A, Hummel T, et al</AU>
<TI>Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization-dependent neutrophil functions</TI>
<SO>Intensive Care Medicine</SO>
<YR>2008</YR>
<VL>34</VL>
<PG>344-9</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:34:04 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691139"/><IDENTIFIER MODIFIED="2010-09-07 16:34:04 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="17906853 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691138"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klastersky-1971" MODIFIED="2014-11-07 12:28:53 +0000" MODIFIED_BY="[Empty name]" NAME="Klastersky 1971" YEAR="1971">
<REFERENCE MODIFIED="2014-11-07 12:28:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klastersky J, Cappel R, Debusscher L</AU>
<TI>Effectiveness of betamethasone in management of severe infections. A double-blind study</TI>
<SO>New England Journal of Medicine</SO>
<YR>1971</YR>
<VL>284</VL>
<NO>22</NO>
<PG>1248-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691141"/><IDENTIFIER TYPE="PUBMED" VALUE="4929896"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691140"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lucas-1984" MODIFIED="2014-11-07 12:29:08 +0000" MODIFIED_BY="[Empty name]" NAME="Lucas 1984" YEAR="1984">
<REFERENCE MODIFIED="2014-11-07 12:29:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lucas C, Ledgerwood A</AU>
<TI>The cardiopulmonary response to massive doses of steroids in patients with septic shock</TI>
<SO>Archives of Surgery</SO>
<YR>1984</YR>
<VL>119</VL>
<NO>5</NO>
<PG>537-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691143"/><IDENTIFIER TYPE="PUBMED" VALUE="6712466 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691142"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McKee-1983" MODIFIED="2010-09-07 16:34:36 +0100" MODIFIED_BY="Jane Cracknell" NAME="McKee 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-09-07 16:34:36 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McKee JI, Finlay WE</AU>
<TI>Cortisol replacement in severely stressed patients</TI>
<SO>Lancet</SO>
<YR>1983</YR>
<VL>1</VL>
<NO>8322</NO>
<PG>484</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:34:36 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691145"/><IDENTIFIER MODIFIED="2010-09-07 16:34:36 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="6131207 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691144"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Meduri-1998b" MODIFIED="2010-09-07 16:35:06 +0100" MODIFIED_BY="Jane Cracknell" NAME="Meduri 1998b" YEAR="1998">
<REFERENCE MODIFIED="2010-09-07 16:35:06 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, et al</AU>
<TI>Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>1998</YR>
<VL>280</VL>
<NO>2</NO>
<PG>159-65</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:35:06 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691147"/><IDENTIFIER MODIFIED="2010-09-07 16:35:06 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9669790"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691146"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mikami-2007" MODIFIED="2010-09-07 16:35:34 +0100" MODIFIED_BY="Jane Cracknell" NAME="Mikami 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-09-07 16:35:34 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mikami K, Suzuki M, Kitagawa H, Kawakami M, Hirota N, Yamaguchi H, et al</AU>
<TI>Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization</TI>
<SO>Lung</SO>
<YR>2007</YR>
<VL>185</VL>
<PG>249-55</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:35:34 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691149"/><IDENTIFIER MODIFIED="2010-09-07 16:35:34 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 17710485"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691148"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rogers-1970" MODIFIED="2010-09-07 16:36:11 +0100" MODIFIED_BY="Jane Cracknell" NAME="Rogers 1970" YEAR="1970">
<REFERENCE MODIFIED="2010-09-07 16:36:11 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rogers J</AU>
<TI>Large doses of steroids in septicaemic shock</TI>
<SO>British Journal of Urology</SO>
<YR>1970</YR>
<VL>42</VL>
<NO>6</NO>
<PG>742</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:36:11 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691151"/><IDENTIFIER MODIFIED="2010-09-07 16:36:11 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="4923652"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691150"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-1976" MODIFIED="2010-09-07 16:36:19 +0100" MODIFIED_BY="Jane Cracknell" NAME="Thompson 1976" YEAR="1976">
<REFERENCE MODIFIED="2010-09-07 16:36:19 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson WL, Gurley HT, Lutz BA, Jackson DL, Kvols LK, Morris IA</AU>
<TI>Inefficacy of glucocorticoids in shock (double-blind study)</TI>
<SO>Clinical Research</SO>
<YR>1976</YR>
<VL>24</VL>
<PG>258A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691153"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691152"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Venet-2015" MODIFIED="2015-02-16 06:58:30 +0000" MODIFIED_BY="djillali annane" NAME="Venet 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-02-16 06:58:30 +0000" MODIFIED_BY="djillali annane" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Venet F, Plassais J, Textoris J, Cazalis MA, Pachot A, Bertin-Maghit M, et al</AU>
<TI>Low-dose hydrocortisone reduces norepinephrine duration in severe burn patients: a randomized clinical trial</TI>
<SO>Critical Care</SO>
<YR>2015</YR>
<VL>19</VL>
<PG>21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691155"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691154"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wagner-1955" MODIFIED="2014-11-07 12:29:25 +0000" MODIFIED_BY="[Empty name]" NAME="Wagner 1955" YEAR="1955">
<REFERENCE MODIFIED="2014-11-07 12:29:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wagner HN, Bennett IL, Lasagna L, Cluff LE, Rosenthal MB, Mirick GS</AU>
<TI>The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin</TI>
<SO>Bulletin of Johns Hopkins Hospital</SO>
<YR>1955</YR>
<VL>98</VL>
<PG>197-215</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691157"/><IDENTIFIER TYPE="PUBMED" VALUE="13304518"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691156"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weigelt-1985" MODIFIED="2010-09-07 16:37:18 +0100" MODIFIED_BY="Jane Cracknell" NAME="Weigelt 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-09-07 16:37:18 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weigelt JA, Norcross JF, Borman KR, Snyder WH 3rd</AU>
<TI>Early steroid therapy for respiratory failure</TI>
<SO>Archives of Surgery</SO>
<YR>1985</YR>
<VL>120</VL>
<NO>5</NO>
<PG>536-40</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:37:18 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691159"/><IDENTIFIER MODIFIED="2010-09-07 16:37:18 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3885915 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691158"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-03-27 10:55:22 +0000" MODIFIED_BY="Djillali Annane"/>
<ONGOING_STUDIES MODIFIED="2015-10-28 11:08:02 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Blum--2015" MODIFIED="2015-10-28 11:08:02 +0000" MODIFIED_BY="Jane Cracknell" NAME="Blum  2015" YEAR="2014">
<REFERENCE MODIFIED="2015-10-28 11:08:02 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, et al</AU>
<TI>Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.</TI>
<SO>Lancet</SO>
<YR>2015</YR>
<VL>385</VL>
<PG>1511-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691161"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691160"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gordon-2014a" MODIFIED="2015-02-01 13:30:17 +0000" MODIFIED_BY="djillali annane" NAME="Gordon 2014a" YEAR="2014">
<REFERENCE MODIFIED="2015-02-01 13:30:17 +0000" MODIFIED_BY="djillali annane" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gordon AC, Mason AJ, Perkins GD, Ashby D, Brett SJ</AU>
<TI>Protocol for a randomised controlled trial of VAsopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH)</TI>
<SO>British Medical Journal Open</SO>
<YR>2014</YR>
<VL>4</VL>
<PG>e005866</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691163"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691162"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00127985-2005" MODIFIED="2008-08-26 06:59:07 +0100" MODIFIED_BY="Djillali Annane" NAME="NCT00127985 2005" YEAR="2005">
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691164"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00368381-2008" MODIFIED="2008-03-27 10:58:45 +0000" MODIFIED_BY="Djillali Annane" NAME="NCT00368381 2008" YEAR="2008">
<IDENTIFIERS MODIFIED="2008-03-27 10:58:45 +0000" MODIFIED_BY="Djillali Annane"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691165"/><IDENTIFIER MODIFIED="2008-03-27 10:58:45 +0000" MODIFIED_BY="Djillali Annane" TYPE="CTG" VALUE="NCT00368381"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00562835-2008" MODIFIED="2008-08-26 06:57:28 +0100" MODIFIED_BY="Djillali Annane" NAME="NCT00562835 2008" YEAR="2008">
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691166"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00625209-2008" MODIFIED="2008-03-27 10:55:42 +0000" MODIFIED_BY="Djillali Annane" NAME="NCT00625209 2008" YEAR="2008">
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691167"/><IDENTIFIER TYPE="CTG" VALUE="NCT00625209"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00670254-2008" MODIFIED="2008-08-26 06:54:00 +0100" MODIFIED_BY="Djillali Annane" NAME="NCT00670254 2008" YEAR="2008">
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691168"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00732277--2008" MODIFIED="2008-08-26 06:57:00 +0100" MODIFIED_BY="Djillali Annane" NAME="NCT00732277  2008" YEAR="2008">
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691169"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Venkatesh-2013" MODIFIED="2015-02-01 13:30:46 +0000" MODIFIED_BY="djillali annane" NAME="Venkatesh 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-02-01 13:30:46 +0000" MODIFIED_BY="djillali annane" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Venkatesh B, Myburgh J, Finfer S, Webb SA, Cohen J, Bellomo R, et al, ANZICS CTG Investigtors</AU>
<TI>The ADRENAL study protocol: adjunctive corticosteroid treatment in critically ill patients with septic shock</TI>
<SO>Critical Care resuscitation</SO>
<YR>2013</YR>
<VL>15</VL>
<PG>83-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2691171"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2691170"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2018-03-13 11:55:08 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-01-18 15:45:56 +0000" MODIFIED_BY="Jane Cracknell">
<REFERENCE ID="REF-ACCP_x002f_SCCM-1992" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="ACCP/SCCM 1992" TYPE="JOURNAL_ARTICLE">
<AU>ACCP/SCCM Consensus Conference Panel</AU>
<TI>American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>1992</YR>
<VL>20</VL>
<NO>6</NO>
<PG>864-74</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:39:25 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 16:39:25 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1597042 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Angus-2013" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Angus 2013" TYPE="JOURNAL_ARTICLE">
<AU>Angus DC, van der Poll T</AU>
<TI>Severe sepsis and septic shock</TI>
<SO>New England Journal of Medicine</SO>
<YR>2013</YR>
<VL>369</VL>
<PG>840-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Annane-2000" MODIFIED="2010-09-24 16:18:04 +0100" MODIFIED_BY="Jane Cracknell" NAME="Annane 2000" TYPE="JOURNAL_ARTICLE">
<AU>Annane D, Sébille V, Troché G, Raphael JC, Gajdos P, Bellissant E</AU>
<TI>A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>283</VL>
<NO>8</NO>
<PG>1038-45</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:41:12 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 16:41:12 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10697064"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Annane-2003" MODIFIED="2010-09-07 16:41:50 +0100" MODIFIED_BY="Jane Cracknell" NAME="Annane 2003" TYPE="JOURNAL_ARTICLE">
<AU>Annane D, Aegerter P, Jars-Guincestre MC, Guidet B; CUB-Rea Network</AU>
<TI>Current epidemiology of septic shock: the CUB-Réa Network</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2003</YR>
<VL>168</VL>
<NO>2</NO>
<PG>165-72</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:41:50 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 16:41:50 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12851245"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Annane-2005" MODIFIED="2010-09-07 16:42:23 +0100" MODIFIED_BY="Jane Cracknell" NAME="Annane 2005" TYPE="JOURNAL_ARTICLE">
<AU>Annane D, Bellissant E, Cavaillon JM</AU>
<TI>Septic shock</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<PG>63-78</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:42:23 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 16:42:23 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="15639681"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Annane-2009b" MODIFIED="2010-10-07 13:22:15 +0100" MODIFIED_BY="[Empty name]" NAME="Annane 2009b" TYPE="JOURNAL_ARTICLE">
<AU>Annane D</AU>
<TI>Improving clinical trials in the critically ill: unique challenge: sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>2009</YR>
<VL>37 Suppl</VL>
<PG>117-28</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:43:31 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 16:43:31 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="19104211"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Annane-2013" MODIFIED="2015-02-01 13:31:59 +0000" MODIFIED_BY="djillali annane" NAME="Annane 2013" TYPE="JOURNAL_ARTICLE">
<AU>Annane D, Timsit JF, Megarbane B, Martin C, Misset B, Mourvillier B, et al, on behalf of the APROCCHSS Trial Investigators</AU>
<TI>Recombinant human activated protein C for adults with septic shock: a randomised controlled trial</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2013</YR>
<VL>187</VL>
<PG>1091&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barczyk-2010" MODIFIED="2015-02-01 13:32:19 +0000" MODIFIED_BY="djillali annane" NAME="Barczyk 2010" TYPE="JOURNAL_ARTICLE">
<AU>Barczyk K, Ehrchen J, Tenbrock K, Ahlmann M, Kneidl J, Viemann D, et al</AU>
<TI>Glucocorticoids promote survival of anti-inflammatory macrophages via stimulation of adenosine receptor A3</TI>
<SO>Blood</SO>
<YR>2010</YR>
<VL>116</VL>
<PG>446-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1995" MODIFIED="2010-10-07 13:23:04 +0100" MODIFIED_BY="[Empty name]" NAME="Barnes 1995" TYPE="JOURNAL_ARTICLE">
<AU>Barnes PJ, Greening AP, Crompton GK</AU>
<TI>Glucocorticoid resistance in asthma</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1995</YR>
<VL>152 Suppl</VL>
<NO>6 Pt 2</NO>
<PG>125-40</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:47:19 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 16:47:19 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7489120"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bone-1991" MODIFIED="2010-09-07 16:47:46 +0100" MODIFIED_BY="Jane Cracknell" NAME="Bone 1991" TYPE="JOURNAL_ARTICLE">
<AU>Bone RC</AU>
<TI>Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1991</YR>
<VL>114</VL>
<NO>4</NO>
<PG>332-3</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:47:46 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 16:47:46 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1987879"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boonen-2013" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Boonen 2013" TYPE="JOURNAL_ARTICLE">
<AU>Boonen E, Vervenne H, Meersseman P, Andrew R, Mortier L, Declercq PE, et al</AU>
<TI>Reduced cortisol metabolism during critical illness</TI>
<SO>New England Journal of Medicine</SO>
<YR>2013</YR>
<VL>388</VL>
<PG>1477-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Briegel-1994" MODIFIED="2010-11-04 12:22:17 +0000" MODIFIED_BY="Jane Cracknell" NAME="Briegel 1994" TYPE="JOURNAL_ARTICLE">
<AU>Briegel J, Kellermann W, Forst H, Haller M, Bittl M, Hoffmann GE, et al</AU>
<TI>Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group</TI>
<SO>Clinical Investigation</SO>
<YR>1994</YR>
<VL>72</VL>
<PG>782-7</PG>
<IDENTIFIERS MODIFIED="2010-11-04 12:22:16 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-11-04 12:22:16 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7865982"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cai-2008" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Cai 2008" TYPE="JOURNAL_ARTICLE">
<AU>Cai L, Ji A, de Beer FC, Tannock LR, van der Westhuyzen DR</AU>
<TI>SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>2008</YR>
<VL>118</VL>
<PG>364&#8211;75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chrousos-1995" MODIFIED="2010-09-07 16:49:37 +0100" MODIFIED_BY="Jane Cracknell" NAME="Chrousos 1995" TYPE="JOURNAL_ARTICLE">
<AU>Chrousos GP</AU>
<TI>The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>322</VL>
<NO>20</NO>
<PG>1351-62</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:49:37 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 16:49:37 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7715646"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cooper-2003" MODIFIED="2010-09-07 16:51:13 +0100" MODIFIED_BY="Jane Cracknell" NAME="Cooper 2003" TYPE="JOURNAL_ARTICLE">
<AU>Cooper MS, Stewart PM</AU>
<TI>Corticosteroid insufficiency in acutely ill patients</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>348</VL>
<NO>8</NO>
<PG>727-34</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:51:13 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 16:51:13 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 12594318 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cronin-1995" MODIFIED="2010-09-07 16:51:41 +0100" MODIFIED_BY="Jane Cracknell" NAME="Cronin 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MAD, et al</AU>
<TI>Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature</TI>
<SO>Critical Care Medicine</SO>
<YR>1995</YR>
<VL>23</VL>
<NO>8</NO>
<PG>1430-9</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:51:41 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 16:51:41 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7634816 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-de-Kruif-2007" MODIFIED="2010-09-24 16:18:04 +0100" MODIFIED_BY="Jane Cracknell" NAME="de Kruif 2007" TYPE="JOURNAL_ARTICLE">
<AU>de Kruif MD, Lemaire LC, Giebelen IA, van Zoelen MA, Pater JM, van den Pangaart PS, et al</AU>
<TI>Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia</TI>
<SO>Journal of Immunology</SO>
<YR>2007</YR>
<VL>178</VL>
<PG>1845-51</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:52:17 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 16:52:17 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="17237435"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dellinger-2008" MODIFIED="2010-09-07 16:52:56 +0100" MODIFIED_BY="Jane Cracknell" NAME="Dellinger 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al</AU>
<TI>Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008</TI>
<SO>Critical Care Medicine</SO>
<YR>2008</YR>
<VL>36</VL>
<PG>296-327</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:52:56 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 16:52:56 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="20035219 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dellinger-2013" MODIFIED="2015-02-01 13:32:43 +0000" MODIFIED_BY="djillali annane" NAME="Dellinger 2013" TYPE="JOURNAL_ARTICLE">
<AU>Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al ;Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup</AU>
<TI>Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012</TI>
<SO>Intensive care Medicine</SO>
<YR>2013</YR>
<VL>39</VL>
<PG>165-228</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Devereaux-2001" MODIFIED="2010-09-24 16:18:05 +0100" MODIFIED_BY="Jane Cracknell" NAME="Devereaux 2001" TYPE="JOURNAL_ARTICLE">
<AU>Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, et al</AU>
<TI>Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>2000-3</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:53:35 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 16:53:35 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="11308438 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-di-Villa-Bianca-2003" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="di Villa Bianca 2003" TYPE="JOURNAL_ARTICLE">
<AU>Villa Bianca RE, Lippolis L, Autore G, Popolo A, Marzocco S, Sorrentino L, et al</AU>
<TI>Dexamethasone improves vascular hyporeactivity induced by LPS in vivo by modulating ATP-sensitive potassium channel activity</TI>
<SO>British Journal of Pharmacology</SO>
<YR>2003</YR>
<VL>140</VL>
<PG>91&#8211;6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duma-2004" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Duma 2004" TYPE="JOURNAL_ARTICLE">
<AU>Duma D, Silva-Santos JE, Assreuy J</AU>
<TI>Inhibition of glucocorticoid receptor binding by nitric oxide in endotoxemic rats</TI>
<SO>Critical Care Medicine</SO>
<YR>2004</YR>
<VL>32</VL>
<PG>2304&#8211;10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-09-24 16:18:05 +0100" MODIFIED_BY="Jane Cracknell" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:55:29 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 16:55:29 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9310563"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Erschen-2007" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Erschen 2007" TYPE="JOURNAL_ARTICLE">
<AU>Ehrchen J, Steinmüller L, Barczyk K, Tenbrock K, Nacken W, Eisenacher M, et al</AU>
<TI>Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes</TI>
<SO>Blood</SO>
<YR>2007</YR>
<VL>109</VL>
<PG>1265-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fabian-1982" MODIFIED="2010-09-07 16:56:08 +0100" MODIFIED_BY="Jane Cracknell" NAME="Fabian 1982" TYPE="JOURNAL_ARTICLE">
<AU>Fabian TC, Patterson R</AU>
<TI>Steroid therapy in septic shock. Survival studies in a laboratory model</TI>
<SO>American Surgeon</SO>
<YR>1982</YR>
<VL>48</VL>
<NO>12</NO>
<PG>614-7</PG>
<IDENTIFIERS MODIFIED="2010-09-07 16:56:08 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 16:56:08 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="6760756"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Finfer-2004" MODIFIED="2010-10-07 13:23:40 +0100" MODIFIED_BY="[Empty name]" NAME="Finfer 2004" TYPE="JOURNAL_ARTICLE">
<AU>Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J</AU>
<TI>Adult population incidence of severe sepsis in Australian and New Zealand intensive care units</TI>
<SO>Intensive Care Medicine</SO>
<YR>2004</YR>
<VL>30</VL>
<PG>589&#8211;96</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:00:55 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:00:55 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 14963646"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Galigniana-1999" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Galigniana 1999" TYPE="JOURNAL_ARTICLE">
<AU>Galigniana MD, Piwien-Pilipuk G, Assreuy J</AU>
<TI>Inhibition of glucocorticoid receptor binding by nitric oxide</TI>
<SO>Molecular Pharmacology</SO>
<YR>1999</YR>
<VL>55</VL>
<PG>317&#8211;23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodwin-2013" MODIFIED="2015-02-01 13:33:36 +0000" MODIFIED_BY="djillali annane" NAME="Goodwin 2013" TYPE="JOURNAL_ARTICLE">
<AU>Goodwin JE, Feng Y, Velazquez H, Sessa WC</AU>
<TI>Endothelial glucocorticoid receptor is required for protection against sepsis</TI>
<SO>Proceeding of the National Academy of Science</SO>
<YR>2013</YR>
<VL>110</VL>
<PG>306&#8211;11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008a" MODIFIED="2010-10-07 13:24:15 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al; GRADE Working Group</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>924-6</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:07:17 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:07:17 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="18436948 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008b" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Guyatt 2008b" TYPE="BOOK_SECTION">
<AU>Guyatt GH, Wyer P, Ioannidis J</AU>
<TI>When to believe a subgroup analysis</TI>
<SO>User&#8217;s Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice</SO>
<YR>2008</YR>
<ED>Guyatt G, Rennie R, Meade M, Cook D</ED>
<PB>McGraw-Hill</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heller-2003" MODIFIED="2015-02-01 13:34:14 +0000" MODIFIED_BY="djillali annane" NAME="Heller 2003" TYPE="JOURNAL_ARTICLE">
<AU>Heller AR, Heller SC, Borkenstein A, Stehr SN, Koch T</AU>
<TI>Modulation of host defense by hydrocortisone in stress doses during endotoxaemia</TI>
<SO>Intensive Care Medicine</SO>
<YR>2003</YR>
<VL>29</VL>
<PG>1456-63</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:10:43 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:10:43 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12879235 ["/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>In: The Cochrane Collaboration, 2011. www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hotta-1986" MODIFIED="2010-09-24 16:18:05 +0100" MODIFIED_BY="Jane Cracknell" NAME="Hotta 1986" TYPE="JOURNAL_ARTICLE">
<AU>Hotta M, Baird A</AU>
<TI>Differential effects of transforming growth factor type beta on the growth and function of adrenocortical cells in vitro</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>1986</YR>
<VL>83</VL>
<NO>20</NO>
<PG>7795-9</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:11:27 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:11:27 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3020557"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Huang-1987" MODIFIED="2010-09-07 17:15:00 +0100" MODIFIED_BY="Jane Cracknell" NAME="Huang 1987" TYPE="JOURNAL_ARTICLE">
<AU>Huang ZH, Gao H, Xu RB</AU>
<TI>Study on glucocorticoid receptors during intestinal ischemia shock and septic shock</TI>
<SO>Circulatory Shock</SO>
<YR>1987</YR>
<VL>23</VL>
<NO>1</NO>
<PG>27-36</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:15:00 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:15:00 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 3690811"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2004" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Ioannidis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JPA</AU>
<TI>Better reporting of harms in randomized trials: an extension of the CONSORT statement</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>141</VL>
<PG>781-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jaattela-1991" MODIFIED="2010-09-07 17:15:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Jaattela 1991" TYPE="JOURNAL_ARTICLE">
<AU>Jaattela M, Ilvesmaki V, Voutilainen R, Stenman UH, Saksela E</AU>
<TI>Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells</TI>
<SO>Endocrinology</SO>
<YR>1991</YR>
<VL>128</VL>
<NO>1</NO>
<PG>623-9</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:15:32 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:15:32 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1702707"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kalil-2011" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Kalil 2011" TYPE="JOURNAL_ARTICLE">
<AU>Kalil AC, Sun J</AU>
<TI>Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies</TI>
<SO>Intensive Care Medicine</SO>
<YR>2011</YR>
<VL>37</VL>
<PG>420&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kanczkowski-2013" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Kanczkowski 2013" TYPE="JOURNAL_ARTICLE">
<AU>Kanczkowski W, Alexaki VI, Tran N, Großklaus S, Zacharowski K, Martinez A, et al</AU>
<TI>Hypothalamo-pituitary and immune-dependent adrenal regulation during systemic inflammation</TI>
<SO>Proceedings of the National Academy of Science</SO>
<YR>2013</YR>
<VL>110</VL>
<PG>14801&#8211;6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Katsenos-2014" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Katsenos 2014" TYPE="JOURNAL_ARTICLE">
<AU>Katsenos CS, Antonopoulou AN, Apostolidou EN, Ioakeimidou A, Kalpakou GT, Papanikolaou MN, et al; on behalf of the Hellenic Sepsis Study Group</AU>
<TI>Early administration of hydrocortisone replacement after the advent of septic shock: impact on survival and immune response</TI>
<SO>Critical Care Medicine</SO>
<YR>2014</YR>
<VL>42</VL>
<PG>1651-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kellum-2007" MODIFIED="2010-09-24 16:18:05 +0100" MODIFIED_BY="Jane Cracknell" NAME="Kellum 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al</AU>
<TI>Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2007</YR>
<VL>168</VL>
<PG>1468-9</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:22:30 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:22:30 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="17698689"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefering-1995" MODIFIED="2010-09-07 17:23:01 +0100" MODIFIED_BY="Jane Cracknell" NAME="Lefering 1995" TYPE="JOURNAL_ARTICLE">
<AU>Lefering R, Neugebauer EAM</AU>
<TI>Steroid controversy in sepsis and septic shock: a meta-analysis</TI>
<SO>Critical Care Medicine</SO>
<YR>1995</YR>
<VL>23</VL>
<NO>7</NO>
<PG>1294-303</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:23:01 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:23:01 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7600840 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lipiner-2007" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Lipiner 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lipiner D, Sprung CL, Laterre PF, Weiss Y, Goodman SV, Vogeser M, et al</AU>
<TI>Adrenal function in sepsis: the retrospective CORTICUS cohort study</TI>
<SO>Critical Care Medicine</SO>
<YR>2007</YR>
<VL>35</VL>
<PG>1012-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loisa-2007" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Loisa 2007" TYPE="JOURNAL_ARTICLE">
<AU>Loisa P, Parviainen I, Tenhunen J, Hovilehto S, Ruokonen E</AU>
<TI>Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock: a prospective randomized trial</TI>
<SO>Critical Care</SO>
<YR>2007</YR>
<VL>11</VL>
<PG>R21</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:29:37 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:29:37 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="17306016 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lowenberg-2005" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Lowenberg 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lowenberg M, Tuynman J, Bilderbeek J, Gaber T, Buttgereit F, van Deventer S, et al</AU>
<TI>Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn</TI>
<SO>Blood</SO>
<YR>2005</YR>
<VL>106</VL>
<PG>1703-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marik-2008" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Marik 2008" TYPE="JOURNAL_ARTICLE">
<AU>Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Arlt W, et al</AU>
<TI>Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine</TI>
<SO>Critical Care Medicine</SO>
<YR>2008</YR>
<VL>36</VL>
<PG>1937&#8211;49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martin-2003" MODIFIED="2010-09-24 16:18:05 +0100" MODIFIED_BY="Jane Cracknell" NAME="Martin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Martin GS, Mannino DM, Eaton S, Moss M</AU>
<TI>The epidemiology of sepsis in the United States from 1979 through 2000</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>348</VL>
<PG>1546-54</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:30:22 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:30:22 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12700374 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Meduri-1998a" MODIFIED="2010-09-07 17:30:49 +0100" MODIFIED_BY="Jane Cracknell" NAME="Meduri 1998a" TYPE="JOURNAL_ARTICLE">
<AU>Meduri GU, Chrousos GP</AU>
<TI>Duration of glucocorticoid treatment and outcome in sepsis: is the right drug used the wrong way?</TI>
<SO>Chest</SO>
<YR>1998</YR>
<VL>114</VL>
<NO>2</NO>
<PG>355-60</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:30:49 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:30:49 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9726712"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Melby-1958" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Melby 1958" TYPE="JOURNAL_ARTICLE">
<AU>Melby JC, Spink WW</AU>
<TI>Comparative studies on adrenal cortical function and cortisol metabolism in healthy adults and in patients with shock due to infection</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1958</YR>
<VL>37</VL>
<PG>1791-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Menon-2013" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Menon 2013" TYPE="JOURNAL_ARTICLE">
<AU>Menon K, McNally D, Choong K, Sampson M</AU>
<TI>A systematic review and meta-analysis on the effect of steroids in pediatric shock</TI>
<SO>Pediatric Critical Care Medicine</SO>
<YR>2013</YR>
<VL>14</VL>
<PG>474-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Molijn-1995" MODIFIED="2010-09-07 17:31:39 +0100" MODIFIED_BY="Jane Cracknell" NAME="Molijn 1995" TYPE="JOURNAL_ARTICLE">
<AU>Molijn GJ, Koper JW, van Uffelen CJ, de Jong FH, Brinkmann AO, Bruining HA, et al</AU>
<TI>Temperature-induced down-regulation of the glucocorticoid receptor in peripheral blood mononuclear leucocyte in patients with sepsis or septic shock</TI>
<SO>Clinical Endocrinology</SO>
<YR>1995</YR>
<VL>43</VL>
<NO>2</NO>
<PG>197-203</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:31:39 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:31:39 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7554315 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moran-2010" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Moran 2010" TYPE="JOURNAL_ARTICLE">
<AU>Moran JL, Graham PL, Rockliff S, Bersten AD</AU>
<TI>Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective</TI>
<SO>Critical Care</SO>
<YR>2010</YR>
<VL>14</VL>
<PG>R134</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norman-2004" MODIFIED="2015-02-01 13:37:55 +0000" MODIFIED_BY="djillali annane" NAME="Norman 2004" TYPE="JOURNAL_ARTICLE">
<AU>Norman AW, Mizwicki MT, Norman DP</AU>
<TI>Steroid-hormone rapid actions, membrane receptors, and a conformational ensemble model</TI>
<SO>Nature Revue Drug Discovery</SO>
<YR>2004</YR>
<VL>3</VL>
<PG>27-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Padkin-2003" MODIFIED="2010-10-08 13:07:19 +0100" MODIFIED_BY="[Empty name]" NAME="Padkin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K</AU>
<TI>Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland</TI>
<SO>Critical Care Medicine</SO>
<YR>2003</YR>
<VL>31</VL>
<PG>2332&#8211;8</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:32:19 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:32:19 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="14501964 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Park-2012" MODIFIED="2015-02-01 13:38:09 +0000" MODIFIED_BY="djillali annane" NAME="Park 2012" TYPE="JOURNAL_ARTICLE">
<AU>Park HY, Suh GY, Song JU, Yoo H, Jo IJ, Shin TG, et al</AU>
<TI>Early initiation of low-dose corticosteroid therapy in the management of septic shock: a retrospective observational study</TI>
<SO>Critical Care</SO>
<YR>2012</YR>
<VL>16</VL>
<PG>R3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parrillo-1993" MODIFIED="2010-07-29 16:38:04 +0100" MODIFIED_BY="[Empty name]" NAME="Parrillo 1993" TYPE="JOURNAL_ARTICLE">
<AU>Parrillo JE</AU>
<TI>Pathogenic mechanisms of septic shock</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>328</VL>
<NO>20</NO>
<PG>1471-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peters-2008" MODIFIED="2010-09-24 16:18:04 +0100" MODIFIED_BY="Jane Cracknell" NAME="Peters 2008" TYPE="JOURNAL_ARTICLE">
<AU>Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L</AU>
<TI>Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<PG>991-6</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:33:43 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:33:43 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=""/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Polito-2011" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Polito 2011" TYPE="JOURNAL_ARTICLE">
<AU>Polito A, Sonneville R, Guidoux C, Barrett L, Viltart O, Mattot V, et al</AU>
<TI>Changes in CRH and ACTH synthesis during experimental and human septic shock</TI>
<SO>PLoS One</SO>
<YR>2011</YR>
<VL>6</VL>
<PG>e25905</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-5" MODIFIED="2010-07-29 16:38:04 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 5" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan) Version 5.0</TI>
<YR>2008</YR>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rhen-2005" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Rhen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rhen T, Cidlowski JA</AU>
<TI>Antiinflammatory action of glucocorticoids: new mechanisms for old drugs</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<PG>1711-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rothwell-1991" MODIFIED="2010-09-07 17:33:41 +0100" MODIFIED_BY="Jane Cracknell" NAME="Rothwell 1991" TYPE="JOURNAL_ARTICLE">
<AU>Rothwell PM, Udwadia ZF, Lawler PG</AU>
<TI>Cortisol response to corticotropin and survival in septic shock</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<NO>8741</NO>
<PG>582-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sharshar-2003" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Sharshar 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sharshar T1, Gray F, Lorin de la Grandmaison G, Hopkinson NS, Ross E, Dorandeu A, et al</AU>
<TI>Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock</TI>
<SO>The Lancet</SO>
<YR>2003</YR>
<VL>362</VL>
<PG>1799-805</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sherwin-2012" MODIFIED="2015-02-01 11:05:40 +0000" MODIFIED_BY="djillali annane" NAME="Sherwin 2012" TYPE="JOURNAL_ARTICLE">
<AU>Sherwin RL, Garcia AJ, Bilkovski R</AU>
<TI>Do low-dose corticosteroids improve mortality or shock reversal in patients with septic shock? A systematic review and position statement prepared for the American Academy of Emergency Medicine</TI>
<SO>Journal of Emergency Medicine</SO>
<YR>2012</YR>
<VL>43</VL>
<PG>7-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Singer-2015" MODIFIED="2016-01-18 15:45:56 +0000" MODIFIED_BY="Jane Cracknell" NAME="Singer 2015" TYPE="JOURNAL_ARTICLE">
<AU>Singer M, Deutschman CS, Seymour CW, Shankar Hari M, Angus DC, Annane D, et al; The Sepsis Definitions Task Force</AU>
<TI>The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)</TI>
<SO>JAMA</SO>
<YR>2015</YR>
<PG>in press</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-The-EPISPESIS-Group-2004" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="The EPISPESIS Group 2004" TYPE="JOURNAL_ARTICLE">
<AU>The EPISPESIS Group</AU>
<TI>EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units</TI>
<SO>Intensive Care Medicine</SO>
<YR>2004</YR>
<VL>30</VL>
<PG>580-8</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:34:26 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:34:26 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="14997295"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tsao-2004" MODIFIED="2010-09-24 16:18:04 +0100" MODIFIED_BY="Jane Cracknell" NAME="Tsao 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tsao CM, Ho ST, Chen A, Wang JJ, Li CY, Tsai SK, et al</AU>
<TI>Low-dose dexamethasone ameliorates circulatory failure and renal dysfunction in conscious rats with endotoxemia</TI>
<SO>Shock</SO>
<YR>2004</YR>
<VL>21:</VL>
<PG>484-91</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:35:05 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:35:05 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=""/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vachharajani-2006" MODIFIED="2010-09-07 17:35:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Vachharajani 2006" TYPE="JOURNAL_ARTICLE">
<AU>Vachharajani V, Vital S, Russell J, Scott LK, Granger DN</AU>
<TI>Glucocorticoids inhibit the cerebral microvascular dysfunction associated with sepsis in obese mice</TI>
<SO>Microcirculation</SO>
<YR>2006</YR>
<VL>13</VL>
<PG>477-87</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:35:32 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:35:32 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="16864414 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Varga-2008" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Varga 2008" TYPE="JOURNAL_ARTICLE">
<AU>Varga G, Ehrchen J, Tsianakas A, Tenbrock K, Rattenholl A, Seeliger S, et al</AU>
<TI>Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells</TI>
<SO>Journal of Leukocyte Biology</SO>
<YR>2008</YR>
<VL>84</VL>
<PG>644-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vincent-1996" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Vincent 1996" TYPE="JOURNAL_ARTICLE">
<AU>Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al</AU>
<TI>The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine</TI>
<SO>Intensive Care Medicine</SO>
<YR>1996</YR>
<VL>22</VL>
<PG>707-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vincent-2013" MODIFIED="2015-02-01 13:41:02 +0000" MODIFIED_BY="djillali annane" NAME="Vincent 2013" TYPE="JOURNAL_ARTICLE">
<AU>Vincent JL, Opal SM, Marshall JC, Tracey KJ</AU>
<TI>Sepsis definitions: time for change</TI>
<SO>Lancet</SO>
<YR>2013</YR>
<VL>381</VL>
<PG>774-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2018-03-13 11:55:08 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Annane-2004" MODIFIED="2013-05-31 17:45:09 +0100" MODIFIED_BY="Jane Cracknell" NAME="Annane 2004" TYPE="COCHRANE_REVIEW">
<AU>Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y</AU>
<TI>Corticosteroids for treating severe sepsis and septic shock</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-05-31 17:45:09 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2013-05-31 17:45:09 +0100" MODIFIED_BY="Jane Cracknell" TYPE="DOI" VALUE="10.1002/14651858.CD002243.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Annane-2009" MODIFIED="2010-09-24 16:18:05 +0100" MODIFIED_BY="Jane Cracknell" NAME="Annane 2009" TYPE="JOURNAL_ARTICLE">
<AU>Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, et al</AU>
<TI>Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review</TI>
<SO>JAMA</SO>
<YR>2009</YR>
<VL>301</VL>
<PG>2362-75</PG>
<IDENTIFIERS MODIFIED="2010-09-07 17:36:16 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-09-07 17:36:16 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="19509383 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Annane-2015" MODIFIED="2018-03-13 11:55:07 +0000" MODIFIED_BY="[Empty name]" NAME="Annane 2015" TYPE="COCHRANE_REVIEW">
<AU>Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y</AU>
<TI>Corticosteroids for treating sepsis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2018-03-13 11:55:07 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2018-03-13 11:55:05 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002243.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES><CHARACTERISTICS_OF_STUDIES MODIFIED="2015-11-30 11:24:00 +0000" MODIFIED_BY="Jane Cracknell"><CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-11-30 11:24:00 +0000" MODIFIED_BY="Jane Cracknell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Annane-2002"><CHAR_METHODS MODIFIED="2015-02-01 13:00:46 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 2 parallel groups</P><P>19 centres</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Adults (n = 300) with vasopressor- and ventilator-dependent septic shock</P><P>Stratification according to cortisol response to 250 µg Synacthene into non-responders (delta cortisol &#8804; 9 µg/dL) and responders (&gt; 9 µg/dL)</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (50 mg intravenous bolus every 6 hours for 7 days) plus fludrocortisone (50 µg taken orally every 24 hours for 7 days)</LI><LI>Respective placebos</LI></UL><P>Treatments have to be initiated within 8 hours from shock onset</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>28-Day mortality in non-responders</LI></UL><P>SECONDARY</P><UL><LI>28-Day mortality in responders and in all participants</LI></UL><UL><LI>Intensive care unit mortality rate</LI></UL><UL><LI>Hospital mortality rate</LI></UL><UL><LI>1-Year mortality rate</LI></UL><UL><LI>Shock reversal</LI></UL><UL><LI>Organ system failure-free days</LI></UL><UL><LI>Length of stay in ICU and at hospital</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Study location: France</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Annane-2010"><CHAR_METHODS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Randomized controlled trial with 2 × 2 factorial design</P><P>11 centres</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Adults (n = 509) with vasopressor-dependent septic shock</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (50 mg intravenous bolus every 6 hours for 7 days) plus fludrocortisone (50 µg taken orally every 24 hours for 7 days) and intravenous insulin to maintain blood glucose between 80 and 110 mg/dL</LI></UL><UL><LI>Hydrocortisone (50 mg intravenous bolus every 6 hours for 7 days) and intravenous insulin to maintain blood glucose between 80 and 110 mg/dL</LI></UL><UL><LI>Hydrocortisone (50 mg intravenous bolus every 6 hours for 7 days) plus fludrocortisone (50 µg taken orally every 24 hours for 7 days) and conventional control of blood glucose levels</LI></UL><UL><LI>Hydrocortisone (50 mg intravenous bolus every 6 hours for 7 days) and conventional control of blood glucose levels</LI></UL><P>Treatments have to be initiated within 24 hours from shock onset</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Hospital mortality in non-responders.</LI></UL><P>SECONDARY</P><UL><LI>Mortality rates at 28 days, 90 days and 180 days and at ICU discharge</LI></UL><UL><LI>Vasopressor-free days</LI></UL><UL><LI>Organ failure-free days</LI></UL><UL><LI>ICU and hospital length of stay</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: France</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Arabi-2011"><CHAR_METHODS MODIFIED="2015-02-01 13:01:41 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Adult (n = 75) with liver cirrhosis and septic shock</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (50 mg intravenous bolus every 6 hours until shock resolution, then treatment tapered off by 1 mL every 2 days until discontinuation)</LI></UL><UL><LI>Placebo (normal saline)</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Primary</P><UL><LI>28-Day all-cause mortality</LI></UL><P>Secondary</P><UL><LI>ICU and hospital mortality</LI></UL><UL><LI>Shock reversal</LI></UL><UL><LI>Mechanical ventilation-free days</LI></UL><UL><LI>Renal replacement therapy-free days</LI></UL><UL><LI>Length of stay</LI></UL><UL><LI>SOFA score at day 7</LI></UL><UL><LI>Adverse events</LI></UL><P>Outcomes were also analysed in relation to adrenal insufficiency<BR/></P><P><BR/></P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: Saudi Arabia</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Bollaert-1998"><CHAR_METHODS MODIFIED="2015-02-01 13:01:51 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 2 parallel groups</P><P>2 centres</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Adults (n = 41) with vasopressor- and ventilator-dependent septic shock</P><P>Stratification according to cortisol response to 250 µg Synacthene into non-responders (delta cortisol &#8804; 6 µg/dL) and responders (&gt; 6 µg/dL)</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (100 mg intravenous bolus every 8 hours for 5 days, then tapered over 6 days)</LI></UL><UL><LI>Placebo</LI></UL><P>Treatments have to be initiated after 48 hours or longer from shock onset</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Shock reversal</LI></UL><P>SECONDARY</P><UL><LI>28-Day mortality</LI></UL><UL><LI>ICU mortality</LI></UL><UL><LI>Hospital mortality</LI></UL><UL><LI>Improvement in haemodynamics</LI></UL><UL><LI>Length of stay in ICU and at hospital</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Study location: France</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Bone-1987"><CHAR_METHODS MODIFIED="2015-02-01 13:02:13 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 2 parallel groups</P><P>19 centres</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Adults (n = 382) with sepsis (n = 234) or septic shock (n = 148)</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Methylprednisolone (30 mg/kg 20-minute intravenous infusion, every 6 hours for 24 hours)</LI></UL><UL><LI>Placebo</LI></UL><P>Treatments have to be initiated 2 hours from time entry criteria were met</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>14-Day development of shock for sepsis</LI></UL><UL><LI>Shock reversal for septic shock</LI></UL><UL><LI>14-Day death and safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: USA</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Briegel-1999"><CHAR_METHODS MODIFIED="2015-02-01 13:02:31 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 2 parallel groups</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Adults (n = 40) with vasopressor- and ventilator-dependent septic shock</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (100 mg 30-minute intravenous infusion followed by 0.18 mg/kg/h continuous infusion until shock reversal, then tapered off)</LI></UL><UL><LI>Placebo</LI></UL><P>Treatments have to be initiated within 72 hours from shock onset</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Shock reversal</LI></UL><P>SECONDARY</P><UL><LI>28-Day mortality</LI></UL><UL><LI>ICU mortality</LI></UL><UL><LI>Hospital mortality</LI></UL><UL><LI>Improvement in haemodynamics</LI></UL><UL><LI>Organ system failure (SOFA at day 7)</LI></UL><UL><LI>Length of stay in ICU</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: Germany</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Chawla-1999"><CHAR_METHODS MODIFIED="2015-02-01 13:06:14 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 2 parallel groups</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Adults (n = 44) with vasopressor-dependent septic shock</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (100 mg intravenous bolus every 8 hours for 3 days, then tapered over 4 days)</LI></UL><UL><LI>Placebo</LI></UL><P>Treatments have to be initiated after 72 hours or longer from shock onset</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Shock reversal</LI></UL><P>SECONDARY</P><UL><LI>28-Day mortality</LI></UL><UL><LI>Hospital mortality</LI></UL><UL><LI>Improvement in haemodynamics</LI></UL><UL><LI>Length of stay in ICU</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: USA</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Cicarelli-2007"><CHAR_METHODS MODIFIED="2015-02-01 13:06:33 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 2 parallel groups</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Adults (n = 29) with vasopressor-dependent septic shock</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Dexamethasone (0.2 mg/kg intravenous, 3 doses at intervals of 36 hours)</LI></UL><UL><LI>Placebo (normal saline)</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Duration of vasopressor support (SOFA score for cardiovascular system &#8805; 2)</LI></UL><UL><LI>Duration of mechanical ventilation</LI></UL><UL><LI>28-Day mortality</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Study location: Brazil</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Confalonieri-2005"><CHAR_METHODS MODIFIED="2015-02-01 13:06:53 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 2 parallel groups</P><P>6 centres</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Adults (n = 46) with severe community-acquired pneumonia</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (200 mg intravenous loading bolus followed by a continuous infusion at a rate of 10 mg/h for 7 days, then tapered over 4 days)</LI></UL><UL><LI>Placebo</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Improvement in PaO<SUB>2</SUB>:FiO<SUB>2</SUB> and in multiple organ dysfunction syndrome score by study day 8</LI></UL><P>SECONDARY</P><UL><LI>Duration of mechanical ventilation</LI></UL><UL><LI>Length of stay</LI></UL><UL><LI>60-Day mortality</LI></UL><UL><LI>ICU mortality</LI></UL><UL><LI>Hospital mortality</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: Italy</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-CSG-1963"><CHAR_METHODS MODIFIED="2015-02-01 13:07:16 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 2 parallel groups</P><P>5 centres</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Adults (n = 194) and children (n = 135) with vasopressor-dependent septic shock</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (intravenous infusion of 300 mg for 24 hours, then 250 mg for 24 hours, followed by 200 mg orally on day 3, then tapered off in steps of 50 mg per day, i.e. total duration of treatment - 6 days)</LI></UL><UL><LI>Placebo</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Hospital mortality</LI></UL><P>SECONDARY</P><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: USA</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Gordon-2014"><CHAR_METHODS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Randomized controlled trial with 2 parallel groups</P><P>4 centres</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Adults (n = 61) with septic shock on a maximal dose of vasopressin of up to 0.06 U/min</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone phosphate (50 mg IV bolus 6-hourly for 5 days, 12-hourly for 3 days, then once daily for 3 days)</LI></UL><UL><LI>Placebo (0.5 mL of 0.9% saline)</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Difference in plasma vasopressin concentration between treatment groups</LI></UL><P>SECONDARY</P><UL><LI>Difference in vasopressin requirements</LI></UL><UL><LI>28-Day mortality</LI></UL><UL><LI>ICU mortality</LI></UL><UL><LI>Hospital mortality</LI></UL><UL><LI>Organ failure-free days to 28 days post randomization</LI></UL><UL><LI>Shock reversal</LI></UL><UL><LI>Length of stay in ICU and at hospital</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: United Kingdom</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Hu-2009"><CHAR_METHODS MODIFIED="2015-02-01 13:07:38 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Adults (n = 77) with septic shock</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (50 mg intravenous bolus 6-hourly for 7 days, then 50 mg 8-hourly for 3 days, then 50 mg 12-hourly for 2 days and 50 mg once daily for 2 days)</LI></UL><UL><LI>Control group: no mention of placebo</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Time on norepinephrine and lactate clearance</LI></UL><P>SECONDARY</P><UL><LI>ICU mortality</LI></UL><UL><LI>ICU length of stay</LI></UL><UL><LI>Shock reversal</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: China</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Huh-2007"><CHAR_METHODS MODIFIED="2015-02-01 13:07:47 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 2 parallel groups</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Adults (n = 82) with septic shock and adrenal insufficiency</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (50 mg intravenous bolus every 6 hours for 7 days)</LI></UL><UL><LI>Hydrocortisone (50 mg intravenous bolus every 6 hours for 3 days)</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>28-Day mortality</LI></UL><P>SECONDARY</P><UL><LI>Shock reversal</LI></UL><UL><LI>Duration of mechanical ventilation</LI></UL><UL><LI>Length of stay</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: South Korea</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Keh-2003"><CHAR_METHODS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Randomized controlled trial with cross-over design</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Adults (n = 40) with vasopressor-dependent septic shock</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (100 mg 30-minute intravenous infusion followed by 10 mg/h continuous infusion for 3 days)</LI></UL><UL><LI>Placebo</LI></UL><P>All participants received hydrocortisone for 3 days preceded or followed by placebo for 3 days</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Immune response</LI></UL><P>SECONDARY</P><UL><LI>Improvement in haemodynamics and organ system failure</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: Germany</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Liu-2012"><CHAR_METHODS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with parallel groups</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Adults (n = 26) with ARDS and sepsis, including septic shock (n = 12)</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (100 mg intravenous bolus 8-hourly for 7 consecutive days)</LI></UL><UL><LI>Placebo (normal saline)</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Unclear</LI></UL><P>SECONDARY</P><UL><LI>28-Day mortality</LI></UL><UL><LI>Prevalence of shock within 28 days</LI></UL><UL><LI>SOFA score (information for SOFA score at day 7 not available)</LI></UL><UL><LI>ICU length of stay</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: China</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Luce-1988"><CHAR_METHODS MODIFIED="2015-02-01 13:08:24 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Adults (n = 75) with sepsis and septic shock</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Methylprednisolone (30 mg/kg 15-minute intravenous infusion every 6 hours for 24 hours)</LI></UL><UL><LI>Placebo</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Prevention of ARDS</LI></UL><P>SECONDARY</P><UL><LI>Hospital mortality</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: USA</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Meduri-2007"><CHAR_METHODS MODIFIED="2015-02-01 13:08:47 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial (2:1 scheme)</P><P>5 centres</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Adults (n = 91) with early ARDS (&#8804; 72 hours from diagnosis of ARDS). 61 (67%) had sepsis or septic shock, and the primary author provided separate data for these participants</P><P>Stratification according to cortisol response to 250 µg Synacthene into non-responders (delta cortisol &#8804; 9 µg/dL) and responders (&gt; 9 µg/dL)</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Methylprednisolone loading dose of 1 mg/kg followed by continuous infusion of 1 mg/kg/d from day 1 to day 14, then 0.5 mg/kg/d from day 15 to day 21, then 0.25 mg/kg/d from day 22 to day 25, then 0.125 mg/kg/d from day 26 to day 28. If participant was extubated before day 14, he/she was advanced to day 15 of drug therapy. Treatment was given intravenously until enteral intake was restored, then was given as a single oral dose</LI></UL><UL><LI>Placebo</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Improvement in Lung Injury Score (LIS) at day 7. This improvement was defined as a reduction in score &#8805; 1 point and a day 7 score &#8804; 2 (if randomization LIS score &lt; 3) or &#8804; 2.5 (if randomization LIS score &lt; 3)</LI></UL><P>SECONDARY</P><UL><LI>Mechanical ventilation-free days</LI></UL><UL><LI>Multiple organ dysfunction (MOD) score at study day 7</LI></UL><UL><LI>28-Day mortality</LI></UL><UL><LI>ICU mortality</LI></UL><UL><LI>Hospital mortality</LI></UL><UL><LI>Length of stay in ICU and at hospital</LI></UL><UL><LI>C-reactive protein levels at study day 7</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>If participant failed to improve on Lung Injury Score between day 7 and day 9, he/she received open-label methylprednisolone at 2 mg/kg/d for unresolving ARDS</P><P>Study location: USA</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Meijvis-2011"><CHAR_METHODS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 2 parallel groups</P><P>2 centres</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Adults (n = 304) with confirmed community-acquired pneumonia who presented to emergency departments </P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Dexamethasone (5 mg intravenous bolus once a day for 4 days)</LI></UL><UL><LI>Placebo (normal saline)</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Length of hospital stay</LI></UL><P>SECONDARY</P><UL><LI>30-Day mortality</LI></UL><UL><LI>Hospital mortality</LI></UL><UL><LI>Duration of treatment with intravenous antibiotics</LI></UL><UL><LI>Admission to ICU</LI></UL><UL><LI>Inflammation markers and health performance</LI></UL><UL><LI>Lung function</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Study location: The Netherlands</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Oppert-2005"><CHAR_METHODS MODIFIED="2015-02-01 13:09:20 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 2 parallel groups</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Adults (n = 40) with vasopressor-dependent septic shock</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (50 mg of intravenous bolus followed by 0.18 mg/kg/h continuous infusion up to cessation of vasopressor for &#8805; 1 hour, reduced to a dose of 0.02 mg/kg/h for 24 hours, then reduced by 0.02 mg/kg/h every day)</LI></UL><UL><LI>Placebo</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Time to cessation of vasopressor support</LI></UL><P>SECONDARY</P><UL><LI>Cytokine response</LI></UL><UL><LI>28-Day survival</LI></UL><UL><LI>Sequential organ failure assessment (SOFA) score</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: Germany</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Rezk--2013"><CHAR_METHODS MODIFIED="2015-02-01 13:09:56 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial (2:1 scheme) with 2 parallel groups</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Adults (n = 27) with ARDS and hospital- or community-acquired pneumonia</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Methylprednisolone (loading dose of 1 mg/kg followed by infusion of 1 mg/kg/d from day 1 to day 14, 0.5 mg/kg/d from day 15 to day 21, 0.25 mg/kg/d from day 22 to day 25 and 0.125 mg/kg/d from day 26 to day 28</LI></UL><UL><LI>Placebo (normal saline)</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Unclear</LI></UL><P>SECONDARY</P><UL><LI>Short-term mortality (time point unclear)</LI></UL><UL><LI>Time on mechanical ventilation</LI></UL><UL><LI>Vital signs</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: Egypt</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Rinaldi-2006"><CHAR_METHODS MODIFIED="2015-02-01 13:10:05 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 2 parallel groups</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Adults (n = 40) with sepsis and not receiving vasopressor support</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (300 mg per day as a continuous infusion for 6 days, then tapered off)</LI></UL><UL><LI>Standard therapy</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Not explicitly stated</LI></UL><P>SECONDARY</P><UL><LI>Markers of inflammation: microalbuminuria-to-creatinine ratio, serum levels of C-reactive protein and procalcitonin</LI></UL><UL><LI>Duration of mechanical ventilation</LI></UL><UL><LI>Sequential organ failure assessment (SOFA) score</LI></UL><UL><LI>Length of stay</LI></UL><UL><LI>Hospital mortality</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: Italy</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Sabry-2011"><CHAR_METHODS MODIFIED="2015-02-01 13:10:16 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial</P><P>3 centres</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Adults (n = 80) admitted to ICU with community-acquired pneumonia and sepsis</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (intravenous loading dose of 200 mg over 30 minutes, followed by 300 mg in 500 mL 0.9% saline at a rate of 12.5 mg/h) for 7 days</LI></UL><UL><LI>Placebo (normal saline)</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Improvement in PaO<SUB>2</SUB>:FiO<SUB>2</SUB> (PaO<SUB>2</SUB>:FiO<SUB>2</SUB> &gt; 300 or &#8805; 100 increase from study entry)</LI></UL><P>SECONDARY</P><UL><LI>SOFA score by day 8</LI></UL><UL><LI>Development of delayed septic shock</LI></UL><UL><LI>ICU mortality rate</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: Egypt</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Schumer-1976"><CHAR_METHODS MODIFIED="2015-02-01 13:10:24 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 3 parallel groups</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Adults (n = 172) with septic shock with positive blood culture</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Dexamethasone (3 mg/kg as a single intravenous bolus)</LI></UL><UL><LI>Methylprednisolone (30 mg/kg as a single intravenous bolus)</LI></UL><UL><LI>Placebo</LI></UL><P>Treatments might have been repeated once after 4 hours and had to be initiated at the time of diagnosis</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Hospital mortality</LI></UL><P>SECONDARY</P><UL><LI>Complication rates</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: USA</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Slusher-1996"><CHAR_METHODS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial</P><P>2 centres</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>African children (n = 72; 1 to 16 years of age) with sepsis or septic shock</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Dexamethasone (0.20 mg/kg every 8 hours for 2 days)</LI></UL><UL><LI>Placebo</LI></UL><P>Treatments had to be initiated 5 to 10 minutes before first dose of antibiotic</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Hospital mortality (unclear)</LI></UL><P>SECONDARY</P><UL><LI>Haemodynamic stability at 48 hours</LI></UL><UL><LI>Complications</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Study location: USA, Kenya and Nigeria</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Snijders-2010"><CHAR_METHODS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 2 parallel groups</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Adults (n = 213) with severe community-acquired pneumonia</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Prednisolone (40 mg intravenous once per day for 7 days)</LI></UL><UL><LI>Placebo</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Day 7 and day 30 rate of treatment failure, defined by persistence or progression of all signs and symptoms that developed during acute disease episode after randomization, or development of new pulmonary or extra-pulmonary respiratory tract infection, or deterioration of chest radiography after randomization or death due to pneumonia, or inability to complete the study due to adverse events</LI></UL><P>SECONDARY</P><UL><LI>Time to clinical stability</LI></UL><UL><LI>Length of hospital stay</LI></UL><UL><LI>30-Day mortality</LI></UL><UL><LI>Inflammatory markers</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Study location: The Netherlands</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Sprung-1984"><CHAR_METHODS MODIFIED="2015-02-01 13:11:12 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 3 parallel groups</P><P>2 centres</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Adults (n = 59) with vasopressor-dependent septic shock</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Dexamethasone (6 mg/kg as a single intravenous 10 to 15-minute infusion)</LI></UL><UL><LI>Methylprednisolone (30 mg/kg as a single intravenous 10 to 15-minute infusion)</LI></UL><UL><LI>No treatment</LI></UL><UL><LI>Placebo</LI></UL><P>Treatments might have been repeated once after 4 hours if shock persisted and had to be initiated at time of diagnosis</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Hospital mortality</LI></UL><UL><LI>Shock reversal</LI></UL><P>SECONDARY</P><UL><LI>Complications of septic shock</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: USA</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Sprung-2008"><CHAR_METHODS MODIFIED="2015-02-01 13:11:43 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 2 parallel groups</P><P>52 centres</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Adults (n = 499) with septic shock</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (50 mg every 6 hours for 5 days, then 50 mg every 12 hours for 3 days, then 50 mg once a day for 3 days)</LI></UL><UL><LI>Placebo</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>28-Day mortality in non-responders</LI></UL><P>SECONDARY</P><UL><LI>28-Day mortality in responders and in all participants</LI></UL><UL><LI>ICU mortality rate</LI></UL><UL><LI>Hospital mortality rate</LI></UL><UL><LI>1-Year mortality rate</LI></UL><UL><LI>Shock reversal</LI></UL><UL><LI>Organ system failure-free days</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Study locations: Europe and Israel</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Tandan-2005"><CHAR_METHODS MODIFIED="2015-02-01 13:12:17 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 2 parallel groups</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Adults (n = 28) with septic shock and adrenal insufficiency</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (stated low dose but actual dose and duration not reported)</LI></UL><UL><LI>Placebo</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>28-Day mortality or survival to hospital discharge</LI></UL><P>SECONDARY</P><UL><LI>Shock reversal</LI></UL><UL><LI>Improvement in APACHE II score</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: India</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Torres-2015"><CHAR_METHODS MODIFIED="2015-02-01 13:12:32 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial with 2 parallel groups</P><P>3 centres</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Adults (n = 61) with both severe CAP and high inflammatory response, defined as levels of C-reactive protein &gt; 15 mg/dL on admission</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Methlyprednisolone (intravenous bolus of 0.5 mg/kg/12 h for 5 days started within 36 hours of hospital admission)</LI></UL><UL><LI>Placebo (normal saline)</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Rate of treatment failure, which includes early and/or late treatment failure. Early treatment failure was defined as clinical deterioration within 72 hours of treatment, as indicated by development of shock or need for invasive mechanical ventilation not present at baseline, or death. Late treatment failure was defined as radiographic progression (increase of &#8805; 50% of pulmonary infiltrates compared with baseline), persistence of severe respiratory failure (PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &lt; 200, with respiratory rate &#8805; 30 min<SUP>-1 </SUP>in non-intubated participants), development of shock or need for invasive mechanical ventilation not present at baseline or death between 72 and 120 hours after treatment initiation.</LI></UL><P>SECONDARY</P><UL><LI>Time to clinical stability</LI></UL><UL><LI>Length of ICU and hospital stay</LI></UL><UL><LI>In-hospital mortality</LI></UL><UL><LI>Inflammatory markers</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane"><P>Study location: Spain</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Valoor-2009"><CHAR_METHODS MODIFIED="2015-02-01 13:13:09 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial on 2 parallel groups</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Children (n = 38; 2 months to 12 years of age) with septic shock unresponsive to fluid therapy alone</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Hydrocortisone (intravenous dose of 5 mg/kg/d in 4 divided doses followed by half the dose for a total duration of 7 days)</LI></UL><UL><LI>Placebo (normal saline)</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Time to shock reversal</LI></UL><P>SECONDARY</P><UL><LI>Vasopressor doses</LI></UL><UL><LI>Mortality (unclear time point)</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane"><P>Study location: India</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-VASSCSG-1987"><CHAR_METHODS MODIFIED="2015-02-01 13:13:19 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial</P><P>10 centres</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane"><P>Adults (n = 223) with sepsis or septic shock (n = 100)</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Methylprednisolone (30 mg/kg as a single intravenous 10 to 15-minute infusion, followed by a constant infusion of 5 mg/kg/h for 9 hours)</LI></UL><UL><LI>Placebo</LI></UL><P>Treatment had to be initiated within 2 hours</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>14-Day mortality</LI></UL><P>SECONDARY</P><UL><LI>Complications</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane"><P>Study location: USA</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Yildiz-2002"><CHAR_METHODS MODIFIED="2015-02-01 13:13:40 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Adults (n = 40) with sepsis (n = 14), severe sepsis (n = 17) and septic shock (n = 9)</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Prednisolone (2 intravenous boluses: 5 mg at 06:00 and 2.5 mg at 18:00 for 10 days)</LI></UL><UL><LI>Placebo</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>28-Day mortality</LI></UL><P>SECONDARY</P><UL><LI>Hospital mortality</LI></UL><UL><LI>Safety</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane"><P>Study location: Turkey</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Yildiz-2011"><CHAR_METHODS MODIFIED="2015-02-01 13:14:20 +0000" MODIFIED_BY="djillali annane"><P>Randomized controlled trial on 2 parallel groups</P><P>1 centre</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane"><P>Adults (n = 55) with sepsis or septic shock</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Prednisolone (intravenous 3 times a day at 06:00 (10 mg), 14:00 (5 mg) and 22:00 (5 mg) for 10 days)</LI></UL><UL><LI>Placebo (normal saline)</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>28-Day mortality from all causes</LI></UL><P>SECONDARY</P><UL><LI>Reversal of organ failure</LI></UL><UL><LI>Length of stay</LI></UL><UL><LI>Safety</LI></UL><P>Outcomes were also assessed in relation to adrenal insufficiency</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane"><P>Study location: Turkey</P></CHAR_NOTES></INCLUDED_CHAR><FOOTNOTES><P>Abbreviations:</P><P>APACHE II: Acute Physiology and Chronic Health Evaluation II.</P><P>ARDS: acute respiratory distress syndrome.</P><P>CAP: community acquired pneumonia.</P><P>FiO<SUB>2</SUB>: fractional inspired oxygen.</P><P>ICU: intensive care unit.</P><P>LIS: Lung Injury Scale score.</P><P>MOD: multiple organ dysfunction.</P><P>PaO<SUB>2</SUB>: arterial oxygen tension.</P><P>SOFA: sequential organ failure assessment</P></FOOTNOTES></CHARACTERISTICS_OF_INCLUDED_STUDIES><CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" SORT_BY="STUDY"><EXCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Cicarelli-2006"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Mixed population of critically ill patients; separate data on septic shock not available</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Hahn-1951"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Patients with acute streptococcal infection</P><P>This trial investigated effects of hydrocortisone on fever, anti-streptolysin titers and onset of rheumatic fever. No data are reported for analysis of the various outcomes considered in this systematic review</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Hughes-1984"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Only acute effects (within 1 hour) of methylprednisolone and/or naloxone on haemodynamic data were available; no data for any of the outcomes considered in this systematic review were reported</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Kaufman-2008"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>In this study, participants were randomly assigned to receive hydrocortisone or its placebo for 24 hours only. Then, treatment with open-labelled hydrocortisone was given at physicians' discretion. This study was aimed at exploring effects of hydrocortisone on immune cell function</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Klastersky-1971"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>This study was not a randomized trial. Investigators did not describe how participants were allocated to experimental treatment</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Lucas-1984"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>This study was not a randomized trial. Participants were allocated to experimental treatment according to their hospital number</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-McKee-1983"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Mixed population of critically ill patients; separate data on septic shock not available</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Meduri-1998b"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>This trial included participants with late acute respiratory distress syndrome phase - not those with septic shock</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Mikami-2007"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>This study included participants with community-acquired pneumonia and explicitly excluded patients with sepsis, those needing admission to the intensive care unit and those requiring mechanical ventilation</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Rogers-1970"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Study published only as an abstract; no contact with study authors was possible; incomplete information on primary and secondary outcomes</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Thompson-1976"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Study published only as an abstract; no contact with study authors was possible; incomplete information on primary and secondary outcomes</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Venet-2015"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>This study included severely burned patients without sepsis</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Wagner-1955"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>This study was not a randomized trial. Participants were allocated to experimental treatment according to their hospital numbers</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Weigelt-1985"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Mixed population of critically ill patients</P><P>Separate data on septic shock not available</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><FOOTNOTES/></CHARACTERISTICS_OF_EXCLUDED_STUDIES><CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-03-27 10:55:22 +0000" MODIFIED_BY="Djillali Annane" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><FOOTNOTES/></CHARACTERISTICS_OF_AWAITING_STUDIES><CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><ONGOING_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Blum--2015"><CHAR_STUDY_NAME MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane"><P>STEP</P></CHAR_STUDY_NAME><CHAR_METHODS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Multi-centre. randomized, placebo-controlled, 2-parallel-group study</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>800 adult patients hospitalized with community-acquired pneumonia</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Prednisone 50 mg per day for 7 days</P><P>Placebo</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Clinical stability</LI></UL><P>SECONDARY</P><UL><LI>All-cause mortality within 30 and 180 days post randomization</LI></UL><UL><LI>ICU admission and length of stay</LI></UL><UL><LI>Duration of antibiotic treatment</LI></UL><UL><LI>Disease activity scores</LI></UL><UL><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_STARTING_DATE MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane"><P>December 2009</P></CHAR_STARTING_DATE><CHAR_CONTACT_INFORMATION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Mirjam Christ-Crain; Mirjam.Christ@usb.ch</P></CHAR_CONTACT_INFORMATION><CHAR_NOTES/></ONGOING_CHAR><ONGOING_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Gordon-2014a"><CHAR_STUDY_NAME MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane"><P>VANISH</P></CHAR_STUDY_NAME><CHAR_METHODS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Multi-centre, factorial (2 × 2), randomized, double-blind, placebo-controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>412 adult patients who require vasopressors for management of sepsis despite fluid resuscitation. In this trial, hydrocortisone or its placebo will be initiated only when participants will require the maximum dose of vasopressin or norepinephrine as defined in the protocol<BR/></P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Vasopressin + hydrocortisone</LI></UL><UL><LI>Vasopressin + placebo</LI></UL><UL><LI>Noradrenaline + hydrocortisone</LI></UL><UL><LI>Noradrenaline + placebo</LI></UL><P>Hydrocrotisone phosphate (50 mg, i.e. 0.5 mL) will be administered by intravenous injection 6-hourly for 5 days, then tapered to 0.5 mL every 12 hours for days 6 to 8, 0.5 mL every 24 hours for days 9 to 11, then stopped<BR/>Placebo = 0.9% saline<BR/></P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Difference in renal failure-free days (number of days alive and free of renal failure) between treatment groups during the 28 days after randomization</LI></UL><P>SECONDARY</P><UL><LI>Rates and duration of renal replacement therapy</LI></UL><UL><LI>Length of renal failure in survivors and non-survivors</LI></UL><UL><LI>28-Day ICU and hospital mortality rates</LI></UL><UL><LI>Organ failure-free days in the first 28 days, assessed using the Serial Organ Failure Assessment (SOFA) score</LI></UL><UL><LI>Organ support data assessed using standard National Health Service Healthcare Resource Groups</LI></UL><UL><LI>Blood and urinary biomarkers of renal function and inflammation (for subsequent analyses)</LI></UL></CHAR_OUTCOMES><CHAR_STARTING_DATE MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane"><P>February 2013</P></CHAR_STARTING_DATE><CHAR_CONTACT_INFORMATION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Anthony Gordon; anthony.gordon@imperial.ac.uk<BR/></P></CHAR_CONTACT_INFORMATION><CHAR_NOTES MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane"><P>EudraCT 2011-005363-24; ISRCTN20769191</P></CHAR_NOTES></ONGOING_CHAR><ONGOING_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-NCT00127985-2005"><CHAR_STUDY_NAME MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>6-Methylprednisolone for multiple organ dysfunction syndrome</P></CHAR_STUDY_NAME><CHAR_METHODS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Randomized, double-blind, placebo-controlled 2-parallel-group study</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2010-09-23 17:01:18 +0100" MODIFIED_BY="[Empty name]"><P>Adults with persistent multiple organ dysfunction</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Intravenous administration of 6-methylprednisolone or placebo for 32 days</P><P>Loading dose of 160 mg followed by IV bolus q6 of 40 mg from day 1 to 14, 20 mg from day 15 to 21, 10 mg from day 22 to 28, 5 mg on days 29 and 30 and 2.5 mg on days 31 and 32</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY </P><UL><LI>28-Day all-cause mortality</LI></UL></CHAR_OUTCOMES><CHAR_STARTING_DATE MODIFIED="2008-10-24 08:49:50 +0100" MODIFIED_BY="Djillali Annane"><P>01/08/2005</P></CHAR_STARTING_DATE><CHAR_CONTACT_INFORMATION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Miguel Sanchez; miguelsanchez.areachip@wanadoo.es</P></CHAR_CONTACT_INFORMATION><CHAR_NOTES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>This trial has been halted for low recruitment rate and lack of funding</P></CHAR_NOTES></ONGOING_CHAR><ONGOING_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-NCT00368381-2008"><CHAR_STUDY_NAME MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Hydrocortisone versus hydrocortisone plus fludrocortisone for treatment of adrenal insufficiency in sepsis</P></CHAR_STUDY_NAME><CHAR_METHODS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Treatment, randomized, single-blind, placebo-controlled, parallel-assignment efficacy study</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Adults with sepsis and positive corticotropin test (basal cortisol &#8804; 34 µg/dL and delta cortisol &#8804; 9 µg/dL</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Hydrocortisone vs hydrocortisone plus fludrocortisone</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>28-Day mortality</P></CHAR_OUTCOMES><CHAR_STARTING_DATE MODIFIED="2008-04-11 11:29:26 +0100" MODIFIED_BY="Jane Cracknell"><P>September 2006</P></CHAR_STARTING_DATE><CHAR_CONTACT_INFORMATION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Contact: John A. Bethea, PharmD    </P><P>304-388-6260    </P><P><A HREF="mailto:audis.bethea%40camc.org?subject=nct00368381, 06-05-1813, hydrocortisone versus hydrocortisone plus fludrocortisone for the treatment of adrenal insufficiency in severe sepsis">audis.bethea@camc.org</A></P><P>   </P><P>Contact: Carol A. Morreale, PharmD    </P><P>304-388-3767    </P><P><A HREF="mailto:carol.morreale%40camc.org?subject=nct00368381, 06-05-1813, hydrocortisone versus hydrocortisone plus fludrocortisone for the treatment of adrenal insufficiency in severe sepsis">carol.morreale@camc.org</A></P><P>   </P></CHAR_CONTACT_INFORMATION><CHAR_NOTES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>This study has never started to recruit patients</P></CHAR_NOTES></ONGOING_CHAR><ONGOING_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-NCT00562835-2008"><CHAR_STUDY_NAME MODIFIED="2008-10-24 08:49:50 +0100" MODIFIED_BY="Djillali Annane"><P>Steroids in patients with early ARDS</P></CHAR_STUDY_NAME><CHAR_METHODS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Randomized, double-blind, placebo-controlled, 2-parallel-group safety/efficacy study</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Adults with ARDS &lt; 72 hours</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Low-dose methylprednisolone vs placebo</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY </P><UL><LI>28-Day all-cause mortality</LI></UL></CHAR_OUTCOMES><CHAR_STARTING_DATE MODIFIED="2008-10-24 08:49:50 +0100" MODIFIED_BY="Djillali Annane"><P>February 2008</P></CHAR_STARTING_DATE><CHAR_CONTACT_INFORMATION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Massimo Antonelli; m.antonelli@rm.unicatt.it</P></CHAR_CONTACT_INFORMATION><CHAR_NOTES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>This study has never started to recruit patients</P></CHAR_NOTES></ONGOING_CHAR><ONGOING_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-NCT00625209-2008"><CHAR_STUDY_NAME MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Activated protein C and corticosteroids for human septic shock (APROCCHS)<BR/></P></CHAR_STUDY_NAME><CHAR_METHODS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Randomized, double-blind, placebo-controlled trial - 2 × 2 factorial design</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2008-04-11 11:29:26 +0100" MODIFIED_BY="Jane Cracknell"><P>Adults with septic shock</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><UL><LI>Placebo of hydrocortisone, placebo of fludrocortisone and placebo of activated protein C</LI></UL><UL><LI>Hydrocortisone plus fludrocortisone and placebo of activated protein C</LI></UL><UL><LI>Placebo of hydrocortisone, placebo of fludrocortisone and activated protein C</LI></UL><UL><LI>Hydrocortisone plus fludrocortisone plus activated protein C</LI></UL></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>90-Day mortality</P></CHAR_OUTCOMES><CHAR_STARTING_DATE MODIFIED="2008-04-11 11:29:26 +0100" MODIFIED_BY="Jane Cracknell"><P>April 2008</P></CHAR_STARTING_DATE><CHAR_CONTACT_INFORMATION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Djillali Annane; telephone: 331 47 10 77 87; djillali.annane@rpc.aphp.f</P></CHAR_CONTACT_INFORMATION><CHAR_NOTES MODIFIED="2008-03-27 10:55:22 +0000" MODIFIED_BY="Djillali Annane"/></ONGOING_CHAR><ONGOING_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-NCT00670254-2008"><CHAR_STUDY_NAME MODIFIED="2008-10-24 08:49:50 +0100" MODIFIED_BY="Djillali Annane"><P>Hydrocortisone for prevention of septic shock</P></CHAR_STUDY_NAME><CHAR_METHODS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Randomized, double-blind, placebo-controlled, 2-parallel-group efficacy study</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Sepsis</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Hydrocortisone vs placebo</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>Proportion of participants with septic shock at day 14</LI></UL></CHAR_OUTCOMES><CHAR_STARTING_DATE MODIFIED="2008-10-24 08:49:50 +0100" MODIFIED_BY="Djillali Annane"><P>01/06/2008</P></CHAR_STARTING_DATE><CHAR_CONTACT_INFORMATION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Didier Keh; didier.keh@charite.de</P></CHAR_CONTACT_INFORMATION><CHAR_NOTES/></ONGOING_CHAR><ONGOING_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-NCT00732277--2008"><CHAR_STUDY_NAME MODIFIED="2015-02-03 16:32:15 +0000" MODIFIED_BY="Jane Cracknell"><P>Evaluation of corticosteroid therapy in childhood severe sepsis: a randomized pilot study</P></CHAR_STUDY_NAME><CHAR_METHODS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Randomized, open-label, uncontrolled, 2-parallel-group study</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2010-09-23 17:01:19 +0100" MODIFIED_BY="[Empty name]"><P>Children with sepsis</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2010-09-23 17:01:19 +0100" MODIFIED_BY="[Empty name]"><P>Hydrocortisone</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>28-Day all-cause mortality</LI></UL></CHAR_OUTCOMES><CHAR_STARTING_DATE MODIFIED="2008-10-24 08:49:50 +0100" MODIFIED_BY="Djillali Annane"><P>01/04/2008</P></CHAR_STARTING_DATE><CHAR_CONTACT_INFORMATION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Saul N Faust; s.faust@soton.ac.uk</P></CHAR_CONTACT_INFORMATION><CHAR_NOTES/></ONGOING_CHAR><ONGOING_CHAR MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Venkatesh-2013"><CHAR_STUDY_NAME MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane"><P>ADRENAL</P></CHAR_STUDY_NAME><CHAR_METHODS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Multi-centre, randomized, controlled, 2-parallel-group study</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane"><P>3800 ICU adults with septic shock </P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane"><P>Hydrocortisone</P><P>Placebo</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>PRIMARY</P><UL><LI>90-Day all-cause mortality</LI></UL><P>SECONDARY</P><UL><LI>ICU and hospital mortality</LI></UL><UL><LI>Length of ICU stay</LI></UL><UL><LI>Shock reversal</LI></UL><UL><LI>Duration of mechanical ventilation</LI></UL><UL><LI>Quality of life at 6 months</LI></UL><UL><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_STARTING_DATE MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane"><P>February 2013</P></CHAR_STARTING_DATE><CHAR_CONTACT_INFORMATION MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Bala Venkatesh; Bala_Venkatesh@health.qld.gov.au</P></CHAR_CONTACT_INFORMATION><CHAR_NOTES/></ONGOING_CHAR><FOOTNOTES/></CHARACTERISTICS_OF_ONGOING_STUDIES></CHARACTERISTICS_OF_STUDIES><QUALITY_ITEMS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="1"><NAME>Random sequence generation (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2002"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2010"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Arabi-2011"><DESCRIPTION><P>Computer-generated random numbers</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Bollaert-1998"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Bone-1987"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Briegel-1999"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CSG-1963"><DESCRIPTION><P>Not given</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Chawla-1999"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Cicarelli-2007"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Confalonieri-2005"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="YES" STUDY_ID="STD-Gordon-2014"><DESCRIPTION><P>Computer-generated random numbers prepared by an independent statistician</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2009"><DESCRIPTION><P>Not stated in the manuscript</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Huh-2007"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Keh-2003"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Liu-2012"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Luce-1988"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Meduri-2007"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Meijvis-2011"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Oppert-2005"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Rezk--2013"><DESCRIPTION><P>No explicit information in the manuscript</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Rinaldi-2006"><DESCRIPTION><P>Computer-generated randomization list</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Sabry-2011"><DESCRIPTION><P>No information in the manuscript</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-01 13:10:34 +0000" MODIFIED_BY="djillali annane" RESULT="NO" STUDY_ID="STD-Schumer-1976"><DESCRIPTION><P>Randomized card system</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Slusher-1996"><DESCRIPTION><P>Not given</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Snijders-2010"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Sprung-1984"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Sprung-2008"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Tandan-2005"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Torres-2015"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-VASSCSG-1987"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Valoor-2009"><DESCRIPTION><P>No explicit information in the manuscript</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Yildiz-2002"><DESCRIPTION><P>Computer-generated randomization scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Yildiz-2011"><DESCRIPTION><P>Computer-generated random numbers used</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="2"><NAME>Allocation concealment (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2002"><DESCRIPTION><P>Centralized randomization </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2010"><DESCRIPTION><P>Centralized randomization through a secured website</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Arabi-2011"><DESCRIPTION><P>Use of sealed envelopes by pharmacists</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Bollaert-1998"><DESCRIPTION><P>Randomization list kept confidential by the pharmacist</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Bone-1987"><DESCRIPTION><P>Centralized randomization </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Briegel-1999"><DESCRIPTION><P>Adequate randomization</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CSG-1963"><DESCRIPTION><P>Not given</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Chawla-1999"><DESCRIPTION><P>Randomization list was kept confidential by the pharmacist</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Cicarelli-2007"><DESCRIPTION><P>Randomization list kept confidential by the pharmacist</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Confalonieri-2005"><DESCRIPTION><P>Centralized randomization </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Gordon-2014"><DESCRIPTION><P>Randomization done via an online system</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2009"><DESCRIPTION><P>Not stated in the manuscript</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-07 13:18:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huh-2007"><DESCRIPTION><P>Not given</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Keh-2003"><DESCRIPTION><P>Randomization list kept confidential by the pharmacist</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2012"><DESCRIPTION><P>No explicit information in the manuscript</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Luce-1988"><DESCRIPTION><P>Randomization list kept confidential by the pharmacist</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Meduri-2007"><DESCRIPTION><P>Centralized randomization </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Meijvis-2011"><DESCRIPTION><P>Randomization list kept confidential by the pharmacist</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Oppert-2005"><DESCRIPTION><P>Randomization list kept confidential by the pharmacist</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Rezk--2013"><DESCRIPTION><P>No explicit information in the manuscript</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rinaldi-2006"><DESCRIPTION><P>Sealed envelopes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Sabry-2011"><DESCRIPTION><P>No information in the manuscript</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schumer-1976"><DESCRIPTION><P>Unsealed envelopes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-24 08:59:14 +0000" MODIFIED_BY="Djillali Annane" RESULT="UNKNOWN" STUDY_ID="STD-Slusher-1996"><DESCRIPTION><P>Unclear; not reported</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Snijders-2010"><DESCRIPTION><P>Randomization list kept confidential by the pharmacist</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Sprung-1984"><DESCRIPTION><P>At 1 centre, not clear how randomization list was kept confidential</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Sprung-2008"><DESCRIPTION><P>Centralized randomization</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Tandan-2005"><DESCRIPTION><P>Randomization list kept confidential by the local pharmacist</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Torres-2015"><DESCRIPTION><P>Randomization list kept confidential by the pharmacist</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-VASSCSG-1987"><DESCRIPTION><P>Centralized randomization </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Valoor-2009"><DESCRIPTION><P>No explicit information in the manuscript</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Yildiz-2002"><DESCRIPTION><P>Randomization list kept confidential by the pharmacist</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Yildiz-2011"><DESCRIPTION><P>Randomization list kept by the pharmacist</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="3"><NAME>Blinding (performance bias and detection bias)</NAME><DESCRIPTION><P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2002"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Annane-2010"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: no</P><P>Data collectors: yes</P><P>Outcome assessors: no</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Arabi-2011"><DESCRIPTION><P>Pharmacists: no</P><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Bollaert-1998"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Bone-1987"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Briegel-1999"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-CSG-1963"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: unclear</P><P>Outcome assessors: unclear</P><P>Data analysts: unclear</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Chawla-1999"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Cicarelli-2007"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Confalonieri-2005"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Gordon-2014"><DESCRIPTION><P>Hydrocortisone and its placebo presented in indiscernible forms</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2009"><DESCRIPTION><P>Not stated in the manuscript</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Huh-2007"><DESCRIPTION><P>Participants: no</P><P>Care-givers: no</P><P>Data collectors: no</P><P>Outcome assessors: no</P><P>Data analysts: no</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Keh-2003"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2012"><DESCRIPTION><P>No explicit information in the manuscript</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Luce-1988"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Meduri-2007"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Meijvis-2011"><DESCRIPTION><P>Pharmacist: no</P><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Oppert-2005"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Rezk--2013"><DESCRIPTION><P>No explicit information in the manuscript</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Rinaldi-2006"><DESCRIPTION><P>Participants: no</P><P>Care-givers: no</P><P>Data collectors: no</P><P>Outcome assessors: no</P><P>Data analysts: no</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Sabry-2011"><DESCRIPTION><P>No information in the manuscript</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Schumer-1976"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: unclear</P><P>Data collectors: unclear</P><P>Outcome assessors: unclear</P><P>Data analysts: unclear</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Slusher-1996"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Snijders-2010"><DESCRIPTION><P>Pharmacist: no</P><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Sprung-1984"><DESCRIPTION><P>Participants: yes at 1 centre, no at the other</P><P>Care-givers: yes at 1 centre, no at the other</P><P>Data collectors: yes at 1 centre, no at the other</P><P>Outcome assessors: yes at 1 centre, no at the other</P><P>Data analysts: unclear</P><P>University of Miami Research Committee did not allow study to be performed in a double-blind manner, nor that participants received placebo</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Sprung-2008"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Tandan-2005"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Torres-2015"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-VASSCSG-1987"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane" RESULT="NO" STUDY_ID="STD-Valoor-2009"><DESCRIPTION><P>Open label</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Yildiz-2002"><DESCRIPTION><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Yildiz-2011"><DESCRIPTION><P>Pharmacist: no</P><P>Participants: yes</P><P>Care-givers: yes</P><P>Data collectors: yes</P><P>Outcome assessors: yes</P><P>Data analysts: yes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7"><NAME>Blinding of participants and personnel (performance bias)</NAME><DESCRIPTION><P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P></DESCRIPTION><QUALITY_ITEM_DATA/></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8"><NAME>Blinding of outcome assessment (detection bias)</NAME><DESCRIPTION><P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P></DESCRIPTION><QUALITY_ITEM_DATA/></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="4"><NAME>Incomplete outcome data (attrition bias)</NAME><DESCRIPTION><P>Attrition bias due to amount, nature or handling of incomplete outcome data</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2002"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2010"><DESCRIPTION><P>No loss to follow-up</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Arabi-2011"><DESCRIPTION><P>Unexplained discrepancy between reported K-M curves and number of deaths at 28 days in placebo arm</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Bollaert-1998"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Bone-1987"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Briegel-1999"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-CSG-1963"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Chawla-1999"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Cicarelli-2007"><DESCRIPTION><P>Lost to follow-up: none; 3 participants were withdrawn after next of kin refused to consent</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Confalonieri-2005"><DESCRIPTION><P>Lost to follow-up: 2 at 60 days after randomization, all in the placebo group</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="YES" STUDY_ID="STD-Gordon-2014"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Hu-2009"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Huh-2007"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Keh-2003"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2012"><DESCRIPTION><P>No explicit information in the manuscript</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Luce-1988"><DESCRIPTION><P>12 out of 87 randomly assigned participants were not analysed, and their follow-up was not given</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-23 17:01:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meduri-2007"><DESCRIPTION><P>Full access to data excluding any attrition bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Meijvis-2011"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Oppert-2005"><DESCRIPTION><P>7 of 48 randomly assigned participants were not analysed: 5 in the corticosteroid group and 2 in the placebo group. 4 of these 7 participants were lost to follow-up, and 3 died (all in the steroid group)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Rezk--2013"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Rinaldi-2006"><DESCRIPTION><P>12 of 52 participants dropped out of the study: 6 in the control group and 6 in the corticosteroid group; contact with the primary author permitted completion of follow-up for all 12 participants</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Sabry-2011"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Schumer-1976"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Slusher-1996"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Snijders-2010"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Sprung-1984"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Sprung-2008"><DESCRIPTION><P>Lost to follow-up: none; 1 participant withdrew his consent</P><P>Data for serious adverse events reported for only 466 of 499 participants, and analysis of these outcomes was performed per-protocol, not by intent-to-treat</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Tandan-2005"><DESCRIPTION><P>Lost to follow-up: unknown</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Torres-2015"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-VASSCSG-1987"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Valoor-2009"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Yildiz-2002"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Yildiz-2011"><DESCRIPTION><P>Lost to follow-up: none</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="5"><NAME>Selective reporting (reporting bias)</NAME><DESCRIPTION><P>Reporting bias due to selective outcome reporting</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2002"><DESCRIPTION><P>Access to study protocol excluding reporting bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 12:45:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Annane-2010"><DESCRIPTION><P>Access to study protocol excluding reporting bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="YES" STUDY_ID="STD-Arabi-2011"><DESCRIPTION><P>Access to unpublished data</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 12:46:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bollaert-1998"><DESCRIPTION><P>Access to study protocol excluding reporting bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 12:47:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bone-1987"><DESCRIPTION><P>No access to study protocol to exclude reporting bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 12:48:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Briegel-1999"><DESCRIPTION><P>Access to study protocol excluding reporting bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CSG-1963"><DESCRIPTION><P>No access to study protocol to exclude reporting bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="YES" STUDY_ID="STD-Chawla-1999"><DESCRIPTION><P>Access to study protocol excluding reporting bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 12:50:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cicarelli-2007"><DESCRIPTION><P>No access to study protocol to rule out reporting bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Confalonieri-2005"><DESCRIPTION><P>Study was stopped prematurely for apparent benefit; no sample size was defined a priori, but study authors used the triangular test as a stopping rule, analysing the primary outcome after each 20 participants</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="YES" STUDY_ID="STD-Gordon-2014"><DESCRIPTION><P>Reported information matched published statistical plan</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2009"><DESCRIPTION><P>No information</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Huh-2007"><DESCRIPTION><P>No explicit information on plan analysis </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keh-2003"><DESCRIPTION><P>Access to study protocol</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2012"><DESCRIPTION><P>No information</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Luce-1988"><DESCRIPTION><P>No access to study protocol</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Meduri-2007"><DESCRIPTION><P>Study was stopped prematurely for efficacy</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="YES" STUDY_ID="STD-Meijvis-2011"><DESCRIPTION><P>All outcomes reported in the study protocol are reported in the final analysis</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oppert-2005"><DESCRIPTION><P>Access to study protocol excluding reporting bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Rezk--2013"><DESCRIPTION><P>No information</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rinaldi-2006"><DESCRIPTION><P>Access to study protocol excluding any reporting bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Sabry-2011"><DESCRIPTION><P>No information in the manuscript</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schumer-1976"><DESCRIPTION><P>No access to study protocol</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Slusher-1996"><DESCRIPTION><P>No access to study protocol</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Snijders-2010"><DESCRIPTION><P>All outcomes reported in study protocol are reported in final analysis</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sprung-1984"><DESCRIPTION><P>No access to study protocol</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Sprung-2008"><DESCRIPTION><P>Access to study protocol to confirm absence of reporting bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tandan-2005"><DESCRIPTION><P>No access to study protocol</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="YES" STUDY_ID="STD-Torres-2015"><DESCRIPTION><P>Access to full protocol and unpublished information</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-VASSCSG-1987"><DESCRIPTION><P>No access to study protocol</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Valoor-2009"><DESCRIPTION><P>No information</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yildiz-2002"><DESCRIPTION><P>No access to protocol</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Yildiz-2011"><DESCRIPTION><P>No information</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="6"><NAME>Other bias</NAME><DESCRIPTION><P>Bias due to problems not covered elsewhere in the table</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2002"><DESCRIPTION><P>Full access to data excluding selection bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 12:45:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Annane-2010"><DESCRIPTION><P>Full access to data excluding selection bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Arabi-2011"><DESCRIPTION><P>Trial terminated prematurely after enrolment of 75 participants while planned sample size was 150</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 12:46:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bollaert-1998"><DESCRIPTION><P>Full access to data excluding selection bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 12:47:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bone-1987"><DESCRIPTION><P>No access to full data including screening log to exclude selection bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 12:48:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Briegel-1999"><DESCRIPTION><P>Access to full data including screening log</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CSG-1963"><DESCRIPTION><P>No access to data to exclude selection bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="YES" STUDY_ID="STD-Chawla-1999"><DESCRIPTION><P>Access to full data including screening log</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 12:50:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cicarelli-2007"><DESCRIPTION><P>No access to data to rule out selection bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Confalonieri-2005"><DESCRIPTION><P>Access to full data including screening log</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="YES" STUDY_ID="STD-Gordon-2014"><DESCRIPTION><P>Access to unpublished information to exclude other risk of bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2009"><DESCRIPTION><P>No information</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Huh-2007"><DESCRIPTION><P>No information </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keh-2003"><DESCRIPTION><P>Full access to data including screening log</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2012"><DESCRIPTION><P>No information</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Luce-1988"><DESCRIPTION><P>No access to data to exclude selection bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meduri-2007"><DESCRIPTION><P>Full access to data including screening log</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="YES" STUDY_ID="STD-Meijvis-2011"><DESCRIPTION><P>Full access to study protocol</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oppert-2005"><DESCRIPTION><P>Full access to data including screening log</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Rezk--2013"><DESCRIPTION><P>No information</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rinaldi-2006"><DESCRIPTION><P>Full access to data including screening log</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:25 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Sabry-2011"><DESCRIPTION><P>No information in the manuscript</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schumer-1976"><DESCRIPTION><P>No data to exclude selection bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Slusher-1996"><DESCRIPTION><P>No data to exclude selection bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Snijders-2010"><DESCRIPTION><P>No access to full protocol</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sprung-1984"><DESCRIPTION><P>No data to exclude selection bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Sprung-2008"><DESCRIPTION><P>Only 500 participants included; expected sample size 800 participants</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tandan-2005"><DESCRIPTION><P>No data to exclude selection bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane" RESULT="YES" STUDY_ID="STD-Torres-2015"><DESCRIPTION><P>Access to full protocol and unpublished information</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-VASSCSG-1987"><DESCRIPTION><P>No data to exclude selection bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Valoor-2009"><DESCRIPTION><P>No information</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:01:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yildiz-2002"><DESCRIPTION><P>No data to exclude selection bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 23:13:26 +0000" MODIFIED_BY="djillali annane" RESULT="UNKNOWN" STUDY_ID="STD-Yildiz-2011"><DESCRIPTION><P>No information</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM></QUALITY_ITEMS><SOF_TABLES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><SOF_TABLE ID="SOF-01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="1" READONLY="YES"><TITLE MODIFIED="2015-07-05 19:01:43 +0100" MODIFIED_BY="Grade Profiler">Steroids versus control for treating sepsis</TITLE><TABLE COLS="7" ROWS="22"><TR><TD COLSPAN="7"><P><B>Steroids versus control for treating sepsis</B></P></TD></TR><TR><TD COLSPAN="7"><P><B>Patient or population:</B> patients with sepsis<BR/><B>Settings:</B><BR/><B>Intervention:</B> steroids vs control<BR/></P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Outcomes</P></TH><TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP"><P>Illustrative comparative risks* (95% CI)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Relative effect<BR/>(95% CI)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Number of participants<BR/>(studies)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Quality of the evidence<BR/>(GRADE)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Comments</P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Assumed risk</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Corresponding risk</P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P><B>Control</B></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P><B>Steroids vs control</B></P></TH></TR><TR><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>28-Day all-cause mortality</B><BR/>Follow-up: 14 to 30 days</P></TD><TD COLSPAN="2" ROWSPAN="1"><P><B>Study population</B></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>RR 0.87 </B><BR/>(0.76 to 1)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>3176<BR/>(27 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/><B>Low</B><SUP>a,b</SUP></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Trials were conducted over a period from 1976 to 2015. Differences in participant management and in the definition of sepsis were substantial &lt;BR/&gt;18 trial</P></TD></TR><TR><TD VALIGN="TOP"><P><B>318 per 1000</B></P></TD><TD VALIGN="TOP"><P><B>276 per 1000</B><BR/>(241 to 318)</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>28-Day all-cause mortality by subgroups based on treatment dose/duration - long course of low-dose corticosteroids</B><BR/>Follow-up: 14 to 30 days</P></TD><TD COLSPAN="2" ROWSPAN="1"><P><B>Study population</B></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>RR 0.87 </B><BR/>(0.78 to 0.97)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>2266<BR/>(22 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>a</SUP></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Meta-regression analysis also showed evidence of a dose response: Low doses were associated with better treatment response</P></TD></TR><TR><TD VALIGN="TOP"><P><B>321 per 1000</B></P></TD><TD VALIGN="TOP"><P><B>279 per 1000</B><BR/>(250 to 311)</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>Hospital mortality</B><BR/>Follow-up: 14 to 365 days</P></TD><TD COLSPAN="2" ROWSPAN="1"><P><B>Study population</B></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>RR 0.85 </B><BR/>(0.73 to 0.98)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>2014<BR/>(17 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>a,c</SUP></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Low doses of corticosteroids were associated with better treatment response</P></TD></TR><TR><TD VALIGN="TOP"><P><B>413 per 1000</B></P></TD><TD VALIGN="TOP"><P><B>351 per 1000</B><BR/>(302 to 405)</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>Number of participants with shock reversal at day 7</B><BR/>Follow-up: 7 to 28 days</P></TD><TD COLSPAN="2" ROWSPAN="1"><P><B>Study population</B></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>RR 1.31 </B><BR/>(1.14 to 1.51)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>1561<BR/>(12 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8853;<BR/><B>High</B></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Low doses of corticosteroids were associated with better treatment response</P></TD></TR><TR><TD VALIGN="TOP"><P><B>523 per 1000</B></P></TD><TD VALIGN="TOP"><P><B>685 per 1000</B><BR/>(596 to 790)</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>SOFA score at day 7</B><BR/>Follow-up: 7 days</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P/></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean SOFA score at day 7 in intervention groups was<BR/><B>1.53 lower</B><BR/>(2.04 to 1.03 lower)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>1132<BR/>(8 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8853;<BR/><B>High</B></P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>Observed reduction in SOFA score was of a magnitude that exceeded any reduction seen with any other treatment for sepsis</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>Length of ICU stay for survivors</B><BR/>Follow-up: 14 to 365 days</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P/></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean length of ICU stay for survivors in intervention groups was<BR/><B>2.19 lower</B><BR/>(3.93 to 0.46 lower)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>778<BR/>(10 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8853;<BR/><B>High</B></P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>Observed reduction in length of ICU stay was of a magnitude that exceeded any reduction seen with any other treatment for sepsis</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>Length of hospital stay for survivors</B><BR/>Follow-up: 14 to 365 days</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P/></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean length of hospital stay for survivors in intervention groups was<BR/><B>4.11 lower</B><BR/>(8.5 lower to 0.28 higher)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>710<BR/>(9 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>c</SUP></P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>Observed reduction in length of hospital stay was of a magnitude that exceeded any reduction seen with any other treatment for sepsis</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>Number of participants with adverse events - superinfections</B><BR/>Follow-up: 14 to 90 days</P></TD><TD COLSPAN="2" ROWSPAN="1"><P><B>Study population</B></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>RR 1.02 </B><BR/>(0.87 to 1.2)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>2567<BR/>(19 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8853;<BR/><B>High</B></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>One large trial suggested increased risk of new sepsis with corticosteroids</P></TD></TR><TR><TD VALIGN="TOP"><P><B>161 per 1000</B></P></TD><TD VALIGN="TOP"><P><B>164 per 1000</B><BR/>(140 to 193)</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>Number of participants with adverse events - hyperglycaemia</B><BR/>Follow-up: 14 to 90 days</P></TD><TD COLSPAN="2" ROWSPAN="1"><P><B>Study population</B></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>RR 1.26 </B><BR/>(1.16 to 1.37)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>2081<BR/>(13 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8853;<BR/><B>High</B></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>One trial suggested that risk of hyperglycaemia was lower when corticosteroids were given as a continuous perfusion than when they were given as an intravenous bolus</P></TD></TR><TR><TD VALIGN="TOP"><P><B>348 per 1000</B></P></TD><TD VALIGN="TOP"><P><B>438 per 1000</B><BR/>(403 to 476)</P></TD></TR><TR><TD COLSPAN="7"><P>*The basis for the <B>assumed risk</B> is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/><B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P></TD></TR><TR><TD COLSPAN="7"><P>GRADE Working Group grades of evidence<BR/><B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect<BR/><B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/><B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/><B>Very low quality:</B> We are very uncertain about the estimate<BR/></P></TD></TR></TABLE><FOOTNOTES><P><SUP>a</SUP>Quality of evidence was downgraded by 1 point owing to some inconsistency; 1 of the 2 largest trials showed no survival benefit<BR/><BR/><SUP>b</SUP>Quality of evidence was downgraded by 1 point owing to potential publication bias; some asymmetry was noted in the funnel plot<BR/><SUP>c</SUP>Quality of evidence was downgraded by 1 point for imprecision, and the upper limit of the confidence interval approached 1<BR/></P></FOOTNOTES></SOF_TABLE></SOF_TABLES><ADDITIONAL_TABLES MODIFIED="2010-09-24 16:03:56 +0100" MODIFIED_BY="Jane Cracknell"/><ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><COMPARISON ID="CMP-001" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="1"><NAME>Steroids versus control</NAME><DICH_OUTCOME CHI2="44.98548679339542" CI_END="1.0010041243582273" CI_START="0.7553300029193057" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8695334658158574" ESTIMABLE="YES" EVENTS_1="474" EVENTS_2="495" I2="42.20358196986942" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="4.358668722551563E-4" LOG_CI_START="-0.12186326408675444" LOG_EFFECT_SIZE="-0.06071369860724963" METHOD="MH" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.01181432906412272" P_Q="1.0" P_Z="0.05165550923737239" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="YEAR" STUDIES="27" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04398385765432093" TOTALS="YES" TOTAL_1="1618" TOTAL_2="1558" WEIGHT="100.00000000000003" Z="1.945993593009463"><NAME>28-Day all-cause mortality</NAME><GROUP_LABEL_1>Treatment</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_DATA CI_END="0.5349608488848496" CI_START="0.13903852112599463" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="33" LOG_CI_END="-0.2716780006618398" LOG_CI_START="-0.8568648602152855" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="563" O_E="0.0" SE="0.34374165802336654" STUDY_ID="STD-Schumer-1976" TOTAL_1="86" TOTAL_2="86" VAR="0.11815832746065305" WEIGHT="3.182921476125229"/><DICH_DATA CI_END="1.6145545217389314" CI_START="0.7717788063662259" EFFECT_SIZE="1.1162790697674418" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="11" LOG_CI_END="0.20805271525008898" LOG_CI_START="-0.11250715165808765" LOG_EFFECT_SIZE="0.04777278179600068" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="580" O_E="0.0" SE="0.1882984526187957" STUDY_ID="STD-Sprung-1984" TOTAL_1="43" TOTAL_2="16" VAR="0.035456307258632844" WEIGHT="6.496535395587634"/><DICH_DATA CI_END="1.844596050024976" CI_START="0.9837470241692765" EFFECT_SIZE="1.3470767888307156" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="48" LOG_CI_END="0.26590127431466254" LOG_CI_START="-0.007116568369923013" LOG_EFFECT_SIZE="0.12939235297236978" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="562" O_E="0.0" SE="0.16037203225304292" STUDY_ID="STD-Bone-1987" TOTAL_1="191" TOTAL_2="190" VAR="0.025719188728971037" WEIGHT="7.404064384078777"/><DICH_DATA CI_END="1.578666059043726" CI_START="0.571416568763245" EFFECT_SIZE="0.9497767857142857" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.1982902718368346" LOG_CI_START="-0.24304717099190923" LOG_EFFECT_SIZE="-0.02237844957753733" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.2592437985731798" STUDY_ID="STD-VASSCSG-1987" TOTAL_1="112" TOTAL_2="111" VAR="0.06720734709865143" WEIGHT="4.641426849676498"/><DICH_DATA CI_END="1.6013530609278497" CI_START="0.7163652835855632" EFFECT_SIZE="1.0710526315789475" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.20448709426058112" LOG_CI_START="-0.14486546904376124" LOG_EFFECT_SIZE="0.029810812608409926" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="571" O_E="0.0" SE="0.20521142500804926" STUDY_ID="STD-Luce-1988" TOTAL_1="38" TOTAL_2="37" VAR="0.04211172895383422" WEIGHT="5.994335639260728"/><DICH_DATA CI_END="1.0160309717783367" CI_START="0.24979772650962204" EFFECT_SIZE="0.5037878787878788" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.006906946793778492" LOG_CI_START="-0.602411518599269" LOG_EFFECT_SIZE="-0.2977522859027453" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="564" O_E="0.0" SE="0.35791668274692406" STUDY_ID="STD-Bollaert-1998" TOTAL_1="22" TOTAL_2="19" VAR="0.12810435178856228" WEIGHT="2.998961084313066"/><DICH_DATA CI_END="2.9297807522256587" CI_START="0.19199388881665874" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46683512149361056" LOG_CI_START="-0.7167125947102105" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="568" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Briegel-1999" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="0.9787009640662482"/><DICH_DATA CI_END="1.2453879102921923" CI_START="0.24097987387695294" EFFECT_SIZE="0.5478260869565217" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.09530464545566107" LOG_CI_START="-0.6180192272557211" LOG_EFFECT_SIZE="-0.26135729090003" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="561" O_E="0.0" SE="0.4190099738407832" STUDY_ID="STD-Chawla-1999" TOTAL_1="23" TOTAL_2="21" VAR="0.17556935817805383" WEIGHT="2.3506184650118995"/><DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Yildiz-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="3.388231097500697"/><DICH_DATA CI_END="1.0800951347961532" CI_START="0.7319839399101493" EFFECT_SIZE="0.8891638163161342" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="91" LOG_CI_END="0.03346200983636929" LOG_CI_START="-0.13549844747291392" LOG_EFFECT_SIZE="-0.05101821881827232" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="575" O_E="0.0" SE="0.09924820899122541" STUDY_ID="STD-Annane-2002" TOTAL_1="151" TOTAL_2="149" VAR="0.009850206987965956" WEIGHT="9.586603698189556"/><DICH_DATA CI_END="1.8785154666635893" CI_START="0.5197855474364792" EFFECT_SIZE="0.9881422924901185" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.27381477515612307" LOG_CI_START="-0.2841758001636837" LOG_EFFECT_SIZE="-0.005180512503780329" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="0.32776642604074885" STUDY_ID="STD-Oppert-2005" TOTAL_1="23" TOTAL_2="25" VAR="0.1074308300395257" WEIGHT="3.4084265605185164"/><DICH_DATA CI_END="1.2908449954588779" CI_START="0.004583942908815428" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.11087409535823754" LOG_CI_START="-2.338760799971911" LOG_EFFECT_SIZE="-1.1139433523068367" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="570" O_E="0.0" SE="1.438927663405225" STUDY_ID="STD-Confalonieri-2005" TOTAL_1="23" TOTAL_2="23" VAR="2.0705128205128207" WEIGHT="0.24407030217501663"/><DICH_DATA CI_END="1.1533705848073679" CI_START="0.6207686764272098" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.06196887110925881" LOG_CI_START="-0.2070702054064823" LOG_EFFECT_SIZE="-0.07255066714861173" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="569" O_E="0.0" SE="0.15803488531025353" STUDY_ID="STD-Tandan-2005" TOTAL_1="14" TOTAL_2="14" VAR="0.02497502497502499" WEIGHT="7.483964697663173"/><DICH_DATA CI_END="2.2058533355443934" CI_START="0.33306560581902944" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3435766333619987" LOG_CI_START="-0.4774702126232252" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.48228698157915545" STUDY_ID="STD-Rinaldi-2006" TOTAL_1="26" TOTAL_2="26" VAR="0.23260073260073263" WEIGHT="1.8659240658071823"/><DICH_DATA CI_END="1.2036378020776555" CI_START="0.2656640738962389" EFFECT_SIZE="0.5654761904761905" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.08049581896163172" LOG_CI_START="-0.5756671718356619" LOG_EFFECT_SIZE="-0.2475856764370151" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="576" O_E="0.0" SE="0.38543338885351874" STUDY_ID="STD-Meduri-2007" TOTAL_1="42" TOTAL_2="19" VAR="0.14855889724310778" WEIGHT="2.6803700999461237"/><DICH_DATA CI_END="1.1182111086595163" CI_START="0.3493302802797868" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.04852380236154291" LOG_CI_START="-0.4567637676733925" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="565" O_E="0.0" SE="0.2968084198523318" STUDY_ID="STD-Cicarelli-2007" TOTAL_1="14" TOTAL_2="15" VAR="0.08809523809523807" WEIGHT="3.9073998823167004"/><DICH_DATA CI_END="1.4005396690070233" CI_START="0.8473604729134112" EFFECT_SIZE="1.0893860455613444" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="78" LOG_CI_END="0.14629541432835985" LOG_CI_START="-0.07193179853182889" LOG_EFFECT_SIZE="0.03718180789826547" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="566" O_E="0.0" SE="0.12818774507620045" STUDY_ID="STD-Sprung-2008" TOTAL_1="251" TOTAL_2="248" VAR="0.016432097987720957" WEIGHT="8.542211038522288"/><DICH_DATA CI_END="2.234810390447771" CI_START="0.20947819390956535" EFFECT_SIZE="0.6842105263157895" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.34924068188610485" LOG_CI_START="-0.6788611791780892" LOG_EFFECT_SIZE="-0.16481024864599217" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="319" O_E="0.0" SE="0.6039121223753973" STUDY_ID="STD-Hu-2009" TOTAL_1="38" TOTAL_2="39" VAR="0.3647098515519568" WEIGHT="1.262769236626155"/><DICH_DATA CI_END="3.1461733602779907" CI_START="0.34914326418088176" EFFECT_SIZE="1.0480769230769231" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.49778264941815736" LOG_CI_START="-0.45699633213447066" LOG_EFFECT_SIZE="0.020393158641843302" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.560841899996196" STUDY_ID="STD-Snijders-2010" TOTAL_1="104" TOTAL_2="109" VAR="0.3145436367913432" WEIGHT="1.4394595984507887"/><DICH_DATA CI_END="1.7619746384608999" CI_START="0.6944585490345027" EFFECT_SIZE="1.1061728395061727" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.2459996529660672" LOG_CI_START="-0.15835367139911644" LOG_EFFECT_SIZE="0.04382299078347541" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="287" O_E="0.0" SE="0.23751914431334561" STUDY_ID="STD-Yildiz-2011" TOTAL_1="27" TOTAL_2="28" VAR="0.056415343915343905" WEIGHT="5.140338121416456"/><DICH_DATA CI_END="1.5535004046793537" CI_START="0.07152306544396729" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.19131137072262336" LOG_CI_START="-1.1455538801619483" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="0.7852812659593164" STUDY_ID="STD-Sabry-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.6166666666666666" WEIGHT="0.7811782844170947"/><DICH_DATA CI_END="1.9430384523039979" CI_START="0.35370990396150453" EFFECT_SIZE="0.8290186634557496" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.28848139527718897" LOG_CI_START="-0.45135277966613047" LOG_EFFECT_SIZE="-0.08143569219447078" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.43458225659993566" STUDY_ID="STD-Meijvis-2011" TOTAL_1="151" TOTAL_2="153" VAR="0.18886173775149231" WEIGHT="2.216429485337125"/><DICH_DATA CI_END="1.493563365609328" CI_START="0.9190376823484177" EFFECT_SIZE="1.1715976331360947" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" LOG_CI_END="0.17422365261855385" LOG_CI_START="-0.03666668132283872" LOG_EFFECT_SIZE="0.06877848564785757" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.1238780260811632" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" VAR="0.015345765345765351" WEIGHT="8.698619965739079"/><DICH_DATA CI_END="1.8452575373787963" CI_START="0.1844066591708089" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2660569879785712" LOG_CI_START="-0.7342234000453071" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.5875696513930031" STUDY_ID="STD-Liu-2012" TOTAL_1="12" TOTAL_2="14" VAR="0.34523809523809523" WEIGHT="1.3259422788286892"/><DICH_DATA CI_END="1.3162390066867353" CI_START="0.004294988062726441" EFFECT_SIZE="0.07518796992481203" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.11933475695310501" LOG_CI_START="-2.367038038887277" LOG_EFFECT_SIZE="-1.1238516409670858" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="1.4605076880204764" STUDY_ID="STD-Rezk--2013" TOTAL_1="18" TOTAL_2="9" VAR="2.133082706766917" WEIGHT="0.23705561034396846"/><DICH_DATA CI_END="2.4272804897909133" CI_START="0.38583281068383707" EFFECT_SIZE="0.967741935483871" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.38511996509577545" LOG_CI_START="-0.4136008433249959" LOG_EFFECT_SIZE="-0.01424043911461023" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.46917255659812773" STUDY_ID="STD-Gordon-2014" TOTAL_1="31" TOTAL_2="30" VAR="0.22012288786482337" WEIGHT="1.9540805070081542"/><DICH_DATA CI_END="1.8164518823750662" CI_START="0.2615466915055742" EFFECT_SIZE="0.6892655367231638" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.25922389793461503" LOG_CI_START="-0.582450769308732" LOG_EFFECT_SIZE="-0.1616134356870584" MODIFIED="2014-11-07 15:26:43 +0000" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="0.494403865895539" STUDY_ID="STD-Torres-2015" TOTAL_1="59" TOTAL_2="61" VAR="0.2444351826124541" WEIGHT="1.789361211073188"/></DICH_OUTCOME><DICH_OUTCOME CHI2="24.30827607978454" CI_END="1.056814374672277" CI_START="0.8585478570936493" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.952536464772162" ESTIMABLE="YES" EVENTS_1="415" EVENTS_2="403" I2="21.83732018824262" I2_Q="76.26076494815379" ID="CMP-001.02" LOG_CI_END="0.023998711872170654" LOG_CI_START="-0.06623549142629219" LOG_EFFECT_SIZE="-0.021118389777060795" METHOD="MH" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.18459193571303334" P_Q="0.040128821542203874" P_Z="0.3589231644990789" Q="4.212435648478191" RANDOM="NO" SCALE="5.0" SORT_BY="YEAR" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1312" TOTAL_2="1258" WEIGHT="100.0" Z="0.917418935647058"><NAME>All-cause mortality by subgroup based on mortality rate</NAME><GROUP_LABEL_1>Treatment</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="19.893864560671254" CI_END="1.0033163950339028" CI_START="0.8022021612916261" DF="17" EFFECT_SIZE="0.8971413381154163" ESTIMABLE="YES" EVENTS_1="327" EVENTS_2="331" I2="14.546517856526567" ID="CMP-001.02.01" LOG_CI_END="0.0014379090415529432" LOG_CI_START="-0.09571617227738051" LOG_EFFECT_SIZE="-0.0471391316179138" MODIFIED="2014-11-07 12:28:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2796940173178364" P_Z="0.05717796679592161" STUDIES="18" TAU2="0.0" TOTAL_1="1009" TOTAL_2="957" WEIGHT="82.54383466815914" Z="1.9019478951235613"><NAME>Studies reporting 28-day mortality</NAME><DICH_DATA CI_END="1.6145545217389314" CI_START="0.7717788063662259" EFFECT_SIZE="1.1162790697674418" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="11" LOG_CI_END="0.20805271525008898" LOG_CI_START="-0.11250715165808765" LOG_EFFECT_SIZE="0.04777278179600068" MODIFIED="2010-07-29 16:19:46 +0100" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="0.1882984526187957" STUDY_ID="STD-Sprung-1984" TOTAL_1="43" TOTAL_2="16" VAR="0.035456307258632844" WEIGHT="3.87479442245598"/><DICH_DATA CI_END="1.0160309717783367" CI_START="0.24979772650962204" EFFECT_SIZE="0.5037878787878788" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.006906946793778492" LOG_CI_START="-0.602411518599269" LOG_EFFECT_SIZE="-0.2977522859027453" ORDER="264" O_E="0.0" SE="0.35791668274692406" STUDY_ID="STD-Bollaert-1998" TOTAL_1="22" TOTAL_2="19" VAR="0.12810435178856228" WEIGHT="3.1121434499135945"/><DICH_DATA CI_END="1.2453879102921923" CI_START="0.24097987387695294" EFFECT_SIZE="0.5478260869565217" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.09530464545566107" LOG_CI_START="-0.6180192272557211" LOG_EFFECT_SIZE="-0.26135729090003" ORDER="266" O_E="0.0" SE="0.4190099738407832" STUDY_ID="STD-Chawla-1999" TOTAL_1="23" TOTAL_2="21" VAR="0.17556935817805383" WEIGHT="2.526473203571384"/><DICH_DATA CI_END="2.9297807522256587" CI_START="0.19199388881665874" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46683512149361056" LOG_CI_START="-0.7167125947102105" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="261" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Briegel-1999" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="0.9666506170186164"/><DICH_DATA CI_END="1.0800951347961532" CI_START="0.7319839399101493" EFFECT_SIZE="0.8891638163161342" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="91" LOG_CI_END="0.03346200983636929" LOG_CI_START="-0.13549844747291392" LOG_EFFECT_SIZE="-0.05101821881827232" ORDER="269" O_E="0.0" SE="0.09924820899122541" STUDY_ID="STD-Annane-2002" TOTAL_1="151" TOTAL_2="149" VAR="0.009850206987965956" WEIGHT="22.137910214088013"/><DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="262" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Yildiz-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="2.8999518510558495"/><DICH_DATA CI_END="1.1533705848073679" CI_START="0.6207686764272098" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.06196887110925881" LOG_CI_START="-0.2070702054064823" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="268" O_E="0.0" SE="0.15803488531025353" STUDY_ID="STD-Tandan-2005" TOTAL_1="14" TOTAL_2="14" VAR="0.02497502497502499" WEIGHT="3.1416145053105033"/><DICH_DATA CI_END="1.2908449954588779" CI_START="0.004583942908815428" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.11087409535823754" LOG_CI_START="-2.338760799971911" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="273" O_E="0.0" SE="1.438927663405225" STUDY_ID="STD-Confalonieri-2005" TOTAL_1="23" TOTAL_2="23" VAR="2.0705128205128207" WEIGHT="1.5708072526552517"/><DICH_DATA CI_END="1.8785154666635893" CI_START="0.5197855474364792" EFFECT_SIZE="0.9881422924901185" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.27381477515612307" LOG_CI_START="-0.2841758001636837" LOG_EFFECT_SIZE="-0.005180512503780329" ORDER="271" O_E="0.0" SE="0.32776642604074885" STUDY_ID="STD-Oppert-2005" TOTAL_1="23" TOTAL_2="25" VAR="0.1074308300395257" WEIGHT="2.5475271469344785"/><DICH_DATA CI_END="2.2058533355443934" CI_START="0.33306560581902944" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3435766333619987" LOG_CI_START="-0.4774702126232252" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2010-09-23 19:04:39 +0100" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="0.48228698157915545" STUDY_ID="STD-Rinaldi-2006" TOTAL_1="26" TOTAL_2="26" VAR="0.23260073260073263" WEIGHT="1.6916385797825788"/><DICH_DATA CI_END="1.2036378020776555" CI_START="0.2656640738962389" EFFECT_SIZE="0.5654761904761905" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.08049581896163172" LOG_CI_START="-0.5756671718356619" LOG_EFFECT_SIZE="-0.2475856764370151" ORDER="265" O_E="0.0" SE="0.38543338885351874" STUDY_ID="STD-Meduri-2007" TOTAL_1="42" TOTAL_2="19" VAR="0.14855889724310778" WEIGHT="2.662250879657829"/><DICH_DATA CI_END="1.1182111086595163" CI_START="0.3493302802797868" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.04852380236154291" LOG_CI_START="-0.4567637676733925" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="281" O_E="0.0" SE="0.2968084198523318" STUDY_ID="STD-Cicarelli-2007" TOTAL_1="14" TOTAL_2="15" VAR="0.08809523809523807" WEIGHT="2.799953511364268"/><DICH_DATA CI_END="1.4005396690070233" CI_START="0.8473604729134112" EFFECT_SIZE="1.0893860455613444" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="78" LOG_CI_END="0.14629541432835985" LOG_CI_START="-0.07193179853182889" LOG_EFFECT_SIZE="0.03718180789826547" ORDER="272" O_E="0.0" SE="0.12818774507620045" STUDY_ID="STD-Sprung-2008" TOTAL_1="251" TOTAL_2="248" VAR="0.016432097987720957" WEIGHT="18.96301180359767"/><DICH_DATA CI_END="3.1461733602779907" CI_START="0.34914326418088176" EFFECT_SIZE="1.0480769230769231" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.49778264941815736" LOG_CI_START="-0.45699633213447066" LOG_EFFECT_SIZE="0.020393158641843302" MODIFIED="2014-10-11 16:39:53 +0100" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.560841899996196" STUDY_ID="STD-Snijders-2010" TOTAL_1="104" TOTAL_2="109" VAR="0.3145436367913432" WEIGHT="1.4159389319709312"/><DICH_DATA CI_END="1.9430384523039979" CI_START="0.35370990396150453" EFFECT_SIZE="0.8290186634557496" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.28848139527718897" LOG_CI_START="-0.45135277966613047" LOG_EFFECT_SIZE="-0.08143569219447078" MODIFIED="2014-06-12 18:32:31 +0100" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.43458225659993566" STUDY_ID="STD-Meijvis-2011" TOTAL_1="151" TOTAL_2="153" VAR="0.18886173775149231" WEIGHT="2.6408004520853976"/><DICH_DATA CI_END="1.493563365609328" CI_START="0.9190376823484177" EFFECT_SIZE="1.1715976331360947" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" LOG_CI_END="0.17422365261855385" LOG_CI_START="-0.03666668132283872" LOG_EFFECT_SIZE="0.06877848564785757" MODIFIED="2014-05-17 16:41:13 +0100" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.1238780260811632" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" VAR="0.015345765345765351" WEIGHT="6.5345581710458465"/><DICH_DATA CI_END="1.8452575373787963" CI_START="0.1844066591708089" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2660569879785712" LOG_CI_START="-0.7342234000453071" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2014-06-12 19:02:10 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.5875696513930031" STUDY_ID="STD-Liu-2012" TOTAL_1="12" TOTAL_2="14" VAR="0.34523809523809523" WEIGHT="1.3384393158719303"/><DICH_DATA CI_END="2.4272804897909133" CI_START="0.38583281068383707" EFFECT_SIZE="0.967741935483871" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.38511996509577545" LOG_CI_START="-0.4136008433249959" LOG_EFFECT_SIZE="-0.01424043911461023" MODIFIED="2014-05-17 14:54:48 +0100" MODIFIED_BY="[Empty name]" ORDER="278" O_E="0.0" SE="0.46917255659812773" STUDY_ID="STD-Gordon-2014" TOTAL_1="31" TOTAL_2="30" VAR="0.22012288786482337" WEIGHT="1.7193703597790146"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="1.3167795492836567" CI_END="1.5856991181764677" CI_START="0.9301645999133711" DF="1" EFFECT_SIZE="1.214479800507855" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="72" I2="24.057143768369464" ID="CMP-001.02.02" LOG_CI_END="0.20022078467633075" LOG_CI_START="-0.03144019283442512" LOG_EFFECT_SIZE="0.08439029592095279" MODIFIED="2014-11-07 12:29:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2511709732511025" P_Z="0.15330179175642095" STUDIES="2" TAU2="0.0" TOTAL_1="303" TOTAL_2="301" WEIGHT="17.45616533184086" Z="1.4279654901487708"><NAME>Studies reporting only 14-day mortality</NAME><DICH_DATA CI_END="1.578666059043726" CI_START="0.571416568763245" EFFECT_SIZE="0.9497767857142857" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.1982902718368346" LOG_CI_START="-0.24304717099190923" LOG_EFFECT_SIZE="-0.02237844957753733" ORDER="278" O_E="0.0" SE="0.2592437985731798" STUDY_ID="STD-VASSCSG-1987" TOTAL_1="112" TOTAL_2="111" VAR="0.06720734709865143" WEIGHT="5.825912238892468"/><DICH_DATA CI_END="1.844596050024976" CI_START="0.9837470241692765" EFFECT_SIZE="1.3470767888307156" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="48" LOG_CI_END="0.26590127431466254" LOG_CI_START="-0.007116568369923013" LOG_EFFECT_SIZE="0.12939235297236978" ORDER="279" O_E="0.0" SE="0.16037203225304292" STUDY_ID="STD-Bone-1987" TOTAL_1="191" TOTAL_2="190" VAR="0.025719188728971037" WEIGHT="11.630253092948394"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="69.13514884804056" CI_END="1.0327596050935277" CI_START="0.8922219320640264" CI_STUDY="95" CI_TOTAL="95" DF="54" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9599222730066368" ESTIMABLE="YES" EVENTS_1="1229" EVENTS_2="1208" I2="21.89211869827271" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.013999242786574953" LOG_CI_START="-0.04952710539689725" LOG_EFFECT_SIZE="-0.017763931305161178" METHOD="MH" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="0.08048596662837071" P_Q="0.9562783460596505" P_Z="0.27302056079335346" Q="0.08941250568378777" RANDOM="YES" SCALE="5.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-05" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.012912141036953938" TOTALS="SUB" TOTAL_1="3502" TOTAL_2="3382" WEIGHT="300.0" Z="1.0961330716320883"><NAME>28-Day all-cause mortality by subgroups based on methodological quality</NAME><GROUP_LABEL_1>Treatment</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="23.110358434452248" CI_END="1.1000068764896107" CI_START="0.8611914597558161" DF="18" EFFECT_SIZE="0.9733018687465486" ESTIMABLE="YES" EVENTS_1="430" EVENTS_2="408" I2="22.112848006865505" ID="CMP-001.03.01" LOG_CI_END="0.0413954000783689" LOG_CI_START="-0.06490028562898896" LOG_EFFECT_SIZE="-0.011752442775310016" MODIFIED="2014-10-11 18:17:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.18638490183393286" P_Z="0.6647229788984843" STUDIES="19" TAU2="0.014102461951800512" TOTAL_1="1200" TOTAL_2="1142" WEIGHT="100.00000000000001" Z="0.4334016835526399"><NAME>Adequate generation of allocation sequence</NAME><DICH_DATA CI_END="1.0800951347961532" CI_START="0.7319839399101493" EFFECT_SIZE="0.8891638163161342" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="91" LOG_CI_END="0.03346200983636929" LOG_CI_START="-0.13549844747291392" LOG_EFFECT_SIZE="-0.05101821881827232" ORDER="527" O_E="0.0" SE="0.09924820899122541" STUDY_ID="STD-Annane-2002" TOTAL_1="151" TOTAL_2="149" VAR="0.009850206987965956" WEIGHT="16.27618313798193"/><DICH_DATA CI_END="1.493563365609328" CI_START="0.9190376823484177" EFFECT_SIZE="1.1715976331360947" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" LOG_CI_END="0.17422365261855385" LOG_CI_START="-0.03666668132283872" LOG_EFFECT_SIZE="0.06877848564785757" MODIFIED="2014-05-17 16:42:10 +0100" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.1238780260811632" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" VAR="0.015345765345765351" WEIGHT="13.2387604308975"/><DICH_DATA CI_END="1.2453879102921923" CI_START="0.24097987387695294" EFFECT_SIZE="0.5478260869565217" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.09530464545566107" LOG_CI_START="-0.6180192272557211" LOG_EFFECT_SIZE="-0.26135729090003" ORDER="514" O_E="0.0" SE="0.4190099738407832" STUDY_ID="STD-Chawla-1999" TOTAL_1="23" TOTAL_2="21" VAR="0.17556935817805383" WEIGHT="2.0554346240795467"/><DICH_DATA CI_END="3.1461733602779907" CI_START="0.34914326418088176" EFFECT_SIZE="1.0480769230769231" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.49778264941815736" LOG_CI_START="-0.45699633213447066" LOG_EFFECT_SIZE="0.020393158641843302" MODIFIED="2014-10-11 16:40:34 +0100" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.560841899996196" STUDY_ID="STD-Snijders-2010" TOTAL_1="104" TOTAL_2="109" VAR="0.3145436367913432" WEIGHT="1.186254843121651"/><DICH_DATA CI_END="2.2058533355443934" CI_START="0.33306560581902944" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3435766333619987" LOG_CI_START="-0.4774702126232252" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="517" O_E="0.0" SE="0.48228698157915545" STUDY_ID="STD-Rinaldi-2006" TOTAL_1="26" TOTAL_2="26" VAR="0.23260073260073263" WEIGHT="1.5802714959334418"/><DICH_DATA CI_END="1.8785154666635893" CI_START="0.5197855474364792" EFFECT_SIZE="0.9881422924901185" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.27381477515612307" LOG_CI_START="-0.2841758001636837" LOG_EFFECT_SIZE="-0.005180512503780329" MODIFIED="2008-10-30 12:10:23 +0000" MODIFIED_BY="Djillali Annane" ORDER="518" O_E="0.0" SE="0.32776642604074885" STUDY_ID="STD-Oppert-2005" TOTAL_1="23" TOTAL_2="25" VAR="0.1074308300395257" WEIGHT="3.207829064112857"/><DICH_DATA CI_END="1.4005396690070233" CI_START="0.8473604729134112" EFFECT_SIZE="1.0893860455613444" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="78" LOG_CI_END="0.14629541432835985" LOG_CI_START="-0.07193179853182889" LOG_EFFECT_SIZE="0.03718180789826547" MODIFIED="2008-11-21 06:39:49 +0000" MODIFIED_BY="Djillali Annane" ORDER="528" O_E="0.0" SE="0.12818774507620045" STUDY_ID="STD-Sprung-2008" TOTAL_1="251" TOTAL_2="248" VAR="0.016432097987720957" WEIGHT="12.767763055346665"/><DICH_DATA CI_END="2.9297807522256587" CI_START="0.19199388881665874" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46683512149361056" LOG_CI_START="-0.7167125947102105" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="522" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Briegel-1999" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="0.7837353684682485"/><DICH_DATA CI_END="1.0160309717783367" CI_START="0.24979772650962204" EFFECT_SIZE="0.5037878787878788" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.006906946793778492" LOG_CI_START="-0.602411518599269" LOG_EFFECT_SIZE="-0.2977522859027453" ORDER="529" O_E="0.0" SE="0.35791668274692406" STUDY_ID="STD-Bollaert-1998" TOTAL_1="22" TOTAL_2="19" VAR="0.12810435178856228" WEIGHT="2.741486262528056"/><DICH_DATA CI_END="2.4272804897909133" CI_START="0.38583281068383707" EFFECT_SIZE="0.967741935483871" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.38511996509577545" LOG_CI_START="-0.4136008433249959" LOG_EFFECT_SIZE="-0.01424043911461023" MODIFIED="2014-05-17 14:55:55 +0100" MODIFIED_BY="[Empty name]" ORDER="280" O_E="0.0" SE="0.46917255659812773" STUDY_ID="STD-Gordon-2014" TOTAL_1="31" TOTAL_2="30" VAR="0.22012288786482337" WEIGHT="1.6644570137788766"/><DICH_DATA CI_END="1.844596050024976" CI_START="0.9837470241692765" EFFECT_SIZE="1.3470767888307156" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="48" LOG_CI_END="0.26590127431466254" LOG_CI_START="-0.007116568369923013" LOG_EFFECT_SIZE="0.12939235297236978" ORDER="516" O_E="0.0" SE="0.16037203225304292" STUDY_ID="STD-Bone-1987" TOTAL_1="191" TOTAL_2="190" VAR="0.025719188728971037" WEIGHT="9.790102108834455"/><DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="524" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Yildiz-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="3.184183395053482"/><DICH_DATA CI_END="1.578666059043726" CI_START="0.571416568763245" EFFECT_SIZE="0.9497767857142857" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.1982902718368346" LOG_CI_START="-0.24304717099190923" LOG_EFFECT_SIZE="-0.02237844957753733" ORDER="526" O_E="0.0" SE="0.2592437985731798" STUDY_ID="STD-VASSCSG-1987" TOTAL_1="112" TOTAL_2="111" VAR="0.06720734709865143" WEIGHT="4.794723181125508"/><DICH_DATA CI_END="1.1182111086595163" CI_START="0.3493302802797868" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.04852380236154291" LOG_CI_START="-0.4567637676733925" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="525" O_E="0.0" SE="0.2968084198523318" STUDY_ID="STD-Cicarelli-2007" TOTAL_1="14" TOTAL_2="15" VAR="0.08809523809523807" WEIGHT="3.814743640293768"/><DICH_DATA CI_END="1.7619746384608999" CI_START="0.6944585490345027" EFFECT_SIZE="1.1061728395061727" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.2459996529660672" LOG_CI_START="-0.15835367139911644" LOG_EFFECT_SIZE="0.04382299078347541" MODIFIED="2014-10-11 18:17:22 +0100" MODIFIED_BY="[Empty name]" ORDER="289" O_E="0.0" SE="0.23751914431334561" STUDY_ID="STD-Yildiz-2011" TOTAL_1="27" TOTAL_2="28" VAR="0.056415343915343905" WEIGHT="5.528504772845362"/><DICH_DATA CI_END="1.6013530609278497" CI_START="0.7163652835855632" EFFECT_SIZE="1.0710526315789475" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.20448709426058112" LOG_CI_START="-0.14486546904376124" LOG_EFFECT_SIZE="0.029810812608409926" ORDER="520" O_E="0.0" SE="0.20521142500804926" STUDY_ID="STD-Luce-1988" TOTAL_1="38" TOTAL_2="37" VAR="0.04211172895383422" WEIGHT="6.935224362857679"/><DICH_DATA CI_END="1.6145545217389314" CI_START="0.7717788063662259" EFFECT_SIZE="1.1162790697674418" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="11" LOG_CI_END="0.20805271525008898" LOG_CI_START="-0.11250715165808765" LOG_EFFECT_SIZE="0.04777278179600068" ORDER="515" O_E="0.0" SE="0.1882984526187957" STUDY_ID="STD-Sprung-1984" TOTAL_1="43" TOTAL_2="16" VAR="0.035456307258632844" WEIGHT="7.866580072876703"/><DICH_DATA CI_END="1.2908449954588779" CI_START="0.004583942908815428" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.11087409535823754" LOG_CI_START="-2.338760799971911" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="521" O_E="0.0" SE="1.438927663405225" STUDY_ID="STD-Confalonieri-2005" TOTAL_1="23" TOTAL_2="23" VAR="2.0705128205128207" WEIGHT="0.18701677455140067"/><DICH_DATA CI_END="1.2036378020776555" CI_START="0.2656640738962389" EFFECT_SIZE="0.5654761904761905" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.08049581896163172" LOG_CI_START="-0.5756671718356619" LOG_EFFECT_SIZE="-0.2475856764370151" ORDER="523" O_E="0.0" SE="0.38543338885351874" STUDY_ID="STD-Meduri-2007" TOTAL_1="42" TOTAL_2="19" VAR="0.14855889724310778" WEIGHT="2.396746395312883"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="22.64568012126944" CI_END="1.0927217220341903" CI_START="0.8396104616277769" DF="17" EFFECT_SIZE="0.9578416306821425" ESTIMABLE="YES" EVENTS_1="397" EVENTS_2="397" I2="24.93049487158861" ID="CMP-001.03.02" LOG_CI_END="0.0385095764305847" LOG_CI_START="-0.07592215870456175" LOG_EFFECT_SIZE="-0.01870629113698852" MODIFIED="2014-10-11 18:17:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1611449908803415" P_Z="0.52165571475398" STUDIES="18" TAU2="0.016987515178870205" TOTAL_1="1157" TOTAL_2="1126" WEIGHT="100.00000000000001" Z="0.6407952631237779"><NAME>Adequate allocation concealment</NAME><DICH_DATA CI_END="1.8785154666635893" CI_START="0.5197855474364792" EFFECT_SIZE="0.9881422924901185" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.27381477515612307" LOG_CI_START="-0.2841758001636837" LOG_EFFECT_SIZE="-0.005180512503780329" MODIFIED="2008-10-30 12:11:52 +0000" MODIFIED_BY="Djillali Annane" ORDER="542" O_E="0.0" SE="0.32776642604074885" STUDY_ID="STD-Oppert-2005" TOTAL_1="23" TOTAL_2="25" VAR="0.1074308300395257" WEIGHT="3.6314807771172437"/><DICH_DATA CI_END="1.4005396690070233" CI_START="0.8473604729134112" EFFECT_SIZE="1.0893860455613444" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="78" LOG_CI_END="0.14629541432835985" LOG_CI_START="-0.07193179853182889" LOG_EFFECT_SIZE="0.03718180789826547" MODIFIED="2008-11-21 06:40:17 +0000" MODIFIED_BY="Djillali Annane" ORDER="544" O_E="0.0" SE="0.12818774507620045" STUDY_ID="STD-Sprung-2008" TOTAL_1="251" TOTAL_2="248" VAR="0.016432097987720957" WEIGHT="13.519690569997952"/><DICH_DATA CI_END="1.493563365609328" CI_START="0.9190376823484177" EFFECT_SIZE="1.1715976331360947" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" LOG_CI_END="0.17422365261855385" LOG_CI_START="-0.03666668132283872" LOG_EFFECT_SIZE="0.06877848564785757" MODIFIED="2014-05-17 16:42:22 +0100" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.1238780260811632" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" VAR="0.015345765345765351" WEIGHT="13.973924750292085"/><DICH_DATA CI_END="2.4272804897909133" CI_START="0.38583281068383707" EFFECT_SIZE="0.967741935483871" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.38511996509577545" LOG_CI_START="-0.4136008433249959" LOG_EFFECT_SIZE="-0.01424043911461023" MODIFIED="2014-05-17 14:56:44 +0100" MODIFIED_BY="[Empty name]" ORDER="281" O_E="0.0" SE="0.46917255659812773" STUDY_ID="STD-Gordon-2014" TOTAL_1="31" TOTAL_2="30" VAR="0.22012288786482337" WEIGHT="1.9055377713565866"/><DICH_DATA CI_END="1.0800951347961532" CI_START="0.7319839399101493" EFFECT_SIZE="0.8891638163161342" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="91" LOG_CI_END="0.03346200983636929" LOG_CI_START="-0.13549844747291392" LOG_EFFECT_SIZE="-0.05101821881827232" ORDER="536" O_E="0.0" SE="0.09924820899122541" STUDY_ID="STD-Annane-2002" TOTAL_1="151" TOTAL_2="149" VAR="0.009850206987965956" WEIGHT="16.835364274680032"/><DICH_DATA CI_END="1.2453879102921923" CI_START="0.24097987387695294" EFFECT_SIZE="0.5478260869565217" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.09530464545566107" LOG_CI_START="-0.6180192272557211" LOG_EFFECT_SIZE="-0.26135729090003" ORDER="540" O_E="0.0" SE="0.4190099738407832" STUDY_ID="STD-Chawla-1999" TOTAL_1="23" TOTAL_2="21" VAR="0.17556935817805383" WEIGHT="2.3464383332805867"/><DICH_DATA CI_END="3.1461733602779907" CI_START="0.34914326418088176" EFFECT_SIZE="1.0480769230769231" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.49778264941815736" LOG_CI_START="-0.45699633213447066" LOG_EFFECT_SIZE="0.020393158641843302" MODIFIED="2014-10-11 16:40:41 +0100" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.560841899996196" STUDY_ID="STD-Snijders-2010" TOTAL_1="104" TOTAL_2="109" VAR="0.3145436367913432" WEIGHT="1.3628367237777286"/><DICH_DATA CI_END="2.9297807522256587" CI_START="0.19199388881665874" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46683512149361056" LOG_CI_START="-0.7167125947102105" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="532" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Briegel-1999" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="0.9030661630929843"/><DICH_DATA CI_END="1.0160309717783367" CI_START="0.24979772650962204" EFFECT_SIZE="0.5037878787878788" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.006906946793778492" LOG_CI_START="-0.602411518599269" LOG_EFFECT_SIZE="-0.2977522859027453" ORDER="533" O_E="0.0" SE="0.35791668274692406" STUDY_ID="STD-Bollaert-1998" TOTAL_1="22" TOTAL_2="19" VAR="0.12810435178856228" WEIGHT="3.1140465583970918"/><DICH_DATA CI_END="2.2058533355443934" CI_START="0.33306560581902944" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3435766333619987" LOG_CI_START="-0.4774702126232252" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="539" O_E="0.0" SE="0.48228698157915545" STUDY_ID="STD-Rinaldi-2006" TOTAL_1="26" TOTAL_2="26" VAR="0.23260073260073263" WEIGHT="1.8102728513897053"/><DICH_DATA CI_END="1.6013530609278497" CI_START="0.7163652835855632" EFFECT_SIZE="1.0710526315789475" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.20448709426058112" LOG_CI_START="-0.14486546904376124" LOG_EFFECT_SIZE="0.029810812608409926" ORDER="535" O_E="0.0" SE="0.20521142500804926" STUDY_ID="STD-Luce-1988" TOTAL_1="38" TOTAL_2="37" VAR="0.04211172895383422" WEIGHT="7.645154106654834"/><DICH_DATA CI_END="1.578666059043726" CI_START="0.571416568763245" EFFECT_SIZE="0.9497767857142857" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.1982902718368346" LOG_CI_START="-0.24304717099190923" LOG_EFFECT_SIZE="-0.02237844957753733" ORDER="531" O_E="0.0" SE="0.2592437985731798" STUDY_ID="STD-VASSCSG-1987" TOTAL_1="112" TOTAL_2="111" VAR="0.06720734709865143" WEIGHT="5.366394299595756"/><DICH_DATA CI_END="1.1182111086595163" CI_START="0.3493302802797868" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.04852380236154291" LOG_CI_START="-0.4567637676733925" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="543" O_E="0.0" SE="0.2968084198523318" STUDY_ID="STD-Cicarelli-2007" TOTAL_1="14" TOTAL_2="15" VAR="0.08809523809523807" WEIGHT="4.299685865698269"/><DICH_DATA CI_END="1.7619746384608999" CI_START="0.6944585490345027" EFFECT_SIZE="1.1061728395061727" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.2459996529660672" LOG_CI_START="-0.15835367139911644" LOG_EFFECT_SIZE="0.04382299078347541" MODIFIED="2014-10-11 18:17:34 +0100" MODIFIED_BY="[Empty name]" ORDER="290" O_E="0.0" SE="0.23751914431334561" STUDY_ID="STD-Yildiz-2011" TOTAL_1="27" TOTAL_2="28" VAR="0.056415343915343905" WEIGHT="6.1553846070412295"/><DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="545" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Yildiz-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="3.6053285175239145"/><DICH_DATA CI_END="1.844596050024976" CI_START="0.9837470241692765" EFFECT_SIZE="1.3470767888307156" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="48" LOG_CI_END="0.26590127431466254" LOG_CI_START="-0.007116568369923013" LOG_EFFECT_SIZE="0.12939235297236978" ORDER="541" O_E="0.0" SE="0.16037203225304292" STUDY_ID="STD-Bone-1987" TOTAL_1="191" TOTAL_2="190" VAR="0.025719188728971037" WEIGHT="10.579669879378915"/><DICH_DATA CI_END="1.2908449954588779" CI_START="0.004583942908815428" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.11087409535823754" LOG_CI_START="-2.338760799971911" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="530" O_E="0.0" SE="1.438927663405225" STUDY_ID="STD-Confalonieri-2005" TOTAL_1="23" TOTAL_2="23" VAR="2.0705128205128207" WEIGHT="0.2164420389573882"/><DICH_DATA CI_END="1.2036378020776555" CI_START="0.2656640738962389" EFFECT_SIZE="0.5654761904761905" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.08049581896163172" LOG_CI_START="-0.5756671718356619" LOG_EFFECT_SIZE="-0.2475856764370151" ORDER="537" O_E="0.0" SE="0.38543338885351874" STUDY_ID="STD-Meduri-2007" TOTAL_1="42" TOTAL_2="19" VAR="0.14855889724310778" WEIGHT="2.72928191176771"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="23.325739549902806" CI_END="1.075463119927623" CI_START="0.8351796721383857" DF="17" EFFECT_SIZE="0.9477367439843607" ESTIMABLE="YES" EVENTS_1="402" EVENTS_2="403" I2="27.119138222261274" ID="CMP-001.03.03" LOG_CI_END="0.03159552203491901" LOG_CI_START="-0.0782200847268287" LOG_EFFECT_SIZE="-0.023312281345954835" MODIFIED="2014-11-07 12:28:53 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.13894346301582705" P_Z="0.40532734052374564" STUDIES="18" TAU2="0.01714316391725349" TOTAL_1="1145" TOTAL_2="1114" WEIGHT="99.99999999999996" Z="0.8321445955248706"><NAME>Blinded trials</NAME><DICH_DATA CI_END="1.4005396690070233" CI_START="0.8473604729134112" EFFECT_SIZE="1.0893860455613444" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="78" LOG_CI_END="0.14629541432835985" LOG_CI_START="-0.07193179853182889" LOG_EFFECT_SIZE="0.03718180789826547" MODIFIED="2008-11-21 06:40:35 +0000" MODIFIED_BY="Djillali Annane" ORDER="558" O_E="0.0" SE="0.12818774507620045" STUDY_ID="STD-Sprung-2008" TOTAL_1="251" TOTAL_2="248" VAR="0.016432097987720957" WEIGHT="12.393213344448505"/><DICH_DATA CI_END="1.493563365609328" CI_START="0.9190376823484177" EFFECT_SIZE="1.1715976331360947" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" LOG_CI_END="0.17422365261855385" LOG_CI_START="-0.03666668132283872" LOG_EFFECT_SIZE="0.06877848564785757" MODIFIED="2014-05-17 16:42:28 +0100" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.1238780260811632" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" VAR="0.015345765345765351" WEIGHT="12.807605338896872"/><DICH_DATA CI_END="1.0160309717783367" CI_START="0.24979772650962204" EFFECT_SIZE="0.5037878787878788" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.006906946793778492" LOG_CI_START="-0.602411518599269" LOG_EFFECT_SIZE="-0.2977522859027453" ORDER="556" O_E="0.0" SE="0.35791668274692406" STUDY_ID="STD-Bollaert-1998" TOTAL_1="22" TOTAL_2="19" VAR="0.12810435178856228" WEIGHT="2.8648020715676994"/><DICH_DATA CI_END="1.0800951347961532" CI_START="0.7319839399101493" EFFECT_SIZE="0.8891638163161342" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="91" LOG_CI_END="0.03346200983636929" LOG_CI_START="-0.13549844747291392" LOG_EFFECT_SIZE="-0.05101821881827232" ORDER="551" O_E="0.0" SE="0.09924820899122541" STUDY_ID="STD-Annane-2002" TOTAL_1="151" TOTAL_2="149" VAR="0.009850206987965956" WEIGHT="15.415095259689284"/><DICH_DATA CI_END="1.2453879102921923" CI_START="0.24097987387695294" EFFECT_SIZE="0.5478260869565217" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.09530464545566107" LOG_CI_START="-0.6180192272557211" LOG_EFFECT_SIZE="-0.26135729090003" ORDER="553" O_E="0.0" SE="0.4190099738407832" STUDY_ID="STD-Chawla-1999" TOTAL_1="23" TOTAL_2="21" VAR="0.17556935817805383" WEIGHT="2.159202626585392"/><DICH_DATA CI_END="3.1461733602779907" CI_START="0.34914326418088176" EFFECT_SIZE="1.0480769230769231" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.49778264941815736" LOG_CI_START="-0.45699633213447066" LOG_EFFECT_SIZE="0.020393158641843302" MODIFIED="2014-10-11 16:40:53 +0100" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.560841899996196" STUDY_ID="STD-Snijders-2010" TOTAL_1="104" TOTAL_2="109" VAR="0.3145436367913432" WEIGHT="1.2545129411093212"/><DICH_DATA CI_END="1.8785154666635893" CI_START="0.5197855474364792" EFFECT_SIZE="0.9881422924901185" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.27381477515612307" LOG_CI_START="-0.2841758001636837" LOG_EFFECT_SIZE="-0.005180512503780329" MODIFIED="2008-10-30 12:11:01 +0000" MODIFIED_BY="Djillali Annane" ORDER="547" O_E="0.0" SE="0.32776642604074885" STUDY_ID="STD-Oppert-2005" TOTAL_1="23" TOTAL_2="25" VAR="0.1074308300395257" WEIGHT="3.340226725238096"/><DICH_DATA CI_END="2.4272804897909133" CI_START="0.38583281068383707" EFFECT_SIZE="0.967741935483871" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.38511996509577545" LOG_CI_START="-0.4136008433249959" LOG_EFFECT_SIZE="-0.01424043911461023" MODIFIED="2014-10-11 18:20:35 +0100" MODIFIED_BY="[Empty name]" ORDER="282" O_E="0.0" SE="0.46917255659812773" STUDY_ID="STD-Gordon-2014" TOTAL_1="31" TOTAL_2="30" VAR="0.22012288786482337" WEIGHT="1.753750192068209"/><DICH_DATA CI_END="2.9297807522256587" CI_START="0.19199388881665874" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46683512149361056" LOG_CI_START="-0.7167125947102105" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="552" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Briegel-1999" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="0.8314184305756529"/><DICH_DATA CI_END="1.844596050024976" CI_START="0.9837470241692765" EFFECT_SIZE="1.3470767888307156" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="48" LOG_CI_END="0.26590127431466254" LOG_CI_START="-0.007116568369923013" LOG_EFFECT_SIZE="0.12939235297236978" ORDER="549" O_E="0.0" SE="0.16037203225304292" STUDY_ID="STD-Bone-1987" TOTAL_1="191" TOTAL_2="190" VAR="0.025719188728971037" WEIGHT="9.707945509163157"/><DICH_DATA CI_END="1.6013530609278497" CI_START="0.7163652835855632" EFFECT_SIZE="1.0710526315789475" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.20448709426058112" LOG_CI_START="-0.14486546904376124" LOG_EFFECT_SIZE="0.029810812608409926" ORDER="557" O_E="0.0" SE="0.20521142500804926" STUDY_ID="STD-Luce-1988" TOTAL_1="38" TOTAL_2="37" VAR="0.04211172895383422" WEIGHT="7.022295775461836"/><DICH_DATA CI_END="1.7619746384608999" CI_START="0.6944585490345027" EFFECT_SIZE="1.1061728395061727" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.2459996529660672" LOG_CI_START="-0.15835367139911644" LOG_EFFECT_SIZE="0.04382299078347541" MODIFIED="2014-05-17 15:42:19 +0100" MODIFIED_BY="[Empty name]" ORDER="290" O_E="0.0" SE="0.23751914431334561" STUDY_ID="STD-Yildiz-2011" TOTAL_1="27" TOTAL_2="28" VAR="0.056415343915343905" WEIGHT="5.656794790223927"/><DICH_DATA CI_END="1.1182111086595163" CI_START="0.3493302802797868" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.04852380236154291" LOG_CI_START="-0.4567637676733925" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="560" O_E="0.0" SE="0.2968084198523318" STUDY_ID="STD-Cicarelli-2007" TOTAL_1="14" TOTAL_2="15" VAR="0.08809523809523807" WEIGHT="3.953931035884525"/><DICH_DATA CI_END="1.578666059043726" CI_START="0.571416568763245" EFFECT_SIZE="0.9497767857142857" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.1982902718368346" LOG_CI_START="-0.24304717099190923" LOG_EFFECT_SIZE="-0.02237844957753733" ORDER="555" O_E="0.0" SE="0.2592437985731798" STUDY_ID="STD-VASSCSG-1987" TOTAL_1="112" TOTAL_2="111" VAR="0.06720734709865143" WEIGHT="4.933051132382862"/><DICH_DATA CI_END="1.1533705848073679" CI_START="0.6207686764272098" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.06196887110925881" LOG_CI_START="-0.2070702054064823" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="559" O_E="0.0" SE="0.15803488531025353" STUDY_ID="STD-Tandan-2005" TOTAL_1="14" TOTAL_2="14" VAR="0.02497502497502499" WEIGHT="9.879470006374548"/><DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="548" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Yildiz-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="3.3162017828174344"/><DICH_DATA CI_END="1.2036378020776555" CI_START="0.2656640738962389" EFFECT_SIZE="0.5654761904761905" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.08049581896163172" LOG_CI_START="-0.5756671718356619" LOG_EFFECT_SIZE="-0.2475856764370151" ORDER="554" O_E="0.0" SE="0.38543338885351874" STUDY_ID="STD-Meduri-2007" TOTAL_1="42" TOTAL_2="19" VAR="0.14855889724310778" WEIGHT="2.511166010671341"/><DICH_DATA CI_END="1.2908449954588779" CI_START="0.004583942908815428" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.11087409535823754" LOG_CI_START="-2.338760799971911" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="550" O_E="0.0" SE="1.438927663405225" STUDY_ID="STD-Confalonieri-2005" TOTAL_1="23" TOTAL_2="23" VAR="2.0705128205128207" WEIGHT="0.19931702684131591"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="44.985486793395395" CI_END="0.9851669644217969" CI_START="0.8121997716040669" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8945123719073176" ESTIMABLE="YES" EVENTS_1="474" EVENTS_2="495" I2="42.20358196986939" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.006490159774336196" LOG_CI_START="-0.09033713697243766" LOG_EFFECT_SIZE="-0.048413648373386936" METHOD="MH" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="4" P_CHI2="0.011814329064122053" P_Q="0.3538818189994556" P_Z="0.023611949074172287" Q="0.8594889943716244" RANDOM="NO" SCALE="5.0" SORT_BY="YEAR" STUDIES="27" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1618" TOTAL_2="1558" WEIGHT="200.0" Z="2.263385284548413"><NAME>28-Day all-cause mortality by subgroups based on treatment dose/duration</NAME><GROUP_LABEL_1>Treatment</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="25.090623444144516" CI_END="0.9704950950569596" CI_START="0.7761643696346108" DF="21" EFFECT_SIZE="0.8679076642641006" ESTIMABLE="YES" EVENTS_1="322" EVENTS_2="359" I2="16.303394984388714" ID="CMP-001.04.01" LOG_CI_END="-0.013006655221604492" LOG_CI_START="-0.11004629772876001" LOG_EFFECT_SIZE="-0.061526476475182244" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.24326052528099185" P_Z="0.012941707180929227" STUDIES="22" TAU2="0.0" TOTAL_1="1148" TOTAL_2="1118" WEIGHT="100.00000000000003" Z="2.4853693783572233"><NAME>Long course of low-dose corticosteroids</NAME><DICH_DATA CI_END="1.0160309717783367" CI_START="0.24979772650962204" EFFECT_SIZE="0.5037878787878788" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.006906946793778492" LOG_CI_START="-0.602411518599269" LOG_EFFECT_SIZE="-0.2977522859027453" MODIFIED="2008-11-21 15:10:49 +0000" MODIFIED_BY="Djillali Annane" ORDER="592" O_E="0.0" SE="0.35791668274692406" STUDY_ID="STD-Bollaert-1998" TOTAL_1="22" TOTAL_2="19" VAR="0.12810435178856228" WEIGHT="3.522268565334862"/><DICH_DATA CI_END="2.9297807522256587" CI_START="0.19199388881665874" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46683512149361056" LOG_CI_START="-0.7167125947102105" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2008-11-21 15:10:50 +0000" MODIFIED_BY="Djillali Annane" ORDER="585" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Briegel-1999" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="1.0940379634752222"/><DICH_DATA CI_END="1.2453879102921923" CI_START="0.24097987387695294" EFFECT_SIZE="0.5478260869565217" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.09530464545566107" LOG_CI_START="-0.6180192272557211" LOG_EFFECT_SIZE="-0.26135729090003" MODIFIED="2008-11-21 15:10:51 +0000" MODIFIED_BY="Djillali Annane" ORDER="581" O_E="0.0" SE="0.4190099738407832" STUDY_ID="STD-Chawla-1999" TOTAL_1="23" TOTAL_2="21" VAR="0.17556935817805383" WEIGHT="2.8594174045375125"/><DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2008-11-21 15:12:09 +0000" MODIFIED_BY="Djillali Annane" ORDER="591" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Yildiz-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="3.2821138904256664"/><DICH_DATA CI_END="1.0800951347961532" CI_START="0.7319839399101493" EFFECT_SIZE="0.8891638163161342" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="91" LOG_CI_END="0.03346200983636929" LOG_CI_START="-0.13549844747291392" LOG_EFFECT_SIZE="-0.05101821881827232" MODIFIED="2008-11-21 15:12:09 +0000" MODIFIED_BY="Djillali Annane" ORDER="587" O_E="0.0" SE="0.09924820899122541" STUDY_ID="STD-Annane-2002" TOTAL_1="151" TOTAL_2="149" VAR="0.009850206987965956" WEIGHT="25.05529276018838"/><DICH_DATA CI_END="1.8785154666635893" CI_START="0.5197855474364792" EFFECT_SIZE="0.9881422924901185" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.27381477515612307" LOG_CI_START="-0.2841758001636837" LOG_EFFECT_SIZE="-0.005180512503780329" MODIFIED="2008-11-21 15:10:52 +0000" MODIFIED_BY="Djillali Annane" ORDER="586" O_E="0.0" SE="0.32776642604074885" STUDY_ID="STD-Oppert-2005" TOTAL_1="23" TOTAL_2="25" VAR="0.1074308300395257" WEIGHT="2.8832458829086582"/><DICH_DATA CI_END="1.2908449954588779" CI_START="0.004583942908815428" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.11087409535823754" LOG_CI_START="-2.338760799971911" LOG_EFFECT_SIZE="-1.1139433523068367" MODIFIED="2010-02-24 12:18:26 +0000" MODIFIED_BY="Djillali Annane" ORDER="584" O_E="0.0" SE="1.438927663405225" STUDY_ID="STD-Confalonieri-2005" TOTAL_1="23" TOTAL_2="23" VAR="2.0705128205128207" WEIGHT="1.777811690647236"/><DICH_DATA CI_END="1.1533705848073679" CI_START="0.6207686764272098" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.06196887110925881" LOG_CI_START="-0.2070702054064823" LOG_EFFECT_SIZE="-0.07255066714861173" MODIFIED="2008-11-21 15:12:11 +0000" MODIFIED_BY="Djillali Annane" ORDER="588" O_E="0.0" SE="0.15803488531025353" STUDY_ID="STD-Tandan-2005" TOTAL_1="14" TOTAL_2="14" VAR="0.02497502497502499" WEIGHT="3.555623381294472"/><DICH_DATA CI_END="2.2058533355443934" CI_START="0.33306560581902944" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3435766333619987" LOG_CI_START="-0.4774702126232252" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2008-11-21 15:10:53 +0000" MODIFIED_BY="Djillali Annane" ORDER="590" O_E="0.0" SE="0.48228698157915545" STUDY_ID="STD-Rinaldi-2006" TOTAL_1="26" TOTAL_2="26" VAR="0.23260073260073263" WEIGHT="1.9145664360816388"/><DICH_DATA CI_END="1.1182111086595163" CI_START="0.3493302802797868" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.04852380236154291" LOG_CI_START="-0.4567637676733925" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2008-11-21 15:12:12 +0000" MODIFIED_BY="Djillali Annane" ORDER="582" O_E="0.0" SE="0.2968084198523318" STUDY_ID="STD-Cicarelli-2007" TOTAL_1="14" TOTAL_2="15" VAR="0.08809523809523807" WEIGHT="3.1689375493765057"/><DICH_DATA CI_END="1.2036378020776555" CI_START="0.2656640738962389" EFFECT_SIZE="0.5654761904761905" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.08049581896163172" LOG_CI_START="-0.5756671718356619" LOG_EFFECT_SIZE="-0.2475856764370151" MODIFIED="2008-11-21 15:10:55 +0000" MODIFIED_BY="Djillali Annane" ORDER="583" O_E="0.0" SE="0.38543338885351874" STUDY_ID="STD-Meduri-2007" TOTAL_1="42" TOTAL_2="19" VAR="0.14855889724310778" WEIGHT="3.0130881617022514"/><DICH_DATA CI_END="1.4005396690070233" CI_START="0.8473604729134112" EFFECT_SIZE="1.0893860455613444" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="78" LOG_CI_END="0.14629541432835985" LOG_CI_START="-0.07193179853182889" LOG_EFFECT_SIZE="0.03718180789826547" MODIFIED="2008-11-21 15:10:56 +0000" MODIFIED_BY="Djillali Annane" ORDER="589" O_E="0.0" SE="0.12818774507620045" STUDY_ID="STD-Sprung-2008" TOTAL_1="251" TOTAL_2="248" VAR="0.016432097987720957" WEIGHT="21.461999247412727"/><DICH_DATA CI_END="2.234810390447771" CI_START="0.20947819390956535" EFFECT_SIZE="0.6842105263157895" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.34924068188610485" LOG_CI_START="-0.6788611791780892" LOG_EFFECT_SIZE="-0.16481024864599217" MODIFIED="2014-05-18 18:18:17 +0100" MODIFIED_BY="[Empty name]" ORDER="321" O_E="0.0" SE="0.6039121223753973" STUDY_ID="STD-Hu-2009" TOTAL_1="38" TOTAL_2="39" VAR="0.3647098515519568" WEIGHT="1.6197445173529263"/><DICH_DATA CI_END="3.1461733602779907" CI_START="0.34914326418088176" EFFECT_SIZE="1.0480769230769231" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.49778264941815736" LOG_CI_START="-0.45699633213447066" LOG_EFFECT_SIZE="0.020393158641843302" MODIFIED="2014-10-11 16:41:28 +0100" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.560841899996196" STUDY_ID="STD-Snijders-2010" TOTAL_1="104" TOTAL_2="109" VAR="0.3145436367913432" WEIGHT="1.6025344817101848"/><DICH_DATA CI_END="1.493563365609328" CI_START="0.9190376823484177" EFFECT_SIZE="1.1715976331360947" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" LOG_CI_END="0.17422365261855385" LOG_CI_START="-0.03666668132283872" LOG_EFFECT_SIZE="0.06877848564785757" MODIFIED="2014-06-12 17:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.1238780260811632" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" VAR="0.015345765345765351" WEIGHT="7.395696633092502"/><DICH_DATA CI_END="1.7619746384608999" CI_START="0.6944585490345027" EFFECT_SIZE="1.1061728395061727" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.2459996529660672" LOG_CI_START="-0.15835367139911644" LOG_EFFECT_SIZE="0.04382299078347541" MODIFIED="2014-05-17 15:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.0" SE="0.23751914431334561" STUDY_ID="STD-Yildiz-2011" TOTAL_1="27" TOTAL_2="28" VAR="0.056415343915343905" WEIGHT="4.0280488655224085"/><DICH_DATA CI_END="1.9430384523039979" CI_START="0.35370990396150453" EFFECT_SIZE="0.8290186634557496" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.28848139527718897" LOG_CI_START="-0.45135277966613047" LOG_EFFECT_SIZE="-0.08143569219447078" MODIFIED="2014-06-12 18:32:54 +0100" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.43458225659993566" STUDY_ID="STD-Meijvis-2011" TOTAL_1="151" TOTAL_2="153" VAR="0.18886173775149231" WEIGHT="2.9888109495597766"/><DICH_DATA CI_END="1.5535004046793537" CI_START="0.07152306544396729" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.19131137072262336" LOG_CI_START="-1.1455538801619483" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-05-17 16:14:42 +0100" MODIFIED_BY="[Empty name]" ORDER="297" O_E="0.0" SE="0.7852812659593164" STUDY_ID="STD-Sabry-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.6166666666666666" WEIGHT="1.6410569452128332"/><DICH_DATA CI_END="1.8452575373787963" CI_START="0.1844066591708089" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2660569879785712" LOG_CI_START="-0.7342234000453071" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2014-06-12 19:02:18 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.5875696513930031" STUDY_ID="STD-Liu-2012" TOTAL_1="12" TOTAL_2="14" VAR="0.34523809523809523" WEIGHT="1.5148217955810768"/><DICH_DATA CI_END="1.3162390066867353" CI_START="0.004294988062726441" EFFECT_SIZE="0.07518796992481203" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.11933475695310501" LOG_CI_START="-2.367038038887277" LOG_EFFECT_SIZE="-1.1238516409670858" MODIFIED="2014-06-12 17:45:22 +0100" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="1.4605076880204764" STUDY_ID="STD-Rezk--2013" TOTAL_1="18" TOTAL_2="9" VAR="2.133082706766917" WEIGHT="1.254371113294867"/><DICH_DATA CI_END="2.4272804897909133" CI_START="0.38583281068383707" EFFECT_SIZE="0.967741935483871" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.38511996509577545" LOG_CI_START="-0.4136008433249959" LOG_EFFECT_SIZE="-0.01424043911461023" MODIFIED="2014-05-17 14:55:26 +0100" MODIFIED_BY="[Empty name]" ORDER="279" O_E="0.0" SE="0.46917255659812773" STUDY_ID="STD-Gordon-2014" TOTAL_1="31" TOTAL_2="30" VAR="0.22012288786482337" WEIGHT="1.9459527710993707"/><DICH_DATA CI_END="1.8164518823750662" CI_START="0.2615466915055742" EFFECT_SIZE="0.6892655367231638" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.25922389793461503" LOG_CI_START="-0.582450769308732" LOG_EFFECT_SIZE="-0.1616134356870584" MODIFIED="2014-06-12 17:01:05 +0100" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="0.494403865895539" STUDY_ID="STD-Torres-2015" TOTAL_1="59" TOTAL_2="61" VAR="0.2444351826124541" WEIGHT="2.420558994188929"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="18.7323799344328" CI_END="1.1646778980237693" CI_START="0.7966402507236446" DF="4" EFFECT_SIZE="0.9632389592899278" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="136" I2="78.64660009032048" ID="CMP-001.04.02" LOG_CI_END="0.06620583398640414" LOG_CI_START="-0.09873775438469548" LOG_EFFECT_SIZE="-0.016265960199145647" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="8.870238730634972E-4" P_Z="0.6990783904428455" STUDIES="5" TAU2="0.0" TOTAL_1="470" TOTAL_2="440" WEIGHT="99.99999999999999" Z="0.38656484291538995"><NAME>Short course of high-dose corticosteroids</NAME><DICH_DATA CI_END="0.5349608488848496" CI_START="0.13903852112599463" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="33" LOG_CI_END="-0.2716780006618398" LOG_CI_START="-0.8568648602152855" LOG_EFFECT_SIZE="-0.5642714304385626" ORDER="594" O_E="0.0" SE="0.34374165802336654" STUDY_ID="STD-Schumer-1976" TOTAL_1="86" TOTAL_2="86" VAR="0.11815832746065305" WEIGHT="23.31592392655752"/><DICH_DATA CI_END="1.6145545217389314" CI_START="0.7717788063662259" EFFECT_SIZE="1.1162790697674418" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="11" LOG_CI_END="0.20805271525008898" LOG_CI_START="-0.11250715165808765" LOG_EFFECT_SIZE="0.04777278179600068" ORDER="595" O_E="0.0" SE="0.1882984526187957" STUDY_ID="STD-Sprung-1984" TOTAL_1="43" TOTAL_2="16" VAR="0.035456307258632844" WEIGHT="11.328641003864107"/><DICH_DATA CI_END="1.578666059043726" CI_START="0.571416568763245" EFFECT_SIZE="0.9497767857142857" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.1982902718368346" LOG_CI_START="-0.24304717099190923" LOG_EFFECT_SIZE="-0.02237844957753733" ORDER="593" O_E="0.0" SE="0.2592437985731798" STUDY_ID="STD-VASSCSG-1987" TOTAL_1="112" TOTAL_2="111" VAR="0.06720734709865143" WEIGHT="17.033076101260118"/><DICH_DATA CI_END="1.844596050024976" CI_START="0.9837470241692765" EFFECT_SIZE="1.3470767888307156" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="48" LOG_CI_END="0.26590127431466254" LOG_CI_START="-0.007116568369923013" LOG_EFFECT_SIZE="0.12939235297236978" ORDER="596" O_E="0.0" SE="0.16037203225304292" STUDY_ID="STD-Bone-1987" TOTAL_1="191" TOTAL_2="190" VAR="0.025719188728971037" WEIGHT="34.00308447604857"/><DICH_DATA CI_END="1.6013530609278497" CI_START="0.7163652835855632" EFFECT_SIZE="1.0710526315789475" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.20448709426058112" LOG_CI_START="-0.14486546904376124" LOG_EFFECT_SIZE="0.029810812608409926" ORDER="597" O_E="0.0" SE="0.20521142500804926" STUDY_ID="STD-Luce-1988" TOTAL_1="38" TOTAL_2="37" VAR="0.04211172895383422" WEIGHT="14.319274492269669"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="43.14847696475624" CI_END="0.9933542954986395" CI_START="0.8168938013710072" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9008135026508552" ESTIMABLE="YES" EVENTS_1="467" EVENTS_2="483" I2="42.06052737291273" I2_Q="73.4558732684487" ID="CMP-001.05" LOG_CI_END="-0.0028958258883753224" LOG_CI_START="-0.0878343993750413" LOG_EFFECT_SIZE="-0.04536511263170832" METHOD="MH" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="5" P_CHI2="0.013480785665953454" P_Q="0.010200388845471808" P_Z="0.03629502258665671" Q="11.30193519018312" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="26" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1604" TOTAL_2="1543" WEIGHT="400.0" Z="2.0936067857722964"><NAME>28-Day all-cause mortality by subgroups based on targeted population</NAME><GROUP_LABEL_1>Treatment</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="4.528036569390169" CI_END="1.3414663780735578" CI_START="0.9133829602892996" DF="5" EFFECT_SIZE="1.1069202914091831" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="126" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.12757979217746207" LOG_CI_START="-0.03934709467926792" LOG_EFFECT_SIZE="0.04411634874909706" MODIFIED="2015-02-01 13:43:00 +0000" MODIFIED_BY="djillali annane" NO="1" P_CHI2="0.4761410786541329" P_Z="0.30021150715965705" STUDIES="6" TAU2="0.0" TOTAL_1="414" TOTAL_2="412" WEIGHT="100.0" Z="1.035979958721106"><NAME>Sepsis</NAME><DICH_DATA CI_END="1.844596050024976" CI_START="0.9837470241692765" EFFECT_SIZE="1.3470767888307156" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="48" LOG_CI_END="0.26590127431466254" LOG_CI_START="-0.007116568369923013" LOG_EFFECT_SIZE="0.12939235297236978" MODIFIED="2014-11-07 16:05:43 +0000" MODIFIED_BY="[Empty name]" ORDER="562" O_E="0.0" SE="0.16037203225304292" STUDY_ID="STD-Bone-1987" TOTAL_1="191" TOTAL_2="190" VAR="0.025719188728971037" WEIGHT="38.12637210289928"/><DICH_DATA CI_END="1.6013530609278497" CI_START="0.7163652835855632" EFFECT_SIZE="1.0710526315789475" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.20448709426058112" LOG_CI_START="-0.14486546904376124" LOG_EFFECT_SIZE="0.029810812608409926" MODIFIED="2014-11-07 16:09:08 +0000" MODIFIED_BY="[Empty name]" ORDER="571" O_E="0.0" SE="0.20521142500804926" STUDY_ID="STD-Luce-1988" TOTAL_1="38" TOTAL_2="37" VAR="0.04211172895383422" WEIGHT="16.055660712791617"/><DICH_DATA CI_END="2.2058533355443934" CI_START="0.33306560581902944" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3435766333619987" LOG_CI_START="-0.4774702126232252" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2014-11-07 16:15:49 +0000" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.48228698157915545" STUDY_ID="STD-Rinaldi-2006" TOTAL_1="26" TOTAL_2="26" VAR="0.23260073260073263" WEIGHT="5.545540706720789"/><DICH_DATA CI_END="1.578666059043726" CI_START="0.571416568763245" EFFECT_SIZE="0.9497767857142857" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.1982902718368346" LOG_CI_START="-0.24304717099190923" LOG_EFFECT_SIZE="-0.02237844957753733" MODIFIED="2014-11-07 16:09:29 +0000" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.2592437985731798" STUDY_ID="STD-VASSCSG-1987" TOTAL_1="112" TOTAL_2="111" VAR="0.06720734709865143" WEIGHT="19.098543779199847"/><DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-11-07 16:09:40 +0000" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Yildiz-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="9.506641211521353"/><DICH_DATA CI_END="1.7619746384608999" CI_START="0.6944585490345027" EFFECT_SIZE="1.1061728395061727" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.2459996529660672" LOG_CI_START="-0.15835367139911644" LOG_EFFECT_SIZE="0.04382299078347541" MODIFIED="2014-11-07 16:09:52 +0000" MODIFIED_BY="[Empty name]" ORDER="287" O_E="0.0" SE="0.23751914431334561" STUDY_ID="STD-Yildiz-2011" TOTAL_1="27" TOTAL_2="28" VAR="0.056415343915343905" WEIGHT="11.667241486867114"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="25.457044327798187" CI_END="0.9905051926653201" CI_START="0.7831431348627569" DF="11" EFFECT_SIZE="0.8807424945361486" ESTIMABLE="YES" EVENTS_1="291" EVENTS_2="302" I2="56.78995621660449" ID="CMP-001.05.02" LOG_CI_END="-0.0041432433561422065" LOG_CI_START="-0.10615885480030843" LOG_EFFECT_SIZE="-0.05515104907822532" MODIFIED="2015-02-01 13:43:11 +0000" MODIFIED_BY="djillali annane" NO="2" P_CHI2="0.007810494294684389" P_Z="0.03407633741394367" STUDIES="12" TAU2="0.0" TOTAL_1="741" TOTAL_2="703" WEIGHT="99.99999999999999" Z="2.1191672210303447"><NAME>Septic shock only</NAME><DICH_DATA CI_END="1.0800951347961532" CI_START="0.7319839399101493" EFFECT_SIZE="0.8891638163161342" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="91" LOG_CI_END="0.03346200983636929" LOG_CI_START="-0.13549844747291392" LOG_EFFECT_SIZE="-0.05101821881827232" MODIFIED="2014-11-07 16:14:45 +0000" MODIFIED_BY="[Empty name]" ORDER="575" O_E="0.0" SE="0.09924820899122541" STUDY_ID="STD-Annane-2002" TOTAL_1="151" TOTAL_2="149" VAR="0.009850206987965956" WEIGHT="29.54476251304295"/><DICH_DATA CI_END="1.493563365609328" CI_START="0.9190376823484177" EFFECT_SIZE="1.1715976331360947" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" LOG_CI_END="0.17422365261855385" LOG_CI_START="-0.03666668132283872" LOG_EFFECT_SIZE="0.06877848564785757" MODIFIED="2014-11-07 16:14:45 +0000" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.1238780260811632" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" VAR="0.015345765345765351" WEIGHT="8.720875973575591"/><DICH_DATA CI_END="1.0160309717783367" CI_START="0.24979772650962204" EFFECT_SIZE="0.5037878787878788" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.006906946793778492" LOG_CI_START="-0.602411518599269" LOG_EFFECT_SIZE="-0.2977522859027453" MODIFIED="2014-11-07 16:14:45 +0000" MODIFIED_BY="[Empty name]" ORDER="564" O_E="0.0" SE="0.35791668274692406" STUDY_ID="STD-Bollaert-1998" TOTAL_1="22" TOTAL_2="19" VAR="0.12810435178856228" WEIGHT="4.15339741850187"/><DICH_DATA CI_END="2.9297807522256587" CI_START="0.19199388881665874" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46683512149361056" LOG_CI_START="-0.7167125947102105" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2014-11-07 16:14:45 +0000" MODIFIED_BY="[Empty name]" ORDER="568" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Briegel-1999" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="1.2900704102922473"/><DICH_DATA CI_END="1.2453879102921923" CI_START="0.24097987387695294" EFFECT_SIZE="0.5478260869565217" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.09530464545566107" LOG_CI_START="-0.6180192272557211" LOG_EFFECT_SIZE="-0.26135729090003" MODIFIED="2014-11-07 16:14:45 +0000" MODIFIED_BY="[Empty name]" ORDER="561" O_E="0.0" SE="0.4190099738407832" STUDY_ID="STD-Chawla-1999" TOTAL_1="23" TOTAL_2="21" VAR="0.17556935817805383" WEIGHT="3.3717749359911013"/><DICH_DATA CI_END="2.4272804897909133" CI_START="0.38583281068383707" EFFECT_SIZE="0.967741935483871" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.38511996509577545" LOG_CI_START="-0.4136008433249959" LOG_EFFECT_SIZE="-0.01424043911461023" MODIFIED="2014-11-07 16:14:45 +0000" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.46917255659812773" STUDY_ID="STD-Gordon-2014" TOTAL_1="31" TOTAL_2="30" VAR="0.22012288786482337" WEIGHT="2.294633434700145"/><DICH_DATA CI_END="2.234810390447771" CI_START="0.20947819390956535" EFFECT_SIZE="0.6842105263157895" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.34924068188610485" LOG_CI_START="-0.6788611791780892" LOG_EFFECT_SIZE="-0.16481024864599217" MODIFIED="2014-11-07 16:14:45 +0000" MODIFIED_BY="[Empty name]" ORDER="319" O_E="0.0" SE="0.6039121223753973" STUDY_ID="STD-Hu-2009" TOTAL_1="38" TOTAL_2="39" VAR="0.3647098515519568" WEIGHT="1.9099743736794312"/><DICH_DATA CI_END="1.8785154666635893" CI_START="0.5197855474364792" EFFECT_SIZE="0.9881422924901185" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.27381477515612307" LOG_CI_START="-0.2841758001636837" LOG_EFFECT_SIZE="-0.005180512503780329" MODIFIED="2014-11-07 16:14:45 +0000" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="0.32776642604074885" STUDY_ID="STD-Oppert-2005" TOTAL_1="23" TOTAL_2="25" VAR="0.1074308300395257" WEIGHT="3.3998730604576934"/><DICH_DATA CI_END="0.5349608488848496" CI_START="0.13903852112599463" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="33" LOG_CI_END="-0.2716780006618398" LOG_CI_START="-0.8568648602152855" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2014-11-07 16:13:41 +0000" MODIFIED_BY="[Empty name]" ORDER="563" O_E="0.0" SE="0.34374165802336654" STUDY_ID="STD-Schumer-1976" TOTAL_1="86" TOTAL_2="86" VAR="0.11815832746065305" WEIGHT="10.64308088491104"/><DICH_DATA CI_END="1.6145545217389314" CI_START="0.7717788063662259" EFFECT_SIZE="1.1162790697674418" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="11" LOG_CI_END="0.20805271525008898" LOG_CI_START="-0.11250715165808765" LOG_EFFECT_SIZE="0.04777278179600068" MODIFIED="2014-11-07 16:14:45 +0000" MODIFIED_BY="[Empty name]" ORDER="580" O_E="0.0" SE="0.1882984526187957" STUDY_ID="STD-Sprung-1984" TOTAL_1="43" TOTAL_2="16" VAR="0.035456307258632844" WEIGHT="5.171214441256212"/><DICH_DATA CI_END="1.4005396690070233" CI_START="0.8473604729134112" EFFECT_SIZE="1.0893860455613444" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="78" LOG_CI_END="0.14629541432835985" LOG_CI_START="-0.07193179853182889" LOG_EFFECT_SIZE="0.03718180789826547" MODIFIED="2014-11-07 16:14:45 +0000" MODIFIED_BY="[Empty name]" ORDER="566" O_E="0.0" SE="0.12818774507620045" STUDY_ID="STD-Sprung-2008" TOTAL_1="251" TOTAL_2="248" VAR="0.016432097987720957" WEIGHT="25.307613720141905"/><DICH_DATA CI_END="1.1533705848073679" CI_START="0.6207686764272098" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.06196887110925881" LOG_CI_START="-0.2070702054064823" LOG_EFFECT_SIZE="-0.07255066714861173" MODIFIED="2014-11-07 16:14:45 +0000" MODIFIED_BY="[Empty name]" ORDER="569" O_E="0.0" SE="0.15803488531025353" STUDY_ID="STD-Tandan-2005" TOTAL_1="14" TOTAL_2="14" VAR="0.02497502497502499" WEIGHT="4.192728833449804"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="1.9687517822951888" CI_END="0.8492565594202529" CI_START="0.25328647159918477" DF="2" EFFECT_SIZE="0.4637943481954252" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="-0.07096109007581028" LOG_CI_START="-0.5963880058933236" LOG_EFFECT_SIZE="-0.3336745479845669" MODIFIED="2015-02-01 13:43:23 +0000" MODIFIED_BY="djillali annane" NO="3" P_CHI2="0.3736724629500179" P_Z="0.012797094812314148" STUDIES="3" TAU2="0.0" TOTAL_1="72" TOTAL_2="42" WEIGHT="100.00000000000001" Z="2.4893665585817515"><NAME>Sepsis and ARDS</NAME><DICH_DATA CI_END="1.8452575373787963" CI_START="0.1844066591708089" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2660569879785712" LOG_CI_START="-0.7342234000453071" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2014-11-07 16:17:05 +0000" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.5875696513930031" STUDY_ID="STD-Liu-2012" TOTAL_1="12" TOTAL_2="14" VAR="0.34523809523809523" WEIGHT="26.19765066919522"/><DICH_DATA CI_END="1.2036378020776555" CI_START="0.2656640738962389" EFFECT_SIZE="0.5654761904761905" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.08049581896163172" LOG_CI_START="-0.5756671718356619" LOG_EFFECT_SIZE="-0.2475856764370151" MODIFIED="2014-11-07 16:17:05 +0000" MODIFIED_BY="[Empty name]" ORDER="576" O_E="0.0" SE="0.38543338885351874" STUDY_ID="STD-Meduri-2007" TOTAL_1="42" TOTAL_2="19" VAR="0.14855889724310778" WEIGHT="52.108988216322736"/><DICH_DATA CI_END="1.3162390066867353" CI_START="0.004294988062726441" EFFECT_SIZE="0.07518796992481203" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.11933475695310501" LOG_CI_START="-2.367038038887277" LOG_EFFECT_SIZE="-1.1238516409670858" MODIFIED="2014-11-07 16:17:05 +0000" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="1.4605076880204764" STUDY_ID="STD-Rezk--2013" TOTAL_1="18" TOTAL_2="9" VAR="2.133082706766917" WEIGHT="21.69336111448206"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="4.076336169894277" CI_END="1.021352722199652" CI_START="0.3813221219951219" DF="4" EFFECT_SIZE="0.6240708191661147" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="38" I2="1.8726662059438701" ID="CMP-001.05.04" LOG_CI_END="0.009175750755649517" LOG_CI_START="-0.4187079988655335" LOG_EFFECT_SIZE="-0.20476612405494202" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="4" P_CHI2="0.3957736951302143" P_Z="0.06066858548060064" STUDIES="5" TAU2="0.0" TOTAL_1="377" TOTAL_2="386" WEIGHT="99.99999999999999" Z="1.875903110397902"><NAME>Sepsis and community-acquired pneumonia</NAME><DICH_DATA CI_END="1.2908449954588779" CI_START="0.004583942908815428" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.11087409535823754" LOG_CI_START="-2.338760799971911" LOG_EFFECT_SIZE="-1.1139433523068367" MODIFIED="2014-11-07 16:18:50 +0000" MODIFIED_BY="[Empty name]" ORDER="570" O_E="0.0" SE="1.438927663405225" STUDY_ID="STD-Confalonieri-2005" TOTAL_1="23" TOTAL_2="23" VAR="2.0705128205128207" WEIGHT="17.043911129080143"/><DICH_DATA CI_END="1.9430384523039979" CI_START="0.35370990396150453" EFFECT_SIZE="0.8290186634557496" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.28848139527718897" LOG_CI_START="-0.45135277966613047" LOG_EFFECT_SIZE="-0.08143569219447078" MODIFIED="2014-11-07 16:18:50 +0000" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.43458225659993566" STUDY_ID="STD-Meijvis-2011" TOTAL_1="151" TOTAL_2="153" VAR="0.18886173775149231" WEIGHT="28.653781766601337"/><DICH_DATA CI_END="1.5535004046793537" CI_START="0.07152306544396729" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.19131137072262336" LOG_CI_START="-1.1455538801619483" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-11-07 16:18:50 +0000" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="0.7852812659593164" STUDY_ID="STD-Sabry-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.6166666666666666" WEIGHT="15.732841042227825"/><DICH_DATA CI_END="3.1461733602779907" CI_START="0.34914326418088176" EFFECT_SIZE="1.0480769230769231" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.49778264941815736" LOG_CI_START="-0.45699633213447066" LOG_EFFECT_SIZE="0.020393158641843302" MODIFIED="2014-11-07 16:18:50 +0000" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.560841899996196" STUDY_ID="STD-Snijders-2010" TOTAL_1="104" TOTAL_2="109" VAR="0.3145436367913432" WEIGHT="15.363525524804638"/><DICH_DATA CI_END="1.8164518823750662" CI_START="0.2615466915055742" EFFECT_SIZE="0.6892655367231638" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.25922389793461503" LOG_CI_START="-0.582450769308732" LOG_EFFECT_SIZE="-0.1616134356870584" MODIFIED="2014-11-07 16:18:50 +0000" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="0.494403865895539" STUDY_ID="STD-Torres-2015" TOTAL_1="59" TOTAL_2="61" VAR="0.2444351826124541" WEIGHT="23.205940537286043"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="2.933934847818251" CI_END="1.0208940427290147" CI_START="0.7569234928558037" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8790555640334279" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="153" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.008980669563865683" LOG_CI_START="-0.12094801522873712" LOG_EFFECT_SIZE="-0.0559836728324357" METHOD="MH" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="6" P_CHI2="0.8910457876155963" P_Q="1.0" P_Z="0.09121586606137626" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="294" TOTAL_2="289" WEIGHT="99.99999999999999" Z="1.6890185973789589"><NAME>28-Day mortality in participants with critical illness-related corticosteroid insufficiency</NAME><GROUP_LABEL_1>Treatment</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_DATA CI_END="1.035835346751013" CI_START="0.6636697634568325" EFFECT_SIZE="0.829127613554434" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="73" LOG_CI_END="0.015290726760074562" LOG_CI_START="-0.17804796819942093" LOG_EFFECT_SIZE="-0.08137862071967321" MODIFIED="2008-03-27 07:30:17 +0000" MODIFIED_BY="Djillali Annane" ORDER="237" O_E="0.0" SE="0.11356810646118266" STUDY_ID="STD-Annane-2002" TOTAL_1="114" TOTAL_2="115" VAR="0.01289771480517852" WEIGHT="45.16193268426338"/><DICH_DATA CI_END="1.5395214803035135" CI_START="0.20552246529072216" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.18738575281193853" LOG_CI_START="-0.6871406992451383" LOG_EFFECT_SIZE="-0.2498774732165999" MODIFIED="2008-03-27 07:41:09 +0000" MODIFIED_BY="Djillali Annane" ORDER="238" O_E="0.0" SE="0.5137011669140814" STUDY_ID="STD-Bollaert-1998" TOTAL_1="8" TOTAL_2="9" VAR="0.2638888888888889" WEIGHT="2.207314336972924"/><DICH_DATA CI_END="2.7514307510854565" CI_START="0.363447271789593" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.4395585868182921" LOG_CI_START="-0.4395585868182921" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-24 07:32:55 +0100" MODIFIED_BY="Djillali Annane" ORDER="474" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Meduri-2007" TOTAL_1="10" TOTAL_2="6" VAR="0.2666666666666667" WEIGHT="2.1843214792961225"/><DICH_DATA CI_END="2.3966252111090953" CI_START="0.394394603295229" EFFECT_SIZE="0.9722222222222222" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.37960012353153405" LOG_CI_START="-0.4040690363655573" LOG_EFFECT_SIZE="-0.012234456417011635" MODIFIED="2008-03-27 07:41:12 +0000" MODIFIED_BY="Djillali Annane" ORDER="240" O_E="0.0" SE="0.4603311437484563" STUDY_ID="STD-Oppert-2005" TOTAL_1="12" TOTAL_2="14" VAR="0.21190476190476196" WEIGHT="2.748809052597368"/><DICH_DATA CI_END="1.5138179483503127" CI_START="0.778425009931642" EFFECT_SIZE="1.0855384615384616" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="39" LOG_CI_END="0.18007365007765538" LOG_CI_START="-0.10878321911583987" LOG_EFFECT_SIZE="0.03564521548090775" MODIFIED="2008-03-27 07:25:56 +0000" MODIFIED_BY="Djillali Annane" ORDER="241" O_E="0.0" SE="0.1696759548288222" STUDY_ID="STD-Sprung-2008" TOTAL_1="125" TOTAL_2="108" VAR="0.028789929647072506" WEIGHT="20.23227340090181"/><DICH_DATA CI_END="1.1533705848073679" CI_START="0.6207686764272098" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.06196887110925881" LOG_CI_START="-0.2070702054064823" LOG_EFFECT_SIZE="-0.07255066714861173" MODIFIED="2008-03-27 07:41:14 +0000" MODIFIED_BY="Djillali Annane" ORDER="242" O_E="0.0" SE="0.15803488531025353" STUDY_ID="STD-Tandan-2005" TOTAL_1="14" TOTAL_2="14" VAR="0.02497502497502499" WEIGHT="23.32272854160446"/><DICH_DATA CI_END="2.444274179582082" CI_START="0.21208749997458762" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.38814992006514243" LOG_CI_START="-0.6734849272026054" LOG_EFFECT_SIZE="-0.14266750356873156" MODIFIED="2008-03-27 07:41:15 +0000" MODIFIED_BY="Djillali Annane" ORDER="243" O_E="0.0" SE="0.6236095644623235" STUDY_ID="STD-Yildiz-2002" TOTAL_1="5" TOTAL_2="9" VAR="0.38888888888888884" WEIGHT="1.497820442945913"/><DICH_DATA CI_END="2.1951942259275006" CI_START="0.3487732388128493" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.34147295169287367" LOG_CI_START="-0.45745684564824723" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2014-10-11 18:36:21 +0100" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.0" SE="0.46929531772445293" STUDY_ID="STD-Yildiz-2011" TOTAL_1="6" TOTAL_2="14" VAR="0.2202380952380952" WEIGHT="2.644800061418009"/></DICH_OUTCOME><DICH_OUTCOME CHI2="17.207879969668163" CI_END="0.9954955838118146" CI_START="0.6807907137335325" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8232400312313687" ESTIMABLE="YES" EVENTS_1="264" EVENTS_2="289" I2="30.26450660306757" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.001960662236686253" LOG_CI_START="-0.16698637683914114" LOG_EFFECT_SIZE="-0.0844735195379137" METHOD="MH" MODIFIED="2015-10-28 11:08:02 +0000" MODIFIED_BY="Jane Cracknell" NO="7" P_CHI2="0.1419435989842589" P_Q="1.0" P_Z="0.044799043654050456" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.026804226024389574" TOTALS="YES" TOTAL_1="748" TOTAL_2="715" WEIGHT="99.99999999999999" Z="2.0065364520977327"><NAME>Intensive care unit mortality</NAME><GROUP_LABEL_1>Treatment</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_DATA CI_END="1.0440400534436185" CI_START="0.740531869155808" EFFECT_SIZE="0.8792866041571045" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="101" LOG_CI_END="0.01871716021401221" LOG_CI_START="-0.13045624666243838" LOG_EFFECT_SIZE="-0.05586954322421309" ORDER="96" O_E="0.0" SE="0.08762519761950023" STUDY_ID="STD-Annane-2002" TOTAL_1="151" TOTAL_2="149" VAR="0.007678175257856469" WEIGHT="27.250906053975246"/><DICH_DATA CI_END="1.2955678379880804" CI_START="0.6576815053084075" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.11246015826552833" LOG_CI_START="-0.18198437078395222" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2014-05-17 16:44:16 +0100" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.17295817388759027" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" VAR="0.029914529914529912" WEIGHT="16.567300574608893"/><DICH_DATA CI_END="1.103743919522074" CI_START="0.3003384935391356" EFFECT_SIZE="0.5757575757575758" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.042868324082536075" LOG_CI_START="-0.522389001932653" LOG_EFFECT_SIZE="-0.2397603389250585" MODIFIED="2008-10-29 22:58:53 +0000" MODIFIED_BY="Djillali Annane" ORDER="97" O_E="0.0" SE="0.33203495137021255" STUDY_ID="STD-Bollaert-1998" TOTAL_1="22" TOTAL_2="19" VAR="0.11024720893141943" WEIGHT="6.856379710004151"/><DICH_DATA CI_END="2.0086608078120443" CI_START="0.2212640594748102" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3029066058709399" LOG_CI_START="-0.6550891239823023" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2008-10-29 22:58:54 +0000" MODIFIED_BY="Djillali Annane" ORDER="98" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Briegel-1999" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="2.7358262311420343"/><DICH_DATA CI_END="1.647263524998469" CI_START="0.2846704331490971" EFFECT_SIZE="0.6847826086956522" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2167630820463089" LOG_CI_START="-0.5456576378302559" LOG_EFFECT_SIZE="-0.16444727789197353" MODIFIED="2008-10-29 22:58:54 +0000" MODIFIED_BY="Djillali Annane" ORDER="99" O_E="0.0" SE="0.44784970489892456" STUDY_ID="STD-Chawla-1999" TOTAL_1="23" TOTAL_2="21" VAR="0.2005693581780538" WEIGHT="4.1327433930113715"/><DICH_DATA CI_END="1.103173648741048" CI_START="0.004028780463997201" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.042643879397819114" LOG_CI_START="-2.3948263975091817" LOG_EFFECT_SIZE="-1.1760912590556813" MODIFIED="2008-10-29 22:59:09 +0000" MODIFIED_BY="Djillali Annane" ORDER="227" O_E="0.0" SE="1.4317821063276355" STUDY_ID="STD-Confalonieri-2005" TOTAL_1="23" TOTAL_2="23" VAR="2.0500000000000003" WEIGHT="0.4524628109298382"/><DICH_DATA CI_END="2.0444980029519373" CI_START="0.35071031315474344" EFFECT_SIZE="0.8467741935483871" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3105866906754478" LOG_CI_START="-0.4550514628600417" LOG_EFFECT_SIZE="-0.07223238609229699" MODIFIED="2014-05-17 14:53:14 +0100" MODIFIED_BY="[Empty name]" ORDER="276" O_E="0.0" SE="0.4497396413567304" STUDY_ID="STD-Gordon-2014" TOTAL_1="31" TOTAL_2="30" VAR="0.2022657450076805" WEIGHT="4.102138196570543"/><DICH_DATA CI_END="2.234810390447771" CI_START="0.20947819390956535" EFFECT_SIZE="0.6842105263157895" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.34924068188610485" LOG_CI_START="-0.6788611791780892" LOG_EFFECT_SIZE="-0.16481024864599217" MODIFIED="2014-05-18 18:17:46 +0100" MODIFIED_BY="[Empty name]" ORDER="320" O_E="0.0" SE="0.6039121223753973" STUDY_ID="STD-Hu-2009" TOTAL_1="38" TOTAL_2="39" VAR="0.3647098515519568" WEIGHT="2.4001095533396826"/><DICH_DATA CI_END="0.9657951479982271" CI_START="0.2563946578801228" EFFECT_SIZE="0.4976190476190476" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="-0.015114980756845793" LOG_CI_START="-0.5910910278168472" LOG_EFFECT_SIZE="-0.30310300428684644" MODIFIED="2008-10-29 22:58:56 +0000" MODIFIED_BY="Djillali Annane" ORDER="464" O_E="0.0" SE="0.33833118117046007" STUDY_ID="STD-Meduri-2007" TOTAL_1="42" TOTAL_2="19" VAR="0.11446798815219869" WEIGHT="6.651532173788825"/><DICH_DATA CI_END="2.3933274515473086" CI_START="0.2901585589533432" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.37900212221190543" LOG_CI_START="-0.5373646143071551" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2008-10-29 22:58:57 +0000" MODIFIED_BY="Djillali Annane" ORDER="245" O_E="0.0" SE="0.538278357119799" STUDY_ID="STD-Rinaldi-2006" TOTAL_1="26" TOTAL_2="26" VAR="0.2897435897435898" WEIGHT="2.968514174006239"/><DICH_DATA CI_END="1.5535004046793537" CI_START="0.07152306544396729" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.19131137072262336" LOG_CI_START="-1.1455538801619483" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-05-17 16:15:40 +0100" MODIFIED_BY="[Empty name]" ORDER="298" O_E="0.0" SE="0.7852812659593164" STUDY_ID="STD-Sabry-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.6166666666666666" WEIGHT="1.4603250722470844"/><DICH_DATA CI_END="1.4103025421365802" CI_START="0.9018919385313696" EFFECT_SIZE="1.1278033931688975" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="89" LOG_CI_END="0.14931228874482488" LOG_CI_START="-0.04484549495356006" LOG_EFFECT_SIZE="0.05223339689563241" MODIFIED="2008-10-29 22:57:59 +0000" MODIFIED_BY="Djillali Annane" ORDER="422" O_E="0.0" SE="0.114049243240961" STUDY_ID="STD-Sprung-2008" TOTAL_1="251" TOTAL_2="247" VAR="0.013007229883835889" WEIGHT="23.603172916462356"/><DICH_DATA CI_END="1.454232453998451" CI_START="0.0229129363810248" EFFECT_SIZE="0.18253968253968253" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.16263383253392805" LOG_CI_START="-1.639919250733868" LOG_EFFECT_SIZE="-0.7386427090999701" MODIFIED="2014-09-25 10:43:42 +0100" MODIFIED_BY="[Empty name]" ORDER="355" O_E="0.0" SE="1.0588286038931705" STUDY_ID="STD-Torres-2015" TOTAL_1="42" TOTAL_2="46" VAR="1.1211180124223603" WEIGHT="0.8185891399137247"/></DICH_OUTCOME><DICH_OUTCOME CHI2="30.10736203257067" CI_END="0.9843005202433842" CI_START="0.7299697244423574" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8476494437740948" ESTIMABLE="YES" EVENTS_1="383" EVENTS_2="402" I2="46.85685187997899" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.006872285351699909" LOG_CI_START="-0.13669515190733136" LOG_EFFECT_SIZE="-0.07178371862951562" METHOD="MH" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="8" P_CHI2="0.017453432585708306" P_Q="0.5718090513838897" P_Z="0.030199129960384038" Q="0.3196651869463735" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03251169623923865" TOTALS="YES" TOTAL_1="1041" TOTAL_2="973" WEIGHT="100.0" Z="2.167468750659852"><NAME>Hospital mortality</NAME><GROUP_LABEL_1>Treatment</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="14.217498964835015" CI_END="1.0093925615199721" CI_START="0.8192444374531344" DF="13" EFFECT_SIZE="0.9093619968042472" ESTIMABLE="YES" EVENTS_1="319" EVENTS_2="338" I2="8.563383530720326" ID="CMP-001.08.01" LOG_CI_END="0.004060099978870761" LOG_CI_START="-0.0865864987299753" LOG_EFFECT_SIZE="-0.04126319937555231" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.35870703218690936" P_Z="0.07436052077503395" STUDIES="14" TAU2="0.0033445005409413952" TOTAL_1="874" TOTAL_2="834" WEIGHT="79.79132022191433" Z="1.7843887319532874"><NAME>Long course of low-dose corticosteroids</NAME><DICH_DATA CI_END="1.0710446838037353" CI_START="0.7733637536365819" EFFECT_SIZE="0.9101138044107246" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="103" LOG_CI_END="0.029807589902426133" LOG_CI_START="-0.11161618649686579" LOG_EFFECT_SIZE="-0.040904298297219824" ORDER="113" O_E="0.0" SE="0.08307302631592767" STUDY_ID="STD-Annane-2002" TOTAL_1="151" TOTAL_2="149" VAR="0.006901127701286811" WEIGHT="14.755028048765539"/><DICH_DATA CI_END="1.1588009463292048" CI_START="0.8300893152277415" EFFECT_SIZE="0.9807692307692307" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="32" LOG_CI_END="0.0640088411963634" LOG_CI_START="-0.08087517627008904" LOG_EFFECT_SIZE="-0.008433167536862813" MODIFIED="2014-05-17 16:46:34 +0100" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.08510558904724728" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" VAR="0.007242961287078936" WEIGHT="14.628155766114533"/><DICH_DATA CI_END="1.103743919522074" CI_START="0.3003384935391356" EFFECT_SIZE="0.5757575757575758" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.042868324082536075" LOG_CI_START="-0.522389001932653" LOG_EFFECT_SIZE="-0.2397603389250585" ORDER="114" O_E="0.0" SE="0.33203495137021255" STUDY_ID="STD-Bollaert-1998" TOTAL_1="22" TOTAL_2="19" VAR="0.11024720893141943" WEIGHT="4.073562500555218"/><DICH_DATA CI_END="2.2928589592378805" CI_START="0.3028727264913275" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.36037734077066724" LOG_CI_START="-0.5187398328659169" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="115" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Briegel-1999" TOTAL_1="20" TOTAL_2="20" VAR="0.2666666666666667" WEIGHT="1.9437813519502762"/><DICH_DATA CI_END="1.2453879102921923" CI_START="0.24097987387695294" EFFECT_SIZE="0.5478260869565217" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.09530464545566107" LOG_CI_START="-0.6180192272557211" LOG_EFFECT_SIZE="-0.26135729090003" ORDER="116" O_E="0.0" SE="0.4190099738407832" STUDY_ID="STD-Chawla-1999" TOTAL_1="23" TOTAL_2="21" VAR="0.17556935817805383" WEIGHT="2.7947634365465936"/><DICH_DATA CI_END="1.103173648741048" CI_START="0.004028780463997201" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.042643879397819114" LOG_CI_START="-2.3948263975091817" LOG_EFFECT_SIZE="-1.1760912590556813" MODIFIED="2008-10-30 12:23:47 +0000" MODIFIED_BY="Djillali Annane" ORDER="212" O_E="0.0" SE="1.4317821063276355" STUDY_ID="STD-Confalonieri-2005" TOTAL_1="23" TOTAL_2="23" VAR="2.0500000000000003" WEIGHT="0.27924804637289496"/><DICH_DATA CI_END="1.932424262505909" CI_START="0.3829231256709999" EFFECT_SIZE="0.8602150537634409" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.28610248162253643" LOG_CI_START="-0.4168884047465195" LOG_EFFECT_SIZE="-0.06539296156199152" MODIFIED="2014-05-17 14:58:11 +0100" MODIFIED_BY="[Empty name]" ORDER="283" O_E="0.0" SE="0.4129403265141935" STUDY_ID="STD-Gordon-2014" TOTAL_1="31" TOTAL_2="30" VAR="0.17051971326164875" WEIGHT="2.8642726962941634"/><DICH_DATA CI_END="1.094634467852794" CI_START="0.3159557087113444" EFFECT_SIZE="0.5880952380952381" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.03926911908749661" LOG_CI_START="-0.500373793363966" LOG_EFFECT_SIZE="-0.23055233713823473" MODIFIED="2008-10-24 07:03:38 +0100" MODIFIED_BY="Djillali Annane" ORDER="466" O_E="0.0" SE="0.31698891804948753" STUDY_ID="STD-Meduri-2007" TOTAL_1="42" TOTAL_2="19" VAR="0.1004819741661847" WEIGHT="4.372669172530759"/><DICH_DATA CI_END="2.6300460789205182" CI_START="0.3903602698659584" EFFECT_SIZE="1.0132450331125828" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.4199633574804828" LOG_CI_START="-0.408534390431624" LOG_EFFECT_SIZE="0.005714483524429395" MODIFIED="2014-09-20 13:58:56 +0100" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="0.4866636782535659" STUDY_ID="STD-Meijvis-2011" TOTAL_1="151" TOTAL_2="153" VAR="0.2368415357312903" WEIGHT="2.159013717671446"/><DICH_DATA CI_END="2.2058533355443934" CI_START="0.33306560581902944" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3435766333619987" LOG_CI_START="-0.4774702126232252" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2008-10-09 06:32:06 +0100" MODIFIED_BY="Djillali Annane" ORDER="213" O_E="0.0" SE="0.48228698157915545" STUDY_ID="STD-Rinaldi-2006" TOTAL_1="26" TOTAL_2="26" VAR="0.23260073260073263" WEIGHT="2.193549828154387"/><DICH_DATA CI_END="1.33002492947334" CI_START="0.8826141831412841" EFFECT_SIZE="1.0834661354581674" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="100" LOG_CI_END="0.1238597812913276" LOG_CI_START="-0.05422909795102401" LOG_EFFECT_SIZE="0.03481534167015179" MODIFIED="2008-10-30 12:25:01 +0000" MODIFIED_BY="Djillali Annane" ORDER="424" O_E="0.0" SE="0.10461028922112711" STUDY_ID="STD-Sprung-2008" TOTAL_1="251" TOTAL_2="245" VAR="0.010943312610927864" WEIGHT="13.382515344287699"/><DICH_DATA CI_END="1.1533705848073679" CI_START="0.6207686764272098" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.06196887110925881" LOG_CI_START="-0.2070702054064823" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="226" O_E="0.0" SE="0.15803488531025353" STUDY_ID="STD-Tandan-2005" TOTAL_1="14" TOTAL_2="14" VAR="0.02497502497502499" WEIGHT="10.116028718284594"/><DICH_DATA CI_END="1.6992929326921815" CI_START="0.24467724620556414" EFFECT_SIZE="0.644808743169399" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.23026825119736946" LOG_CI_START="-0.6114064160459775" LOG_EFFECT_SIZE="-0.19056908242430406" MODIFIED="2014-09-20 13:50:47 +0100" MODIFIED_BY="[Empty name]" ORDER="345" O_E="0.0" SE="0.494403865895539" STUDY_ID="STD-Torres-2015" TOTAL_1="61" TOTAL_2="59" VAR="0.24443518261245406" WEIGHT="2.099815405520165"/><DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="117" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Yildiz-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="4.128916188866058"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="17.898316032320512" CI_END="1.599595965374546" CI_START="0.3252280792383486" DF="2" EFFECT_SIZE="0.721272156246292" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="64" I2="88.8257644105265" ID="CMP-001.08.02" LOG_CI_END="0.2040103000515184" LOG_CI_START="-0.4878119657476183" LOG_EFFECT_SIZE="-0.14190083284804997" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="1.298469610809816E-4" P_Z="0.42138367435736324" STUDIES="3" TAU2="0.4328777635371624" TOTAL_1="167" TOTAL_2="139" WEIGHT="20.208679778085667" Z="0.8040230432223918"><NAME>Short course of high-dose corticosteroids</NAME><DICH_DATA CI_END="1.6013530609278497" CI_START="0.7163652835855632" EFFECT_SIZE="1.0710526315789475" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.20448709426058112" LOG_CI_START="-0.14486546904376124" LOG_EFFECT_SIZE="0.029810812608409926" ORDER="120" O_E="0.0" SE="0.20521142500804926" STUDY_ID="STD-Luce-1988" TOTAL_1="38" TOTAL_2="37" VAR="0.04211172895383422" WEIGHT="7.792959398726366"/><DICH_DATA CI_END="0.5349608488848496" CI_START="0.13903852112599463" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="33" LOG_CI_END="-0.2716780006618398" LOG_CI_START="-0.8568648602152855" LOG_EFFECT_SIZE="-0.5642714304385626" ORDER="121" O_E="0.0" SE="0.34374165802336654" STUDY_ID="STD-Schumer-1976" TOTAL_1="86" TOTAL_2="86" VAR="0.11815832746065305" WEIGHT="3.859674993360535"/><DICH_DATA CI_END="1.6145545217389314" CI_START="0.7717788063662259" EFFECT_SIZE="1.1162790697674418" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="11" LOG_CI_END="0.20805271525008898" LOG_CI_START="-0.11250715165808765" LOG_EFFECT_SIZE="0.04777278179600068" ORDER="123" O_E="0.0" SE="0.1882984526187957" STUDY_ID="STD-Sprung-1984" TOTAL_1="43" TOTAL_2="16" VAR="0.035456307258632844" WEIGHT="8.556045385998763"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="25.32919913739953" CI_END="1.5087461279602652" CI_START="1.1408702060385543" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3119769456304857" ESTIMABLE="YES" EVENTS_1="532" EVENTS_2="395" I2="56.57186024583746" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.17861616853529902" LOG_CI_START="0.05723623862716494" LOG_EFFECT_SIZE="0.11792620358123194" METHOD="MH" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="9" P_CHI2="0.008156724862531828" P_Q="0.40670784505089297" P_Z="1.3987402017762802E-4" Q="0.688404917535638" RANDOM="YES" SCALE="5.0" SORT_BY="YEAR" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.027754112995960516" TOTALS="YES" TOTAL_1="806" TOTAL_2="755" WEIGHT="99.99999999999999" Z="3.808390926369518"><NAME>Number of participants with shock reversal at day 7</NAME><GROUP_LABEL_1>Treatment</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours corticosteroids</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="7.7235025983490875" CI_END="1.4568028615589275" CI_START="1.223481098594576" DF="9" EFFECT_SIZE="1.3350545927024253" ESTIMABLE="YES" EVENTS_1="422" EVENTS_2="306" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.16340078586074558" LOG_CI_START="0.08759726437887161" LOG_EFFECT_SIZE="0.1254990251198086" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.5622327817788562" P_Z="8.596962696372545E-11" STUDIES="10" TAU2="0.0" TOTAL_1="633" TOTAL_2="625" WEIGHT="82.09855172019053" Z="6.4897662937342355"><NAME>Shock reversal at day 7 in trials on long course of low-dose corticosteroids</NAME><DICH_DATA CI_END="8.09694191500798" CI_START="1.295398386942416" EFFECT_SIZE="3.2386363636363638" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="0.908321023791185" LOG_CI_START="0.11240335192549838" LOG_EFFECT_SIZE="0.5103621878583416" ORDER="150" O_E="0.0" SE="0.46752598030992115" STUDY_ID="STD-Bollaert-1998" TOTAL_1="22" TOTAL_2="19" VAR="0.21858054226475276" WEIGHT="2.0636852233466687"/><DICH_DATA CI_END="2.1185442410539554" CI_START="0.9473224139260876" EFFECT_SIZE="1.4166666666666667" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" LOG_CI_END="0.32603753769975946" LOG_CI_START="-0.023502187038461287" LOG_EFFECT_SIZE="0.15126767533064914" ORDER="152" O_E="0.0" SE="0.20532136456077343" STUDY_ID="STD-Briegel-1999" TOTAL_1="20" TOTAL_2="20" VAR="0.04215686274509803" WEIGHT="7.271493247964678"/><DICH_DATA CI_END="2.8502201931272912" CI_START="0.9243989664613496" EFFECT_SIZE="1.6231884057971016" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="0.4548784126282137" LOG_CI_START="-0.034140548762361056" LOG_EFFECT_SIZE="0.21036893193292633" ORDER="153" O_E="0.0" SE="0.2872521586037227" STUDY_ID="STD-Chawla-1999" TOTAL_1="23" TOTAL_2="21" VAR="0.08251380262249827" WEIGHT="4.61020039427163"/><DICH_DATA CI_END="2.0586269388529272" CI_START="1.0642006228403567" EFFECT_SIZE="1.4801324503311257" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="40" LOG_CI_END="0.313577651583034" LOG_CI_START="0.02702350876653752" LOG_EFFECT_SIZE="0.1703005801747858" ORDER="149" O_E="0.0" SE="0.16832332195629376" STUDY_ID="STD-Annane-2002" TOTAL_1="151" TOTAL_2="149" VAR="0.028332740714402126" WEIGHT="9.06374942486398"/><DICH_DATA CI_END="1.6123859516042136" CI_START="0.7752785392758661" EFFECT_SIZE="1.1180555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.2074690055766793" LOG_CI_START="-0.11054223770347917" LOG_EFFECT_SIZE="0.04846338393660007" ORDER="155" O_E="0.0" SE="0.18680137848380737" STUDY_ID="STD-Oppert-2005" TOTAL_1="18" TOTAL_2="23" VAR="0.034894755003450656" WEIGHT="8.114387446944892"/><DICH_DATA CI_END="1.4403145702604911" CI_START="1.115291644574726" EFFECT_SIZE="1.267426844346751" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="145" LOG_CI_END="0.15845735404557684" LOG_CI_START="0.04738844861066221" LOG_EFFECT_SIZE="0.10292290132811954" MODIFIED="2008-11-21 06:44:03 +0000" MODIFIED_BY="Djillali Annane" ORDER="156" O_E="0.0" SE="0.06524242485241782" STUDY_ID="STD-Sprung-2008" TOTAL_1="251" TOTAL_2="248" VAR="0.004256574000623388" WEIGHT="15.880858418127051"/><DICH_DATA CI_END="1.5995766877955526" CI_START="0.9836878475250858" EFFECT_SIZE="1.2543859649122806" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" LOG_CI_END="0.20400506610694022" LOG_CI_START="-0.0071426938497618575" LOG_EFFECT_SIZE="0.09843118612858918" MODIFIED="2014-05-18 18:20:21 +0100" MODIFIED_BY="[Empty name]" ORDER="322" O_E="0.0" SE="0.12402923939683533" STUDY_ID="STD-Hu-2009" TOTAL_1="38" TOTAL_2="39" VAR="0.01538325222535749" WEIGHT="11.784613767011091"/><DICH_DATA CI_END="2.5542246239762836" CI_START="0.9803544220970429" EFFECT_SIZE="1.5824175824175823" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="14" LOG_CI_END="0.40725908739245903" LOG_CI_START="-0.008616887844146891" LOG_EFFECT_SIZE="0.19932109977415605" MODIFIED="2014-06-12 18:06:16 +0100" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.24428760647326067" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" VAR="0.05967643467643467" WEIGHT="5.814411571165707"/><DICH_DATA CI_END="1.854744273902424" CI_START="1.1516922869705488" EFFECT_SIZE="1.4615384615384615" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" LOG_CI_END="0.26828403897045583" LOG_CI_START="0.061336458321528474" LOG_EFFECT_SIZE="0.16481024864599217" MODIFIED="2014-05-17 16:18:33 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.12156203328022558" STUDY_ID="STD-Sabry-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.01477732793522267" WEIGHT="11.952503299435886"/><DICH_DATA CI_END="2.3219177862067646" CI_START="0.8615743890724579" EFFECT_SIZE="1.41439205955335" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.365846838301415" LOG_CI_START="-0.06470721923865107" LOG_EFFECT_SIZE="0.15056980953138197" MODIFIED="2014-06-12 14:52:03 +0100" MODIFIED_BY="[Empty name]" ORDER="324" O_E="0.0" SE="0.25290958467599245" STUDY_ID="STD-Gordon-2014" TOTAL_1="31" TOTAL_2="30" VAR="0.06396325802098299" WEIGHT="5.542648927058951"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="2.47269901631675" CI_END="1.7914427731275298" CI_START="0.6391852097568792" DF="1" EFFECT_SIZE="1.0700765041383562" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="89" I2="59.55836139371437" ID="CMP-001.09.02" LOG_CI_END="0.25320293937241106" LOG_CI_START="-0.19437328281059835" LOG_EFFECT_SIZE="0.02941482828090635" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.11583910986865142" P_Z="0.7967011903193951" STUDIES="2" TAU2="0.09444382993989307" TOTAL_1="173" TOTAL_2="130" WEIGHT="17.90144827980946" Z="0.2576187079859368"><NAME>Shock reversal at day 7 in trials on short course of high-dose corticosteroids</NAME><DICH_DATA CI_END="3.0649409436900115" CI_START="0.7842571014516958" EFFECT_SIZE="1.550387596899225" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="6" LOG_CI_END="0.48642211080332665" LOG_CI_START="-0.10554154007386213" LOG_EFFECT_SIZE="0.19044028536473226" MODIFIED="2014-11-07 17:43:10 +0000" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="0.34772237879259127" STUDY_ID="STD-Sprung-1984" TOTAL_1="43" TOTAL_2="16" VAR="0.12091085271317831" WEIGHT="3.4194820927367933"/><DICH_DATA CI_END="1.0623583023252787" CI_START="0.7591605792189573" EFFECT_SIZE="0.8980537534754403" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="83" LOG_CI_END="0.026271016254527317" LOG_CI_START="-0.11966635151881802" LOG_EFFECT_SIZE="-0.046697667632145334" MODIFIED="2014-11-07 17:43:17 +0000" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="0.08572433223168427" STUDY_ID="STD-Bone-1987" TOTAL_1="130" TOTAL_2="114" VAR="0.007348661136568183" WEIGHT="14.481966187072667"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="5.261104349023706" CI_END="1.2051233298516915" CI_START="1.0243340581493865" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1110575462312853" ESTIMABLE="YES" EVENTS_1="345" EVENTS_2="297" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.08103149399243434" LOG_CI_START="0.010441612842443958" LOG_EFFECT_SIZE="0.04573655341743912" METHOD="MH" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="10" P_CHI2="0.5107870703044092" P_Q="1.0" P_Z="0.011091670723280536" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="512" TOTAL_2="501" WEIGHT="100.0" Z="2.5397973764738473"><NAME>Number of participants with shock reversal at 28 days</NAME><GROUP_LABEL_1>Treatment</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours corticosteroids</GRAPH_LABEL_2><DICH_DATA CI_END="1.5210950059336197" CI_START="0.8844274143809037" EFFECT_SIZE="1.159869873358894" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="57" LOG_CI_END="0.18215634045940718" LOG_CI_START="-0.05333780416452792" LOG_EFFECT_SIZE="0.06440926814743964" MODIFIED="2014-11-07 17:49:51 +0000" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="0.13833042626691577" STUDY_ID="STD-Annane-2002" TOTAL_1="151" TOTAL_2="149" VAR="0.01913530683118662" WEIGHT="8.985136412404085"/><DICH_DATA CI_END="3.5602020950971065" CI_START="0.9619967989388668" EFFECT_SIZE="1.8506493506493507" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.551474651426343" LOG_CI_START="-0.016826373082248724" LOG_EFFECT_SIZE="0.2673241391720471" MODIFIED="2014-11-07 17:49:51 +0000" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="0.33382283493178777" STUDY_ID="STD-Bollaert-1998" TOTAL_1="22" TOTAL_2="19" VAR="0.11143768512189561" WEIGHT="1.5428653420371305"/><DICH_DATA CI_END="1.4639602780167191" CI_START="0.8645214074486971" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.1655292930665088" LOG_CI_START="-0.06322424817174624" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2014-11-07 17:49:51 +0000" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.13437096247164246" STUDY_ID="STD-Briegel-1999" TOTAL_1="20" TOTAL_2="20" VAR="0.018055555555555547" WEIGHT="9.522462027955546"/><DICH_DATA CI_END="2.584992570858021" CI_START="0.9320119073042509" EFFECT_SIZE="1.5521739130434782" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.41245929929069514" LOG_CI_START="-0.030578539101494533" LOG_EFFECT_SIZE="0.1909403800946003" MODIFIED="2014-11-07 17:49:51 +0000" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="0.26024261934424164" STUDY_ID="STD-Chawla-1999" TOTAL_1="23" TOTAL_2="21" VAR="0.06772622092315186" WEIGHT="2.538652531144624"/><DICH_DATA CI_END="1.4494720340407843" CI_START="0.7750440094092041" EFFECT_SIZE="1.0599078341013826" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.16120984054031987" LOG_CI_START="-0.11067363620219309" LOG_EFFECT_SIZE="0.0252681021690634" MODIFIED="2014-11-07 17:49:51 +0000" MODIFIED_BY="[Empty name]" ORDER="325" O_E="0.0" SE="0.1597057000834675" STUDY_ID="STD-Gordon-2014" TOTAL_1="31" TOTAL_2="30" VAR="0.02550591063915047" WEIGHT="6.740921530067202"/><DICH_DATA CI_END="1.1897983436035549" CI_START="0.9800322574172836" EFFECT_SIZE="1.0798336707813554" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="183" LOG_CI_END="0.0754733599794853" LOG_CI_START="-0.008759629422025607" LOG_EFFECT_SIZE="0.03335686527872982" MODIFIED="2014-11-07 17:49:51 +0000" MODIFIED_BY="[Empty name]" ORDER="426" O_E="0.0" SE="0.04947887493446967" STUDY_ID="STD-Sprung-2008" TOTAL_1="251" TOTAL_2="248" VAR="0.002448159064780891" WEIGHT="70.22964506058656"/><DICH_DATA CI_END="5.6721586684890735" CI_START="0.48972145176568393" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7537483709559422" LOG_CI_START="-0.3100508717232294" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2014-11-07 17:49:51 +0000" MODIFIED_BY="[Empty name]" ORDER="246" O_E="0.0" SE="0.6248809410409238" STUDY_ID="STD-Tandan-2005" TOTAL_1="14" TOTAL_2="14" VAR="0.39047619047619053" WEIGHT="0.4403170958048548"/></DICH_OUTCOME><CONT_OUTCOME CHI2="10.803330232295766" CI_END="-1.0314114950707878" CI_START="-2.0357494579586515" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5335804765147196" ESTIMABLE="YES" I2="35.20516498631124" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="11" P_CHI2="0.1474308368511752" P_Q="1.0" P_Z="2.1564678449824277E-9" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.15085653122358061" TOTALS="YES" TOTAL_1="570" TOTAL_2="562" UNITS="" WEIGHT="99.99999999999999" Z="5.98555986616275"><NAME>SOFA score at day 7</NAME><GROUP_LABEL_1>Treatment</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><CONT_DATA CI_END="-1.1990837953078772" CI_START="-2.8009162046921228" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="9.5" MODIFIED="2009-04-28 18:21:55 +0100" MODIFIED_BY="Djillali Annane" ORDER="274" SD_1="3.0" SD_2="4.0" SE="0.4086382255029416" STUDY_ID="STD-Annane-2002" TOTAL_1="151" TOTAL_2="149" WEIGHT="20.6534528571707"/><CONT_DATA CI_END="1.3025867119328112" CI_START="-2.502586711932814" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="12.3" MODIFIED="2014-09-19 22:24:43 +0100" MODIFIED_BY="[Empty name]" ORDER="342" SD_1="4.2" SD_2="4.2" SE="0.970725343394151" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" WEIGHT="6.005071385410154"/><CONT_DATA CI_END="3.3101818635089706" CI_START="-3.3101818635089706" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="9.0" MODIFIED="2009-04-28 18:10:26 +0100" MODIFIED_BY="Djillali Annane" ORDER="275" SD_1="4.0" SD_2="5.0" SE="1.6888993316302048" STUDY_ID="STD-Cicarelli-2007" TOTAL_1="15" TOTAL_2="14" WEIGHT="2.1858175499337813"/><CONT_DATA CI_END="1.6646475497200774" CI_START="-2.264647549720077" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="6.5" MODIFIED="2014-06-12 14:55:24 +0100" MODIFIED_BY="[Empty name]" ORDER="327" SD_1="4.3" SD_2="3.5" SE="1.0023896179812315" STUDY_ID="STD-Gordon-2014" TOTAL_1="31" TOTAL_2="30" WEIGHT="5.680420204983668"/><CONT_DATA CI_END="0.26513858844388283" CI_START="-4.265138588443882" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="8.0" MODIFIED="2009-04-28 18:12:29 +0100" MODIFIED_BY="Djillali Annane" ORDER="276" SD_1="4.0" SD_2="4.0" SE="1.1557041896233844" STUDY_ID="STD-Oppert-2005" TOTAL_1="23" TOTAL_2="25" WEIGHT="4.416071816867304"/><CONT_DATA CI_END="1.4791801292182467" CI_START="-3.4791801292182467" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="2.0" MODIFIED="2009-04-28 18:15:17 +0100" MODIFIED_BY="Djillali Annane" ORDER="278" SD_1="4.0" SD_2="4.0" SE="1.2649110640673518" STUDY_ID="STD-Rinaldi-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.7493244484710324"/><CONT_DATA CI_END="-1.6763239494689475" CI_START="-2.3236760505310525" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="3.0" MODIFIED="2014-05-17 16:16:55 +0100" MODIFIED_BY="[Empty name]" ORDER="299" SD_1="0.53" SD_2="0.9" SE="0.16514387666516733" STUDY_ID="STD-Sabry-2011" TOTAL_1="40" TOTAL_2="40" WEIGHT="36.85266322502037"/><CONT_DATA CI_END="-0.19180367620639882" CI_START="-1.8081963237936012" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="7.1" MODIFIED="2009-04-28 18:09:09 +0100" MODIFIED_BY="Djillali Annane" ORDER="277" SD_1="4.4" SD_2="4.8" SE="0.4123526402365302" STUDY_ID="STD-Sprung-2008" TOTAL_1="251" TOTAL_2="248" WEIGHT="20.457178512142985"/></CONT_OUTCOME><CONT_OUTCOME CHI2="16.02639451403662" CI_END="-0.09361291034708352" CI_START="-3.2722046230252895" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.6829087666861866" ESTIMABLE="YES" I2="31.36322714154006" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="12" P_CHI2="0.14015387583349737" P_Q="1.0" P_Z="0.03794854875710071" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="EFFECT_SIZE" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="2.0075151504788904" TOTALS="YES" TOTAL_1="708" TOTAL_2="676" UNITS="" WEIGHT="100.0" Z="2.0754100369766957"><NAME>Length of ICU stay for all participants</NAME><GROUP_LABEL_1>Treatment</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><CONT_DATA CI_END="3.6413878565953226" CI_START="-21.641387856595323" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="38.0" MODIFIED="2014-11-07 17:53:36 +0000" MODIFIED_BY="[Empty name]" ORDER="485" SD_1="16.0" SD_2="24.0" SE="6.44980619863884" STUDY_ID="STD-Briegel-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.5078286110224013"/><CONT_DATA CI_END="2.848385810291793" CI_START="-17.848385810291795" EFFECT_SIZE="-7.5" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="14.5" MODIFIED="2014-11-07 17:53:36 +0000" MODIFIED_BY="[Empty name]" ORDER="486" SD_1="14.0" SD_2="21.0" SE="5.279885697859012" STUDY_ID="STD-Meduri-2007" TOTAL_1="42" TOTAL_2="19" WEIGHT="2.200210847199839"/><CONT_DATA CI_END="-2.0542875648802585" CI_START="-11.94571243511974" EFFECT_SIZE="-6.999999999999999" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="14.2" MODIFIED="2014-11-07 17:53:36 +0000" MODIFIED_BY="[Empty name]" ORDER="487" SD_1="7.1" SD_2="9.8" SE="2.523369038477691" STUDY_ID="STD-Confalonieri-2005" TOTAL_1="23" TOTAL_2="23" WEIGHT="7.851151455141283"/><CONT_DATA CI_END="2.2055683294807844" CI_START="-12.605568329480782" EFFECT_SIZE="-5.199999999999999" ESTIMABLE="YES" MEAN_1="14.3" MEAN_2="19.5" MODIFIED="2014-11-07 17:53:36 +0000" MODIFIED_BY="[Empty name]" ORDER="328" SD_1="14.6" SD_2="14.9" SE="3.778420617876125" STUDY_ID="STD-Gordon-2014" TOTAL_1="31" TOTAL_2="30" WEIGHT="4.037874587740931"/><CONT_DATA CI_END="1.2965353232978938" CI_START="-8.296535323297894" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="25.5" MODIFIED="2014-11-07 17:53:36 +0000" MODIFIED_BY="[Empty name]" ORDER="490" SD_1="24.0" SD_2="18.0" SE="2.447256868561031" STUDY_ID="STD-Annane-2002" TOTAL_1="151" TOTAL_2="149" WEIGHT="8.222596166558837"/><CONT_DATA CI_END="0.821418184561586" CI_START="-7.421418184561584" EFFECT_SIZE="-3.299999999999999" ESTIMABLE="YES" MEAN_1="7.4" MEAN_2="10.7" MODIFIED="2014-11-07 17:53:36 +0000" MODIFIED_BY="[Empty name]" ORDER="489" SD_1="6.2" SD_2="7.6" SE="2.1028030193772973" STUDY_ID="STD-Chawla-1999" TOTAL_1="23" TOTAL_2="21" WEIGHT="10.227039194078497"/><CONT_DATA CI_END="8.885505490182611" CI_START="-12.885505490182611" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="21.0" MODIFIED="2014-11-07 17:53:36 +0000" MODIFIED_BY="[Empty name]" ORDER="491" SD_1="21.0" SD_2="19.0" SE="5.553931386518369" STUDY_ID="STD-Rinaldi-2006" TOTAL_1="26" TOTAL_2="26" WEIGHT="2.0013794808191463"/><CONT_DATA CI_END="0.016951137755608192" CI_START="-2.3769511377556096" EFFECT_SIZE="-1.1800000000000006" ESTIMABLE="YES" MEAN_1="4.18" MEAN_2="5.36" MODIFIED="2014-11-07 17:53:36 +0000" MODIFIED_BY="[Empty name]" ORDER="323" SD_1="2.86" SD_2="2.48" SE="0.6107005777641867" STUDY_ID="STD-Hu-2009" TOTAL_1="38" TOTAL_2="39" WEIGHT="27.62170892216371"/><CONT_DATA CI_END="4.597865758920217" CI_START="-3.5978657589202188" EFFECT_SIZE="0.4999999999999991" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="7.7" MODIFIED="2014-11-07 17:53:36 +0000" MODIFIED_BY="[Empty name]" ORDER="356" SD_1="10.7" SD_2="8.7" SE="2.0907862548718548" STUDY_ID="STD-Torres-2015" TOTAL_1="42" TOTAL_2="46" WEIGHT="10.307832878199635"/><CONT_DATA CI_END="3.788309949855516" CI_START="-2.1883099498555145" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="9.7" MODIFIED="2014-11-07 17:53:36 +0000" MODIFIED_BY="[Empty name]" ORDER="341" SD_1="6.7" SD_2="6.5" SE="1.5246759498781215" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" WEIGHT="15.17782858901719"/><CONT_DATA CI_END="5.379985783776333" CI_START="-3.379985783776333" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="18.0" MODIFIED="2014-11-07 17:53:36 +0000" MODIFIED_BY="[Empty name]" ORDER="492" SD_1="31.0" SD_2="17.0" SE="2.2347276880213625" STUDY_ID="STD-Sprung-2008" TOTAL_1="251" TOTAL_2="248" WEIGHT="9.391193757782212"/><CONT_DATA CI_END="19.88733325367781" CI_START="-5.887333253677811" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="19.0" MODIFIED="2014-11-07 17:53:36 +0000" MODIFIED_BY="[Empty name]" ORDER="488" SD_1="24.0" SD_2="18.0" SE="6.5752908498990035" STUDY_ID="STD-Bollaert-1998" TOTAL_1="22" TOTAL_2="19" WEIGHT="1.4533555102763172"/></CONT_OUTCOME><CONT_OUTCOME CHI2="8.63092646107744" CI_END="-0.462762874307743" CI_START="-3.926884963814647" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.194823919061195" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2015-10-28 11:08:02 +0000" MODIFIED_BY="Jane Cracknell" NO="13" P_CHI2="0.47201613795017017" P_Q="1.0" P_Z="0.013005569189863389" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="411" TOTAL_2="367" UNITS="" WEIGHT="100.00000000000001" Z="2.483616756347827"><NAME>Length of ICU stay for survivors</NAME><GROUP_LABEL_1>Treatment</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><CONT_DATA CI_END="8.375012162476406" CI_START="-12.375012162476406" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="33.0" MODIFIED="2014-11-07 17:52:58 +0000" MODIFIED_BY="[Empty name]" ORDER="240" SD_1="30.0" SD_2="25.0" SE="5.2934708210524155" STUDY_ID="STD-Annane-2002" TOTAL_1="60" TOTAL_2="48" WEIGHT="2.787078232740054"/><CONT_DATA CI_END="2.4064168563960986" CI_START="-3.2064168563960993" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="9.2" MEAN_2="9.6" MODIFIED="2014-11-07 17:52:58 +0000" MODIFIED_BY="[Empty name]" ORDER="315" SD_1="6.4" SD_2="6.0" SE="1.4318716458734737" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" WEIGHT="38.09096962501552"/><CONT_DATA CI_END="19.095347735697544" CI_START="-33.095347735697544" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="36.0" MODIFIED="2014-11-07 17:52:58 +0000" MODIFIED_BY="[Empty name]" ORDER="228" SD_1="24.0" SD_2="33.0" SE="13.314197577881183" STUDY_ID="STD-Bollaert-1998" TOTAL_1="14" TOTAL_2="8" WEIGHT="0.4405550780908568"/><CONT_DATA CI_END="5.815935090674936" CI_START="-23.815935090674934" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="38.0" MODIFIED="2014-11-07 17:52:58 +0000" MODIFIED_BY="[Empty name]" ORDER="232" SD_1="16.0" SD_2="24.0" SE="7.559289460184544" STUDY_ID="STD-Briegel-1999" TOTAL_1="16" TOTAL_2="14" WEIGHT="1.3666844563149796"/><CONT_DATA CI_END="-0.6913069294542256" CI_START="-8.508693070545775" EFFECT_SIZE="-4.6000000000000005" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="11.4" MODIFIED="2014-11-07 17:52:58 +0000" MODIFIED_BY="[Empty name]" ORDER="239" SD_1="4.7" SD_2="5.9" SE="1.9942678035805999" STUDY_ID="STD-Chawla-1999" TOTAL_1="17" TOTAL_2="13" WEIGHT="19.636462417107005"/><CONT_DATA CI_END="-1.2647940865178962" CI_START="-13.335205913482103" EFFECT_SIZE="-7.3" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="14.5" MODIFIED="2014-11-07 17:52:58 +0000" MODIFIED_BY="[Empty name]" ORDER="229" SD_1="7.1" SD_2="10.8" SE="3.0792432723698178" STUDY_ID="STD-Confalonieri-2005" TOTAL_1="23" TOTAL_2="16" WEIGHT="8.236490539577751"/><CONT_DATA CI_END="5.229789418570752" CI_START="-21.229789418570753" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="20.0" MODIFIED="2014-11-07 17:52:58 +0000" MODIFIED_BY="[Empty name]" ORDER="470" SD_1="13.0" SD_2="19.0" SE="6.75001659363419" STUDY_ID="STD-Meduri-2007" TOTAL_1="31" TOTAL_2="9" WEIGHT="1.7140383139075759"/><CONT_DATA CI_END="7.282550867852777" CI_START="-11.282550867852777" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="23.0" MODIFIED="2014-11-07 17:52:58 +0000" MODIFIED_BY="[Empty name]" ORDER="230" SD_1="16.0" SD_2="16.0" SE="4.736082367366111" STUDY_ID="STD-Rinaldi-2006" TOTAL_1="21" TOTAL_2="25" WEIGHT="3.4817029287915586"/><CONT_DATA CI_END="4.139665279076453" CI_START="-7.739665279076455" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" MEAN_1="18.7" MEAN_2="20.5" MODIFIED="2014-11-07 17:52:58 +0000" MODIFIED_BY="[Empty name]" ORDER="231" SD_1="33.2" SD_2="16.8" SE="3.0304971550129367" STUDY_ID="STD-Sprung-2008" TOTAL_1="149" TOTAL_2="158" WEIGHT="8.5035925961999"/><CONT_DATA CI_END="4.565433396453974" CI_START="-4.165433396453972" EFFECT_SIZE="0.20000000000000107" ESTIMABLE="YES" MEAN_1="8.4" MEAN_2="8.2" MODIFIED="2014-11-07 17:52:58 +0000" MODIFIED_BY="[Empty name]" ORDER="357" SD_1="10.8" SD_2="9.2" SE="2.227302864179115" STUDY_ID="STD-Torres-2015" TOTAL_1="41" TOTAL_2="40" WEIGHT="15.742425812254817"/></CONT_OUTCOME><CONT_OUTCOME CHI2="14.080504298586291" CI_END="0.6084393473419231" CI_START="-2.553388107108851" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.972474379883464" ESTIMABLE="YES" I2="21.8777980764196" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="14" P_CHI2="0.2285708799994869" P_Q="1.0" P_Z="0.22795587908513293" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.4491792358588582" TOTALS="YES" TOTAL_1="917" TOTAL_2="885" UNITS="" WEIGHT="100.0" Z="1.2056412235756218"><NAME>Length of hospital stay for all participants</NAME><GROUP_LABEL_1>Treatment</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><CONT_DATA CI_END="-0.13200341691285455" CI_START="-9.867996583087145" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="25.0" MODIFIED="2014-11-07 17:55:20 +0000" MODIFIED_BY="[Empty name]" ORDER="493" SD_1="21.0" SD_2="22.0" SE="2.4837173649542956" STUDY_ID="STD-Annane-2002" TOTAL_1="151" TOTAL_2="149" WEIGHT="8.5403842864111"/><CONT_DATA CI_END="4.381691559714959" CI_START="-13.181691559714956" EFFECT_SIZE="-4.399999999999999" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="26.4" MODIFIED="2014-11-07 17:55:20 +0000" MODIFIED_BY="[Empty name]" ORDER="360" SD_1="13.4" SD_2="23.6" SE="4.480537208328224" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" WEIGHT="3.022659644485522"/><CONT_DATA CI_END="28.449268378872954" CI_START="-6.449268378872954" EFFECT_SIZE="11.0" ESTIMABLE="YES" MEAN_1="35.0" MEAN_2="24.0" MODIFIED="2014-11-07 17:55:20 +0000" MODIFIED_BY="[Empty name]" ORDER="494" SD_1="31.0" SD_2="26.0" SE="8.902851540390822" STUDY_ID="STD-Bollaert-1998" TOTAL_1="22" TOTAL_2="19" WEIGHT="0.8061077726763062"/><CONT_DATA CI_END="4.146482801151102" CI_START="-12.346482801151105" EFFECT_SIZE="-4.100000000000001" ESTIMABLE="YES" MEAN_1="16.9" MEAN_2="21.0" MODIFIED="2014-11-07 17:55:20 +0000" MODIFIED_BY="[Empty name]" ORDER="495" SD_1="13.3" SD_2="14.5" SE="4.207466497445007" STUDY_ID="STD-Chawla-1999" TOTAL_1="23" TOTAL_2="21" WEIGHT="3.3970902033777914"/><CONT_DATA CI_END="0.6692744652821077" CI_START="-15.269274465282109" EFFECT_SIZE="-7.300000000000001" ESTIMABLE="YES" MEAN_1="17.7" MEAN_2="25.0" MODIFIED="2014-11-07 17:55:20 +0000" MODIFIED_BY="[Empty name]" ORDER="496" SD_1="9.9" SD_2="16.8" SE="4.066031074112957" STUDY_ID="STD-Confalonieri-2005" TOTAL_1="23" TOTAL_2="23" WEIGHT="3.6181559960640715"/><CONT_DATA CI_END="12.706380855625627" CI_START="-16.506380855625622" EFFECT_SIZE="-1.8999999999999986" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="35.9" MODIFIED="2014-11-07 17:55:20 +0000" MODIFIED_BY="[Empty name]" ORDER="329" SD_1="32.8" SD_2="25.0" SE="7.4523720695068345" STUDY_ID="STD-Gordon-2014" TOTAL_1="31" TOTAL_2="30" WEIGHT="1.1416793489774684"/><CONT_DATA CI_END="7.162267630619198" CI_START="-22.162267630619198" EFFECT_SIZE="-7.5" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="20.5" MODIFIED="2014-11-07 17:55:20 +0000" MODIFIED_BY="[Empty name]" ORDER="497" SD_1="19.0" SD_2="30.0" SE="7.480886254172675" STUDY_ID="STD-Meduri-2007" TOTAL_1="42" TOTAL_2="19" WEIGHT="1.1332119375374448"/><CONT_DATA CI_END="1.642310120156068" CI_START="-3.642310120156068" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="7.5" MODIFIED="2014-12-19 07:58:28 +0000" MODIFIED_BY="[Empty name]" ORDER="321" SD_1="9.3" SD_2="13.8" SE="1.348142180671825" STUDY_ID="STD-Meijvis-2011" TOTAL_1="151" TOTAL_2="153" WEIGHT="19.916606830635644"/><CONT_DATA CI_END="2.730632634446795" CI_START="-3.9306326344467943" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="10.6" MODIFIED="2014-11-07 17:55:20 +0000" MODIFIED_BY="[Empty name]" ORDER="344" SD_1="12.0" SD_2="12.8" SE="1.6993335901671662" STUDY_ID="STD-Snijders-2010" TOTAL_1="104" TOTAL_2="109" WEIGHT="15.001661440968943"/><CONT_DATA CI_END="6.8507323073700475" CI_START="-6.8507323073700475" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="34.0" MODIFIED="2014-11-07 17:55:20 +0000" MODIFIED_BY="[Empty name]" ORDER="498" SD_1="41.0" SD_2="37.0" SE="3.4953358130086825" STUDY_ID="STD-Sprung-2008" TOTAL_1="251" TOTAL_2="248" WEIGHT="4.760594723549388"/><CONT_DATA CI_END="5.428992308735785" CI_START="-6.228992308735786" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="14.5" MEAN_2="14.9" MODIFIED="2014-11-07 17:55:20 +0000" MODIFIED_BY="[Empty name]" ORDER="358" SD_1="14.5" SD_2="17.6" SE="2.9740303162273047" STUDY_ID="STD-Torres-2015" TOTAL_1="60" TOTAL_2="58" WEIGHT="6.320253457420423"/><CONT_DATA CI_END="2.4699729884050408" CI_START="-0.46997298840504076" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="13.0" MODIFIED="2014-11-07 17:55:20 +0000" MODIFIED_BY="[Empty name]" ORDER="499" SD_1="3.0" SD_2="1.5" SE="0.75" STUDY_ID="STD-Yildiz-2002" TOTAL_1="20" TOTAL_2="20" WEIGHT="32.3415943578959"/></CONT_OUTCOME><CONT_OUTCOME CHI2="14.158429576921922" CI_END="0.2804545992770304" CI_START="-8.500925191646383" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.110235296184676" ESTIMABLE="YES" I2="43.49655831152412" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2015-10-28 11:08:02 +0000" MODIFIED_BY="Jane Cracknell" NO="15" P_CHI2="0.07772836383476456" P_Q="1.0" P_Z="0.06653953747276758" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="16.68502290100728" TOTALS="YES" TOTAL_1="383" TOTAL_2="327" UNITS="" WEIGHT="100.0" Z="1.8347716054449712"><NAME>Length of hospital stay for survivors</NAME><GROUP_LABEL_1>Treatment</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><CONT_DATA CI_END="29.802043727937928" CI_START="-5.802043727937928" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="60.0" MEAN_2="48.0" MODIFIED="2014-11-07 17:55:08 +0000" MODIFIED_BY="[Empty name]" ORDER="241" SD_1="60.0" SD_2="28.0" SE="9.082842270755064" STUDY_ID="STD-Annane-2002" TOTAL_1="55" TOTAL_2="46" WEIGHT="5.05978313821428"/><CONT_DATA CI_END="-4.289344725005851" CI_START="-27.910655274994145" EFFECT_SIZE="-16.099999999999998" ESTIMABLE="YES" MEAN_1="27.2" MEAN_2="43.3" MODIFIED="2014-11-07 17:55:08 +0000" MODIFIED_BY="[Empty name]" ORDER="316" SD_1="12.8" SD_2="34.0" SE="6.025955256400163" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" WEIGHT="9.46927552629177"/><CONT_DATA CI_END="28.697329507046756" CI_START="-31.29732950704675" EFFECT_SIZE="-1.2999999999999972" ESTIMABLE="YES" MEAN_1="42.7" MEAN_2="44.0" MODIFIED="2014-11-07 17:55:08 +0000" MODIFIED_BY="[Empty name]" ORDER="233" SD_1="24.2" SD_2="36.7" SE="15.305041186298249" STUDY_ID="STD-Bollaert-1998" TOTAL_1="14" TOTAL_2="7" WEIGHT="1.999944564609976"/><CONT_DATA CI_END="0.8777823813283092" CI_START="-13.67778238132831" EFFECT_SIZE="-6.4" ESTIMABLE="YES" MEAN_1="11.9" MEAN_2="18.3" MODIFIED="2014-11-07 17:55:08 +0000" MODIFIED_BY="[Empty name]" ORDER="240" SD_1="8.2" SD_2="10.4" SE="3.7132225075228567" STUDY_ID="STD-Chawla-1999" TOTAL_1="17" TOTAL_2="11" WEIGHT="16.468479554188367"/><CONT_DATA CI_END="-2.040950410584818" CI_START="-21.35904958941518" EFFECT_SIZE="-11.7" ESTIMABLE="YES" MEAN_1="17.7" MEAN_2="29.4" MODIFIED="2014-11-07 17:55:08 +0000" MODIFIED_BY="[Empty name]" ORDER="235" SD_1="9.9" SD_2="17.9" SE="4.928177081622178" STUDY_ID="STD-Confalonieri-2005" TOTAL_1="23" TOTAL_2="16" WEIGHT="12.248493892081603"/><CONT_DATA CI_END="11.273823193407253" CI_START="-49.27382319340725" EFFECT_SIZE="-19.0" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="41.0" MODIFIED="2014-11-07 17:55:08 +0000" MODIFIED_BY="[Empty name]" ORDER="471" SD_1="31.0" SD_2="43.0" SE="15.44611198583408" STUDY_ID="STD-Meduri-2007" TOTAL_1="29" TOTAL_2="9" WEIGHT="1.9659569144022055"/><CONT_DATA CI_END="10.537117638545118" CI_START="-9.137117638545126" EFFECT_SIZE="0.6999999999999957" ESTIMABLE="YES" MEAN_1="42.8" MEAN_2="42.1" MODIFIED="2014-11-07 17:55:08 +0000" MODIFIED_BY="[Empty name]" ORDER="237" SD_1="45.2" SD_2="39.2" SE="5.019029796536595" STUDY_ID="STD-Sprung-2008" TOTAL_1="140" TOTAL_2="145" WEIGHT="11.984155741940581"/><CONT_DATA CI_END="5.711713551310429" CI_START="-7.51171355131043" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="15.4" MEAN_2="16.3" MODIFIED="2014-11-07 17:55:08 +0000" MODIFIED_BY="[Empty name]" ORDER="359" SD_1="15.0" SD_2="18.8" SE="3.373385227209674" STUDY_ID="STD-Torres-2015" TOTAL_1="54" TOTAL_2="49" WEIGHT="17.88167336966412"/><CONT_DATA CI_END="3.4729853592928928" CI_START="-5.472985359292893" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="8.0" MODIFIED="2014-11-07 17:55:08 +0000" MODIFIED_BY="[Empty name]" ORDER="238" SD_1="5.0" SD_2="5.0" SE="2.282177322938192" STUDY_ID="STD-Yildiz-2002" TOTAL_1="12" TOTAL_2="8" WEIGHT="22.92223729860709"/></CONT_OUTCOME><DICH_OUTCOME CHI2="53.82336319693504" CI_END="1.3150174944691129" CI_START="1.1333559539134503" CI_STUDY="95" CI_TOTAL="95" DF="45" EFFECT_MEASURE="RR" EFFECT_SIZE="1.220812396257884" ESTIMABLE="YES" EVENTS_1="891" EVENTS_2="702" I2="16.393184433033507" I2_Q="66.03197736324975" ID="CMP-001.16" LOG_CI_END="0.1189315305450623" LOG_CI_START="0.05436633046531332" LOG_EFFECT_SIZE="0.08664893050518782" METHOD="MH" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="16" P_CHI2="0.17241344159192218" P_Q="0.019098895615037415" P_Z="1.435150476612641E-7" Q="11.775781130316286" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4403" TOTAL_2="4243" WEIGHT="500.0000000000001" Z="5.260690987693526"><NAME>Number of participants with adverse events</NAME><GROUP_LABEL_1>Treatment</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="9.087020947207137" CI_END="1.6717592057231179" CI_START="0.9236390018546755" DF="12" EFFECT_SIZE="1.2426190100410768" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="62" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.223173723368121" LOG_CI_START="-0.03449773671995016" LOG_EFFECT_SIZE="0.0943379933240854" MODIFIED="2014-10-11 17:14:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6954803380245607" P_Z="0.15124331584981032" STUDIES="19" TAU2="0.0" TOTAL_1="1219" TOTAL_2="1163" WEIGHT="100.00000000000001" Z="1.4351536582731332"><NAME>Gastroduodenal bleeding</NAME><DICH_DATA CI_END="3.278112068043215" CI_START="0.5615652712237177" EFFECT_SIZE="1.3567880794701987" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5156237966111772" LOG_CI_START="-0.2505997580404051" LOG_EFFECT_SIZE="0.13251201928538608" ORDER="169" O_E="0.0" SE="0.45008350887010556" STUDY_ID="STD-Annane-2002" TOTAL_1="151" TOTAL_2="149" VAR="0.20257516495682637" WEIGHT="12.436513297207275"/><DICH_DATA CI_END="8.361410389591947" CI_START="1.0763734323102898" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.9222795397302105" LOG_CI_START="0.03196296970911448" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-05-17 16:50:51 +0100" MODIFIED_BY="[Empty name]" ORDER="317" O_E="0.0" SE="0.5229763603684907" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" VAR="0.2735042735042735" WEIGHT="6.424159186636872"/><DICH_DATA CI_END="2.5424318740758354" CI_START="0.03259642759973053" EFFECT_SIZE="0.2878787878787879" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4052493245802956" LOG_CI_START="-1.4868299937583749" LOG_EFFECT_SIZE="-0.5407903345890397" ORDER="170" O_E="0.0" SE="1.1114167575358127" STUDY_ID="STD-Bollaert-1998" TOTAL_1="22" TOTAL_2="19" VAR="1.2352472089314195" WEIGHT="4.971792991534164"/><DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="171" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Briegel-1999" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.7721345176246239"/><DICH_DATA CI_END="4.675347755802239" CI_START="0.044576812075643235" EFFECT_SIZE="0.45652173913043476" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6698139195527121" LOG_CI_START="-1.3508909934480218" LOG_EFFECT_SIZE="-0.34053853694765485" ORDER="172" O_E="0.0" SE="1.1869720685472709" STUDY_ID="STD-Chawla-1999" TOTAL_1="23" TOTAL_2="21" VAR="1.4089026915113871" WEIGHT="3.2289261646120635"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-03-25 18:55:56 +0000" MODIFIED_BY="Djillali Annane" ORDER="427" O_E="0.0" SE="0.0" STUDY_ID="STD-Cicarelli-2007" TOTAL_1="14" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/><DICH_DATA CI_END="15.042527544933725" CI_START="0.06647818971997141" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1773208154172596" LOG_CI_START="-1.1773208154172596" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-03-26 15:24:01 +0000" MODIFIED_BY="Djillali Annane" ORDER="222" O_E="0.0" SE="1.3831281496162493" STUDY_ID="STD-Confalonieri-2005" TOTAL_1="23" TOTAL_2="23" VAR="1.9130434782608696" WEIGHT="1.5442690352492479"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-11 17:05:07 +0100" MODIFIED_BY="[Empty name]" ORDER="373" O_E="0.0" SE="0.0" STUDY_ID="STD-Gordon-2014" TOTAL_1="31" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/><DICH_DATA CI_END="1.7919585104746467" CI_START="0.6686188991051735" EFFECT_SIZE="1.0945945945945945" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.2533279501472499" LOG_CI_START="-0.17482135185190284" LOG_EFFECT_SIZE="0.039253299147673525" ORDER="174" O_E="0.0" SE="0.251497019367528" STUDY_ID="STD-Luce-1988" TOTAL_1="37" TOTAL_2="36" VAR="0.06325075075075075" WEIGHT="25.04677448952205"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-24 07:30:27 +0100" MODIFIED_BY="Djillali Annane" ORDER="472" O_E="0.0" SE="0.0" STUDY_ID="STD-Meduri-2007" TOTAL_1="42" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/><DICH_DATA CI_END="74.02756726585291" CI_START="0.12479675637361866" EFFECT_SIZE="3.039473684210526" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8693934775954149" LOG_CI_START="-0.9037967023727088" LOG_EFFECT_SIZE="0.4827983876113529" MODIFIED="2014-10-11 17:05:39 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.628985639226061" STUDY_ID="STD-Meijvis-2011" TOTAL_1="151" TOTAL_2="153" VAR="2.6535942128047387" WEIGHT="0.7670878867904761"/><DICH_DATA CI_END="6.755362190128103" CI_START="0.14803055289342476" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.829648638769922" LOG_CI_START="-0.829648638769922" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-05-17 16:20:12 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.9746794344808963" STUDY_ID="STD-Sabry-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.95" WEIGHT="3.0885380704984957"/><DICH_DATA CI_END="21.648196417223353" CI_START="0.18477289853198078" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3354217196881961" LOG_CI_START="-0.7333617283602337" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="175" O_E="0.0" SE="1.2152136380268745" STUDY_ID="STD-Schumer-1976" TOTAL_1="86" TOTAL_2="86" VAR="1.4767441860465116" WEIGHT="1.5442690352492479"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-11 17:14:10 +0100" MODIFIED_BY="[Empty name]" ORDER="376" O_E="0.0" SE="0.0" STUDY_ID="STD-Snijders-2010" TOTAL_1="104" TOTAL_2="109" VAR="0.0" WEIGHT="0.0"/><DICH_DATA CI_END="1.9137597778918756" CI_START="0.018086546121813478" EFFECT_SIZE="0.18604651162790697" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.28188742263441047" LOG_CI_START="-1.7426443598096963" LOG_EFFECT_SIZE="-0.730378468587643" ORDER="176" O_E="0.0" SE="1.1892199906016176" STUDY_ID="STD-Sprung-1984" TOTAL_1="43" TOTAL_2="16" VAR="1.4142441860465116" WEIGHT="4.501936848523231"/><DICH_DATA CI_END="2.350597550996326" CI_START="0.5567520042425683" EFFECT_SIZE="1.143984220907298" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.37117827934060577" LOG_CI_START="-0.2543382108814032" LOG_EFFECT_SIZE="0.058420034229601334" MODIFIED="2008-03-25 18:58:08 +0000" MODIFIED_BY="Djillali Annane" ORDER="431" O_E="0.0" SE="0.36743148271297205" STUDY_ID="STD-Sprung-2008" TOTAL_1="234" TOTAL_2="232" VAR="0.13500589448865308" WEIGHT="20.16165839153739"/><DICH_DATA CI_END="2.9903092561172606" CI_START="0.6437983783990627" EFFECT_SIZE="1.3875" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.47571610514046336" LOG_CI_START="-0.19125012155103566" LOG_EFFECT_SIZE="0.14223299179471383" ORDER="177" O_E="0.0" SE="0.3917792630946551" STUDY_ID="STD-VASSCSG-1987" TOTAL_1="112" TOTAL_2="111" VAR="0.153490990990991" WEIGHT="15.511940085014867"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="178" O_E="0.0" SE="0.0" STUDY_ID="STD-Yildiz-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-05-17 15:46:21 +0100" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.0" STUDY_ID="STD-Yildiz-2011" TOTAL_1="27" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="18.98449392441208" CI_END="1.204192551752304" CI_START="0.86558021238989" DF="15" EFFECT_SIZE="1.0209433112098256" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="203" I2="20.988149277387045" ID="CMP-001.16.02" LOG_CI_END="0.08069593665382471" LOG_CI_START="-0.06269268031988529" LOG_EFFECT_SIZE="0.009001628166969696" MODIFIED="2014-11-07 12:28:53 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.21443755649765828" P_Z="0.8056167249756203" STUDIES="19" TAU2="0.0" TOTAL_1="1307" TOTAL_2="1260" WEIGHT="100.00000000000003" Z="0.24608462487251265"><NAME>Superinfections</NAME><DICH_DATA CI_END="1.3462195287368475" CI_START="0.4801982679747765" EFFECT_SIZE="0.8040225656119696" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" LOG_CI_END="0.1291158862958536" LOG_CI_START="-0.3185794107312065" LOG_EFFECT_SIZE="-0.09473176221767646" MODIFIED="2013-05-30 17:51:17 +0100" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.26297843360115664" STUDY_ID="STD-Annane-2002" TOTAL_1="151" TOTAL_2="149" VAR="0.06915765653931794" WEIGHT="13.000065283971393"/><DICH_DATA CI_END="1.7301403878988848" CI_START="0.7356899013577267" EFFECT_SIZE="1.1282051282051282" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.23808134429418762" LOG_CI_START="-0.13330520537481125" LOG_EFFECT_SIZE="0.05238806945968822" MODIFIED="2014-10-11 17:23:58 +0100" MODIFIED_BY="[Empty name]" ORDER="377" O_E="0.0" SE="0.21815429766864" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" VAR="0.047591297591297585" WEIGHT="8.953687347900827"/><DICH_DATA CI_END="1.4563209139184" CI_START="0.3098245410523563" EFFECT_SIZE="0.6717171717171717" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.16325708636914213" LOG_CI_START="-0.5088841849580328" LOG_EFFECT_SIZE="-0.1728135492944453" ORDER="180" O_E="0.0" SE="0.39481910993053526" STUDY_ID="STD-Bollaert-1998" TOTAL_1="22" TOTAL_2="19" VAR="0.15588212956634007" WEIGHT="4.61963230895446"/><DICH_DATA CI_END="1.4768823635424857" CI_START="0.5917729036895621" EFFECT_SIZE="0.9348684210526316" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" LOG_CI_END="0.16934590431738136" LOG_CI_START="-0.22784492435198703" LOG_EFFECT_SIZE="-0.0292495100173028" ORDER="181" O_E="0.0" SE="0.2333118588866982" STUDY_ID="STD-Bone-1987" TOTAL_1="152" TOTAL_2="147" VAR="0.05443442349716657" WEIGHT="14.588805386340427"/><DICH_DATA CI_END="2.9965801800903877" CI_START="0.6810484632081674" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.47662590269158706" LOG_CI_START="-0.1668219827201008" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="182" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Briegel-1999" TOTAL_1="20" TOTAL_2="20" VAR="0.14285714285714285" WEIGHT="3.348066850176591"/><DICH_DATA CI_END="2.3633248346229667" CI_START="0.22575608897611832" EFFECT_SIZE="0.7304347826086957" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.373523418707557" LOG_CI_START="-0.646360527291017" LOG_EFFECT_SIZE="-0.13641855429173003" ORDER="183" O_E="0.0" SE="0.5990848783865164" STUDY_ID="STD-Chawla-1999" TOTAL_1="23" TOTAL_2="21" VAR="0.35890269151138715" WEIGHT="2.500179790716286"/><DICH_DATA CI_END="8.069223012379133" CI_START="0.015666905338032795" EFFECT_SIZE="0.35555555555555557" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9068317184046119" LOG_CI_START="-1.8050167806434498" LOG_EFFECT_SIZE="-0.4490925311194189" MODIFIED="2008-03-25 18:58:29 +0000" MODIFIED_BY="Djillali Annane" ORDER="432" O_E="0.0" SE="1.592953232207399" STUDY_ID="STD-Cicarelli-2007" TOTAL_1="14" TOTAL_2="15" VAR="2.5374999999999996" WEIGHT="0.6942995772255605"/><DICH_DATA CI_END="1.9526962636120182" CI_START="0.006322375498127466" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.29063469526127145" LOG_CI_START="-2.1991197141399215" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2008-03-26 15:23:22 +0000" MODIFIED_BY="Djillali Annane" ORDER="218" O_E="0.0" SE="1.462494064565354" STUDY_ID="STD-Confalonieri-2005" TOTAL_1="23" TOTAL_2="23" VAR="2.1388888888888893" WEIGHT="2.152328689399237"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-11 17:04:01 +0100" MODIFIED_BY="[Empty name]" ORDER="371" O_E="0.0" SE="0.0" STUDY_ID="STD-Gordon-2014" TOTAL_1="31" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/><DICH_DATA CI_END="3.033788396983134" CI_START="0.17552492421058752" EFFECT_SIZE="0.7297297297297297" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4819852860000223" LOG_CI_START="-0.7556612058160377" LOG_EFFECT_SIZE="-0.1368379599080077" ORDER="186" O_E="0.0" SE="0.7269996757416942" STUDY_ID="STD-Luce-1988" TOTAL_1="37" TOTAL_2="36" VAR="0.5285285285285285" WEIGHT="1.9393890169320374"/><DICH_DATA CI_END="4.371165857240555" CI_START="0.46034958180238317" EFFECT_SIZE="1.4185430463576159" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6405972854459071" LOG_CI_START="-0.33691224704057227" LOG_EFFECT_SIZE="0.1518425192026674" MODIFIED="2014-10-11 17:01:27 +0100" MODIFIED_BY="[Empty name]" ORDER="370" O_E="0.0" SE="0.5741939381327821" STUDY_ID="STD-Meijvis-2011" TOTAL_1="151" TOTAL_2="153" VAR="0.3296986785884332" WEIGHT="2.3757429247023745"/><DICH_DATA CI_END="1.3162390066867353" CI_START="0.004294988062726441" EFFECT_SIZE="0.07518796992481203" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.11933475695310501" LOG_CI_START="-2.367038038887277" LOG_EFFECT_SIZE="-1.1238516409670858" MODIFIED="2014-10-11 17:09:12 +0100" MODIFIED_BY="[Empty name]" ORDER="375" O_E="0.0" SE="1.4605076880204764" STUDY_ID="STD-Rezk--2013" TOTAL_1="18" TOTAL_2="9" VAR="2.133082706766917" WEIGHT="2.19356103977087"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="187" O_E="0.0" SE="0.0" STUDY_ID="STD-Schumer-1976" TOTAL_1="86" TOTAL_2="86" VAR="0.0" WEIGHT="0.0"/><DICH_DATA CI_END="8.094818028009673" CI_START="0.8481237880251626" EFFECT_SIZE="2.6201923076923075" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.9082070902333645" LOG_CI_START="-0.07154075560560277" LOG_EFFECT_SIZE="0.41833316731388087" MODIFIED="2014-10-11 16:50:40 +0100" MODIFIED_BY="[Empty name]" ORDER="368" O_E="0.0" SE="0.5755087344758634" STUDY_ID="STD-Snijders-2010" TOTAL_1="104" TOTAL_2="109" VAR="0.33121030345800984" WEIGHT="1.86827070378734"/><DICH_DATA CI_END="29.203585506298005" CI_START="0.5736569356876046" EFFECT_SIZE="4.093023255813954" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.465436175763647" LOG_CI_START="-0.24134775129452032" LOG_EFFECT_SIZE="0.6120442122345633" ORDER="188" O_E="0.0" SE="1.0025733274706656" STUDY_ID="STD-Sprung-1984" TOTAL_1="43" TOTAL_2="16" VAR="1.0051532769556024" WEIGHT="0.6971761479786606"/><DICH_DATA CI_END="1.6799507176726687" CI_START="0.9567032486540515" EFFECT_SIZE="1.2677595628415301" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="61" LOG_CI_END="0.22529654163256072" LOG_CI_START="-0.01922275131162028" LOG_EFFECT_SIZE="0.10303689516047022" MODIFIED="2008-03-25 19:02:43 +0000" MODIFIED_BY="Djillali Annane" ORDER="220" O_E="0.0" SE="0.14363184306543295" STUDY_ID="STD-Sprung-2008" TOTAL_1="234" TOTAL_2="232" VAR="0.02063010634237316" WEIGHT="29.301230054825666"/><DICH_DATA CI_END="1.2332827132650777" CI_START="0.38541761658046525" EFFECT_SIZE="0.6894409937888198" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="23" LOG_CI_END="0.09106264410343179" LOG_CI_START="-0.4140684385938163" LOG_EFFECT_SIZE="-0.1615028972451923" ORDER="189" O_E="0.0" SE="0.2967164984155495" STUDY_ID="STD-VASSCSG-1987" TOTAL_1="112" TOTAL_2="111" VAR="0.08804068043198478" WEIGHT="11.050121980851888"/><DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="190" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Yildiz-2002" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.7174428964664123"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-05-17 15:46:55 +0100" MODIFIED_BY="[Empty name]" ORDER="294" O_E="0.0" SE="0.0" STUDY_ID="STD-Yildiz-2011" TOTAL_1="27" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="13.600705021707647" CI_END="1.3679952911379187" CI_START="1.1554507573872665" DF="10" EFFECT_SIZE="1.257239513874553" ESTIMABLE="YES" EVENTS_1="460" EVENTS_2="353" I2="26.47439979001587" ID="CMP-001.16.03" LOG_CI_END="0.13608460247449392" LOG_CI_START="0.06275144159298664" LOG_EFFECT_SIZE="0.09941802203374024" MODIFIED="2014-10-11 17:04:45 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.19199596139247643" P_Z="1.0709160861168569E-7" STUDIES="13" TAU2="0.0" TOTAL_1="1066" TOTAL_2="1015" WEIGHT="100.00000000000004" Z="5.314260022561719"><NAME>Hyperglycaemia</NAME><DICH_DATA CI_END="1.3025220106700717" CI_START="1.0390721263281104" EFFECT_SIZE="1.1633633633633633" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="111" LOG_CI_END="0.11478507095949861" LOG_CI_START="0.016645694794045676" LOG_EFFECT_SIZE="0.06571538287677212" MODIFIED="2008-09-09 15:15:53 +0100" MODIFIED_BY="Djillali Annane" ORDER="242" O_E="0.0" SE="0.05764755535733391" STUDY_ID="STD-Annane-2002" TOTAL_1="150" TOTAL_2="149" VAR="0.0033232406386768778" WEIGHT="31.179186715797464"/><DICH_DATA CI_END="7.817156590537276" CI_START="0.24525026985315165" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8930488116788926" LOG_CI_START="-0.6103905060859539" LOG_EFFECT_SIZE="0.1413291527964693" MODIFIED="2014-05-17 16:51:34 +0100" MODIFIED_BY="[Empty name]" ORDER="318" O_E="0.0" SE="0.8831276973997191" STUDY_ID="STD-Arabi-2011" TOTAL_1="39" TOTAL_2="36" VAR="0.7799145299145298" WEIGHT="0.5823111051738367"/><DICH_DATA CI_END="3.785936400528155" CI_START="0.1970101157776949" EFFECT_SIZE="0.8636363636363636" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5781733140304" LOG_CI_START="-0.7055114737691546" LOG_EFFECT_SIZE="-0.06366907986937727" ORDER="191" O_E="0.0" SE="0.7540427986956395" STUDY_ID="STD-Bollaert-1998" TOTAL_1="22" TOTAL_2="19" VAR="0.5685805422647527" WEIGHT="0.9013258194529367"/><DICH_DATA CI_END="1.771115202235617" CI_START="0.6081520706774597" EFFECT_SIZE="1.037837837837838" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.24824681080500394" LOG_CI_START="-0.21598781020393232" LOG_EFFECT_SIZE="0.01612950030053583" ORDER="192" O_E="0.0" SE="0.27269371437908474" STUDY_ID="STD-Luce-1988" TOTAL_1="37" TOTAL_2="36" VAR="0.07436186186186185" WEIGHT="4.256884396357736"/><DICH_DATA CI_END="3.4143966023010557" CI_START="0.8058190245464583" EFFECT_SIZE="1.6587301587301588" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="6" LOG_CI_END="0.5333139655739692" LOG_CI_START="-0.09376248358698681" LOG_EFFECT_SIZE="0.21977574099349112" MODIFIED="2008-10-24 07:31:32 +0100" MODIFIED_BY="Djillali Annane" ORDER="473" O_E="0.0" SE="0.36834781031563074" STUDY_ID="STD-Meduri-2007" TOTAL_1="42" TOTAL_2="19" VAR="0.13568010936431987" WEIGHT="2.313089509833021"/><DICH_DATA CI_END="2.7288691284472932" CI_START="1.3786682544886961" EFFECT_SIZE="1.9396404919583727" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="35" LOG_CI_END="0.4359827082034066" LOG_CI_START="0.13945977554655384" LOG_EFFECT_SIZE="0.28772124187498016" MODIFIED="2014-10-11 16:59:56 +0100" MODIFIED_BY="[Empty name]" ORDER="369" O_E="0.0" SE="0.17417903845482452" STUDY_ID="STD-Meijvis-2011" TOTAL_1="151" TOTAL_2="153" VAR="0.030338337437047235" WEIGHT="9.734040330350854"/><DICH_DATA CI_END="15.731190021478056" CI_START="0.0635679817378522" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1967615770551223" LOG_CI_START="-1.1967615770551223" LOG_EFFECT_SIZE="0.0" ORDER="193" O_E="0.0" SE="1.4059673488550548" STUDY_ID="STD-Schumer-1976" TOTAL_1="86" TOTAL_2="86" VAR="1.9767441860465116" WEIGHT="0.2799572621028061"/><DICH_DATA CI_END="13.209194096386868" CI_START="0.5197446323517835" EFFECT_SIZE="2.6201923076923075" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1208763217652624" LOG_CI_START="-0.28420998713750056" LOG_EFFECT_SIZE="0.41833316731388087" MODIFIED="2014-10-11 16:49:30 +0100" MODIFIED_BY="[Empty name]" ORDER="367" O_E="0.0" SE="0.8253546531388855" STUDY_ID="STD-Snijders-2010" TOTAL_1="104" TOTAL_2="109" VAR="0.6812103034580099" WEIGHT="0.5467709907735555"/><DICH_DATA CI_END="61.18353785427328" CI_START="0.197625473189112" EFFECT_SIZE="3.477272727272727" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.786634585858298" LOG_CI_START="-0.7041570771954754" LOG_EFFECT_SIZE="0.5412387543314113" ORDER="194" O_E="0.0" SE="1.463103352495368" STUDY_ID="STD-Sprung-1984" TOTAL_1="43" TOTAL_2="16" VAR="2.140671420083185" WEIGHT="0.20193638577907325"/><DICH_DATA CI_END="1.275292990105477" CI_START="1.0287466140735955" EFFECT_SIZE="1.1454053193183629" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="161" LOG_CI_END="0.10560997250974695" LOG_CI_START="0.012308418823899974" LOG_EFFECT_SIZE="0.05895919566682346" MODIFIED="2008-03-25 19:04:47 +0000" MODIFIED_BY="Djillali Annane" ORDER="221" O_E="0.0" SE="0.054805794485205915" STUDY_ID="STD-Sprung-2008" TOTAL_1="234" TOTAL_2="232" VAR="0.003003675109154627" WEIGHT="45.26656606206488"/><DICH_DATA CI_END="2.4121807838254776" CI_START="0.7725703980661833" EFFECT_SIZE="1.365129835718071" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.3824098534165411" LOG_CI_START="-0.11206193637085492" LOG_EFFECT_SIZE="0.1351739585228431" ORDER="195" O_E="0.0" SE="0.29045517699595147" STUDY_ID="STD-VASSCSG-1987" TOTAL_1="111" TOTAL_2="112" VAR="0.08436420984374948" WEIGHT="4.737931422313857"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="196" O_E="0.0" SE="0.0" STUDY_ID="STD-Yildiz-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-05-17 15:47:34 +0100" MODIFIED_BY="[Empty name]" ORDER="295" O_E="0.0" SE="0.0" STUDY_ID="STD-Yildiz-2011" TOTAL_1="27" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="1.6604862832029614" CI_END="2.0946043383302935" CI_START="1.2794003079374148" DF="2" EFFECT_SIZE="1.6370209025748028" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="77" I2="0.0" ID="CMP-001.16.04" LOG_CI_END="0.32110199870653816" LOG_CI_START="0.10700645091140465" LOG_EFFECT_SIZE="0.21405422480897138" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="4" P_CHI2="0.43594352286998794" P_Z="8.885392062757055E-5" STUDIES="3" TAU2="0.0" TOTAL_1="404" TOTAL_2="401" WEIGHT="100.0" Z="3.919171376377033"><NAME>Hypernatraemia</NAME><DICH_DATA CI_END="2.2710834982908557" CI_START="1.0959395566423038" EFFECT_SIZE="1.5776470588235294" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="34" LOG_CI_END="0.3562331017143815" LOG_CI_START="0.03978660256023081" LOG_EFFECT_SIZE="0.19800985213730618" MODIFIED="2008-09-09 15:17:00 +0100" MODIFIED_BY="Djillali Annane" ORDER="243" O_E="0.0" SE="0.18588224003858209" STUDY_ID="STD-Annane-2002" TOTAL_1="150" TOTAL_2="149" VAR="0.03455220716176105" WEIGHT="44.135024278348894"/><DICH_DATA CI_END="45.42222706811206" CI_START="0.7925635162277901" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6572684240202276" LOG_CI_START="-0.10096592325294032" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2008-03-26 17:23:15 +0000" MODIFIED_BY="Djillali Annane" ORDER="242" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Briegel-1999" TOTAL_1="20" TOTAL_2="20" VAR="1.0666666666666667" WEIGHT="1.293761986198659"/><DICH_DATA CI_END="2.222801911831719" CI_START="1.1253678863718086" EFFECT_SIZE="1.5816035816035816" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="42" LOG_CI_END="0.346900761650146" LOG_CI_START="0.05129451791721959" LOG_EFFECT_SIZE="0.1990976397836828" MODIFIED="2008-03-26 17:26:17 +0000" MODIFIED_BY="Djillali Annane" ORDER="243" O_E="0.0" SE="0.17364057084322687" STUDY_ID="STD-Sprung-2008" TOTAL_1="234" TOTAL_2="232" VAR="0.030151047842761687" WEIGHT="54.57121373545244"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="2.8604256950095626" CI_END="1.8817504705213184" CI_START="0.20521881639705006" DF="2" EFFECT_SIZE="0.6214262661933249" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="30.080337220809582" ID="CMP-001.16.05" LOG_CI_END="0.27456203329926215" LOG_CI_START="-0.6877828215194796" LOG_EFFECT_SIZE="-0.2066103941101087" MODIFIED="2010-09-07 13:45:24 +0100" MODIFIED_BY="Jane Cracknell" NO="5" P_CHI2="0.23925833941036523" P_Z="0.4000186279646526" STUDIES="3" TAU2="0.0" TOTAL_1="407" TOTAL_2="404" WEIGHT="100.0" Z="0.8415879801502383"><NAME>Neuromuscular weakness</NAME><DICH_DATA CI_END="102.58979205993325" CI_START="0.2404719818606478" EFFECT_SIZE="4.966887417218543" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0111041495419273" LOG_CI_START="-0.6189355173448658" LOG_EFFECT_SIZE="0.6960843160985306" MODIFIED="2008-09-09 15:17:25 +0100" MODIFIED_BY="Djillali Annane" ORDER="244" O_E="0.0" SE="1.5448983192356194" STUDY_ID="STD-Annane-2002" TOTAL_1="150" TOTAL_2="149" VAR="2.386710816777042" WEIGHT="6.256040129128736"/><DICH_DATA CI_END="2.6189118760956447" CI_START="0.007792611676468944" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4181208850730818" LOG_CI_START="-2.108316965101596" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2008-03-26 15:27:19 +0000" MODIFIED_BY="Djillali Annane" ORDER="223" O_E="0.0" SE="1.4840420992616592" STUDY_ID="STD-Confalonieri-2005" TOTAL_1="23" TOTAL_2="23" VAR="2.2023809523809526" WEIGHT="43.64727335123923"/><DICH_DATA CI_END="2.680240053757018" CI_START="0.09168759276647605" EFFECT_SIZE="0.49572649572649574" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4281736930411678" LOG_CI_START="-1.0376894294076167" LOG_EFFECT_SIZE="-0.30475786818322437" MODIFIED="2008-03-26 15:28:39 +0000" MODIFIED_BY="Djillali Annane" ORDER="225" O_E="0.0" SE="0.8610552542658976" STUDY_ID="STD-Sprung-2008" TOTAL_1="234" TOTAL_2="232" VAR="0.7414161508989096" WEIGHT="50.09668651963203"/></DICH_SUBGROUP></DICH_OUTCOME></COMPARISON></ANALYSES_AND_DATA><FIGURES MODIFIED="2015-11-30 11:18:04 +0000" MODIFIED_BY="Jane Cracknell"><FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-02-03 16:32:15 +0000" MODIFIED_BY="Jane Cracknell" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>Flow diagram.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-11-30 11:18:04 +0000" MODIFIED_BY="Jane Cracknell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT"><CAPTION><P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Graph dose at day 1 .png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>Figure represents the results from meta-regression of log of risk ratio of dying and log of the dose of corticosteroids given at day 1 and expressed as equivalent mg of hydrocortisone. Estimates from each study are represented by circles. Circle sizes depend on the precision of each estimate (the inverse of its within-study variance), which is the weight given to each study in the fixed-effect model.</P><P>Meta-regression included 26 trials. The trial by Schummer et al was not included.</P><P>REML estimate of between-study variance tau<SUP>2</SUP> = .01078.<BR/>% residual variation due to heterogeneity: I<SUP>2</SUP> res = 5.07%<BR/>Proportion of between-study variance explained Adj R<SUP>2</SUP> = 11.16%<BR/></P><P><BR/></P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Graph total dose.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>Figure represents results from meta-regression of log of risk ratio of dying and log of cumulated dose of corticosteroids expressed as equivalent mg of hydrocortisone. Estimates from each study are represented by circles. Circle sizes depend on the precision of each estimate (the inverse of its within-study variance), which is the weight given to each study in the fixed-effect model.</P><P>Meta-regression included 26 trials. The trial by Schummer et al was not included.</P><P>REML estimate of between-study variance tau<SUP>2</SUP> = .01183<BR/>% residual variation due to heterogeneity I<SUP>2</SUP> res = 6.99%<BR/>Proportion of between-study variance explained Adj R<SUP>2</SUP> = 2.49%<BR/></P></CAPTION><FILE>iVBORw0KGgoAAAANSUhEUgAAA1gAAAJuCAIAAAAiqTT7AAApPUlEQVR42u3dy3HjyJqAUdnRdmi4GQPaC0XQgjZCG3E3XmijkB9aKeRGL7sMqCkRFF9IAIl3ZuKc+Bf3qlV6EA9+Agng4d//fhljjDHGmA3Og4fAGGOMMUYIGmOMMcYYIWiMMcYYY4SgMcYYY4wRgsYYY4wxRggaY4wxxhghaIwxxhhjhKAxxhhjjBGCxhhjjDFGCBpjjDHGGCFojDHGGGOEoDHGGGOMEYLGGGOMMUYIGmOMMcYYIWiMMcYYY4SgMcYYY4wRgsYYY4wxRggaY4wxxhghaIwxxhhjhKAxxhhjjBGCxhhjjDFGCBpjjDHGGCF49cs/PPwGAMiQEBSCAIAQFIJCEAAQgkJQCAIAQlAICkEAQAgKQSEIAAhBISgEAQAhKASFIAAgBIUgAIAQFIIAAEJQCAIACMFF5/3poZf9qxAEAIRgGUcEX/dCEABgkyH4PW/7MZF3F3xNrEYAgBBMcT5edscUfPceQQCAbYXgv/99PX+n4O75UwgCAGwrBH/9+3l4nO2goBAEAISgy8cAAAhBIQgAIASFIACAEBSCAABCUAgCAAhBIQgAIASFIACAEBSCAABCUAgCAAhBIQgAIASFIACAEBSCAABCUAgCAAhBIQgAIASFIACAEBSCAABCUAgCAEJQCApBAEAICkEhCAAIQSEoBAEAISgEhSAAIASFoBAEAISgEBSCAIAQFIIAAEJQCAIACEEhCAAgBIUgAIAQFIIAAEJQCAIACEEhCAAgBIUgAIAQFIIAAEJQCAIACEEhCAAgBIUgAIAQFIIAAEJQCAIACEEhCAAgBIUgAIAQFIIAAEJQCAIAQlAICkEAQAgKQSEIAAhBISgEAQAhKASFIAAgBIWgEAQAhKAQFIIAgBAUggAAQlAIAgAIQSEIACAEhSAAgBAUggAAQlAIAgAIQSEIACAEhSAAgBAUggAAQlAIAgAIQSEIACAEhSAAgBAUggAAQlAIAgAIQSEIACTvr7//aRohKAQBgA3F3wJdKASFIACQSgL2+nwhKAQBgLwrcMl/KwSFIACQZQJO/nWEoBAEADKrwKm+mhAUggDAohWYzpcVgkIQAFguBJP6ykJQCAIAGVfgmK8vBIUgALBEBS4Qgn2/hRAUggDAEiGY4HcRgkJwW3+KLXm5dgBYrAKHfS8hKAT1nyIEYPZnojS/nRAUgltJwLn/IQA0Pa0k+x2FoBAsvALX/SIAeEoSgkKQnBJQDgIgBIWgENx6BWpBAPKqwL7fVwgKQQkoBwEQgkJQCKpALQiAEBSCQjC7Ciz4OwIgBIWgECSVJsuiBV0uEUAICkEhaAMr7VtPEn+iEEAICkEhaOsqpwWHVZ0WBBCCQlAIZrlppRCCKZTTVBknBwGEoBAUgjatnH6MaetNCwIIQSEoBG1XGfww80WbHAQQgkJQCKa7UaUWgiueuTzTt9aCQMtuwXuLU25Bt5gTgraoTWzkC3xTe3nAxQeEoBAUgiowoR9s4b2tnTtIwJj9gBwUgkIQIVhmltmzw8YrcO5/tZFHMs1vJwSFoBDMLwQ98kBqCSgHE9mF9v1eQlAI2pay+cHW/fXt0zN9IveCHascwbLK5fI0IQSFoK0ojx9v9b2q3XruCagIWX5XZmUbsAsdvNkO27qFoBAUgjmFoEVA5JNH5Gd63Jj17z1rWvwudPzZ2cMeaiEoBIVgBj9eOr+7fXr6FTjH52M3a6cx66Mx/g+5wY+zEBSCQjD1Hy+pJ2z1UNJRHEuTJXdiHuHgRjfJ2dljtmUhKATtpOxD7dO3u2lYmizwV4E/OZoabsyx+ane+CsEhaAQTPrHS/O3tk8vaVlYmvzexruck23BSb7O4C8iBIWgnVT2Idj3Lcbjf0779JKO4jhagxDMrgUn3LELQSFoP5VrCA7ov6l2HPbpha11FqgVqfgroSbi//7nf/tO+25//GMrBIWgXVW6P17wa47vuQnfnmK1LGaVs0CtS0JwsbbrNZF/xjtZRAjaVW0iBOd4hXdMTVothSDWpcLWscXCLv4P9fmuJi0EhaBdVTYhOOuF3wZ8cd0gBLEu5bKOzd12iTwOQlAI2lWVGYLL3Bms73fRDUIQ69Ja3yWpsEvn0RaCQtCuqvAQXOy3iH8ZwmopBLEuTfJdsm67dB5q9xoWgvZWRf1ga13XI/42R9bJFcNdCJLF0i877ISgEBSCQnD2w4GrN41u6JuAS76aLwRZa+lrOyEoBIWgEJzxKXn1y/y2/wy6IabahSB57VpnPXpnHROCQpD1N6GZDtsUGYLtv5p9+uqPkhBk+YN2aZ4tKwSFoBC0FY1KwJHVNd/zcSL7zeWPdZW0TqZ2hqAnaW23yuuzVjAhKASZ+GjZ4Aoc9gnT/jyRXy2pEAxe2toKuWII/naLOWE3Xdi517AQFIJCsNgNqe+18QZ88Zl6K51dZ8o/mxCc6v0SFuWWD9rNuhq0/DG58ClWQnCrIfi2f2jw+PIlBIvflhL55NyPuqV5tHLjIfh7ujfOWo4rtl3xjRL8M3Km9+oIQSF4PV/Pu4co+3chmOO2NNMNMOY7fNj3m6a2KxSCfdeZ9C8ouNnluJHLF6ewPrRUYOfetbyVUwguOh8vpwx8eus+WDj40KAQTHlzmvVtf3NX4LTHe6b6O3sLr91M+JfJkiE44BsVtii13YrrUswX7Lv3KHVv4xZzCx8O3L92f+b7059P3B0+hGBxm9N8JwIvdsLm+IM9c5wiLQR7PdQL/wAlLUdhl3um1F9GmOkd3kJQCDbkXdxrvq/7yGQMh+CWz5VZd877iPZPGPyVB3/fyb/XgMekPsHPmeNht0Ku8vjEf/cVf8i5D9pZCZfZtQ74ImO+YGE7nJm2vnX3zJsIwZZ3GNprJLtFzRGCk29skU/bw+Kvc+yUy47RaRe9ttvgWjTJV5jqqxX2CKf/Nb007KXh/F6Vm/ZF1QVeTRv5TsemFyL7fr6XhrfzUrV32jHrxh78V85tX/H9RVt+afh8ssju+dPJIlpw7EY1UwCNOfe55UeKfI+jENwIbcdUf1HEf/LkxVPYbmfCHenIL1X4dQRf93GXjxl6OFAIJp6Dk4TgrOnT9939kT9S3yvg9P0ZhKCwY8s52OvsKCE4awuO/yKbuKD0+ToydW1XlhGC+bfg+BBMpAJ/93lVd9ipo31fodaCGYWdtmPuIlwg4Aq+rODIyz+NfFjcYk4IbmJvteQ/n2+/1jfaBvRu/NcUgsIOlgy4su81Mt/TgRAUglrwn5EH3pLaP057P5X4I3yJ3/4u96oTdgjBzYZg8KlnmQQUgkJwizk45p0uiVTgHEcE2//VurfNyLHqhB0IwbmfsKb6vkJQCMrBNW8FMd8xzgFv3Gk583rFG+k6XAdC8PeWXoVY+LlJCArBzbXgyINt64ZgZ5zF/Ebx5/dNdVaKqgMhKATTJASFoOOC/6xybbwB71zsW67Dftn4x2SqR0zYgRAUgkKw9bYfEQZfEVoIysFV9i8DLvISf2Cv81eO//yFD+BZRUEICkEhOCQER14XWgiSeAjGdNu0obxA9uk/sLtTgUIw8q7BtYs/n+4Od7qbcHUTkeWPCwpB1g3Bzhacr94SObYKZLG7G3nzd/uW7YbgsfAa7hf8eXj8TsH3Sy8uflBQCDJrBS52uZP443Yt2Wd/DUx+SM9eZeMheHxp+JR6TZl4fVDw9L+F4Nx/2DkCNNJi9Tbsujkx1xQs5uKCQJrHBT3LCEEhmHoCysEFCm/M7ZIHnygdc+3AlK8vCKT8JDLH51NqCFZvEGx4abjKxNPLwdVnCsGlN+DtbKurFN5aD6wQBNbKQQkoBIMnhTSdLPLz8er/Nh87FIJzZEHuz/0rngM77V2DhSCQYwt6oUkIRs3Hy6798oE/n9B04FAIzluBKT/9J3uVEyEIyEH9JwR7X0QmeNXA6tox94cMhWBZyVLYFeyEIABC0C3mNheCa130RF4LQQCEoBCcrFck3QItmGYItryCowIBhKAQzJieE4Lt3zfmFHILF0AITn/icIOlLxmTYwgukHQKYCMh+LvrpD9LFkAILnHKsBBc5ohd1mcNa8E5fioVCCAEl7yg9AoXCFwxBBN8QbbU6wgKQYsbQAgmf4u5VY/5TRWCWb/fzp1FhKAQBBCCK4Xg1SUDNxKCySaL1wTXqq7FHuHIuz9ZcABCcIn3CB4vFr3CLUNcPiY+B21Is4bgwu3lcCCAEEzqrOHq1eFEW3BrIUjZLagCAYRggu8RdNYwQrDf8dcBR21jPlkIAghBISgEWa0FB1RgZA6qQAAh6M4iQpDVQnCqFqx/2vjI85ZQACEoBIUga7bgmFdvY+4apwIBhKAQFIJk0ILtVRf58ZgXjlUggBBcMgRP7wt8evMeQTbagpG92OvIX9Prxd4aCCAEhaAQJK0WHJyDMSE44RkkAAhBLw3D9CHYqwWv/0n7wb9eBwKFIIAQXPfyMeneVqQzBN2QjZEh2Os9fL1mqhgFQAgucx3BFIuwKQQneTJGBfZdYSZZ2ayfAEIwoZeGP152t28KTKgIgyEYeV6n51o6C2zhPx6smQBCMN33CCZYhPUQHHDwxopIy/qwTAiue6xagAIIwRFFuDt8JBaCvZ7/rIh0rgyzplIiCeiNEwBCMHre9ndXkXl8+Vo9BAc8gXnOI35NmDaVUgivXlfAAUAI/nq9KsDjtQYvUbh8C16H4LAnVMc/HGQaHIIjV7lEKtAfSABCcPQZxJ+HxzVeI66H4EwFwMgETD8H+17eedhVY5J6KIQggBCMmCryOk4Q+XrerXCXESGYZgUO+4S8QrBv/qb268e8J9JaDbDxELw+CtgeecfPdERw8xU44WfmEoK5LzUbBYAQTCvvBoTgmOctz3mLVWDKLRh5B5HyFpyNAkAIlnCvYUcEs6jATFuw1JOKnDUMIARbXg6OsfT7AoVgLkeVcnzYt3ZPQtcRBBCCQtDT3tIVmGMLFr8cbQgAQrCxC0+XDLw/lXjNCnQdQSEIAEJw7stHN10y5tiI+/d07jXsziJCEACE4KSHA5tT75iJqbw0PKAthIgQBAAhWFoIZn1Bu41UoBAEQAgmHoLt9wtZ/yqD9RD8nf8tLrbTghYBAEIw7ZNF3vbhO8udPl47iSSBEPyd+U1vhSAACMFULij9um+8cszjy1c6F5TulYNWPiEIAEKw12vEV9K471x7CCIEYcJV3Z+UwGZDMINbzJFXCxb8PCoUtpCAljIgBIUgruMdGw1WlfKa3vIFhKAQpHfVbeHWvfUPWk9KXbG1ICAEhaCnTJdv/N15xSLrSTEL1PIFhKAQJFx4E16+Ma+XWYXgNivQIgaEoBCkrdsGZFx279Bv/5FUghAEyCUE2+8mIgQZ3nADvkiv/5RsOqgEIQiQSwhe3zju+3+vftVoIeg5OIvnXSEoBD1uQCkheDoiKARZ5wk401M1nTUsBAFyD8G2e8qFrPkishDc8hNwyiHoOoJCECDXEPw5KCgEEYJjc9ACFYIA2YXgTRF6aRghiPXQ2ggIQSGIEMSqaFUEthKCLh+DZ182vSq6xRwgBIPvGkziQoNCUAjmGBZOJclxkfX9rwCFhODHy675RJF3IYjDMCMrUElkveAsO6DoEHw7XUvm6e3245+Hx+DHhSATPfWO/5wsjio5sJR1DnpkgLJDsLrd3O75s/MeJEKQWZ53e/2n7H6XfH8pALYQgsfUa37993jpadcRZLkDMNkdjOn1o2pBACEoBIUgHTmY3c8/0+cDIAS9NAxJh+Dc/wQAIehkERCCAAjBBS8fs/pNR4QgQhAAIeiC0pB9BQpBACHoFnNCkO22oBAEEIJCUAgiBAEQgkJQCCIEARCCQlAIkmMIuo4gAEJQCLLdFpzjkwEQgkJQCJJHC7rXMABCUAiy3RBs6rwc754HgBAUgjAkB7O+gTIAGwxBF5SGGVvQgwMgBPO7xdzD/l0IAgAUGoJv+yr5nt5uP/55eAx+XAgCABQRgl/P30cDd8+fza8X7w4fQhAAoLgQPKZe8+u/r/uV3ywoBAEAISgEAQCEoJeGAQCEoJNFAACE4CyXj3l8+XL5GACAYkPQBaUBALYcgm4xBwAgBIUgAIAQFIIAACWF4OntgMfTgetvDQzcb9h1BAEAhKAQBADIOAS9NAwAIASFIADAVkPw+6Xh5qtGVzeg89IwAMDmQrB6B6EQBAAoJQRf9w897A4fQhAAoIwQ/Pfz8Bidgc+f3iMIAFBMCMa+NOxkEQCAYkPQWcMAAEKw8cTh4MkiMVeinuCq1EIQABCCM87Hy25Aw/U740QIAgBCMLUQ7KrA1ncQvu3nvgedEAQAhOB8r/ye7ztchd35NOGoq0mfOnL/LgQBAPIKweNb/c4Zd7yszNUhwGMLdkRe1YtzXWVGCAIAQnCRELz/v8cDfp0XlK6uSjjPQcE/X3jLJ00bY4wxZuMz/0vDl9S7+7/VK79L3GKu5U2K1gBjjDHGCMFZpjr59/xycPV/T28ZrA4QusUcAECJLw1f3W6uem23dve5de87IgQBACE469zeaO6qBYdV4O1hRSEIAAjBzdxiTggCAGR3sogQBADYSgjOcjqIEAQAyOXOIhNfIEYIAgBk8R7B40HBSVtQCAIAZPLScIclLigtBGFyf/39z3k8GgBCUAjCFitQDgIIwTxvqyIEYUQF1j/owQEQgkIQyg/BmA8CIASFIBRegUIQQAgKQdhuCwpBACEoBGErIeg9ggBCUAjCplvQWcMAQlAIwqZb0KMBIASFIACAEPy5oPTzy1fXFaddUBoAoMQQ/L6zyP499J++nnfuLAIAUGwI/tTeTQueE/DbY8chQyEIAJBlCH7P6/5YfLvDR0oJKAQBACG4xMkiHy9XAfjw8PTmZBEAgG2E4Pe87Vd/R6AQBACE4EqXjzm14O75UwgCABQYgsczhXtw1jAAgBAUggAAOYegO4sAAAhBIQgAsOkQ/Dw8Xl0y5upSMuufNSIEAQAhOG8FXi4ffTpx+CGRFhSCAIAQnPe2IufDgdX/PUVh1YjhOxELQQCAvEPweAbx983lrk8ovhwFPHahs4YBAEoNwfMxv+p14UsXVu8XFIIAAKWHYHWayOl14e/5et45IggAUGYIVi/+Vq8F378ufDp92HsEAQCKDMH704RPrwuf7z7irGEAgFJD8KYFz68CH18UvnqzoBAEACgxBN1ZBABACApBAAAhKAQBAEoLwdOJIMe7iZxPCmnh8jEAAEJQCAIA5ByCXhoGABCCyVwmRggCAEJwjVvMCUEAgO2F4Pp3ExaCAIAQXOs9gtX5Iom2oBAEAITgrBXorGEAACEoBAEAthGCLh8DACAEhSAAgBAUggAAQlAIAgAIQSEIACAEhSAAQI4hmPrdRIQgACAEZwrB6/sLf//vx5cvIQgAsJkQPB0RFIIAABsKwV+v+4c+3FkEAKCUEIy7s5wQBAAoMARvitBLwwAAQlAIAgBsJQRdPgYAYOshWH/XYBIXGhSCAIAQnHE+XnbNJ4q8C0EAgEJD8O10LZmnt9uPfx4egx8XggAARYRgdbu53fNn5z1IhCAAQFEheEy95td/j5eedh1BAAAhKAQBAEoJQS8NAwBsNASdLAIAsNkQbL18zOo3HRGCAIAQdEFpAAAh6BZzAABCUAgCAAhBIQgAIASFIACAEBSCAABCUAgCAAhBIQgAIASFIADANkOwfh3ptG4xIgQBACG4cgh+2x0+hCAAQCkh+Ge+no+3Gn56u/342/76RnOv+3WOCwpBAEAIzjXHwts9f4b+6+fh8TsF3y+9uPhBQSEIAAjBOV8aPqVeUyZeHxQ8/W8hCAAgBIUgAECWIVi9QbDhpeEqE08vB1efKQQBAAoJwfNJIU0ni/x8vPq/zccOhSAAQG4h+N+vj5dd++UDfz6h6cChEAQAyDMEry8iE7xqYHXtmPtDhkIQAKCIEHSLOQAAISgEAQC2FIL1e80tfYKwEAQAhGBCJ4ssf5qwEAQAhODal4+p7i+30jkiQhAAEILpXFBaCAIAFBWCPW4xJwQBAISgEAQAyD4EvTQMALDREHSyCADAZkMw4l7DQhAAoMwQdEFpAIAth6BbzAEACEEhCAAgBIUgAEBJIVh/O2A71xEEABCCQhAAIOcQ9NIwAIAQFIIAAEJQCAIACMEe87rvvA1J9ZbEgW80FIIAgBBMcL6eA7em2z1/CkEAgKJD8HSH4t3h4/7o4F0LCkEAQAgWFYLV4cBa3n0eHo8x+PQmBAEAIVhmCB7zbv8e+E+nFjwfFxSCAIAQ3EgIXuKvakEhCAAIwS28NHx/XPDPJwhBAEAIln6yyP287cffp04IAgBCMOnLxzRcQfAnFseF4Javp22MMcaYjU/SJVSlXlMIxp8s8tDMGmCMMcYYIegWcwAAXhoWggAAQjDZGxBfXVNaCAIAQlAICkEAQAgKQSEIAAhBISgEAQAhKASFIAAgBIWgEAQAhKDLxwAACEEhCAAgBIUgAIAQFIIAAEJQCAIACEEhCAAgBIUgAIAQFIIAAEJQCAIACEEhCAAgBIUgAIAQFIIAAEJQCAIACEEhCAAgBIUgAIAQFIIAAEJQCAIAQlAICkEAQAgKQSEIAAhBISgEAQAhKASFIAAgBIWgEAQAhKAQFIIAgBAUglYjAEAICkEAACEoBAEAhKAQBAAQgkIQAEAICkEAACEoBAEAhKAQBAAQgkIQAEAICkEAACEoBAEAhKAQBAAQgkIQAEAICkEAACEoBAEAhKAQBAAQgkIQAEAICkEAQAgKQSEIAAhBISgEAQAhKASFIAAgBIWgEAQAhKAQFIIAgBAUgkIQABCCQhAAQAgKQQAAISgEAQCEoBAEABCCQhAAQAgKQQAAISgEIUF//f1Py3h8AISgEAQhCIAQFIJQXAXeFWH9PwEgBIUgFNuCjggCCEEhKAQRgkIQQAgKQSEIAAhBIWg1AgCEoBAEABCCQhAAQAgKQQAAISgEAQCEoBAEABCCQhAAQAgKQQAAISgEAQCEoBAEABCCQhAAQAgKQQAAISgEAQCEoBAEABCCQhAAQAgKQQAAISgEAQCEoBAEAISgEBSCAIAQFIJCEAAQgkJQCAIAQlAICkEAQAgKQSEIAAhBISgEAQAhKAQBAISgEAQAEIJCEABACApBAAAhKAQBAISgEAQAEIJCEABACApBAAAhKAQBAISgEAQAEIJCEABACApBAAAhKAQBAISgEAQAEIJCEABACApBAAAhKAQBACEoBIUgACAEhaAQBACEoBAUggCAEBSCQhAAEIKlhOD708PF05sQBACEYIEh+PW8+ym+/fv3Rz4Pjw811X8SggCAECwlBG+O/H3bHZ73d0cBT6U4+LigEAQAhGBy83psvseXr+r/frycjg2eP3LTgrvDhxAEAIRgESF4PBx4k3fVwb/d82cwGfevQhAAEILlhODtm/+OBwWFIABA4SEY/4Kvl4YBACFY1nsET28K7Ci808kitTcOCkEAQAhmfNbw5doxwZOCz6ePDD4cWIXglq+nbYwxxpiNT9Il1PS+wHMIRh4LfGhmDTDGGGOMEHSLOQAALw0LQQAAIZjstaZH3mVYCAIAQlAIAgAIQSEIACAEhSAAgBAUggAAQlAIAgAIQZePAQAQgkIQAEAICkEAACEoBAEAhKAQBAAQgumFIABAjoTgJlLVg2DRGMvFcjGWi0Uz1/fycFsVjEVjuRjLxXIxQtDYSo1FY7kYy8VyMULQ2EqNRWO5GMvFcjFC0NhKjUVjuRjLxXIxQtDYSo1FY7kYy8VyMULQ2EotGo+D5WIsF8vFCEFjjDHGGJNldHoIjDHGGGOEoDHGGGOMEYLGGGOMMUYIGmOMMcYYIWiMMcYYY4SgMcYYY4wRgsYYY4wxRggaY4wxxhghaEbN+9PDxePLl8ckqSVSs3/1EK07b/sHm0x68/Gys5kktjgalsLn4fFqUT29ebiSWTR9PkcIFrnr/LE7fHhwhKAJzes+uEzePTKrztdzaE+mMFabU+qFdlZvgU3IX1NJLJpenyMEy1ohds+f93+o2YEm+1Rn0SSwyVwtBZtMSn/QXpbCqTaudm5mhUPm9ZI4/ZV7KT9LKpVF0+dzhGBhxzbu/xSrVgJHONJ8qrNc0lsKFk2ifyPZla1/yPy+JGxByS6a+M8RguW9/uh1xlIO5pvF/p4OPY15bSu9Xdnx497oskJq/FkWVZ3fLZSGZK/2b5bUmosm9nOEYIltYdvL99itWe/tm7WXhr2wlWoI+vNp0T3VeUMIlkS1ROobiyW1+qKJ/RwhWOyxjeujwWrD4UAT04LXZ1epwASWSG0pePPZ+q/XB0OwviurPtmSWnHRDPgcIVhKCD6+HJ6cNexwoBnybmt/PqV2skjgvDd5IQSNEDSdz2fXm9/pPRye2LyV0zRvNYHgsMmkcL7I7TV9DvJCCBohaPo8pXnvYCZnJ5hVd6ANm4xYT+Xt8Oc3cc74ZGaEoBAUgqUURiD47D2Te25zjbqE3qzZuMl4GnM03bQ/jzQ9uVhSQtCk9axmm/RMZpo3GcczHE03Q2sj/Jetl6GEoFn3XTW2yQxj3azY5Q2bjF5P68C5tzunWBsuKC0EhWD6bxN0HzOHNEzjBG5ldj471WJaf7lcnreuLo3r8UmqNtxiTghaBgm/vfrqbDtPaQk9vTmkkeBxdFdcymG5aIska8MFmISgSfWdTw8PD44FOlPExB9K9xyW8J+10jzl2vCkIwSNMcYYY8zWRggaY4wxxghBY4wxxhgjBI0xxhhjjBA07ZPo5YXP19Roe+P85+HxcjLy1i7AO2jB3TxiY5dO3xMa8j1hOWptnHVuF9xMj2TMl3XW+dyr2XYe267Naq5dek6P8yIbvhA0SYbg7RmU4fO/7q+HJwTjHlUhOMfauMAPIASFYEnTvVltPgSX2vCFoEkxBKMuCi8EhWA6a+OyzwdiRQgWcjiwba0Wgi7+LwQ3H4IdG6oQFIIbeXoWgkJwi7+sEBSCQnDNnjjdsed8V5BgbVxdavV7W43eulq/+O1FQZs2g/ubl3x/zmWvcfXWk9BOZNB1R5vfzhLaW93ez/dyDeerb33+IncPY/SXDSy46x/y7vq3oUesxwMybFnH/auIle3utgHBPePAy8lOsDb2eSthxy97fMT+fPD8abvHXeAHCD6S47978Mt2L8SYpdNreZ2+4PWPd3ObyssGdfWtQz/2zSN52ZQ6V5XO32iiFXLYZtWymbdshj33P+vv5Dt36Y3HFGv91P5btK0qcU+Fa274UVtf+3e/PM7tK0PKl+wWghOH4P1eJrx+361Y3+vN0z72DUZtX3x0CFY/RtMtocI/QMdTV+hOU+1HIoMhuL+/CdKfDal2O77z1+kbgg23Kfv5hKYQjHhAAl/5cRf513zHv4pZ2cKfc/vkN2ixTrY2Rqwksb9s9XzwtL/8ms/7mOeDab57zJe9W4gxSyf2ka89c99/l59PaNqgan/53DySH3HfuvM3mmiFnGyz6rz98aD9z/o7+YhdevhVkeMvdbcjbXuc+60q4QMB62z4w1fFzr3HNE+dQjDTEPzZREPPxLU/xUIV0raPiPvi414avv5L5fSR2g6o8UhD637t7iGKL7bL3ja0Ad/vsH4+p18Inr7gzS7gtB+//Gr1FxoiHpBhyzrqX0WtD9VvUT9WevV7DVqs066NXStJ7Lf7WVVul3vXe8an+u4dXzawECOWTuMj3768rlfv++f7S76cH5PaLxh+JLu/dedvNM0KOWqzat/Mm/9s7rP/SWEn371LD90w8/iA3Mdc22/Ruqr0fCpcdMOPXxXbv3vj41zbvnruY4VgpiF494d4wxt76+vfZX/UsmHHffGxIRg4bH5zIKF+xPtmxxHzPpXbHy86BG/+eArtvm9+2l4hGH4zzf3DGH7FpP0BCS7r0EMdWKk6/lWfla3zgEffxTrt2ti5ksR+u9Cq0vl8MNl373qaqS/EIe8wjlxe55+t/mR/epTuFm71KLVtdPErfMtvNMkKOWyzitvMm0Kw3/4nhZ189y498Mft8SN91uGWVaXzF1l3w49cFSN/i8mfOoVgriHY8ubcq0+rcqR2TLhpnYt452/45elhIXiza7spp6YD4O2vrXRubLEhGHptPfTWmSEhGPeeleZjqI0PyO0vErsTj/pXkevD9Q8Z/GWHLdZp18ZBK0n8X2Jjnw9iv/vNl+2xELtfnRy0vK4+M/QkXTsUcXNL+9AjGfOte61vQ1fIYZvVkLemDd3/JLGT79yl3y/0+x8g7nFuXlU6f5F1N/zIVTF2Hzv1U6cQzDUEW1brq//UcCpT14Yd98WnPWs4UE491+aGXcnAk0XmDMHu94LcP2IRD0jTaWs3f3ZHn+wW+GM9Yn2ov6Po5l8NWqzTro3dK0nstwsnTvvzwXTf/ebLRi76jqXT+b711n9bf6Gt7fjEzSbTvNF1fevO32j8Cjlss+rxxrVfXd3ctf9JYiffvWsNbwstxwtDj3Ps49N0TGStDT92Vez87vM8dQpBIZhwCPa/FUcOIXj39FA9dF0vDUc8ICmEYMPz35hXJ4XgZCHYsXRGXfbo/GVDZwQPDsF+37rpNxq1Qg4NwajNfGMheP2R6mu2vSu6sBAcvioOCMHkbj8mBBd/afh6tWh41aBrw4774rOHYN+rUg16S1Do7Uo9Q7Dzy9YLvu97BCMekFVeGu7YvZ7/PG373eNeoJxqbRzxClH33wxzvjR8+937vzTcuXQi3z/ashbtn2o/fMNLw53PrGP2AJ2/UZ8VctRjO/A9gv32P0ns5ONC8PJpdy8T93tp+PbxifxF1t3wO1fFyO8+01OnEHSyyGoni/Q9aaMzO4Yc8Ls7uW9ECLZ82c4/TGtvAW66vFbbAxLclQx7V/uwk0ViV9qei3X2k0Ui3ifafGGUfs8Hk333iFLvXPTdz46Ry+v+YoGd6233X18DV5W+Z5DMtVlFbuaThGBCJ4t0huDPEb79/jF8jZ6oHVFwVRlwssiCG/5UT+gzPXUKwfwvHxO6sNZkl49p/+KxIRh+13DrXuPn2ptXX7l719b0y95fZ6H2XUaGYNeXrR8RrF99I3QJgOvtNuIBab7SQcyD1vqvYtaHwGULGh+ZXot12rWxcyWJ/Hbh54OuoylTffeGL9u8EGOWzn+Nl2tuW16BkxYvD0vLunT3OeFn1pZv3fkbTbRCDtqs4jbzaUIwhZ18dAiGrwUd+zi3bXRDnwqX2PBjVsWo7z7XU6cQzDYEx1xFM2K1iHync48QDN1ZpHND6nn929AvW3+TyvWvU/1tOi4Eu75s6CBE+L287w2PWOQDUv/1Y64rG/Wvoi+1Ouhip8MuazxsbexcSfr8so3PSb0uKN3/u0d82fuFGLN0Yh/5yw9cOxx1+5x3Os6x23Vekrp+kbPOVaXzN5pohRyyWUVt5hOFYAI7+fgQbLiiUJ91OHZViXkqXGrDH74qBjbzOZ46hWC2IRg68a3zFnPfq+n9G3VjTxsMfPHet1r6Xh2j9xq3gRX5B83NZlDf5159zcutnEaGYMeX7Sj479+r9ifj7SPW4wG5uwJt/3thTXqLueDeZ9BinXBt7F5JIr5d93PS1Zvi294zPui7d33ZuFvMRT43NC+vlh+j+mDwFnPBl/bCu6POVaXzN5pohRywWcVs5hOF4Oo7+R4h2H6eTfvj3Laq9L/F3NIbftTWF3uLuTmeOoXgtqbhVD5jjJl8V5PWrU7t5FedlgvmmU2MEFzrIGLohNa0zzA3xghBU9pOvukyMUYImrl3xHV2zcYYIWgnv+CBwKi3pRohaGb7Iyyxy4sbY4Sg2chO/lyrVgYh6FEwxhhjjBGCxhhjjDFGCBpjjDHGGCFojDHGGGOEoDHGGGOMEYLGGGOMMUYIGmOMMcYYIWiMMcYYY4SgMcYYY4wRgsYYY4wxRggaY4wxxhghaIwxxhhjhKAxxhhjjBGCxhhjjDFGCBpjjDHGGCFojDHGGGOEoDHGGGOMEYLGGGOMMUYIGmOMMcYYIWiMMcYYY4SgMcYYY4wRgsYYY4wxRggaY4wxxhghaIwxxhgjBI0xxhhjjBA0xhhjjDFC0BhjjDHGlDr/DwuzfirjqdIpAAAAAElFTkSuQmCC</FILE></FIGURE><FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2015-11-30 11:18:03 +0000" MODIFIED_BY="Jane Cracknell" NO="5" REF_ID="CMP-001.01" SETTINGS="SHOW_CI_LINES:NO;SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT"><CAPTION><P>Funnel plot of comparison: 1 Steroids versus control, outcome: 1.1 28-Day all-cause mortality.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Graph.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>Contour-enhanced funnel plot</P><P>Log of risk ratio for 28-day mortality is plotted against its standard error</P></CAPTION><FILE>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</FILE></FIGURE></FIGURES><FEEDBACK MODIFIED="2018-05-05 00:41:27 +0100" MODIFIED_BY="[Empty name]"><FEEDBACK_ITEM ID="FBK-01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="1"><TITLE MODIFIED="2013-05-31 17:22:53 +0100" MODIFIED_BY="Jane Cracknell">Feedback</TITLE><DATE_SUBMITTED><DATE DAY="9" MONTH="5" YEAR="2013"/></DATE_SUBMITTED><FEEDBACK_SUMMARY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Annane et al (<LINK REF="REF-Annane-2004" TYPE="REFERENCE">Annane 2004</LINK>; updated 2010) in their systematic review of corticosteroids for treating severe sepsis and septic shock concluded &#8220;a long course of low dose corticosteroids reduced mortality without inducing major complications&#8221;.  This was based on a subgroup analysis, as all doses/durations of corticosteroids for septic shock did not show a benefit in reduction of mortality.</P><P>Given that the two largest trials (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>) have contradicting results, we were interested in looking into these trials. Upon our review, we feel that the risk of bias assessment of these trials has not adequately addressed the issue of incomplete data. In one trial (<LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>), authors used a per-protocol analysis for their adverse event data; this was subsequently used in this review. Neither the trial nor the review addresses the reasons for this approach. Using per-protocol data is not the preferred method of outcome reporting, as it does not allow for preservation of randomization. Section 14.6.1<BR/>of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> specifically asks whether any patients were excluded in reporting of adverse events. Participants who experience unfavourable adverse events may drop out of the trial. When the per-protocol analysis is used, adverse effect results may therefore be biased in favour of steroids. The same scenario can be applied for the placebo group.</P><P>In another trial (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>), we are concerned with the way data were collected and reported for adverse events. Events are reported as being &#8220;possibly related to steroids&#8221; and &#8220;possibly related to vasopressors&#8221;. We are unsure as to how one would know whether or not an adverse event was related to the intervention. Neither the review nor the trial specifically outlines the adjusting procedure for determining whether or not adverse events were due to steroids. Patients in the intensive care unit have many risk factors for infection - GI bleeding, psychiatric disorders (e.g. delirium) - therefore it seems inappropriate to try to ascertain whether or not the event was secondary to steroids.Section 14.6.1 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> explains how clinical trials may have a well-designed method for collecting data for the primary outcome, but in fact may take a retrospective, unblinded approach to collecting adverse event data.  An extension of the CONSORT statement for harm also echoes this, recommending that clinical trials should explicitly define how data were defined, collected and analysed for adverse events (<LINK REF="REF-Ioannidis-2004" TYPE="REFERENCE">Ioannidis 2004</LINK>).<BR/><BR/>As <LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK> was a randomized controlled trial, adverse events would not require assessment of whether or not they were thought to be due to treatment. Randomization should take care of confounding factors and thus should be able to show differences (if they truly exist) in adverse events. In our opinion, preference should be given to all-cause adverse events for this reason.<BR/><BR/>Lastly, we note that in Analysis 1.12 for &#8216;superinfections&#8217;, the percentage of participants with an event was used instead of the actual number of events in <LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>.  For example, the number of events for the treatment arm should have been &#8216;22&#8217;, but &#8216;15&#8217; was used instead.<BR/><BR/>Given that these issues on selective reporting (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>) and incomplete data surrounding the two largest trials of this review have not been adequately addressed in the risk of bias assessments, we find it difficult to conclude at this time on the safety profile of corticosteroid use in treating severe sepsis and septic shock. We look forward to hearing your response to our concerns.<BR/><BR/><BR/></P></FEEDBACK_SUMMARY><FEEDBACK_REPLY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>We are grateful to Dr. Harbin and colleagues for their comments on the Cochrane review on corticosteroids for severe sepsis and septic shock.</P><P>Dr. Harbin and colleagues questioned the validity of the concluding statement of this review that corticotherapy was overall well tolerated apart from inducing hyperglycaemia and hypernatraemia. Indeed, they pointed out that Sprung and colleagues reported serious adverse events as per-protocol (<LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>). In fact, in this trial, data for adverse events were reported only for 466 of 499 patients. We have now reported this information in the risk of bias table in a revised version of the review.</P><P>Annane and colleagues reported in their main paper the number of participants with any serious adverse events in each treatment arm as per intent-to-treat analysis (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>). All serious adverse events that were observed were reported in each treatment group. Serious adverse events were further classified according to what was known about complications of corticosteroids or catecholamines. For example, all superinfections, gastroduodenal bleeding, metabolic disorders and psychiatric disorders that occurred at any time from randomization were reported and further classified in a blinded manner as possibly related to corticosteroids. Thus, no manipulation of data occurred. All serious adverse events were carefully scrutinized and reported in the manuscript, and additional unpublished information (i.e. raw data) was available during preparation of the Cochrane review.</P><P>Finally, Dr. Harbin and colleagues highlighted an error in numbers used for Analysis 1.12 (number of participants with superinfection) that is now corrected in the revised version of the review. This modification did not significantly alter the direction and the magnitude of the pooled estimate for evaluation of serious adverse events. Thus, we believe that the conclusion statement - that treatment with corticosteroids in patients with sepsis or septic shock is well tolerated apart from metabolic disorders - is still valid.</P></FEEDBACK_REPLY><FEEDBACK_CONTRIBUTORS MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><P>Megan Harbin, BSc Pharm<BR/>Asal Taheri, BSc Pharm<BR/>Wan-Yun Polinna Tsai, BSc Pharm<BR/>Gloria Su, BSc Pharm<BR/>Aaron M Tejani, BSc Pharm, PharmD</P><P>Reply:</P><P>Djillali Annane</P></FEEDBACK_CONTRIBUTORS></FEEDBACK_ITEM><FEEDBACK_ITEM ID="FBK-02" MODIFIED="2018-05-05 00:41:27 +0100" MODIFIED_BY="[Empty name]" NO="2"><TITLE MODIFIED="2018-03-13 11:52:54 +0000" MODIFIED_BY="[Empty name]">Feedback</TITLE><DATE_SUBMITTED><DATE DAY="9" MONTH="11" YEAR="2017"/></DATE_SUBMITTED><FEEDBACK_SUMMARY MODIFIED="2018-03-13 12:01:28 +0000" MODIFIED_BY="[Empty name]"><OL><LI>Annane and colleagues in their systematic review (<LINK REF="REF-Annane-2015" TYPE="REFERENCE">Annane 2015</LINK>), concluded that &#8220;a long course of low dose corticosteroids reduced mortality without inducing major complications&#8221;. This was based on a subgroup analysis, analysis of outcome 1.4, so we pursued it in more detail. Upon our review, we found that the forest plot was created using a fixed-effect model. However, the largest trial, <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>, only carried 21.5% weight while the second largest trial, <LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>, was allotted a larger weight of 25.1%. Although we acknowledge that given the I<SUP>2</SUP> was 16%, a fixed-effect model was chosen, we felt that because these two trials had conflicting results, suggesting clinical heterogeneity, a random-effects model would have been a more conservative and more appropriate approach in this scenario. We took the initiative to recreate the forest plot using a random-effects model, and found that the treatment effect became not statistically significant. This suggests that perhaps the conclusion is not as simple as &#8220;a long course of low dose corticosteroids reduced mortality&#8221; in severe sepsis and septic shock.</LI><LI>Furthermore, when we reviewed <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> we noticed that footnote &#8220;a&#8221; states that the quality of evidence for the primary outcome was downgraded due to &#8220;1 of the 2 largest trials [showing] no survival benefit&#8221;. We feel that this sentence implies that the other largest trial did show a survival benefit, and may mislead the readers to believe so. However, both of the largest trials (<LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>), did not show a statistical benefit for corticosteroids compared to placebo for mortality benefits in sepsis and septic shock. One trial simply showed that there was no increase in mortality, but did not show that it reduced mortality.</LI><LI>Based on our findings, we feel that there could be an alternative interpretation from the results of the trials. This review includes studies from 1976 to 2015, and when we look at the studies published before 2002, the studies as a group show a more convincing trend toward mortality benefit using corticosteroids. In contrast, the studies published after 2002 show more conflicting results. This may suggest that medical therapy today is better at treating sepsis and hence the benefits from corticosteroids are not as apparent as previously thought. In contrast to the conclusion stated by the authors, we feel that this review presents inconclusive evidence for mortality benefit with corticosteroid use in septic patients. We look forward to your response.</LI></OL></FEEDBACK_SUMMARY><FEEDBACK_REPLY MODIFIED="2018-05-05 00:41:27 +0100" MODIFIED_BY="[Empty name]"><OL><LI>The planned analysis was to use fixed-effect model unless heterogeneity across trials could be suspected (i.e. squared I statistic &gt; 30%). We weighted studies by the amount of information they contribute (more specifically, by the inverse variances of their effect estimates). It is also important to highlight that CORTICUS (<LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>), was terminated prematurely (after 500 participants were recruited out of 800 expected) owing to low recruitment rate and loss of equipoise among investigators. Changing from fixed- to random-effects models did not change the magnitude nor the direction of the point estimate (RR 0.87 versus 0.88) and slightly enlarged the 95% CI 0.78 to 0.97 versus 0.77 to 1.00. Thus, we do not believe that the conclusion from our systematic review was not supported by data analysis, and we disagree about over-interpreting the data.</LI><LI>In the trial <LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>, the primary outcome was time to death in non-responders to ACTH test (modified intent-to-treat analysis). The primary analysis for the primary outcome in this trial found a statistically significant increase in survival time (P = 0.02). The CORTICUS trial (<LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>), found no significant effect of treatment on mortality. Thus, we do not believe that we have misinterpreted (misreported) findings from either the <LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK> or <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK> trials.</LI><LI>The pooled RR of dying from trials published before 2002 was 0.90 ( 95% CI 0.75 to 1.07). The pooled RR of dying from trials published from 2002 was 0.89 ( 95% CI 0.80 to 1.00). Thus, there is no evidence that corticosteroids effect on mortality differed between trials published before 2002 versus those published since 2002. Finally, new trials have been published since the last update of this review including Keh et all JAMA 2016; Bi et al PLoSOne 2016; Menon et al Ped CCM 2017; El Nawawy The Pediatric Infectious Disease Journal 2016 ; Qing-quan Lv et al Am J Emerg Med 2017; Tongyoo et al. Critical Care 2016 ; and two large trials are about to be published in the very next future (ADRENAl, n = 3800 and APROCCHSS, n = 1241). Thus, we believe that there is a need to update the review in light of these newly published studies.</LI></OL></FEEDBACK_REPLY><FEEDBACK_CONTRIBUTORS MODIFIED="2018-03-13 12:08:27 +0000" MODIFIED_BY="[Empty name]"><P><B>Summary</B></P><P>Candy Lee, Karen Ng, Shalini Singla, Marco Yeung</P><P>Pharmacy Residents</P><P>Lower Mainland Pharmacy Services, Pharmacy Association, Vancouver, Canada</P><P>We do not have any affiliation with or involvement in any organisation with a financial interest in the subject matter of my comment</P><P><B>Reply</B></P><P>Djillali Annane</P><P>Department of Critical Care, Hyperbaric Medicine and Home Respiratory Unit<BR/>Center for Neuromuscular Diseases; Raymond Poincaré Hospital (AP-HP)<BR/>Faculty of Health Sciences Simone Veil, University of Versailles SQY- University of Paris Saclay<BR/>104 Boulevard Raymond Poincaré<BR/>92380 Garches<BR/>France</P></FEEDBACK_CONTRIBUTORS></FEEDBACK_ITEM></FEEDBACK><APPENDICES MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><APPENDIX ID="APP-01" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="1"><TITLE MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell">Search strategy for CENTRAL</TITLE><APPENDIX_BODY MODIFIED="2010-09-24 16:10:34 +0100" MODIFIED_BY="Jane Cracknell"><P>#1 MeSH descriptor sepsis explode all trees<BR/>#2 MeSH descriptor shock, septic explode all trees<BR/>#3 steroid* in All Text<BR/>#4 (sepsis in All Text or (septic in All Text and shock in All Text) )<BR/>#5 (#1 or #2 or #3 or #4)<BR/>#6 MeSH descriptor Adrenal Cortex Hormones explode all trees<BR/>#7 corticosteroid* in All Text<BR/>#8 (#6 or #7)<BR/>#9 (#5 and #8)</P></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-02" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="2"><TITLE MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell">Search strategy for MEDLINE (Ovid SP)</TITLE><APPENDIX_BODY MODIFIED="2010-10-08 13:44:39 +0100" MODIFIED_BY="Jane Cracknell"><P>1. exp Sepsis/ </P><P>2. exp Shock, Septic/</P><P>3. (sepsis or septic shock).mp.</P><P>4. 1 or 2 or 3</P><P>5. exp Adrenal Cortex Hormones/</P><P>6. (corticosteroid* or steroid*).mp.</P><P>7. 6 or 5</P><P>8. 4 and 7</P><P>9. ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or randomly.ab. or trial.ti.) not (animals not (humans and animals)).sh.</P><P>10. 8 and 9</P></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-03" MODIFIED="2010-09-24 16:16:15 +0100" MODIFIED_BY="Jane Cracknell" NO="3"><TITLE MODIFIED="2010-09-24 16:14:16 +0100" MODIFIED_BY="Jane Cracknell">Search strategy for EMBASE (Ovid SP)</TITLE><APPENDIX_BODY MODIFIED="2010-09-24 16:16:15 +0100" MODIFIED_BY="Jane Cracknell"><P>1. exp sepsis/<BR/>2.exp septic shock/<BR/>3. (sepsis or septic shock).mp.<BR/>4.1 or 2 or 3<BR/>5.steroid/<BR/>6. (corticosteroid* or steroid*).ti,ab.<BR/>7. 6 or 5<BR/>8. 4 and 7<BR/>9. (placebo.sh. or controlled study.ab. or random*.ti,ab. or trial*.ti,ab.) not (animals not (humans and animals)).sh.<BR/>10. 8 and 9</P></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-04" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="4"><TITLE MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell">Search strategy for LILACS (via BIREME)</TITLE><APPENDIX_BODY MODIFIED="2010-10-07 13:26:05 +0100" MODIFIED_BY="[Empty name]"><P>("sepsis" or "septic$" or "SEPSIS" or "SEPTIC" or "SEPTIC SHOCK/" or "SEPTICEMIA") and  ("corticosteroid$" or "steroid$" or "glucocorticoid$" or "CORTICOSTEROID" or "GLUCOCORTICOIDS/" or "STEROID")</P></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-05" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="5"><TITLE MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell">Unpublished data obtained from trial authors</TITLE><APPENDIX_BODY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><TABLE COLS="2" ROWS="20"><TR><TH><P>Studies</P></TH><TH><P>Type of unpublished data provided by primary authors</P></TH></TR><TR><TD><P><LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK></P></TD><TD><P>Full access to individual data, details for randomization and blinding procedures.</P></TD></TR><TR><TD><P><LINK REF="STD-Annane-2010" TYPE="STUDY">Annane 2010</LINK></P></TD><TD><P>Full access to individual data, details for randomization and blinding procedures.</P></TD></TR><TR><TD><P><LINK REF="STD-Arabi-2011" TYPE="STUDY">Arabi 2011</LINK></P></TD><TD><P>Additional information on mortality data, length of stay, shock reversal and SOFA.</P></TD></TR><TR><TD><P><LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK></P></TD><TD><P>Details for randomization and blinding procedures. Additional information on adrenal function (data according to the review definition: delta cortisol &#8804; 9 µg/dL. Additional information for ICU length of stay and adverse events.</P></TD></TR><TR><TD><P><LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK></P></TD><TD><P>Details for randomization and blinding procedures. Additional information for ICU length of stay and adverse events.</P></TD></TR><TR><TD><P><LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK></P></TD><TD><P>Details for randomization and blinding procedures. Additional information for mortality, shock reversal and ICU length of stay and adverse events.</P></TD></TR><TR><TD><P><LINK REF="STD-Cicarelli-2007" TYPE="STUDY">Cicarelli 2007</LINK></P></TD><TD><P>Details for randomization and blinding procedures.</P></TD></TR><TR><TD><P><LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK></P></TD><TD><P>Full access to individual data, details for randomization and blinding procedures.</P></TD></TR><TR><TD><P><LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK></P></TD><TD><P>Additional information on shock reversal, length of stay, SOFA and adverse events.</P></TD></TR><TR><TD><P><LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK></P></TD><TD><P>Details for randomization and blinding procedures. Additional information for adverse events.</P></TD></TR><TR><TD><P><LINK REF="STD-Meduri-2007" TYPE="STUDY">Meduri 2007</LINK></P></TD><TD><P>Details for randomization and blinding procedures. Additional information for subgroup of patients with sepsis or septic shock on mortality, ICU and hospital length of stay and adverse events.</P></TD></TR><TR><TD><P><LINK REF="STD-Meijvis-2011" TYPE="STUDY">Meijvis 2011</LINK></P></TD><TD><P>Separate information for patients with sepsis.</P></TD></TR><TR><TD><P><LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK></P></TD><TD><P>Details for randomization and blinding procedures. Additional information for mortality, for outcome of patients randomized and not analysed, shock reversal and adverse events.</P></TD></TR><TR><TD><P><LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK></P></TD><TD><P>Details for randomization and blinding procedures. Additional information for mortality, for outcome of patients randomized and not analysed and adverse events.</P></TD></TR><TR><TD><P><LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK></P></TD><TD><P>Additional information for 28.</P></TD></TR><TR><TD><P><LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK></P></TD><TD><P>Full access to individual data, details for randomization and blinding procedures.</P></TD></TR><TR><TD><P><LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK></P></TD><TD><P>Details for randomization and blinding procedures.</P></TD></TR><TR><TD><P><LINK REF="STD-Torres-2015" TYPE="STUDY">Torres 2015</LINK></P></TD><TD><P>Details for randomization and blinding procedures. Additional information for mortality, shock reversal, SOFA, length of stay and adverse events.</P></TD></TR><TR><TD><P><LINK REF="STD-Yildiz-2002" TYPE="STUDY">Yildiz 2002</LINK></P></TD><TD><P>Details for randomization and blinding procedures. Additional information for mortality, hospital length of stay and adverse events.</P></TD></TR></TABLE></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-06" MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell" NO="6"><TITLE MODIFIED="2010-09-24 13:47:15 +0100" MODIFIED_BY="Jane Cracknell">Methodological quality of studies</TITLE><APPENDIX_BODY MODIFIED="2015-11-30 11:17:58 +0000" MODIFIED_BY="Jane Cracknell"><TABLE COLS="4" ROWS="5"><TR><TD><P/></TD><TD><P>Adequate</P></TD><TD><P>Inadequate</P></TD><TD><P>Unclear</P></TD></TR><TR><TD><P>Generation of allocation sequence</P></TD><TD><P><LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Bone-1987" TYPE="STUDY">Bone 1987</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Cicarelli-2007" TYPE="STUDY">Cicarelli 2007</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-CSG-1963" TYPE="STUDY">CSG 1963</LINK>; <LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>; <LINK REF="STD-Klastersky-1971" TYPE="STUDY">Klastersky 1971</LINK>; <LINK REF="STD-Luce-1988" TYPE="STUDY">Luce 1988</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Slusher-1996" TYPE="STUDY">Slusher 1996</LINK>; <LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>;<LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-VASSCSG-1987" TYPE="STUDY">VASSCSG 1987</LINK>; <LINK REF="STD-Yildiz-2002" TYPE="STUDY">Yildiz 2002</LINK></P></TD><TD><P><LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK>; <LINK REF="STD-Schumer-1976" TYPE="STUDY">Schumer 1976</LINK>; <LINK REF="STD-Wagner-1955" TYPE="STUDY">Wagner 1955</LINK></P></TD><TD><P><LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>; <LINK REF="STD-Mikami-2007" TYPE="STUDY">Mikami 2007</LINK>; <LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK></P></TD></TR><TR><TD><P>Allocation concealment</P></TD><TD><P><LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Bone-1987" TYPE="STUDY">Bone 1987</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Cicarelli-2007" TYPE="STUDY">Cicarelli 2007</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-CSG-1963" TYPE="STUDY">CSG 1963</LINK>; <LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>; <LINK REF="STD-Klastersky-1971" TYPE="STUDY">Klastersky 1971</LINK>; <LINK REF="STD-Luce-1988" TYPE="STUDY">Luce 1988</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Slusher-1996" TYPE="STUDY">Slusher 1996</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-VASSCSG-1987" TYPE="STUDY">VASSCSG 1987</LINK>; <LINK REF="STD-Yildiz-2002" TYPE="STUDY">Yildiz 2002</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK></P></TD><TD><P><LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK>; <LINK REF="STD-Schumer-1976" TYPE="STUDY">Schumer 1976</LINK>; <LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>; <LINK REF="STD-Wagner-1955" TYPE="STUDY">Wagner 1955</LINK></P></TD><TD><P><LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>; <LINK REF="STD-Mikami-2007" TYPE="STUDY">Mikami 2007</LINK>; <LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK></P></TD></TR><TR><TD><P>Blinding</P></TD><TD><P><LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Bone-1987" TYPE="STUDY">Bone 1987</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Cicarelli-2007" TYPE="STUDY">Cicarelli 2007</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>;<LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>; <LINK REF="STD-Klastersky-1971" TYPE="STUDY">Klastersky 1971</LINK>; <LINK REF="STD-Luce-1988" TYPE="STUDY">Luce 1988</LINK>; <LINK REF="STD-Mikami-2007" TYPE="STUDY">Mikami 2007</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Slusher-1996" TYPE="STUDY">Slusher 1996</LINK>; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK>; <LINK REF="STD-VASSCSG-1987" TYPE="STUDY">VASSCSG 1987</LINK>; <LINK REF="STD-Yildiz-2002" TYPE="STUDY">Yildiz 2002</LINK>;</P></TD><TD><P><LINK REF="STD-CSG-1963" TYPE="STUDY">CSG 1963</LINK>; <LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK>; <LINK REF="STD-Mikami-2007" TYPE="STUDY">Mikami 2007</LINK>; <LINK REF="STD-Schumer-1976" TYPE="STUDY">Schumer 1976</LINK>; <LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>; <LINK REF="STD-Wagner-1955" TYPE="STUDY">Wagner 1955</LINK></P></TD><TD><P/></TD></TR><TR><TD><P>Lost to follow-up</P></TD><TD><P><LINK REF="STD-Annane-2002" TYPE="STUDY">Annane 2002</LINK>; <LINK REF="STD-Bollaert-1998" TYPE="STUDY">Bollaert 1998</LINK>; <LINK REF="STD-Briegel-1999" TYPE="STUDY">Briegel 1999</LINK>; <LINK REF="STD-Keh-2003" TYPE="STUDY">Keh 2003</LINK>; <LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK>f; <LINK REF="STD-Sprung-2008" TYPE="STUDY">Sprung 2008</LINK>; <LINK REF="STD-VASSCSG-1987" TYPE="STUDY">VASSCSG 1987</LINK></P></TD><TD><P/></TD><TD><P><LINK REF="STD-Bone-1987" TYPE="STUDY">Bone 1987</LINK>; <LINK REF="STD-Chawla-1999" TYPE="STUDY">Chawla 1999</LINK>; <LINK REF="STD-Cicarelli-2007" TYPE="STUDY">Cicarelli 2007</LINK>; <LINK REF="STD-Confalonieri-2005" TYPE="STUDY">Confalonieri 2005</LINK>; <LINK REF="STD-CSG-1963" TYPE="STUDY">CSG 1963</LINK>; <LINK REF="STD-Huh-2007" TYPE="STUDY">Huh 2007</LINK>; <LINK REF="STD-Klastersky-1971" TYPE="STUDY">Klastersky 1971</LINK>;<LINK REF="STD-Luce-1988" TYPE="STUDY">Luce 1988</LINK>; <LINK REF="STD-Mikami-2007" TYPE="STUDY">Mikami 2007</LINK>; <LINK REF="STD-Oppert-2005" TYPE="STUDY">Oppert 2005</LINK>; <LINK REF="STD-Rinaldi-2006" TYPE="STUDY">Rinaldi 2006</LINK>; <LINK REF="STD-Schumer-1976" TYPE="STUDY">Schumer 1976</LINK>; <LINK REF="STD-Slusher-1996" TYPE="STUDY">Slusher 1996</LINK>; <LINK REF="STD-Sprung-1984" TYPE="STUDY">Sprung 1984</LINK>;<LINK REF="STD-Tandan-2005" TYPE="STUDY">Tandan 2005</LINK></P></TD></TR></TABLE></APPENDIX_BODY></APPENDIX></APPENDICES><EXTENSIONS MODIFIED="2010-02-24 06:50:37 +0000" MODIFIED_BY="Djillali Annane"><EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART"><ALIAS ALIAS_ID="1"><FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Included: 33&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Number of trials per outcome&lt;/p&gt;&lt;p&gt;28-day mortality:&lt;b&gt; &lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;reporting 28-day mortality&lt;/li&gt;&lt;li&gt;reporting only 14-day mortality&lt;/li&gt;&lt;li&gt;reporting only hospital mortality&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;ICU mortality: 13&lt;/p&gt;&lt;p&gt;Hospital mortality: 17&lt;/p&gt;&lt;p&gt;Shock reversal&lt;/p&gt;&lt;ul&gt;&lt;li&gt;by day-7: 12&lt;/li&gt;&lt;li&gt;by day 28: 7&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;SOFA score at day 7: 8&lt;/p&gt;&lt;p&gt;Length of stay&lt;/p&gt;&lt;ul&gt;&lt;li&gt;in the ICU: 12&lt;/li&gt;&lt;li&gt;in the hospital: 12&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Adverse events: 21&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Other sources; 5&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Conference proceedings: 5&lt;/p&gt;"><OUT TEXT="&lt;p&gt;&lt;b&gt;Excluded: 2&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Insufficient data: 2&lt;/p&gt;"/></FLOWCHARTBOX><FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Full paper review: 42&lt;/b&gt;&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Database search&lt;/b&gt;&lt;b&gt;: 2851&lt;/b&gt;&lt;/p&gt;&lt;p&gt;MEDLINE: 834&lt;/p&gt;&lt;p&gt;EMBASE: 1080&lt;/p&gt;&lt;p&gt;LILACS: 84&lt;/p&gt;&lt;p&gt;COCHRANE Library: 853&lt;/p&gt;"><OUT TEXT="&lt;p&gt;&lt;b&gt;Excluded: 2804&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Irrelevant: 2648&lt;/p&gt;&lt;p&gt;Review: 89&lt;/p&gt;&lt;p&gt;Non RCT: 67&lt;/p&gt;"/></FLOWCHARTBOX><OUT TEXT="&lt;p&gt;&lt;b&gt;Excluded: 12&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Quasi randomised: 3&lt;/p&gt;&lt;p&gt;Participants not relevant: 6&lt;/p&gt;&lt;p&gt;Outcomes not relevant: 3&lt;/p&gt;"/></FLOWCHARTBOX></FLOWCHARTBOX></ALIAS></EXTENSION></EXTENSIONS></COCHRANE_REVIEW>